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1001-203 Long-Term Outcome and Cost-Effectiveness of Stenting 
Versus Balloon Angioplasty in Selected Patients With Acute 
Myocardial Infarction 
Jan Paul Ottervanger, Harry Suryapranata, Edwn Nibbering, Arnoud W. J. van ‘t Hof, Jan 
C. A. Hoorntje, Menko Jan de Boer, Maywen Al. Felix Zijlstra. /sala Klinieke”, hospital De 
Weezenlanden, Zwolle, The Netherlands 
Background: Primary angioplasty has been demonstrated to be beneficial over throm- 
bolysis in acute myacardial Infarction. Use of stents may have additional benefit, com- 
pared to balloon angioplasty. Although the initial results of stenting for acute myocardlal 
infarction have been quite promising, long-term clinical outcome and cost-effectiveness 
have not been reported. Methods: Patients with acute myocardial infarction eligible for 
stenting were randomized to primary stenting (“=I 12) or balloon angioplasty (n=l15). 
Primary endpoint was the cumulative first event rate of death, non-fatal reinfarction, or 
target-vessel revascularization. Secondary endpoints ware restenosis at 6 months and 
cost-effectiveness at follow-up. Results: After 24 months, the combined clinical endpoint 
of deathlreinfarction was 4% after stenting and 11% after balloon angioplasty (p=O.O4). 
Subsequent target-vessel revascularization was necessary in 15 (13%) and 39 (34%) 
patients, respectively (p<O.OOl). The cumulative cardiac event-free survival rate was sig- 
nificantly higher after stenting (84% versus 62%, pcO.001). The anglographic restenosis 
of 12% after stenting was lower compared to 34% after balloon angioplasty (p<O.OOl). 
Despite the higher initial costs of stenting (Dfl. 21,484 versus Dfl. 18,625; p<O.OOi), the 
cumulative costs at 24 months were at least comparable to balloon angioplasty (Dfl. 
31,423 versus Dfl. 32,933; p=O.83) Conclusions: Compared to balloon angioplasty, pri- 
mary stenting for acute myocardial infarction results in a better long-term clinical out- 
come, without Increased costs. 
12:36 p.m. 
1001-204 Is Primary Angioplasty the Optimal Treatment for Acute 
Myocardial Infarction in Elderly Patients? 
Edward J. Kosinski, Bardia Asgari, Maria Capasso, Caroline La&r, Jeffrey N. Berman, 
Karl Alcan, Corina Marcu, Kathleen Harper. St Vincent’s Medical Center, Bridgeport, CT 
Background: Primary angioplasty (PAMI) has emerged as the choice of therapy for 
acute myocardial infarction. However, elderly patients may have a different short and 
long-term outcome due to the chronicity of their coronary disease. Methods: We retro- 
spectively analyzed a two year (1996.1998) single center experience in which all patients 
presenting with ST elevation infarct were treated with primary angioplasty. No patients 
received thrombolytic therapy as part of their treatment. Catheterization, angioplasty and 
hospital records were reviewed for short-term outcomes (less than 30 days). Long-term 
results (average 2.6 years) were assessed by patient interviews and hospital record 
review with 95% complete follow-up. Quality of life assessment was determined in 76% of 
patients. Results: 172 patients comprised the study group with 118 males and 121 
patients 70 years of age. Ten patients presenting in profound cardiogenlc shock were 
excluded. Procedure success, as evidenced by post procedure TIMI 3 flow in the Infarct 
related artery, was comparable, with 88% in patients 70 years and 84% in patients 70 
years. Global ejection fraction and extent of coronary artery disease was not significantly 
different between the two age groups. Overall mortality within 30 days was 2.9%. Despite 
similar acute procedural results, patients 70 years had 1.6% mortality and patients 70 
years experienced a 5.9% mortality. Target vessel revascularization by percutaneous cor- 
onary intervention or CABG was comparable in both age groups (24.6% in patients 70 
years and 23.5% in patrents 70 years). Despite Similar rates of target vessel revascular- 
ization, long term follow-up averaging 2.6 years demonstrated 7.6% overall mortality with 
3.2% in patients 70 years and 17.7% in patients 70 years. Quality of life analysis also 
demonstrated more frequent Class Ill or IV symptoms in.46% of patients 70 years com- 
pared to 31% of patients 70 years. Conclusion: Although primary angloplasty for acute 
myacardial infarction results in excellent short and long-term mortality, the results in eld- 
erly patients are alarming. The substantially higher mortality in the elderly warrants 
reevaluation of current therapies. 
MODERATED POSTER SESSION 
1001 Advances in the Interventional 
Management of Acute Myocardial 
infarction 
Sunday, March 18, 2001, Noon-2:00 p.m. 
Orange County Convention Center, Hall A4 
Noon 
1001-201 Impact of Contrast Agent Type (Nonionic vs. Ionic) Used for 
Coronary Angiography and PCI on Angiographic, 
Electrocardiographic, and Clinical Outcomes Following 
Thrombolytic Administration in Acute Ml 
Sabina A. Murphy, Ajay J. Kirtane, Susan J. Marble, Kristin C. Schuhwerk, James de 
Lemos. C. Michael Gibson. University of California San Francisco, San Francisco, CA, 
Brigham and Women’s Hospital, Boston, IviA 
The choice of contrast agents during angiography and PCI is a subject of controversy 
The goal of this study was to examine the relationship between contrast agent type (ionic 
Vs. non-ionic) and angiograplhlc, electrocardiographic and clinical outcomes after throm- 
bolytic administration We hypothesized that ionic dye may be associated with decreased 
tissue perfusion after thrombolytic administration. Methods: Ionic or non-ionic contrast 
was selected in a non-randomized fashion for 90 min. angiography and PCI after throm- 
bolytic administration in TIMI 14 (tPA or rPA vs low dose lytic -P abciximab). Results: 
Non-ionic contrast was used more frequently than ionic contrast (69%, n&51 vs 3i%, 
“=296). There was no relatlonship between contrast agent type and overall patency, rate 
of TIMI grade 3 flow, or corrected TIMI frame counts (CTFCs) in open culprit arteries at 
90 min or post-PCI. Patlents receiving ionic contrast had greater rates of Q-wave Ml, less 
frequent complete ST segment resolution (>70%). longer chest pain duration, and 
slightly but significantly lower ejectlon fractions at 90 minutes. Conclusion: No signifi- 
cant relationship was Identified between contrast type & epicardial flow at 90 min. or 
post-PC1 in acute MI. However, ionic dye use was associated with poorer ST segment 
resolution, greater rate of Q-wave MI, longer chest pain duration, and slightly lower ejec- 
tlon fractions. perhaps as a result of increased microvascular dysfunction or the trend 
toward increased thrombus burden. !t should be confirmed that dve tvoe is balanced 
across arms of trials &further studies of dye type impact on outcomes are warranted. 
Ionic Dye Non-ionic Dye p-value 
TIMI 3 at 90min (%) 
CTFC at 90min 
TIMI 3 post-PC1 (%) 
CTFC post-PC1 
EF at 90 ml” (%) 
ECG Res >70% (%) 
Q-wave Ml (%) 
Chest pain duration (h(s) 
Thrombus (%) 
63.3% 
34.3e21.6, n=217 
85.7% 
27.7i20.1 ,n=91 
56.2+16.5,n=122 
41.5% 
77 0% 
2.8r5.1, n=255 
32.2% 
62.4% 
36.6?24.4,“=485 
89.4% 
26.5&3.1,n=198 
59.8*14.4,n=322 
50.8% 
55.3% 
1.723.6, n=550 
27.3% 
NS 
NS 
NS 
NS 
0.02 
0.04 
<O.OOi 
0.0003 
0.14 
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1001-202 Is Primary Stenting Better Than Primary Angioplasty in 
Acute Myocardial Infarction? 
Michael M. Zhu, Mahmood Alam, Hal Chadow, Alan Feit, Luther T. Clark. SUNY Health 
Scb~ce Center, Brooklyn. NY 
Background: Several randomized trials have compared primary stentlng with primary 
balloon angioplasty (PTCA) for acute myocardial infarction (Ml). Although stenting has 
been shown to be better in reducing the need for target vessel revascuiarization (NR), 
uncertainty exists in regard to the relative merits of stenting in post-infarction mortality 
and the risk of (e-MI. Methods: We performed a m&-analysis of all the randomized tri- 
als published up to August 2000 which compared these two revascularization strategies 
in acute Ml. Results: Six randomized trials (FRESCO, GRAMI, ESCOBAR, PASTA, 
StewPAMI, STENTIM-2) were identified through searching the Medline database. They 
studied a total of 1,728 patients (pts), with 859 pts randomized to stent implantation and 
869 pts to PTCA. Of the 6 trial?, FRESCO and GRAMI included pts with cardiogenic 
shock at admission (22 pts). The death due to refractory cardiogenic shock was not 
included in the m&-analysis. The summary data are shown below. Conclusions: 
Based on the m&-analysis of these 6 trials, primary stenting is found to be superior to 
primary PTCA mainly‘in reducing the need for TVR due to re-&hernia. There was also a 
iendency for lower incidence of n-MI in the stent group during the l-year follow-up 
period. A nonsigmficantly higher mortality was observed in the stent group. However, this 
finding was based on small number of end points occurred and the mortality difference 
between these two treatment strategies needs to be better defined in future trials. 
Pooled odds ratios (95% confidence interval) for stenting YBWUS PTCA 
Death Re-MI TVR MACE 
1 month 1.42 (0.76-2.66) 0.46 (0.22-0.98) 0.33 (II 19-o 5qt 0.45 (0.30-0.67)+ 
0 6 months 1 31 (0.X-2.34) 0 66 (0.35-l 23) 0 38 (0 28-O 52)t 0.46 (0.35-0.60)+ 
0 12 months 1 46 (0.872 43) 0.67 (0.38-I .19) 0 41 (0 32-c 5qt 0 52 (0 40-o..%)+ 
‘p = 0.05; tp< 0.0001; MACE = ma]or adverse cardiac event (death/n+MlilVR). ’ 
12:48 p.m. 
1001-205 Acute Myocardial Infarction in Patients With Prior Bypass 
Graft Treated With Primary or Rescue PTCA in the Era of 
Stenting 
Christophe Loubeyre, Thlerry LefBvre, Yves Louvard, Pierre Dumas, Jean-Fran@ 
Pi&haud, Marie-Claude Morice. ICPS, Quince France 
Background: Limited data are available on the outcome of primary angioplasty in 
patients with prior coronary artery bypass grafts. The role of stents in this setting has not 
been reported so far. 
Methods: Since 1995, in our institution, primary angioplasty has bee” the only reperfu- 
sion therapy for acute myocardial infarction (AMI) and patients are directly admitted to the 
cath-lab. Until Jan 2000, of 1030 consecutive pts admitted within 12 hours of AMI, 35 pts 
had prior bypass (3.4%). Stents were implanted directly when possible, and use of GP 
Ilb/llla inhibitors, Urokinase, Hydrolyser was at the operator’s dscretion. Except for radial 
access (4 pts), a closer device (Techstar) was used for hemostasis. 
Results: Mean age was 64 *ll years. Prior myocardlal infarction was reported in 15 
(43%) pts. Cardiogenic shock was present in 8 (22%) pts. Four (11%) pts received throm- 
bolysis before admission. Mean time from symptom onset to admission was 229 i 162 
min. The infarct vessel was a native artery in 21 pts and a saphenous vein graft (SVG) in 
14 pts. Stents were implanted in 28 pts (78%). Door to stent time was 46+40 min. Abcix- 
imab was used in 7 pts (07 for SVG), IC Urokinase in 2 pts (SVG), Hydrolyser in one 
IABP was inserted in 8 pts. Angiographic success was achieved in 94.3% of pts (100% i” 
SVG), with TIMI 3 grade flow in 85.7% (78.6% for SVG) No major bleeding occurred and 
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no repeat PTCA or emergency CABG was reported. Reinfarctlon occurred in one pt. In- 
hospital mortality was 25% (28.6% for SVG). In non shock pts mortality rate was 11 .l%. 
Median stay duration was 7f5 days 
Conclusion: 1. Although rare, pts with prior bypass represents a very high risk primary 
PTCA population. 2. In the era of stenting, procedural success can be high, even when 
infarcts vessel are SIG. 3. Efforts must be carried out to increase TIM1 3 grade flow, 
especially in cases of SVG occlusion. 
l:oo p.m. 
1001-206 Primary Angioplasty in Patients With Acute Myocardial 
Infarction and Multi Vessel Disease. One-Year Outcome 
Afler Single Vessel Versus Multi Vessel Angioplasty 
H’elmut Schuhlen, Adnan Kastrati, Josef Dirschinger, Albert Schomig. 1. Medizimsche 
Klinik rechts der Isar, Munich, Germany, Deutsches Herzzentrum, Munich, Germany 
Background: Standard strategy for primary angioplasty in acute myocardial infarction is 
PTCA of the infarct-related artery, even in patients with multi-vessel disease. However, 
ischemia in multi-vessel disease may be induced by multiple arteries, especially in 
patients with myocardial infarction complicated by cardiogenic shock. A strategy of a 
more complete revascularization has not been tested in this setting. Methods: We per- 
formed a retrospective analysis of the one-year follow-up of 439 patients with multi-ves- 
sel disease and acute myocardial infarction; 73 of these patients were in cardiogenic 
shock before PTCA. PTCA of only the infarct-related. artery was performed in 364 
patients (single-vessel), multi-vessel PTCA was done in 75 patients. Results: Angio- 
graphic success was achieved in 95.9% in single-vessel, and 97.3% in multi-vessel 
PTCA. The event rates during follow-up are illustrated in the table below. There were no 
significant differences between the two strategies, neither in patients with or without car- 
diogenic shock. However, in both groups there is a trend for a higher mortality with multi- 
vessel PTCA in the first 30 days which is reversed after one year. 
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lntracoronary (IC) ECG is a more sensitive marker of local ischemia as compared to sur- 
face ECG. Methods: We recorded IC ECG and 12.lead surface ECG in 42 pts with first 
AMI undergoing primary stenting ~12 hours from symptoms onset, and correlated the 
ECG findings with the degree of late recovery of the infarcted area. All pts had TIMI flow 
grade O-1 of the myocardial infarction (MI) vessel, successful stenting (TIMI 3, residual 
stenosis <20%), and TIMI 3 flow at &month angiography IC ECG was recorded proximal 
to the vessel occlusion, distal (baseline ST elevation), and 30’ after a stable TIMI 3 flow 
restoration; surface ECG was recorded before repelfusion and 3 hours later. ST segment 
elevation was measured 20 msec after the J point and STER was defined as >50% 
decrease of ST +vation from baseline. All pts (59+/-l 1 yrs; 71% anterior AMI; ischemic 
time=l94+/-72 min) underwent echocardiography soon before procedure and 6 months 
later. Infarct zone Wall Motion Score Index (WMSI) was derived. Results: IC ST eleva- 
tion was absent proximal to vessel occlusion in all and > 4 mm distal in 37142 pts. After 
stentlng, IC STER was present in 33 pts (79% group A; from 9,3 +/- 8,8 mm to 1,5 +/- 2,5 
mm) and absent in 9 (group B; from 9,l +I- 4,8 mm to 6,7 +/- 1,9 mm). On surface ECG, 
STER was present in 29/33 (87%) group A and in 1 (11%) group 6. Mean ischemic time 
was 201 +/- 103 vs 271 +/- 108 min (p=.O5), peak CK 2706 +/- 2266 vs 4886 +/- 4111 Ui 
I (p=.O8). At 6 months LVEF was 48 +/- 7 vs 37 +/- 9 (p=.OO3), WMSI decreased from 
2,2+/-0,3 to 1,7+/-0,4 in group A, but not in group B (from 2,2+1-0,4 to 2,2+/-0,5; pc.001). 
Conclusions: lntracoronary ST elevation monitoring during primary stenting is a readily 
and inexpensive tool to asse?s myocardial reperfusion after Ml vessel recanalization and 
predicts late WMSI recovery. Thus, it allows prompt identification of pts without tissue 
reperfusion who need additional therapeutical interventions (i.e. GP llbillla inhibitors, 
adenosine, verapamil) 
I:36 pm. 
1001-209 Impact of Operators Skill on Direct PTCA Outcomes in 
Acute Myocardial Infarction. A View of the SOLACI Registry 
Costantino Costantini, Sergio Tarbine, Euardo Sousa, Albert0 Sampaolesi, S. Silva, C. 
Gosttchall, Alfredo Rodriquez, M Martinez Rios, G Bonzon, Espedito Rib&o, F 
Tort&do, Gregg W. Stone. Clinica Cardiologyca C. Costantini, Curitiba, Brazil 
Background: Primary PTCA is one of the most effective reperfusion strategies for the 
treatment of acute myocardial infarction. A wide range of results have been showed in 
randomized trials comparing this technique wth other type of treatment. With the aim of 
analyzing the importance of skilled operators in the outcomes of this method in a medium 
like ours, we analized the results of this retrospective registry with the participation of 68 
Latin American centers members of SOLACI. 
Methods: Since November 1982 and up to June 1997, 6793 procedures ware reported. 
76.3% of patients were male, 43.9% had anterior wall MI, 45.8% had multivessel disease 
and 28.9% was in Killip class Ill, IV, and non-standard. 4.2% of the culprit vessels was 
saphknous vein graft, 7.6% of the procedures was rescue PTCA and only 15.1% used 
stenting. No Ilb/llla inhibitors were used. Three groups were analired: centers with c 100 
patients (pts), 100.200pts and > 200 pts 
Results: 
Patients <lOO 100-200 >200 P value 
Mortality(%) 8.7 9.1 6.7’ 0.009 
Reocclusion (%) 4.5 4.1 2.8’ 0.0001 
Final TIMI 3 (%) 83.0 85.5* 84.6 0.0017 
Global in-hospital reocclusion had an incidence of 5.3%, 3.5% needing complementary 
CABG. Regarding the functional class at discharge, 92.5% of the cases was in class 1 of 
the NYHA classification 
Conclusion: This method of repedusion is being used in numerous centers by ade- 
quately trained personnel, the general results obtained being comparable to those of 
other studies. We must stress the need of a training curve, demonstrated with even better 
results obtained in more experienced centers (mortality 6.7%, reocclusion 2.8%) as 
pointed out in trials as PAMI (mortality 3,0 %, and GUSTO Ilb PTCA arm (mortality 
5.7%). 
Conclusion: Multi-vessel PTCA in patients with acute myocardial infarction and multi- 
vessel disease is feasible and can be achlaved with a similar high angiographic success 
rate. This retrospective analysis did,not reveal a significant difference between the two 
strategies during long-term follow-up. However, an initial trend for a higher mortality 
within the first month after multi-vessel PTCA is reversed after one year. 
1oo1-207 
I:12 pin. 
Adjunctive Thrombectomy Combined With Stenting for AMI: 
The Endicor X-SIZER AMI Registry 
David A. Cox, Thomas Stuckey, Fieggle Low, Louis Cannon, Robert Iwaoka, Alexandra 
Lansky, Gregg Stone. Mid Carolina Cardiology, Charlotte, NC, Lennox Hi// Hospital, New 
York, NY 
Background: Acute Ml is typically caused by plaque rupture followed by thrombotic 
occlusion. Primary PTCA and stenting in AMI may result in distal embolization and 
microvascular obstruction and reduced TIMI flow. The Endicor X-SIZER Catheter System 
is a novel percutaneous thrombectomy device employing a helical cutter with vacuum- 
assisted debris removal. Its utility for treating thrombotic lesions in patients with AMI is 
currently being evaluated in a 100 patient multicenter registry. Methods: 100 patients 
presenting within 24 hours of AMI will be enrolled in this registry, with all patients under- 
going thrombectomy with the Endicor X-SIZER device before stenting. Results: To date, 
24 patients with AMI have been enrolled with data presently available in 11 patients. 
Baseline features include mean age 56.1 years, 87% male, and 13% with diabetes. The 
target vessel was the RCA in 50%, LAD in 25% and SVG in 25%; all vessels were throm- 
botically occluded with pre-procedure TIMI O-l flow. The reference vessel size was by 
protocol 3.0-5.0mm by visual estimate (mean 3.7mm). The culprit lesion was completely 
crossed with the X-SIZER device in 10/l 1 patients (91%), and partially crossed in 1 
patient. Following X-SIZER passage TIMI 2-3 flaw was restored in all patients: distal 
embolization was seen in only 1 patient and no dissections or perforations were noted. 
All lesions were stented resulting in TIMI- flow in all but one patient in whom TIM1 2 flow 
was present. No patients had thrombus present at the target lesion. All patients were dis- 
charged with 0% MACE (death, stroke, reinfarction, or target vessel revascularizatlon). 
Conclusion: This preliminary experience demonstrates that X-SIZER “se as an adjunct 
to percutaneous intervention is save and effectively removes thrombus. Data from the 
complete 100 patient cohort, including quantitative and qualitative core lab anglographic 
results (TIMI flows, myocardial blush, thrombus burden, etc.) will be available in March 
2001. 
1:24 p.m. 
1001-208 Lack of lntracoronary ST Segment Elevation Resolution 
Predicts Absence of Infarct Zone Recovery After Primary 
Stenting in Acute Myocardial Infarction 
Vruyr Balian, Sergio Rep&o, Marcella Luvini, France Galdangelo, Ettore Petrucci, Mauro 
Boscarini, Battistina Castiglioni, Sergio Ghiringhelll, Michele Galli, Raffaella Vaninetti. 
Ospedale Circolo Fondazione Macchi, VARESE, #a/y 
Background: During acute myocardial infarction (AMI), >50% ST-segment elevation res- 
olution (STER) after epicardial recanalization both with thrombolysis or balloon angio- 
plasty is a reliable EGG marker of myocardial reperfusion and predicts LV recovery. 
1:48 p.m. 
1001-210 Predictors of Door-to-Balloon Delay in Primary Angioplasty 
Brad G. Angeja, Richard Chin, Priscilla Hsue, Paul D. Frederick, Nathan R. Every, Allen 
M. Ross, Hal V. Barron, C. Michael Gibson, National Registry of Myocardial Infarction 2. 
3. University of California, San Francisco, Cardiovascular Research Center. George 
Washington University Washington, DC 
Background: Delay in reperfusion increases mortality in acute myocardial Infarction. 
Predictors of delay have been described for thrombolysis but not for primary angioplasty 
(pPTCA). METHODS: Using data from 40,017 patients in the National Registry of Myo- 
cardial Infarction 2-3, we calculated median door-to-balloon times according to measured 
characteristics and determined independent predictors of delay using logistic regression. 
Comparisons were made to patients without the characteristic. RESULTS: Median 
delays (hour) were longer in older (2.0 vs. 1.8), female (2.0 vs. 1.8), and non-white 
patients (1.9 vs. 1.8), in those with complicated medical histories, and with pre-hospital 
delay (2.0 vs. 1.8) or lack of chest pain on admission (2.3 vs. 1.7). Delays were also 
longer with transfer from another hospital (3.3 vs. 1.8), with non-daytime presentation 
(2.0 vs. 1.7), and in low voiume pPTCA hospitals (< 49 par year, 1.9 vs. 1.8). Over six 
years, there was a disproportionate improvement among patients over 65 years (by 15 
minutes), in those without chest pain (by 23 minutes), and among transferred patients 
(by 47 minutes). CONCLUSIONS: Both patient and hospital-related factors delay 
JACC February 2001 
pPTCA, and ?ome factors have been addressed to minimize delay, More improvement 
may be possrble, and these results may also lead to a better choice of thrombolysis, 
pPTCA, or combined strategies in selected patients. 
Significant Predictors N m Comparison Odds Ratio 95% Cl 
bL(%) Group (%) (delay 22 hr) 
Transferred patients 4692 87 38 10.34 9.39. 
11.37 
No chest pain 2261 61 43 2.05 1 85-2.28 
Non-daytime (4pm-Sam) 19103 51 38 1.82 1 73-1.90 
Lyric contrarndicated 5582 60 41 I .4a 1.37-l 59 
Pre-hospital delay > 2 hr 15699 49 40 1.45 1.39-l .53 
Hospital procedures c 49 18371 47 41 1.45 1.38-l .53 
pPTCAfyr 
Female patients 11784 50 42 1.27 1.21-l .34 
Non-white patients 5810 48 43 1.18 1.11-1.26 
Age 2 65 16631 49 41 1.25 ‘1.18-1.31 
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WBC>7000ml. Conclusions:l. Silent ischemia is common in postinfarction patients with 
increased leucocytosis. 2 Postinfarction patients with increased leucocytosis are likely to 
have more ?evere CAD even if they are asymptomatic. 
1015-l 01 Plasma Level of Homocysteine Is Inversely Associated With 
the Development of Collateral Circulation 
Yoshitaka Nagai, Hiromi Tasaki, Ryouji Kouzuma. Masato Tsutsui, Masahiro Okazaki, 
Yasuhtde Nakashima. Univ. Occup. Environ. Health, Kitakyushu, Japan 
[Background] Hyperhomocysteinemia has been established as a new coronary risk factor 
and is assumed to damage the endothelium, leading to coronary atherosclerosis. How- 
ever, it is unclear whether hyperhomonocysteinemia can independently reduce the devel- 
opment of collaterals in coronary artery disease (CAD) patients. To rnvestigate the 
plasma level of homocysteine in relation to the development of collaterals in patients with 
CAD. [Methods] A series of 105 male patients with angiographically-estimated coronary 
stenosis were enrolled. The effect of homocysterne levels were analyzed coronary steno- 
sis and collateral circulatron. [Results] The plasma level of homocysteine was signifi- 
cantly increased (p = 0.013 by Kruskal-Wallis analysis) in order of control group (n = 23. 
9 0 (SD;2.4) micromol/L), single-vessel disease group (n = 49. 11.6 (3.7)micromoliL) and 
multi-vessel group (n = 33, 12.7 (6.8)micromol/L). Unlvariate and multivariate analyses in 
single-vessel group revealed that hyperhomocysteinemia was the negative factor of col- 
lateral development (p = 0.0015 and 0.0011, odds ratio 0.69, 95% confidence interval 
0.52-0.90). Moreover, the level of homocysteine in poorly-developed collateral group was 
significantly higher than that in well-developed collateral group in patients with one-vessel 
disease showrng total occlusion (p = 0.034). [Conclusions] This study emphasized that 
the plasma level of homocysteine is independently- and inversely-associated with the 
development of collateral circulation in CAD patients. 
1015-102 The 5’ Flanking Polymorphism in the Heme Oxygenase-1 
Gene Is Associated With Coronary Artery Disease 
Susceptibility in Japanese Patients With 
Hypercholesterolemia 
Hideaki Kaneda, Junrchi Taguchi, Tadanori Aizawa, Minoru Ohno. Unwersity of Tokyo, 
Tokyo, Japan, Cardiovascular Insfitute, Tokyo, Japan 
Background: Hypercholesteralemia is associated with enhanced oxidative stress due to 
increased lipid peroxidation leading to atherogenesis. Heme oxygenase (HO) is consid- 
ered en important defense mechanism to cope with oxidative stress and as en anti- 
atherogenic mechanism. Previous work has shown that shorter (GT)n repeats in the 
human HO-1 gene promoter have higher transcription activity in response to oxidative 
stress than longer repeats. Method and Results: We screened allelic frequencres of the 
(GT)n repeats in the HO-1 gene promoter in 189 patients with known hypercholester- 
olemia who underwent coronary angiography. Coronary artery disease (CAD) was 
defined es 75% or more stenosis in one or more of the three coronary arteries. As the 
distribution of numbers of (GT)n repeats was bimodal, the alleles were divided into two 
subclasses: shorter (~27 repeats) were class S and longer were class L. Using the chi- 
square test, a significant association was observed between the genotypes and CAD sta- 
tus (p=O.O49). Multivariate logrstic regression models revealed that the genotypes were 
srgnificantly related to CAD status. 
Multivariate Regression Models for CAD 
Risk factor Odds ratio (95% Cl) P 
Genotype S/S * 0.30 (0.10-0.86) 0.026 
Genotype S/L * 0.44 (0.18-1.03) 0.061 
Male 2.8 (1.1-6.8) 0.020 
Age 1.05** (1.01-1 09) 0.015 
Diabetes 2.0 (0.99-4 1) 0.054 
Hypertensron 0.90 (0.44-1.8) 0.76 
Smoker 0.75 (0.33-1.7) 0.48 
HDL-cholesterol 0.97’; (0.94-0.99) 0.0048 
*: genotype UL was regarded as a reference point. **: Odds ratio per one-unit increase. 
Conclusion: The s-flanking polymorphism in the HO-l gene is assocrated with CAD 
susceptibrlity in Japanese hypercholesterolemic patients. HO-1 may play en important 
anti-atherogenetic role in hypercholesterolemic patients. 
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1015-75 Increased White Blood Cell Count in Patients With Rapid 
Angiographic Coronary Artery Disease Progression 
Emmanouil G. Zouridakis, Almudena Castro, Raul Schwartzman, Ian D. Cox, Xavier 
Garcia-Mall, Juan Carlos Kaeki. Cardiological Sciences, Sf George’s HospitalMedicai 
School, London, United Kingdom 
Background. It has been reported that total and differential white blood ceil count 
(WBCC) are prognostic markers in patients (pts) with coronary artery disease (CAD). 
Disruption of atheromatous plaques with ongoing inflammation has been suggested to 
play a significant role in rapid CAD progression. WBCC represents an index of systemic 
inflammatory status. In this study we assessed whether total and/or differential WBCC 
ten predict rapid CAD progression. 
Methods. We studied 121 pts (82 men, age: 591-9 ys) with chronic stable angina who 
were on a waiting list for coronary angioplasty and underwent angiography on 2 occa- 
sions. The 1st (diagnostic) angiogram was carried out at study entry and the 2nd 5.2~3.0 
months later, immediately prior to angioplasty. Quantitative angiographic analysis was 
used to assess differences in stenosis diameter between the angiograms. Accepted crite- 
ria were used to define CAD progression. WBCC was measured in blood samples taken 
before the first angiogram. 
Reeults. We assessed 287 lesions with >30% diameter reduction [2.4/patient). CAD pro- 
gression occurred in 32 (26.4%) pts: 15 (48%) had a >lO% diameter reduction of at least 
one preexisting stenosis x50%, 12 (37%) had a >30% diameter reduction of a pre- 
existing stenosis ~50%. 3 (9%) pts developed a new stenosis and 2 (6%) had progres- 
sion of a lesion to total occlusion. Baseline clinical and angiographic data were similar in 
pts with and without progression. Total WBCC and neutrophil count were significantly 
higher in pts with CAD progression than those wrthout [(in: xlOgcells/L) 7.8k1.4 vs 
6.9fl.5, p=O.OOl and 4.7*1 .ivs 4.0i1.4, p=O.O2 respectively]. Quartile WBCC analysis 
showed that higher WBCC was associated with en increase in the incidence of rapid 
CAD progression (p for trends = 0.005). Pts with WBCC count 28.3 xl OS/L (the median of 
WBCC distribution) had a 3-fold higher risk for rapid CAD progression (Odds ratio:2.9, 
95%CI: 1.2-7.2, p= 0.012). There was no significant difference in lymphocyte or mono- 
cyte count between progressors and non-progressors. 
Conclusions. Increased WBCC is significantly associated with higher risk for rapid CAD 
progression. The use of this simple test may help to risk stratify pts with CAD 
1015-76 Relationship Between White Blood Cell Count and the 
Occurrence of Silent lschemia After Myocardial Infarction 
Malgorzata Kurpesa, Ewa Twos, Maria Krzemihska-Pakula, Zbigniew M. Bednarkiewicz. 
Medical Academy, Lodz, Poland 
Background: Whrte blood cell count (WBC)is a sensitive marker of inflammation which 
may accelerate the progression of coronary artery drsease (CAD). Silent ischemia (SI) is 
known to be at least as prognostically unvafourable as symptomatic one. The aim of the 
study was to assess the relation between WBC and the occurrence of SI in asymptomatic 
patients after Ml. MethodsThe study group consisted of 114 pts who had Q-wave Ml 3. 
6 months beforeAll were clinically asymptomatic. Blood cell count was assessed two 
times in a week interval and the average WBC was calculated for each patient. The pts 
were divided into two groups: Group l-48 pts with WBCc7000m3 and Group II-66 pts with 
WBC2700Oml. Groups were comparable with regard to age, gender, risk factors, localiza- 
tion of MI, left ventricular function, medical treatment.24-hour Halter monitoring was per- 
formed in all patients. Results:115 silent transient ischemic episodes (TIE)were 
recorded. 102 TlE(a9%)were found in Group II, 13TIE(l l%)in Groupl (pcO,Oi) All pts in 
Group /I had SI. In Group I SI was recorded in only 9% of pts(pcO,OOl). The presence of 
Si in totally asymptomatic postinfarction pts appeared to be strongly correlated with 
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1016 Ultrastructural Observations and 
Myocardial tissue was obtained from the margin zones of the ischemlc (non-infarcted) 
areas for using the TUNEL-method (in situ visualization of apoptotic myocytes by direct 
Regulation of Apotosis anti-digoxigenin detection and expressed as the number of apoptotic cells/total number of cardiomyocytes x 100 = apoptosis index (ADX)). Results. Risk areas were similar 
among the-grp(n=6 per grp). Infarct size/risk area was 9&% in grp 1, 37i-13% in grp 2 
(p<O.O5), 27i-12% in grp 3 (~~0.05 vs. grp l), 42212% in grp 4 (p&O5 vs. grp 1 + 3). 
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31*13% in grp 5(p<O.O05 vs. grp 1 + 3), and 48~13% in grp 6. ApX was 5il% in grp 1, in 
grp 2 12*2%, in grp 3 7&l%, in grp 4 13+2%, and significantly smaller compared to con- 
trols (in grp 5 17+3%, ~~0.05, in grp 6 Z&i%, p<O.OOl). Conclusion. Carvediiol as well 
101677 Hypoxia Regulates Connexin 43 Content in Synchronously 
Contracting Cardiac Myocytes 
Mark S. Turner, Guy A. Haywood, W H. Evans, Keith A. Webster, Nanette H. Bishopric. 
University of Miami, Miami, FL, Waies Heart Research lnstifute, Cardiff, United Kingdom 
Background: lschemia causes uncoupling of cardiac myocytes and has been suggested 
to reduce the Connexin 43 (Cx43)content and the number of gap junctions. Ischemia, 
however, is a combination of hypoxia, reduction in glucose, acidosis and buildup of toxic 
metabolites. We used an established hypoxia model in beating cultured neonatal rat car- 
diac myocytes to examine the effect of hypoxia on Cx43 levels. Functional gap junctions 
are responsible for synchronization of beating in this model. Methods: Primary cultures 
of neonatal rat cardiac myocytes were prepared from 1-3 day old Sprague-Dawley rats. 
Cells were cultured with 5% fetal calf serum for 4 days and then for 2 days without serum 
prior to experimentation. All cultures were beating synchronously at 200-300 beats per 
minute. Cells were exposed to hypoxia (~0.5% oxygen) within a sealed chamber for 8-20 
hours. The medium was supplemented with additional glucose and was changed after 6 
hours of hypoxia. Hypoxic samples were harvested within the chamber without reoxygen- 
ation, and cell proteins were analysed by Western blot using a rabbit polyclonal Cx43 
antibody. Blots were subjected to densitometric analysis and results compared “sing a 
paired sample Student’s t test. Results: Cultures continued synchronous beating 
throughout the experiment. The total 6x43 level increased by 2.06~0.28 (SEM) -fold at 8 
hours (p=O.O03, n=9) and 1.97*0.21 fold at 20 hours (p<O.OOl, n=16). Upon reoxygen- 
ation Cx43 levels declined slowly, by 26.4% after 4 hours (n=5, p=O.O38). Conclusions: 
Hypoxia increases the Cx43 content of cardiac myocytes in culture within 8h; this 
increase is sustained for a minimum of 20h and is at least partially reversed by reoxygen- 
ation. Functional coupling is maintained during hypoxia in the absence of glucose deprl- 
vation. Thus, hypoxia alone does not mediate a reduction in gap junction protein content 
or coupling. 
as its metabolite BM 92.0228 reduced Infarct size in a 30 min coronary occlusion model, 
whereas prolonged ischemia eliminates infarct-limiting effects. We hypothesize that the 
cardioprotective effects of Carvedilol are independent on its B-blocking properties, but 
might be mediated by potential antioxidant and direct anti-apoptotic effects. 
1016-80 Induction of Pro-Apoptotic Bcl-Xs Protein Expression 
During Myocardial Infarction but Not After Stunning 
Bysani Chandrasekar, Gregory L. Freeman. University of Texas Health Science Center, 
San Antonio, TX 
Background: Inhibition of NF-kappaB activation Induces apoptosis in a highly cell- and 
stimulus-specific manner. The goals of this study were (1) to determine whether stunning 
induces apoptosis, (2) whether inhibition of NF-kB activation during stunning promotes 
apoptosis, and (3) to analyze whether various genes involved in the regulation of apopto- 
SIS are differentially expressed during stunning and infarction. Methods: 32 male WKY 
rats were used for the study (4 groups of 8 each). The stunning group underwent 15 min 
of LAD coronary artery ligation followed by 3 h reperfusion (R). The second group 
received N-acetyl-L-cysteine (NAC, 600 mgikg, i.p.) 1 h prior to occlusion followed by 3 h 
R. The infarction group underwent 45 min LAD coronary art&y occlusion followed by 3 h 
Ft. The sham-operated fourth group served as controls. At the end of 3 h R, tissue from 
the ischemic zones was separated and frozen for analyses. Expression of pro- (Fas, Fas- 
L, bcl-Xs, bax) and anti-apoptotic (bcl-XL , bcl-2) genes was analyzed by RNase protec- 
tion assay, Bcl-XL and Bcl-Xs protein levels by Western blotting, and the extent of apop- 
tosis by TUNEL assay. Results: No TUNEL positive cells were detected in either saline- 
or NAC-treated stunned myocardlum. However, cells undergoing apoptosis were readily 
detected by both TUNEL and by nuclear morphology in infarcted myocardium. Sham- 
operated animals expressed Fas, bax, b&XL and bcl-2 mRNA, but not bcl-X .s or Fas-L. 
Irrespective of duraton of ischemia, all SIX genes were expressed in both stunned and 
infarcted myocardium. However, significantly higher pro-apoptotic (Vs. stunned; bcl-Xs 
101678 lschemic Preconditioning Prevents Mitochondrial Bcl-2 
11.53.fold, p<O.OOi], Fas-L [1.31 -fold, p<O.d5], bax [1.26-f&l, ~~0.051) and lower anti- 
Depletion and Limits Infarct Size in the lschemic Rabbit 
apoptotic (bcl-2 11.15.fold, p<O.O5]) gene expression was detected in infarcted rnyocar- 
dium. Most importantly, the pro-apoptotic Bcl-Xs protein was only detected in infarcted 
Heart 
Tai-Hwang M. Fan, Zhe Jiao, Olena M. Gorodnya, Xi-Ming Yang. Unwersity of South 
Alabama, Mobile, AL 
myocardium. Conclusions:, InhibItIon of NF-k B activation does not induce apoptosis 
during stunning. The balance between pro- and anti-apoptotic genes is critical in inducing 
apoptosis, and longer durations of ischemia drive this balance towards pro-apoptotic 
gene expression resulting in cell death. 
Background: We have previously shown that ischemic preconditioninq (PC) could sup- 
press cardiomyocyte apoptosis induced by ischemiai rep&ion. The &&ant study was 1016-81 
undertaken to address the question whether Bcl-2, a mitochondnal protein well known for 
Calcineurin Inhibition With Cyclosporin A Preserves Heart 
- 
its anti-apoptosis property, plays a role in the cardioprotection of PC. Methods: The con- 
Function by Decreasing Apoptosis 
trol group consisted of 6 isolated, perfused rabbit hearts subjected to 30 min of global &even Pool, Thomas N. Masters, Alexander Fokin, Miroslav Barancik, Tibor 
&hernia followed by 2 h of reperfusion. The PC hearts (n=6) received 5 min of global Ziegelhoeffer, Francis Robicsek, Jutta Schaper. Max-Planck-lnstitufe, Bad Nauheim, 
ischemia followed by 10 min of reperfusion prior to the 30.min ischemia/2-h reperfusion. Germany, Heineman Medical Research Center, Charlotte, NC 
Infarct size was determined by computer morphometry of TTC stained sections. Mito- 
chondrial Bcl-2 levels were determined by Western blot analysis in a separate series of 
hearts. in which serial biopsies were taken at baseline and at 5, 10, 20, 30 min of 
ischemia. Results: In this global lschemiaireperiusion model, PC effectively reduced the 
infarct size by 50% (pc.01 vs control). Mitochondrial Bcl-2 levels were well maintained in 
the control hearts during the initial 20 min of ischemia, but fell by 40% at 30 min of 
lschemia (pc.02 vs baseline). In contrast, PC hearts exhibited a 38-41% increase in Bcl- 
2,levels (pc.05 vs baseline) during the entire 30 min of ischemia. Interestmgly, 20 min of 
global ischemia followed by 2 h of reperfusion resulted in significant contractile dysfunc- 
tion but produced little evidence of infarction (infarct size 3.3+2.3%, n=6). Conclusion: In 
rabbit hearts, 30 min of ischemia appears to mark the onset of mitochondrial Bcl-2 deple- 
tion and myocardial cell death. PC prevents Bcl-2 depletion and significantly limits myo- 
cardial cell death induced by 30 min of ischemia. Maintaining mitochondrial Bcl-2 above 
a critical level may be an important cardioprotective mechanism of PC. 
Background: Recently, we showed that the addition of cyclosporine A (&A) to the Uni- 
versity of Wisconsin (UW) solution increased functional recovery from 55 to 100% after 
18 hours of hypothermic global ischemia in the working heterotopic heart transplant 
model. Since CsA is known to maintain mitochondrial permeability pores thereby inhibit- 
ing apoptosis and to inhibit calcineurin, we determined the rate of apoptosis, the total 
amount of calcineurin and its degree of activation in this ischemia model. 
Methods: Twelve dog hearts were preserved for 18 hours (2.4°C) under low perfusion 
with UW solution (1 mllmin). Six hearts were treated with cyclosporine A (1O-5 molll; 
GSA+) and six served as control @A-). Four biopsies of each heart were taken: before 
transplantation (A), at the end of preservation (B), after 2 (C), and 6 hours (D) of reper- 
fusion. 
Western blot analysis for total calcineunn was performed and the activity of calcineurin 
was determined “sing radioactively labeled myelin basic proteins and SDS page analysis 
(both % of control). Lamin Bl staining and TUNEL Method were carried out to detect 
1016-79 Antiapoptotic Effects of Carvedilol Are Not Mediated by Its 
apoptosis by immunohistochemistry and confocal microscopy (both % of total myocytes). 
Beta-Adrenergic Receptor Blocking Properties 
Electron nxcroscopy was used to determine the degree of ischemic injury. 
Results: Evidence for necrosis was absent, myocytes showed moderate ischemic injury 
Ernst R. Schwarz, Philipp H. Kersting, Dennis Meven, Thorsten Reffelmann, Erik C. 
Skobel, Peter Hanrath. Med. Clinic L RWTH University Hospital, Aachen, Germany, Dept 
of Cardiology Dr. .S Fakeeh Hospital (Harvard Medical International), Jeddah, Saudi 
Arabia 
Background. Carvedilol is a B-receptor antagonist with additional a-blocking effects, 
which is widely used in the treatment of congestive heart failure. The hydroxylated 
metabolite BM 92.0228 has reduced a-receptor activites and 170.fold weaker beta- 
blocker properties. We studied the effects of Carvedilol and BM 92.0228 on myocardial 
infarct size and apoptosis in a rat model of myocardial ischemla and reperfusion. Meth- 
ods. Anesthesized adult Sprague-Dawley rats were subjected to total occlusion of the left 
coronary artery with subsequent 60 min of reperfusion. Rats were randomized in 6 
groups (grp). Grp 1 and 2 received Carvedilol (Imgikg IV) 5 min prior to 30 min or.60 min 
of coronary occlusion, respectively, grp 3 and 4 received BM 92.0228 (Imglkg IV) prior to 
30 or 60 min of coronary occlusion, respectively, and grp 5 and 6 received vehicle prior to 
30 or 60 min of coronary occlusion. respectively. After excision of the hearts, ischemic 
that rapidly recovered after reperfusion. ATP was moderately decreased in CsA- but well 
preserved in CsA+ animals. Further results see table. 
Conclusions: CsA inhibits apoptosis probably by 2 different mechanisms: It maintains 
the integrity of the mitochondrial permeability pore thereby preventing loss of bcl2 and 
release of cytochrome C, and it prevents stimulation of the proapoptotic factor BAD by 
inhibition of calcineurin. These effects may be responsible for improved recovery by inhi- 
bition of apoptosis in hearts after long ischemic periods which might indicate potential 
usefulness of .CsA in preserving hearts for transplantation. 
A B C D 
Apoptotic cells % CsA-/CsA+ o/o 010 2.711.9 6.012.8 
Lamin Bi % CsA-/CsA+ 99.9/99.5 99.0199.2 98.1198.7 92.3/9&g 
Calcineurin WB % Csa-/&A+ lOOi 00 94198 94191 63173 
Calcineurin-function CsA-ICsA+ 100/l 00 9310 -/- 68/O 
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101682 Cardiac Myofiber Disarray Associated With Postinfarct 
Remodeling in Viable Border Zones Is Prevented by 
Treatment With Angiotensin Converting Enzyme (ACE) 
Inhibitors 
Samuel Wickline, Heather Lewis. Jeffrey Omens, Andrew D. McCulfoch, John Allen, 
Michael Scott, Christopher Hall. Washmngton Universi~ St LOUIS, UCSD, San Diego 
Background: Global cardiac remodeling after infarction implies reorganization of tissue 
microstructural components that are integrally linked. We sought to elucidate the effects 
of ACE Inhibitors on the specific organization of the interstitial collagen matrix and viable 
myocytes in infarct. normal, and border zone tissues. Methods: Myocardial infarction 
was induced by lefi coronary artery occlusion in 12 Sprague-Dawley rats. Ramipril (1 mgi 
kg/d) was administered in drinking water 3 days after infarction for 12 weeks in 7 rats, and 
placebo was administered to 5 rats. Picrosirius stained myocardial cross-sections were 
imaged with circularly polarized light and digitized for collagen analysis; trichrome stains 
were imaged with fight nwroscopy and digitized for analysis of viable myocytes in border 
and remote zones. A&mated software developed at UCSD was employed for ob)ective 
quantification of fiber orientation, which was expressed as an Angular standard Deviation 
(AD: in degrees) with respect to the mean collagen or myocyte orientation in an ROI, to 
provide an index of microscopic fiber disarray Five to 10 ROl’s each (20X power) were 
digitized from contiguous midmyocardial locations in remote, border, and infarct zones, 
and the AD’s averaged for each zone over all animals Results: Ramipril decreased rela- 
tlve heart mass by 17% at 12 weeks (p<O.O5). Ramipnl reduced AD for collagen fibers in 
the border zone from 20.5~2.0 to 14.7r 2.4 degrees; and reduced AD for viable border 
zone myocytes from 13.8+1.5 to 11.4?1 1 degrees (pcO.01 by ANOVA). The AD’s in 
treated border zones approximated those for remote normal tissues for both collagen and 
myocytes, indicating that ramiprii prevented the post infarct disarray of both collagen and 
myocytes. Ramipril did not affect AD’s in either remote normai or central infarct zones. 
Discussion: ACE inhibitors limit both collagen and myocyte disarray in viable border 
zones after infarction. These salutary changes in border zone microarchitecture may pro- 
mote more physiological fiber orientations and strains, potentially improving local con- 
tractile function and reducing the stimulus to global ventricular remodeling. 
101683 Distinct Signaling Pathways Account for Endothelial and 
Myocardial Apoptosis During Ischaemia-Reperfusion Injury 
Tlziano M. Scarabelk, Anastasis Stephanou, Carol A. Chen, Terence J. Cooper, Richard 
A. Knight, David S Latchman. University College London lnstitufe of Child Health, 
London, United Kingdom. Universify of Miami, Miami, FL 
The present study was aimed to evaluate the relative contribution of the receptorial and 
mltochondrial signaling pathways in inducing cardiac apoptosis in different cell types dur- 
ing ischaemia (I)-reperfuslan (R) injury. Materials and Methods. isolated Langendorff per- 
fused rat hearts were randomly divided into 5 groups: control group (60’ of perfwon), I 
group (35’ of zero flow I) and 3 I-R groups (35’ of I followed by 5, 60’ and 120’ of R 
respectively). A few animals were treated with specific and irreversible inhibitors of 
caspase 8 (C8) and 9 (C9) Infused at the onset of I or R. TUNEL staining, propidium 
Iodide and lmmunocytochemical labeling with anti-\/on Wlllebrand and -desmin antibod- 
!es were utilized to assess and address apoptosis in specific ceil types. Additional sec- 
tions were stained with antibodies recognizing the cleaved active form of C8 and C9. 
Confocal microscopy (CM) analysts was integrated with electron microscopy (EM) obser- 
vation. Results. Expression of cleaved C8 and CS was increased both in I and I-R hearts 
compared to the control group (0.1%) although cleavage of CS was more pronounced 
during I (7.7%) whilst C8 was preferentially cleaved during R (6.5% after 60’ R). Cleavage 
of C8 and C9 was confirmed by Western Blotting of frozen samples. The specific inhibitor 
of CS given during I dramatically reduced the magnitude of endothelial apoptosis over the 
3 time points of R (e.g. 4 versus 44% after 60’ R) and only mildly diminished the propor- 
tion of TUNEL positive myocytes (e.g. 4.6 versus 6% after 60’ R) On the other hand, inhi- 
bltion of caspase 8 during I consistently prevented myocardlal apoptosis measured over 
R (e.g. 2.2 versus 8.1 after 120’ R). wthout affecting the extent of the process occurring 
in endothelial cells. Qualitatively identical results were obtained when both inhibitors 
were infused during R. lmmunocytochemicai findings were validated by EM. Conclu- 
sions. Our data suggest that distinct signaling pathways are induced in different cell types 
during I-R. Thus, mltochondrial damage is the main trigger of endothelial apaptosis via 
CS activation, whilst cardiac myocytes seem to commit apoptosis following death-necep- 
tar mediated pathway via C8 actlvatlon 
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1017-84 Myocardial Release of P-Selectin Following lschemia During 
Beating Heart Coronary Artery Bypass Surgery 
Tat W. Koh, Simon Davidson, Gerald S. Carr-White, Anthony DeSouza, John R. Pepper 
Royal Brompton Hospital, London, United Kingdom 
Background: Adhesion of leukocytes to the endothelium is mediated by cell adhesion 
molecules, and has been shown to play a role in myocardial injury during ischemia and 
reperfusion in animal models. Whether lschemia in the human heart is associated with 
release of P-selectin is unclear. Beating heart coronary artery surgery requires a period 
of coronary occlusion to allow grafting in a bloodless field and provides a model of pro- 
longed ischemia in the human heart. Methods: We sampled coronary sinus blood drain- 
ing directly from the heart at the time of coronary artery surgery on the beating heart 
using the ‘Octopus’ stabilisation device. We obtained paired arterial blood for calculation 
of arteno-venous difference and net myocardial release of P-selectin. We studied 16 pts 
undergoing left anterior descending artery grafting: pre coronary occlusion, and 1 & 5 
mins after reperfusion. We analysed the samples for soluble P-selectin and troponin I, a 
specific marker of myocardial injury. Coronary artery occlusion time was 17.225.6 mins. 
Results: P-selectin levels increased in the coronary sinus blood at 5 mins after reperfu- 
sion vs pre (44.9&l vs 37.6242 ng/mL, PcO.05). Arterial P-selectin levels did not 
change at 1 and 5 minutes vs pre (42.6x7.9, 37.9k6.0 vs 44.9k6.4 ngiml). Arterio-venous 
difference at 5 minutes showed net myocardial release of P-se&tin vs pre (-11.5k5.9 vs 
5.85k3.8 rig/ml, PcO.001). Troponin I levels in coronary sinus blood were elevated after 5 
minutes reperfusion vs pre (0.12t0.03 vs 0.05*0.01 mgil, P&05). Coronary sinus P- 
selectin correlated closely with troponln I levels at 5 minutes (r-0.64, P<O.O05). Conclu- 
sion: Myocardiai release of P-selectin occurs after ischemia induced by 17 minutes of 
coronary occlusion during beating heart coronary artery surgery. Coronary sinus P- 
selectin levels correlated with the degree of myocardlal injury assessed by troponin I 
Since leukocyte adhesion may play a role rn ischemia-reperfuwn injury, therapeutic 
measures aimed at interfering with the leukocyte-endothelial interaction mediated by cell 
adhesion molecules, may be a rational target for myocardial protection strategies in beat- 
ing heart coronary artery surgery. 
1017-85 Coronary Bypass Surgery in Women: A 25 Year 
Comparative Study of the Impact of the Internal Mammary 
Artery on Short and Long Term Results in Men and Women 
Paul Kurlansky, Ernest A. Traad, David L. Galbut, Melinda Zucker, George Ebra. Miami 
Heart Research Institute, Miami Beach, FL 
Background: Coronary artery bypass grafting (CABG) carries a higher operative mortal- 
ity and less favorable long-term clinical benefit for women than it does for men. Although 
arterial revascularizaticn has been shown to ameliorate the impact of gender on opera- 
tive mortality, its impact on long-term prognosis has not been clearly defined. Methods: 
A retrospective analysis was performed comparing 261 consecutive women patients 
from a single surgical practice receivmg bilateral internal mammary artery (BIMA) and 
supplemental vein grafts between January 1972 and October 1994 with a computer- 
matched cohort of 261 men undergoing BIMA surgery during the same time period. Fol- 
low-up was complete for 97.6% of women and 96.8% of men, and ranged from 1 month 
to 25 years, vvith a mean follow-up of 9.1 years for women and 8.6 years for men. 
Results: There was no significant difference in operative mortality, nor in the incidence of 
any post-operative complications. Univarlate analysis of preoperative and intraoperative 
variables revealed the same three factors significantly associated with hospital mortality 
in men and women: Canadian Classification System (CCS) Class IV angina, history of 
previous CABG, and preoperative insertion of the intra-aortlc balloon pump. The actuarial 
survival at 15 years was 53.7%+4.8% for women and 50.9%&6% for men (p=O.21). At 
follow-up, 97% of women and 96% of men were in CCS Class I. The need for reoperation 
(1.8% vs. 1.9%) and PTCA (4.8% vs. 3.2%) was comparable in both groups. Rate of non- 
fatal MI was 1.8% in women and 0.6% in men. Cox regression analysis of significant 
univariate preoperative, intraoperative and postoperative variables demonstrated that a 
history of congestive heart failure (p<O.OOi) was the most powerful predictor of late mor- 
tality in both women and men. Other significant variables included low cardiac output 
(p&001) in women and surgical urgency (p<O.O04) in men. Conclusions: Matched 
groups of men and women undergoing BIMA grafbng experience comparable periopera- 
tive outcomes and excellent long-term results. The use of the internal mammary artery in 
these patients seems to eliminate the influence of gender on short and long term results. 
1017-86 Pressure-Flow Relationship in Coronary Bypass Grafts 
Early After Myocardial Revascularisation 
Beat H. Walpoth, Dark Springe, Beat Kipfer, Pascal Berdat, Peter Neidhart, Otto M. Hess, 
Thierry Carrel. SWISS Cardiovasculai Cenfei, Bern, Switzerland 
Background: Coronary bypass flow is dependent on the quaktiy of the anastomosis, 
perfusion pressure and distal coronary vascular resistance. The aim of the present study 
was to assess pressure-flow relations in arterial and venous bypass grafts. Methods: 30 
310A ABSTRACTS - Myocardial lschemia and Infarction 
patients (28 M; 2 F; 62 * 8 yrs) underwent elective coronary bypass grafting (3.5+_1.0 
grafts/patient) under mild hypothermic cardiopulmonary bypass (CPB) (77+24 min.). 
After weaning from CPB, coronary bypass flow was measured on one arterial (IMA) and 
one venous (SVG) bypass graft using the transit time technique (CardioMed, MediStim 
AS, Notway). Mean arterial pressure (MAP) was modified gradually by the infusion of 
norepinephrine (maximum cumulative dose = 13 ug) and/or nitroglycerin (maximum 
cumulative dose = 412 ug) in order to increase respectively decrease MAP by at least 
10%. Results: 
Variable Baseline Norepinephrine Nitroglycerin P 
MAP (mmHg) 75 i. 9 94+11 59 r 9 <0.05 
IMA flow (mlimin) 37217 43+20 27~12 <o.oz 
SVG flow (ml/min) 67 + 37 74246 57 f 34 “S 
With the maximum norepinephrine or nitroglycerin dose respectively, MAP increased by 
25% or decreased by 21% IMA graft flow increased by 16% and decreased by 27% 
(p<O.OOl) and SVG flow increased by 10% and decreased by 15% (p<O.Ol) respectively. 
Resistance changes were not significant for both IMA and SVG grafts. There was a sig- 
nificant pressure-flow relationship with a correlation coefficient of r = 0.6 for IMA and r = 
0.5 for SVG grafts, respectively. Conclusions: There is a 11nea.r pressure-flow relation- 
ship for arterial and venous bypass grafts early after revascularization. Coronary vascular 
resistance remains, however, unchanged suggesting that pressure-flow relationship is 
maintained even after pharmacologic manipulation. Thus, adequate perfusion pressure 
is mandatory after myocardial revascularisation, especially for IMA grafts. 
1017-87 lndomethacin in OPCAB Reduces Postoperative AFIB 
Allison J. McLarty Edward Woodford, Frank Seifert, Thomas V. Bilfinger, Adam E. 
Saltman, Irvin B. Krukenkamp. State University of New York at Stony Brook, Stony Brook, 
NY 
Background: Post-operative atrial fibrillation (AFIB) is a common complication following 
CABG. Previous reports have not shown an impact of off pump CABG (OPCAB) on the 
incidence of AFIB. Methods: We reviewed our experience with CABG over a 12 month 
period to assess the impact of OPCAB on post-operative AFIB in our institution. From 71 
l/98 to 6130199 750 patients underwent CABG only. Results: 379 operations were per- 
formed with extracorporeal circulation (ECC) and 371 were without (OPCAB). There was 
no significant difference between the groups in the mean age of the patient (64+/-SD11 
vs. 63+/-12 years), sex (76 vs. 69% men), ejection fraction (45+/-SD12 vs. 47+/-SD13), 
number of grafts (3.7+1-SD2 vs. 3.1+/-SDl), preoperative AFIB (5%), preoperative treat- 
ment with beta blockers (51 vs. 48%) or calcium-channel blockers (32 vs. 27%) or length 
of stay @+/-SD2 days). Post-operative prophylaxis against AFIB with beta-blockers was 
also comparable between the groups (85 vs. 74%). One surgeon in the group added the 
non-steroidal anti-inflammatory drug (NSAID) lndomethacin to the medical regimen of 
his OPCAB patients to treat the observed increased incidence of post-pericardiotomy 
syndrome. The incidence of AFIB in the entire group was decreased from 26% in patients 
undergoing CABG with ECC to 18% in those with OPCAB (p=O.O13). There was no dif- 
ference in the severity of AFIB between the groups with 63% of patients with ECC experi- 
encing shortlived AFIB (~48 hours)vs. 71% of OPCAB patients. Importantly, in OPCAB 
patients on Indomethacin, the incidence of AFIB was only 7% compared to 20% in those 
not on lndomethacin (p=O.O39). Comparing OPCAB patients not on the NSAID to CABG 
patients with ECC, the rate of AFIB was seen to be the same. Conclusion: We conclude 
that OPCAB does not decrease the incidence of postoperative AFIB. However, the addi- 
tion of the NSAID lndomethacin resulted in a significant decrease in this arrythmia. A pro- 
spective randomized trial of the post-operative use of this agent in patients undergoing 
CABG is warranted. 
1017-88 Effect of Early Postoperative Shear Stress on Late 
Postoperative Remodeling of Aortocoronary Bypass Graft 
Hiroshi Sate, Masao Okamura, Takeyoshi Ohta, Keiji Kurogane, Ryouhei Kuroda, Takashi 
Kajiura. Takafsuki General Hospital, Takatsuki-city Japan 
Although experimental studies have showed that intimal hyperplasia of bypass graft is 
regulated in response to changes in shear stress (SS), little is known about remodeling in 
aortocoronary bypass. The purpose of this study is to explore the effect of early postop- 
erative SS on late postoperative remodeling in bypass graft and clinical outcome. (Meth- 
ods) Thirty five SVGs and 13 LITA were studied at both 1 month and 2 years after 
surgery in each graft. Average peak velocity (APV) by Doppler guidewire and graft diam- 
eter (D) by quantitative angiography were measured. SS was calculated by these param- 
eters (SS = 80 x 0.035 x APV / D dyn/cm2). Thirteen LITA were defined as Group A and 
35 SVGs were divided into two groups according to early postoperative SS: Group H 
(n=19) SS>lO dyn/cm2, Group L (n=16) SSclO dyn/cm2. Normal value of SS in proximal 
coronary artery was l&4+/-7.9 dynIcm2 in our laboratory.(Results) Group A indicated 
higher SS than normal value early after surgery, which decreased significantly with 
enlargement of D late postoperatively (SS: 30.8+/-9.7 to 23.9+/-6.6 dyn/cm2, p<O.O5, D: 
1.9+/-0.3 to 2.2+/-0.4 mm, ~~0.05) with excellent patency (100%). Group H showed nor- 
mal SS early after operation, which did not change significantly late after operation with 
less reduction of D (SS: 17.0+/-6.0 to 15.6+/-6.8 dyn/cm2, n.s., D: 3.5+/-0.5 to 3.1+/-0.6 
mm, p<O.O01) than Group L, and indicating excellent patency (100%). SS in Group L was 
significantly lower than normal value early after surgery, which increased late postopera- 
tively with excessive reduction of D (SS: 5.6~1-1.9 to 8.7+/-4.ldynIcm2, p<O.Oi, D: 4.5+/- 
1.2 to 3.7+1-1.3 mm, p<O.OOOl). Clinically three out of 16 grafts in Group L were 
occluded. (Conclusions) LITA showed enlargement of D to regulate its SS late postoper- 
atively. SVGs with lower SS early after surgery showed excessive reduction of D late 
postoperatively, which would be due to excessive intimal hyperplasia. Even in two years 
follow up periods, graft failures were noted in this group. On the other hand, SVGs with 
normal SS early after surgery showed little remodeling late postoperatively with better 
graft patency. 
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1018-89 The New Definition of Myocardial Infarction: What Does It 
Mean Clinically? 
Mark A. Meier, Wisam H. Al-Badr, Deanna V. Cooper, Eva M. Kline-Rogers, Kim A. Eagle, 
Raj H. Mehta. University of Michigan, Ann Arbor, MI 
Background: The diagnostic criteria for myocardial infarction are being revised to 
include either troponin (I or Tj or CKMB in addition to symptomatology and ECG 
changes. However, the clinical significance of using these new criteria is unknown. 
Methods: All patients admitted to the University of Michigan Medical Center from May 1, 
1999 to January 1,200O with a suspected acute coronary syndrome(ACS) were e@?red 
into the ACS Database. Baseline demographics and in-hospital measures were obtained 
by chart review. By phone call and chart review, a 6 month follow-up was performed. 
Patients were stratified according to peak CKMB and troponin I and compared using chi- 
squared analysis. 
Results: Among patients who had both troponin I and CKMB measured, 305 patients 
with enzyme elevations were identified and separated into two groups. Group A con- 
tained patients with an elevated CKMB regardless of troponin status and Group B con- 
tained patients with an elevated troponin I and normal CKMB. Group A patients were 
significantly younger and required more percutaneous coronary interventions. Although 
not statistically significant, patients in Group B tended to have a shorter hospital stay and 
fewer in-hospital events including shock, need for bypass, death, and reinfarction. In 
addition, patients in Group B tended to have a lower 6 month mortality 
Conclusion: The decision to include troponin in the diagnostic criteria will result in a 
16% increase tn the annual number of myocardial infarctions diagnosed at our institution, 
and may select a clinically less complicated patient population. The implications, both 
clinical and financial, are far-reaching. 
Demographic, In-hospital, and Follow-up Data 
Group A (+CK) % Group B (-CK+Tnl) % p-value 
Total n 264 41 
Male 177 67.0 21 51.2 0.048 
Age 64.1 +/- 13.9 68.8 +/- 11.6 0.043 
In-hospital Events 
CHF 28 10.6 5 12.2 ns 
Shock 25 9.5 2 4.9 ns 
PTCA/Stent 144 54.8 9 22.0 <O.OOl 
CABG 16 6.2 1 2.4 ns 
Death 18 6.8 1 2.4 ns 
Nonfatal Ml 13 4.9 1 2.4 ns 
Length of stay 5.8 +I- 7.1 4.5 +I- 3.9 ns 
Follow-up 
Death at 6 months 18 8.5 2 5.4 ns 
1018-90 Prediction of the Site of Myocardial Infarction Using 
Exercise Echocardiography 
Helen L. Thomson, Abdou Elhendy, Douglas W. Mahoney, Patricia A. Pellikka. Mayo 
Clinic and Foundation, Rochester, MN 
Introduction: Stress echocardiography can predict the occurrence of myocardial infarc- 
tion (Ml) and cardiac death. In this study we investigated if stress echocardiography 
could predict the site of MI 
Method: We identified a cohort of 128 patients (94 male, 34 female, mean age 65110) 
who had stress echocardiography between 1990 and 1995 and subsequently had a Ml. 
Exclusion criteria included coronary revascularization between the stress echocardio- 
graphy and the Ml. Exercise echocardiography was performed in accordlng to our usual 
protocol and the location of wall motion abnormalities at rest and with stress 
was determined. The site of the Ml was localized using post Ml ECG, echocardiogram, 
and/or review of the history.The Ml was classified as anterior, inferior, antero-lateral or 
postero-lateral. The association of ischemia or fixed abnormality in a specific territory 
with the occurrence of Ml in the corresponding territory was investigated using the Chi- 
square test or Fisher’s Exact Test where appropriate. The sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV) of an ischemic finding to pre- 
dict site of Ml were assessed in a standard fashion 
Results: The median time from the exercise echocardiogram to occurrence of Ml was 
2.1 years (range: 1 day-7 years). There was no significant association of ischemic find- 
ings or ischemicc fixed abnormalities in the anterior (p=O.16 & p=O.40), inferior (~~0.46 & 
p=O.30), anterolateral (p=O.48 & p=O.62), or posterolateral (p=O.62 & p=O.99) territories 
with the corresponding territory of MI involvement, respectively. 
Territory Involved’ N Sensitivity(%) Specificity(%) PPV (%) NPV 
Anterior 53 34 (53) 77 (55) 51 (45) 62(62) 
Inferior 58 36 (72) 70 (37) 50 (49) 57 (62) 
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Anterolat 6 17 (33) 90 (78) 8 (7) 96 (96) 
Posierolat 11 18 (36) 89 (66) 13 (9) 92 (92) 
-statlstlcs 101 flxed+lsc”emlc aDnOrmal!tleS are Wlthln parentneses. 
Conclusion: Stress echocardiography had previously been demonstrated to provide 
incremental and independent prognosiic information to the risk of subseauent MI. How- 
ever the resultsof this study suggest the ability of stress echocardiography to predict the 
actual site of subsequent MI is limited. 
episodes. In all patients cllnical and biochemical variables were measured at study entry. 
QT dispersion (QT maximum - QT minimum in every ECG lead) was measured on the 
baseline 12-lead electrocardiogram at study entry using a digltising board. 
Results. No significant clinical, biochemical or angiographic differences were found 
between patients with and ihose without cardiac arrest or syncope. Mean (+ SD) QT dis- 
persion of the whole group was 62.3 + 19.5 ms. QT dispersion was significantly higher in 
patients with cardiac arrest or syncope (79.4 f 17.3 ms) compared to patients with no 
such events (56.3 t 16.9 ms), (95% Cl 7.5-38.8, P=O.O05). 
Conclusion. QT dispersion is increased in patients with Prinzmetal’s variant angina 
complicated by cardiac arrest and syncope compared to patients without such events. 
Increased QT dispersion may be both a substrate for sudden cardiac death and a marker 
of risk in patients with Prinzmetal’s variant angina. 
1018-94 Acute Myocarclial Infarction in Patients With High Lp(a) 
Levels Is Highly Characterized by Absence of Prodromal 
Angina and Early Culprit Artery Patency and Presence of 
Cardiac Dysfunction 
Tatsuaki Murakami, lkuo Moriuchi, Sumio Mizuno. Fukui Cardiovascular Center. Fukui, 
Japan 
Background; Although Lp(a) has been recognized as a related factor to coronary artery 
disease, clinical impacts of high Lp(a) levels on acute myocardial infarction (AMI) 
remained uncertain in the era of aggressive recanalization sirategy. This study investi- 
gated characteristics of AMI in patients with high Lp(a) levels. Methods; We evaluated 
cllnical and angiographic variables in the consecutive AMI patients (n=250) who under- 
went emergent CAG, and compared the variables in patients with high Lp(a) levels 
(Lp(a); 30mgidl or more, Group-L) to those in patients with normal Lp(a) levels (Group- 
C). Results; There were no significant differences in other coronary risk factors, location 
of myocardial infarction, culprit artery, number of ?&nosed vessels, or collateral supply. 
Patients of Group-L (n&O) manifested less frequent prodromal angina (PAP), and more 
frequent cardiac dysfunction defined by abnormal Killip or Forrester class. Patients of 
Group-L had larger elevation of creatine phosphokinase (CK). Incidence of early patency 
(TIMI flow grade 3) was low. Left ventricular enddiastolic pressure (LVEDP) was higher. 
Lefl ventricular ejection fraction (LVEF) was lower. The differences about cardiac dys- 
function remained significant in subgroup absent from PAP or TIMI flow grade 3. Conclu- 
sion; These results indicate that AMI patients with high Lp(a) levels are highly 
characterized by absence of prodromal angina and early culprit artery patency and pres- 
ence of cardiac dysfunction, which may be of great clinical implication on managemnet of 
myocardial infarction. 
Clinical and Angiographic Variables in 2 Groups 
1018-91 Determinants of Persistent Negative T Waves and Early 
Versus Late T Wave Normalization After Acute Myocardial 
Infarction 
Luc A. Pierard, Patrizio Lancellotti, Paul L. Gerard, All R. Bilge, Henri E. Kulbertus. 
University haspi& of Liege, Liege, Belgium 
Background: The clinical 
significance of T wave nor- 
malization vs persistent neg- 
ative T waves in the infarct “: 
related leads after AMI 
remains 
.“wL‘,Li :: 
coniroversial. “I, 
Methods: 127 consecutive 
:: 
‘1 
pis with first AMI and >2 IO n 
negative T waves in infarct 
related leads on 24.hour 
ECG underwent dob- 
utamine-atropine stress 
echocardiography(DSE) 4?2 
days after AMI. Coronary 
anglography was available in all and elective angiograplasty of infarct related artery was 
performed in 77. 12 lead ECG was recorded at hospital discharQe(early) and at 4il 
months&&) Results: T-wave normalization was observed in 88 pts(early in 19 and late 
in 69) DSE showed sustained improvement in 23, ischemia in 73(51 biphasic response 
and 22 ischemia in adjacent area) and unchanged akin&a in 31. Fig represents the rep- 
artition of DSE responses in the 3 ECG subgroups. Conclusions: 1, Early 7 normaliza- 
tion is associated with sustained improvement suggesting stunning myocardium 2. Late 
normalization is mainly observed in pts wth ischemic myocardium frequently revascular- 
ized. 3 Persistent negaiive T-waves correspond io either vansmural necrosis or non 
revascularized hibernating myocardium. 
1018-92 Is Initial Antegrade Flow Same to Early Reperfusion in 
Patients With Acute Myocardial Infarction? 
Masaharu Ishihara, Hikaru S&o, Takuji K~w~Qo~, Yuji Shimatani, Satoshi Kurisu, Kenji 
Nishioka, Yasuyuki Kouno, Takashi Umemura, Shuji Nakamura. Hiroshima City Hospital, 
Hiroshima, Japan 
Background: Antegrade flow before coronary angioplasty has shown to be associated 
with favorable outcome after acute myocardial infarction, justifing aniecedenl intravenous 
ihrombolysis before angioplasty. However, it remains unknown whether spontaneous ini- 
tial antegrade flow is same to antegrade flow achieved by early reperfusion therapy, 
Methods: This study consisted of 450 consecutive patlents with a first anterior wall acute 
myocardial infarcLion in whom coronary angiography was performed within 12 hours after 
the onset chest pain and TIMI grade 3 flow was obtained after reperfusion therapy. They 
were divided into 3 groups: 149 patients with Initial antegrade (TIMI grade l-3) flow 
(group l), 58 patients with initial TIMI grade 0 flow and time to reperfusion <2 hours 
(group 2) and 243 patients with initial TIMI grade 0 flow and time to reperfusion t2 houis 
(group 3). Results: In-hospital mortality was 0.7% in group 1, 3.5% in group 2 and 5.4% 
in group 3 (p=O.O3). Acute left ventricular ejection fraction was significantly better in 
group 1 (54t13%) than group 2 and group 3 (47tlO% and 47tlO%, respectively; 
pcO.001). Predischarge left ventricular ejection fraction was 64+15% in group 1, 55i-13% 
in group 2 and 51&14% in group 3 (p<O.OOl). Transient chest pain episode(s) within 24 
hours before infarction was more frequent in group 1 (42%) than group 2 and group 3 
(33% and 31%. respectively; p=O.O3). Conclusion: Although early reperfusion was 
associated with favorable outcome, initial antegrade flow had more impact than early rep- 
erfusion of initially occluded infarct artery. Our results suggest that pathogenesis of Initial 
antegrade flow might be different from that of early reperfusion, i.e., intermittent occlu- 
sion. 
1018-93 Increased QT Dispersion in Patients With Prinzmetal’s 
Variant Angina and Cardiac Arrest 
Nikhil Parchure, Juan C. Kaski. Cardiological Sciences, St George’s Hospital Medical 
School, London, United Kingdom 
Objectives. We sought to compare QT dispersion in patlents presenting with Prinz- 
metal’s vanant angina complicated by cardiac arrest or syncope and patients with 
uncomplicated variant angina. 
Background. Despite the usually benign course of treated Prinzmetal’s variant angina, a 
proportlon of vasospastic angina patients develop ventricular arrhythmias and sudden 
death in association wiih coronary spasm. Increased QT dispersion has been Suggested 
to increase susceptibility to ventricular arrhythmias in patients with coronary artery 
spasm. 
Methods. We studied 25 consecutive patients (mean age 58 years; 14 men) with classi- 
cal Prinzmetal’s variant angina and documented coronary artery spasm. None of the 
patients had coronary artery stenoses 240%. Five patients had suffered a documented 
cardiac arrest, 2 had recurrent syncope and 18 had no arrhythmic events or syncopal 
PAP 
Cardiac Dysfunction 
CK 
TIMI- 
LVEDP 
LVEF 
Group-L Group-C p value 
11(18%) 62(32%) 0.039 
17(28%) 21(11%) 0.002 
3904i2870 2235t1901 <O.OOl 
6(10%) 47(25%) 0.016 
22+6 18+6 <O.OOl 
50*15 59*13 <O.OOl 
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1019-95 Impact of Intravenous Nicorandil on Coronary 
Microvascular Function in Patients With Acute Myocardial 
Infarction: Study With Doppler Guidewire 
Koichi Yamamoto, Hiroshi Ito, Katsuomi Iwakura, Yasunori Shintani, Akinobu K&h, 
Masashi Ikushima, ShiQeO Kawano, Yorihiko Higashino, Kenshi Fujii. Division of 
Cardioiogy,Sakorabashi Watanabe Hospital, Osaka, Japan 
We previously reported thai intravenous nicorandil (NIC), hybrid of nitrates and K,, 
channel opener, improves myocardial perfusion and provides better clinical outcomes in 
patients with anterior AMI. The goal of this study was to assess whether this beneficial 
effect is related solely to the improvement in coronary microvascular function or not. We 
divided 73 patients with AMI, who underwent PTCA!STENT, into 2 groups: with (NC, 
n=35) and without (C, n=38) Intravenous NIC. In NIC, we injected 6 mg of NIC after the 
diagnosis of AMI, followed by Intravenous injectlon d 6 mQih for 24 hours. In each 
patient, we recorded coronary blood flow velocity with Doppler wire and measured dias- 
tolic deceleration time (DDT, msec) as an estimate of microvascular function. We per- 
formed 2-D echo at days-l and 21 and calculated wall motion score index (WMSI, 
average of segment scores (norm&O to dys/akinesis=3) within the infarct 
zone). Results. There was no WMSI at day-l between 2 groups. DDT and *WMSI(ld- 
216) were sigmficantly higher I” NC than in C (NC vs. C; 410 vs. 340 and 1.1 vs. 0.6, 
p<O 01). The regression line between DDT and l WMSI (Id-21d) in NC is placed upper 
left of thai in C. Multiple regression analysis documented that distributions of plots were 
significantly different between two groups Conclusion. Beneficial effect of intravenous 
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NC was partially explalned by the impr?vement in microvascular function (an increase in 
DDT). But Its direct impact of NIC on myocardial protection is speculated since 
l WMSI(Id-21d) is greater than that expected from DDT value in C. 
1019-96 Elevated C-Reactive Protein Levels on Admission Are 
Related to ST Segment Elevation Resolution in Patients 
With Acute Myocardial Infarction 
Michael Zairis, Stavros Manousakis, Alexander Stefanidis, Denis Vitalis, George 
Andrikopoulos, Stelios Handanis, Kostas Katsaros, John Hadjissavas, Spyros Argyrakis, 
Panayiotis Asimakopoulos, Stefanos Foussas. Cardiobgy Department, Tzanio Hospital, 
Piraeus, Greece 
Background: Failure of ST segment resolution after thrombolysis for acute myocardial 
infarction defines a high-risk group of patients. Additionally, high levels of plasma C-reac- 
tive protein assayed in the first few days after acute myocardial infarction have been 
associated with an unfavorable outcome. However, the possible association of plasma C- 
reactive protein levels with the outcome of thrombolytic therapy has not been clarified yet. 
The aim of this study was to evaluate the possible association of plasma levels of C-reac- 
tive protein to ST segment resolution after thrombolysis for acute myocardial infarction. 
Methods and Results: A total of 214 patients presenting c=6 hours from onset of acute 
myocardlal infarction were studied. ST segment elevation was measured upon admission 
and two hours after the commencement of thrombolytic therapy. High plasma levels of C- 
reactive protein on admission was found to be an independent adverse predictor of, the 
probability of complete ST segment resolution (>=70% resolution of the initial sum of ST 
segment elevation) achievement (b=-0.46, RR=0.63, 95%Cl=O.48-0.82, p=O.OOl) 2 
hours after administration of thrombolysis. Conclusions: Plasma levels of C-reactwe 
protein in the first six hours of acute myocardial infarction can predict the extent of myo- 
cardial reperfusion due to fybrinolytic therapy. Thus, plasma C-reactive protein levels on 
hospital admission may serve as an affordable and widely available marker for the detec- 
tion of patients with myocardial reperfusion failure. These patients could benefit from 
more aggressive pharmaceutical or invasive treatment. 
1019-97 Effects of Angiotensin II Receptor Blockade on Fibrinolysis 
and Coagulation in Patients With Acute Myocardial 
Infarction 
Hirofumi Soejima, Hisao Ogawa, Keijl Takazoe, Shinzo Miyamoto, lchiro Kajiwara, Hideki 
Shlmomura. Departmetit of Cardiovascular Medicine, Kumamoto University School of 
Medicine, Kumamoto City Japan 
Background. It has been reported that angiotensin II type 1 (ATl) receptor antagonism 
is associated with an improvement in mortality in patients with symptomatic heart failure. 
We investigated the effects of AT1 receptor antagonist on plasma plasminogen activator 
inhibitor (PAI), tissue type plasminogen activator (t-PA), and tissue factor (TF) levels in 
patients with acute myocardial infarction. Methods and Results. In a randomized, dou- 
ble-blind, placebo-controlled study beginning one week after acute myocardial infarction, 
14 patients received 4 weeks of losartan 25 mg daily therapy (losartan group) another 14 
received enalapril 5 mg daily therapy (enalapril group), and the other 14 received placebo 
(placebo group). We performed blood sampling on the day before the start of administra- 
tion, and on the day 3, 7 and 28 after the start of administration. There were no significant 
differences in the plasma PAI, t-PA, or TF levels before the administration among the 
three groups. The plasma PAI activity and TF antigen levels significantly decreased by 
the day 28 in the losartan and enalapril groups. These two variables were unchanged 
during the study period in the placebo group. The plasma PAI activity and TF antigen lev- 
els on day 28 in the losartan and enalapril groups were significantly lower than that in the 
placebo group. There were no difference in the decrease in plasma PAI activity and TF 
antigen levels after admimstration between the losartan and enalapril groups. (The 
plasma PAI activity (IUlmL) losartan and enalapril and placebo :l 1.7 and 11.4 and 12.0 
before the administration, 6.7 and 6.7 and 12.7 on day 28) (The plasma TF antigen levels 
(pg/mL) losartan and enalapril and placebo : 231 and 229 and 237 before the administra- 
tion, 184 and 176 and 245 on day 28) T-PA antigen levels did not change in these three 
groups. Conclusions. This study demonstrated that AT1 receptor antagonism as well as 
angiotensin converting enzyme (ACE) inhibition improves impared fibrinolysis and hyper- 
coagulability in patients with acute myocardial infarction. It may be an evidence that 
administration of ATI receptor antagonist as well as ACE inhibitor is effective therapy for 
the patients with acute myocarclial infarction. 
1019-98 Complement Inhibition and Myocardial Protection in 
Patients With Acute Myocardial Infarction 
Chris de Zwaan, Appie Kleine, Jard Dins, Jan Glatz, Paul Strengers, Erik Hack, Maria 
van Dieijen-Visser, Wim Hermens, Hein Wellens. CAR/M University Maastricht, 
Maastricht, The Netherlands, University Amsterdam, Amsterdam, The Netherlands 
Background: One of the consequences of acute myocardial ischemia is activation of the 
complement system by various pro-inflammatory cytokines. This process will lead to 
myocardial cell injury. The Cl-esterase inhibitor (Clinh) inhibits the classical pathway of 
complement activation. We recently studied the effects of Clinh on acute myocardial 
ischemia in dogs and found that intravenous Cl inh, given 2-10 hours after onset of 
ischemia, diminished myocardial cell loss in the reperfused as well as the non-rep&used 
animal heart. This prompted us to study the effects of a continuous infusion of Cl inh in 
patients with acute myocardial infarction after successful thrombolytic therapy. Methods: 
Human Cl inh (Cetor), purified from donor plasma, was intravenously administered as a 
bolus injection, followed by an infusion for 48 hours. Twenty two patients received Clinh. 
Six hours after the onset of acute myocardial infarction and respectively 1 and 2 hours 
after the termination of tPA or streptokinase infusion. Effects of Clinh on evolving myo- 
cardial injury were estimated from plasma concentrations of the cardiac marker proteins: 
creatine kinase (CK), MB isoenzyme of creatine kinase mass (CK-MB mass), alpha- 
hydroxybutyrate dehydrogenase (HBDH) and troponine-T (TnT). Efficacy of complement 
inhibltion was also estimated from the generation of C4 activation fragments. In addition, 
interleukin-6 and C-reactive protein were measured. Results: Clinh resulted in a reduc- 
tion of 38% (P 0.022), 57% (P O.OOi), 18% and 36% of the areas under the - normalized 
to the 6 hours (pretreatment)- plasma concentration curves of CK, CK-MB mass, HBDH 
and TnT, respectively, in comparison with 18 matched control patients. A rebound effect 
or loss of myocardial protection by Cl inh 48 and 72 hours after onset of acute myocardial 
infarction, was not seen. Human Cl inh (Cetor) was found to be safe and well tolerated in 
all patients. Conclusion: The reduction of plasma concentration of the cardiac ‘marker 
proteins CK and CK-MB mass suggests salvage of myocardial tissue, shortening of the 
time of evolving myocardial necrosis and protection of the cardiac muscle. The beneficial 
effects of this type of drug warrant further investigation. 
1019-99 Nicorandil Improves Functional and Clinical Outcomes in 
Patients With Acute Myocardial Infarction 
Nahoko Ikeda, Takanori Yaw, Norifumi Kubo, Yoshitaka Sugawara, Kazuo Matsushima, 
Mikihisa Fuji, Muneyasu Saito. Omiya Medical Center, Jichi Medical School, Omiya, 
Japan 
Background Recent studies in animals and humans suggested that an adenosine triph- 
osphate sensitive Kc channel (K+ ATP channel) opener exerts cardioprotection after pro- 
longed ischemia. Nicorandil IS a hybrid compound of K+ ATP channel opener and donor 
of nitric oxide (NO). We did randomized prospective study to compare the cardioprotec- 
tive effect of nicorandil and isosorbideOdi-nitrate (ISDN) in patients with acute myocardial 
infarction (AMI). Methods Consecutive 60 patients with first episode of AMI within 12 h 
after the onset were randomly divided into two groups, nicorandil (n=30) and ISDN group 
(n=30). Each drug was infused intravenously at 3-8 mglh for 72 h from the admission. All 
the patients underwent direct balloon angloplasty. Fiftysix patients received successful 
revascularization and intracoronary administration of ISDN (2mg) or nicorandil (2mg) just 
after the procedure. Coronary flow velocity and flow reserve also determined by flow 
wire. Coronary arteriography was repeated in all the patients three weeks after the onset. 
Results There were no differences in baseline clinical characteristics between the two 
groups. In the nicorandil group, end-systolic volurix index and left ventricular ejection 
fraction after reperfusion were significantly better. The wall motion analysis by centerline 
method were also better in the nicorandil group (SD/chord: -1.75 vs. -2.66, p<O.O5), and 
those effects lasted to after three weeks (-1.77 vs. 02.50, p<O.O5). The peak systolic car- 
onary antegrade flow velocity was significantly larger (18.8 cm/s vs. 7.9 cm/s), and the 
frequency of early systolic retrograde flow, reflecting no reflow phenomenon, was lower in 
the nicorandil group than in the ISDN group (13% vs. 50%, ~~0.05). There were no differ- 
ences in NO m&b&es in blood sampled from coronary sinus between two groups. 
Conclusions Nicorandil can preserve myocardial microcirculation after reperfusion, and 
leads to improvement of stunned myocardium and decrease of left ventricular remodel- 
ing. Those beneficial effects may be associated with K+ ATP channel opener. Therefore 
nicorandil drip infusion therapy is highly recommended to patients with AMI after suc- 
cessful reperfusion. 
1019-100 Hepatocyte Growth Factor: Potential Role of a Novel 
Vascular Modulator in Acute Myocardial Infarction Patients 
Konstantinos I. Kapetanios, Christos E. Pitsavos, Emmanuel V. Economou, Marina G. 
Toutouza, Christodoulos I, Stefanadis, Pavlos K. Toutouzas. Hippokration Hospital of 
Athens, ATHENS, Greece, University of Athens Medical School, ATHENS, Greece 
Background: Hepatocyte growth factor is a member of the endothelium-specific growth 
factors transducing a wide range of biological signals, acting as an organotrophic factor 
and exhibiting a potent angiogenic and antiapoptotic activity in several cell types. The aim 
of our study was to elucidate any possible role of this factor in acute myocardial infarction 
patients. 
Methods: We measured serum hepatocyte growth factor levels in 17 patients with first 
attack of myocardial infarction, admitted and thrombolysed during the acute phase, and 
no previous history of any other disease, and compared to those of 17 sex and age- 
matched healthy controls with mean values: 0,29+0,05 ngiml. Samples were collected at 
the time of admission to the hospital and 3,6,9,12,18,24,36,48 hours as well as 
3,4,5,7,15 and 30 days thereafter and measured by ELISA method. For the statistical 
analysis non-parametric Wilcoxon test was used. Data is expressed as mean values ? 
SEM in ngiml and considered to be statistically significant with p<O,O5 when compared to 
mean values of healthy controls (*) and the last serum sample (+). 
Results: Hepatocyte growth factor exhibited an initial high level of 7,512,9 (*t), reaching 
a peak of 8,2+2,9 (‘+), 3 hours after admission, followed by a gradual decrease, reaching 
a minimum level of 1,9f0,6 (t) at 36 hours, that was reversed by a rebound up to a max- 
imum level of 5,2i-1,8 (*+) at 3 days This second peak was also followed by a sustained 
decline up to a final nadir of 0,3f0,04, at 30 days. Furthermore, patients with extenwe 
acute myocardial infarction and adverse events exhibited a higher, more sustained initial 
peak compared to those with limited infarct size (16,713,8 versus 5,9r1,3, p<O,O5). 
Conclusion: The initially 27.fold increased hepatocyte growth factor possibly acts as a 
survival factor against endothelial cell death caused by acute hypoxia due to reduced 
vascular perfusion, while the following decrease could be attributed to reperfusion due to 
thrombolytic therapy. Raised levels of this factor, 3 days later, may be fundamental for the 
induction of angiogenesis implicated to the process of remodeling, thus preserving car- 
diac function. 
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1050-101 Prediction of Coronary Heart Disease in African-Americans 
and Whites Using Multiple-Risk-Factor Assessment 
Equations 
Herbert J. Marx, Henry F C. Weil, Thomas A. Pearson, Edward F Philbin, Tara A. Erb, 
Paul L. Jenkins, Charles K. Francis, Roberta G. Reed. Mary lmogene Easseft Hospital, 
Cooperstown, NY Harlem Hospital, New York City, NY 
Background: American Heart Association (AHA)/American College of Cardiology (ACC) 
coronary heart disease (CHD) multiple-risk-factor assessment equations were derived 
from the Framingham Study which largely involved whites (W) of European origin. In the 
past, extension of similarly derived risk prediction models to other ethnic groups yielded 
mixed results. 
Method: Applicability of the AHAIACC risk assessment method to African-Americans 
(AA) was evaluated by determining global CHD risk factor scores (RFS) for a series of 
patients with no prior documented CHD who underwent diagnostic coronary anglography 
at Harlem and Bassett Hospitals. Risk factors consisted of age, total cholesterol. HDL-C, 
hypertension, diabetes, and smoking history. Subjects were categorized by angiagraphy 
into those with 250% stenosis I” a major coronary artery (CHD) and those with < 25% 
stenosis (NL). 
Results: There were no significant differences m overall average age or RFS between 
79AA and 14OW males (M) or between 64AA and 97W females (F). However, those with 
CHD had significantly higher RFS compared with NL (see table). 
RFS * SD AAM WM AAF WF 
CHD 7.9t3.3 8.0i2.7 12.5+3.9 11.&4.4 
NL 5.3t3.3 5.li3.1 8.032.7 7.9t6.5 
p value 0.001 0.0001 0 058 0.005 
Predicted relative risk was below average for NL in all 4 subgroups. For those with CHD. 
it was moderately above average for age for F and average for M. 
Conclusion: AHA/ACC multiple-risk-factor assessment e&ations were equally applica- 
ble to AA and W of both genders in our cohort with higher RFS among those with CHD 
compared with NL. Relative risk was below average for NL in each subgroup and average 
to moderately high for those with CHD. 
1050-102 Effect of Alcohol Consumption on Endothelial Function in 
Men With Coronary Artery Disease 
Hiroki Teragawa, Yukihlro Fukuda, Keijl Matsuda, Kenya Sakal, Sou Takenaka, Fumiharu 
Miura, Hidekazu Hirao, Togo Yamagata, Hideo Matsuura, Kazuaki Chayama. Hiroshima 
Unwersity Hiroshima, Japan 
Background: An inverse association between moderate alcohol consumption and coro- 
nary artery disease (CAD) has been observed in several epidemiological studies. 
Although some possible mechanisms have been proposed, it is unknown whether endot- 
helial function is associated with the beneficial effects of alcohol consumption. Therefore, 
we investigated the effects of alcohol consumption on endothelial function of the brachial 
artery in men with CAD. Methods: Forty-five men (mean age 65 yrs) with CAD, who had 
50% stenosis of the major coronary arteries on coronary angiogram were evaluated. 
Alcohol consumption was defined as alcohol intake on 4 days par week. The patients 
were divided into two groups based on whether they consumed alcohol (Group I) or not 
(Group II), and flow-mediated dilation (FMD), an indicator of the brachial artery diameter 
in response to hyperemlc flow, was measured using high resolution ultrasound (IOMHz). 
Other parameters, including metabolic ones, were also measured. Results: Data are 
presented as mean&EM. Twenty patients consumed alcohol (Group I). The level of lip- 
ids such as total cholesterol, triglycerides, high-density lipoprotein cholesterol and low- 
density lipoprotein cholesterol did not differ between the 2 groups, but the level of fasting 
blood sugartended to be higher in Group I (121rlO vs 99+3 mgldl in Group II, p = .0504). 
FMD was higher in Group I than in Group II (3.0t0.3 vs 2.1+0.3 %, p = .0309) Multivarl- 
ate analysis showed that alcohol consumption (p = .0026) as well as brachial artery 
diameter after the administration of nitroglycerin (p = .0057) and the number of diseased 
vessels (p = .0343) influenced the FMD. Conclusions: These findings suggest that alco- 
hol consumptw may favorably influence endothelial function in men with CAD although it 
may affect some metabolic factors 
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1050-75 Prognostic Value of Remnant-Like Lipoprotein Particles 
Levels in Patients With Coronary Artery Disease in Type 2 
Diabetes Mellitus 
Osamu Honda. Kumamoto University of Medicine, Kumamoto c& Japan 
Several studies showed that triglyceride (TG)-rich lipoproteins contribute to atheroscle- 
rotic complications in type 2 diabetes mellitus (DM). However, it remains undefined which 
TG-rich lipoproteins contribute to the risk, We have shown that measurement of remnant- 
like lipoprotein particles (RLP), assessed by an immunoseparation method that is 
recently developed. is helpful in risk assessment of coronary artery disease (CAD). Thus, 
this study prospectively examined whether high RLP levels may have a significant risk 
and prognostic valuea in type 2 DM patients with CAD. RLP levels in fasting serum ware 
measured in 176 consecutive type 2 DM patients with (n=87) or without (n=89) CAD by 
an imnxmoaffinity gel containing anti-apoA-1 and anti-apoB-100 monoclonai antibodies. 
The patients with CAD were followed up for rr24 months until occurrence of the following 
clinical coronary events; readmission or coronary revascularization due to recurrent or 
refractory angina pectoris. nonfatal myocardial infarction, and cardiac death. Patients 
with CAD had higher RLP levels than those without CAD (7.2+1 .O mg cholesterolidl vs. 
4.2 0.5 mg/dL. P=O.OOl). Multivariate logistic regression analysis showed that high RLP 
levels (>4.7 mg cholesterol/dL; 75th percentile of the distribution of RLP levels in con- 
trols) were a significant risk factor for the presence of CAD independent of age (>70 y), 
sex (male): smoking, hypertension, hypercholesterolemia, high LDL levels, low HDL iev- 
els, and hypertriglyceridemia (Odds ratio;l.9, 95%Cl;i .5-Z.Z,P<O.Ol). Kaplan-Meier 
analysis demonstrated that high RLP levels had higher probability ot developing coronary 
events in patients with CAD (P<O.Ol). In multivariate Cox hazard analysis, high RLP lev- 
els were a significant predictor of developing coronary events independent of other risk 
factors (Odds ratio:5.5, 95%C1;2.0-15.2, P=O.Ol). Thus, the increase in remnant lipopro- 
teins levels IS a significant risk factor of CAD and predicts future coronary events in type 
2 DM patients with CAD independent of other risk factors. Measurement of RLP levels 
may be useful in assessment of CAD risk in type 2 DM. 
1050-76 Circulating Concentration of Cardiac Troponin T Is Ukeful 
for Risk Stratification in Patients With Chronic 
Hemodialysis: One-Year Outcome Analysis in 394 
Hemodialyzed Patients 
Junnichi Ishii, Takanobu Toriyama, Masanori Nomura, Hiroyuki Naruse, Yoshlhisa Mori, 
Masaki Yokoya, Yoshitaka Kumada, Hiroshi Takahashl, Hirohisa Kawahara, Yoshlhiko 
Watanabe, Hitoshi Hishida. Fuji& He&h Universitl: Toyoake. Japan, Nagoya Kyoritsu 
Hospital, Nagoya, Japan 
A recent study has suggested that, in patients on chronic hemodialysls, the increased 
serum level of cardiac troponin T (cTnT) measured by the current cTnT assay originates 
from the heart, not from skeletal muscle expression of cTnT. To evaluate the prognostic 
value of increased serum cTnT in patients on chronic hemodialysis, we prospectively 
studied 394 consecutive patients (mean age 61 yrs; range 30 to 90 yrs; mean period of 
dialysis 8.0 yrs: range 0.5 to 25 yrs) on chronic hemodialysis without acute coronary syn- 
drome m March of 1999. We measured serum cTnT by second-generation assay, serum 
heart-type fatty-acid binding protein (FABP) and plasma brain natriuretic peptide (BNP) in 
pm-dialysis samples. All patients were followed for 1 year. The cutoff value for cTnT was 
0.10 ng/mL, 9 ng/mL for FABP, and 18.4 pg/mL for BNP. Results: cTnT was increased in 
151 patients (38%), FABP in 394 (lOO%), BNP in 393 (99.7%). During the l-yaarfollow- 
up period, 31 (8%) cardiac events (19 deaths, 12 coronary artery disease requiring 
PTCA) occurred. Patients with cardiac events were older (p=O.O007), had higher levels of 
cTnT (p=O.O003) and BNP (p=O.O042), and a more frequent history of diabetes 
(p=O.O063)(Table). In a stepwise Cox regression analysis including cTnT, FABP, BNP, 
age, period of hemodialysls and history of diabetes, cTnT (RR 13.4, p=O.OOS), age (RR 
1.05, p=O.O16) and history of diabetes (RR 2.42, p=O.OOZ) were independent predictors 
of cardiac events. The rate of cardiac events in patients with elevated cTnT was higher 
than in those wlthout elevated cTnT 115% (231151) vs 3% (8/243), p<O,OOOl]. Conclu- 
sion: These findings indicate that an elevated cTnT level is a potential prognostic marker 
of adverse outcome within 1 year in patients on chronic hemodialysis. cTnT could be rea- 
sonably included in the routine risk stratification of this population. 
Data are mean&D. *pcO.Ol vs CEs(-). CEs=cardiac events. 
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1051-77 Factor XII Activation in Acute Coronary Syndromes: 
Fundamental Basis for Pharmacological Targeting of the 
Intrinsic Coagulation Cascade 
Richard C. Becker, You Fu LI, Frederick A. Spencer. University of Massachusetts Medical 
School. Worcester, MA 
Background: The pathobiology of acute coronary syndromes (ACS) is characterized by 
plaque disruption, injured site thrombosis and microcirculatory embolization. Although 
tlssue factor (TF) is a dominant protein in atherothrombosis, the contribution of contact- 
activating factors and the physiologic integration of coagulation pathways must also be 
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considered as potential targets for pharmacologic treatment. Methods: Patients with 
non-ST segment elevation ACS (n=30) undetwent serial blood sampling and were com- 
pared with age-matched controls (n=22) for markers of contact activation (factor Xlla) 
and thrombin generation (Fl.2). The results were as follows: 
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Conclusion: Specific markers of inflammation and infection are colocalized within coro- 
nary atheroma, the more in primary lesions associated with UA. lntlmal persistency of C. 
pneumoniae may be an important chronic stimulus for inflammatory and/or stress events 
involved in plaque rupture. 
1051-80 Endogenous Fibrinolytic Activity and Response to 
Thrombolytic Therapy in Acute Myocardial Infarction 
David E. Newby, Nicholas L. M. Cruden, Laura L. Flint, Nicholas A. Boon, Keith A. A. Fox. 
University of Edinburgh, Edinburgh, United Kingdom 
In a series of in vitro experiments using western blot assays and densitometry, TF and/or 
TF-Vlla augmented intrinsic X ase (factors IXa, Villa)-mediated thrombin generation, but 
had no effect on factor XII activation. In contrast, thrombin readily activated factors XII, IX 
and VIII. Conclusion: The bioamplification sequence of thrombin generation in ACS 
includes coagulation cascade “cross-talk” and upstream events involving contact activa- 
tion. The pharmacologic inhibition of factor Xlla and its overall impact of modulating arte- 
rial thrombosis requires further clinical investigation. 
Background Impaired endogenous fibrinolysis ma’y contribute to the pathogenesis of 
acute myocardial infarction. We postulated that the efficacy and rapidity of reperfusion of 
the infarct-related artery with exogenous thrombolytic therapy would be enhanced in 
those patients with low endogenous plasma tissue plasminogen activator (S-PA) activity 
Methods Admission fibrinolytic parameters were determined in 59 patients, aged 65 i 2 
years (42 male), with acute myocardial infarction who fulfilled clinical and electrocardio- 
graphic criteria for thrombolytic therapy. Continuous ST segment monitoring was per- 
formed, and aspirin and thrombolytic therapy administered. Reperfusion was defined as 
a fall in the ST segments of *50 % or new onset idioventricular rhythm. Results Rep&u- 
sion occurred in 39 (66%) patients 91 +_ 8 min after the initiation of thrombolytlc therapy 
and was associated with a lower admission plasma t-PA activity concentration (1.4 f 0.2 
vs 2.5 i 0.5 IUlmL, p=O.O3). &perfusion time directly correlated with admission plasma 
t-PA activity (r=O.47, p=O.OOS). Conclusions We have shown that patients who fail to 
reperfuse with thrombolytic therapy have higher admission plasma t-PA activity suggest- 
ing the presence of t-PA resistant occlusion of the infarct-related artery. However, in 
patients who repetiuse, lower plasma t-PA activity is associated with a more rapid 
response to thrombolytic therapy suggesting that patients with impaired endogenous 
fibrinolysis benefit most from thrombolytic therapy. 
1051-78 Regulation of Monocyte Procoagulant Activity in Acute 
Myocardial Infarction: Role of Tissue Factor and Tissue 
Factor Pathway Inhibitor 
1051-81 Absence of Interaction Between Clopidogrel and Warfarin in 
Patients on Long-Term Anticoagulation 
llka Ott, Martin Andrassy, Dominik ZieglgBnsberger, Stefanie Geith, Valerie Malcouvier, 
Franz-Josef Neumann. 1. Medizinische Klinik und Deutsches Herzzentrum der TIJ 
Miinchen, Munich, Germany 
C Lidell, L-E Svedberg, P Lindell, S Bandh, L Wallentin. Department of Cardiology, 
Uppsala University Hospital, Uppsala, Sweden 
Background: In acute myocardial infarction (AMI), monocyte procoagulant activity is 
increased and may contribute to the risk of recurrence and other thrombotic events. This 
study sought to investigate the role tissue factor (TF) and its counterpart tissue factor 
pathway inhibitor-l (TFPI-I) in the regulation of monocyte procoagulant activity in AMI. 
Methods: In 40 patients with AMI undergoing revascularization by stent placement, we 
obtained serial venous blood samples. Twenty patients with elective stenting for stable 
angina served as control subjects. We measured TF proteolytic activity with spectrozyme 
factor Xa (FXa), TF and TFPI-1 surface expression of monocytes by flow cytometry, 
mRNA expression by reverse transcription polymerase chain reaction, and concentra- 
tions of prothrombin fragments F1+2 by immunoassay. Results: Forty-eight hours after 
AMI, we found an increase in TF transcription followed by an increase in TF surface 
expression by 24+4% and in plasma concentration of prothrombin fragments Fl+2 by 
103+17% at 96 hours (~~0.05). These changes could not be attributed to the interven- 
tion, as they did not occur in the control group. TFPI-1 transcription and binding to the 
monocyte surface remained unchanged. In vitro, FXa generation by monocytes of 
patients with AMI was increased 3.fold in the presence of polyclonal antlbodies to TFPI- 
1, indicating that cell-associated TFPI-1 inhibited monocyte TF activity. Conclusion: The 
increased monocyte procoagulant activity in AMI is caused by upregulation of TF that is 
only partially inhibited by surface-bound TFPI-1. Anticoagulant therapy by direct inhibition 
of TF activity may, thus, be particularly effective in AMI. 
Background: Clopidogrel (C), an ADP receptor antagonist, is indicated for secondary 
prevention in patients with recent ischaemic stroke, recent myocardial infarction or 
peripheral arterial disease. Warfarin may be used in patients with atherothrombosis, in 
circumstances which are associated with a history of myocardial infarction or ischaemic 
stroke. A randomized, double-blind, placebo-controlled, parallel group trial to test for a 
possible interaction between C and wariarin was conducted. 
Methods: Main inclusion criteria were: age 35-75 years; receiving long-term (> 2 
months) warfarin treatment for chrotiic or recurrent non-valvular atria fibrillation (NVAF), 
with an INR value remaining between 2 and 3 under constant warfarin regimen, as con- 
firmed by 3 weekly controls performed during a run-in period. Patients were randomly 
assigned to C 75 mg QD (n = 20) or matching placebo (n = 23) administered for 8 days 
(Days 1-8) on top of the constant warfarin regimen. Follow-up was continued until Day 
22. The primary endpoint was percent change in INR from baseline through the overall 
evaluation period including Days 3, 6, 9, 13 and 22. The secondary endpoint was percent 
change in plasma levels of warfarin enantiomers from baseline at the same time points. 
Plasma levels of C metabolite SR26334 were also assayed to confirm observance. 
Results: Mean INR remained extremely stable under C, the maximum percent change 
from baseline being 0.6% at Day 6. There was no statistically significant difference 
between the two treatment groups in the percent change from baseline at any time point. 
All the 95% confidence intervals remained between 2.28 and 2.72, and a greater than 
5% increase in INR under C could be ruled out. Plasma levels of R- or S-warfarin 
remained also very stable under C. No serious adverse events were reported during the 
study, and there were no premature discontinuations of study drug. No bleeding occurred 
under C. 
1051-79 Prevalence of C-reactive Protein in Unstable Versus Stable Conclusions: The stable anticoagulation status of patients on long-term warfarin therapy 
Angina Atheroma: Correlation With Persistency of is not modified by concomitant administration of clopidogrel 75 mg QD Safety and toler- 
Chlamydia Pneumoniae ability of such combination were good in this study. 
Gerhard Bauriedel, Rend AndriB, Dirk Skowasch, Peter Braun, Karl W. Heinrich, Berndt 
LOderitz. Department of Cardiology. University of Bonn, Bonn, Germany, Heart Center 
Duisburg, Duisburg, Germany 
Background: There is increasing evidence that inflammation, infection and immune 
reactions play an important role in the acuity/progression of atherosclerosis. Therefore, 
we sought to detect C-reactive protein (CRP), chlamydial heat schock protein 60 (cHSP 
60) indicating persistency of Chlamydia pneumoniae infection, and human (h) HSP 60 
that serves as a target for autoimmune reactions, in primary lesions associated with 
unstable (UA) vs. stable angina (SA). 
Methods: Coronary atherectomy samples retrieved from 45 primary target lesions of 
patients with UA (n=30) or SA (r-1=15) were immunohistochemically examined for the 
presence of CRP, cHSP 60 and hHSP 60. These data were correlated with plaque mor- 
phology and assessed for prevalence and correlation in either lesion group. 
Results: Coronary plaques revealed immunoreactive CRP in 26 (58%), cHSP 60 in 29 
(64%) and hHSP 60 in 36 (80%) of 45 lesions vs. none of 20 undiseased controls. lntimal 
predilection sites were areas with macrophagelfoam cell accumulation, inflammatory 
infiltrates and sparse cellularity. Expression averaged to 1.8% for CRP, 6.6% for cHSP 60 
and 6.5% for hHSP 60. As a key finding, consistently, the expression of each protein was 
significantly higher in UA compared to SA lesions. CRP: 2.3% vs. 1 .l% (~~0.05); cHSP 
60: 8.7% “s. 3.0% (pcO.01); hHSP 60: 8.7% vs. 2.0% (p<O.OOi). Moreover, we found 
positive correlations (p<O.Ol each, n=45) for CRP/cHSP 60 (r=0.38), CRP/hHSP 60 
(r=0.47) and cHSP 6OlhHSP 60 (1=0.44). Subgroup analysis revealed correlations 
(~~0.05) for CRP/cHSP 60 (r=O.38) and cHSP GO/hHSP 60 (r=0.35) only in lesions asso- 
ciated with UA. 
1051-82 Interleukin-6 G-1742 Polymorphism Is Associated With 
Occurrence of Unstable Angina and With In Vitro Increased 
Monocyte Production of Interleukin-6 in Unstable Patients 
Luigi M. Biasucci, Domtnick J. Angiolillo, Pier France Pignatti, Chiara Stranieri, Vittoria 
Rizzello, Christian Colizzi, Giovanna Liuzzo, Attilio Maseri. catholic university Rome, 
/ta/x University of verona, Verona, /ta/y 
Background: Interleukin-6 (IL-6), the main inducer of C-Reactive protein (CRP) produc- 
tion, is raised in acute coronary syndromes. A common polimorphism G-174C of the 
human IL-6 gene in the 5’ region has been described. In normal subjects the G allele has 
been associated with higher IL-6 plasma levels. Aim of this study was to assess the role 
of the G-17& polimorphism in unstable angina (UA). Methods: We studied 52 patients 
with UA, Braunwald’s class 1118, (29 with CRP>3mg/L and 23 with CRP<3mg/), and 17 
patients with stable angina. All patients were genotyped for the G-174C. In 23 of these 
patients 1 mL of whole blood was stimulated in vitro with lng lipopolysaccaride, and IL-6 
was measured 4 hours after stimulation to assess the monocyte response. Results: The 
frequency of the G allele was higher in UA (81%) versus stable angina (62%, p=O.O2), but 
no significant difference was observed between UA wth high or low CRP levels. After 
LPS stimulation of whole blood in vitro, G homozygote patients (n=l5) had higher IL-6 
levels than heterozygotes (n=8): median levels were respectively 4,435 (range 670- 
10,583) and 2,000 (range 75.4,790) picogriml (~~0.05) Conclusion: Our data demon- 
strate that the G allele of the G-174C polymorphism of IL-6 is associated with unstable 
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angina and IS associated with an increased monocyte production of IL-6 in vttro. The G 
allele of the G-174C polimorphism appears associated with unstable angina, possibly in 
part via an enhanced production of IL-6 in response to inflammatory stimulr. 
1051-83 A Polymorphism in the Promoter of the CD14 Receptor 
Gene Is Associated With Circulating Soluble CD14 Levels 
and With an Enhanced Pro-Inflammatory Response in 
Patients With Unstable Angina 
Giovanna Liuzzo, Dominick J. Angioiillo, Pier F. Pignattr, Chiara Stranieri, Matteo 
Santamana, Vittoria Rirzelio, Francesca Ginnetti, Antomno Buffon, Luigi PA. Biasucci, 
Attilio Maseri. Catholic Universifl: Rome, /f&y 
Background: Activation of circulating monocytes (MO) has been shown in unstable 
angina (UA). The CD14 membrane receptor is an important mediator for MO acttvation 
by bacterial lkpopolysaccharide (LPS). CD14 is also present in a soluble form (sCD14), 
and sCDl4 levels are strongly associated with prognosis in gram-negative infections. A 
‘X260) T polymorphism in the promoter of the CD14 receptor gene was recently associ- 
ated with mcreased risk of myocardial infarctron. In this study, we examined whether the 
C(-260) T polymorphism in the CD14 gene influenced sCDl4 levels, the activation of cir- 
culating MO and the acute phase response in UA. Methods: Plasma levels of sCDl4 
and C-reactive protein (CRP), and interleukin-6 (IL-6) production by circulating MO after 
in vitro stimulation of whole blood with a low dose of LPS (lng/mL, for 4 hours) were 
compared in 44 UA patients, 35 stable angina (SA) patients and 20 healthy subjects (C). 
The CD14 C(-260) T polymorphism was assessed in 26 UA, 12 SA and 12 C. Results: 
Data are presented as median. Plasma levels of sCDl4 were significantly higher in UA 
(2.5 mcgiml) than in SA (2.2 mcg/mL) and C (2 mcg/mL) (PcO.05). LPS-stimulated pro- 
duction of IL-6 by clrcuiating MO was significantly higher in UA (4.4 ng/mL) than in SA 
(1.9 ng/mL) and in C (0.5 ng/mL) (P<O.Ol). A positive linear correlation was observed 
between plasma levels of sCD14 and CRP (r=O.42, P<O.Ol), as well as between sCDl4 
and IL-6 production in response to LPS (rzO.38, PcO.01). TT homozygotes had sigmfi- 
cantly higher sCD14 levels (2.4 mcg/mL) than carriers of both the CC (2.1 mcgimi) and 
CT (1.8 mcg/mL) genotypes (P<O.O5). TT homozygotes also showed increased produc- 
tion of IL-6 by circulating MO in response to LPS-challenge (4.0 ng/mL) than carriers of 
the other two genotypes (1.9 and 1.3 ng/mL, respectively; PcO.05). Conclusion: Circu- 
lating MO of UA pattents exhibit an enhanced responsiveness to LPS-challenge, which is 
related to sCDl4 plasma levels: the soluble form of the receptor for bacterial LPS, and to 
a polymorphrsm in the promoter of the CD14 receptor gene. Our data suggest that a 
genetically determined response of crrculating MO to infectious stimuli may contribute to 
determine the inflammatory component in UA. 
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1052-85 Improved Risk Stratification of Patients With Unstable 
Angina Using a Lower Than Usual Cut-Off Point of Troponin 
T Combined With CK-MB Measurement 
B. Charles Solymoss, Martial G. Bourassa, Peter Cernacek, Andre Couturier, Pierre 
Theroux. Monfreal Heart Instifufe, Montreal, PQ, Canada 
Unstable angina (UA) pts with > or = 0.1 ug/L cardrac Troponin T (cTnT) levels have a 
higher risk of future coronary events than those wtth lower values. We examtned, in 131 
pts (Age: 65.5*11.8; Female: 48) with < 24 hrs episode of UA whether a lower cTnT cut- 
off point, combined with CK-MB measurement, improves risk stratification. Plasma sam- 
ples, obtained upon arrival and at 4, 8, and 12 to 24 hours, were analyzed with Elecsys 
1010 and the second generation of cTnT reagents. Peak values were correlated with a 
composite endpoint of new episodes of cTnTpositive UA, myocardial infarction (MI) or 
death during a mean follow-up of 15 (range 13 to 17) months. The risk of events was 
evaluated using the usual cTnT cut-off point (> or = 0.1 us/L), and a lower cut-off point (> 
or = 0.04 ug/L). cTnT positive pts were further subdivided according to CK-MB values (< 
vs. > or = 5.0 pg/L). At baseline, risk factors and history of MI, PCI or CABG were not dif- 
ferent between these groups. During the follow-up, 48 pts (36.6%) underwent PCI or 
CABG with no signtflcant differences in frequency between groups. Using the > or = 0.1 
“g/L cTnT cut-off point, the frequency of subsequent events was S/71 (11.3%) with nega- 
tive cTnT, 4127 (14.8%) with positive cTnT but negative CK-MB, and 1 i/33 (33.3%) with 
both markers positive (overall, p = 0.0207; negative vs. posttive CK-MB, p c 0.09). Wrth 
the lower (> or = 0.04 “g/L) cTnT cut-off point, the respective figures were 2/46 (4.3%) 61 
43 (14%) and 15142 (35.7%) (overall, p = 0.0004; negative vs. positive CK-MB, p = 0.02). 
Thus, the use of a lower cut-off point for cTnT values and the additional analysis of CK- 
MB further improves the risk stratification of UA pts. 
1052-86 High-Sensitivity C-Reactive Protein (hs-CRP) to Predict 6 
Month Mortality and Relative Benefit of Invasive vs. 
Conservative Strategy in Patients With Unstable Angina: 
Primary Results of the TACTICS-TIM1 18 C-Reactive Protein 
Substucly 
Christopher I? Cannon, William S. Weintraub, Laura Demopoulos, Ralph Vicari, Oscar 
Bazzino, Nader Ali, Debbie Robertson, Paul DeLucca, Peter DrBattiste, Nader Rifai, 
Eugene Braunwald, for the TACTICS-TIM1 18 Investigators. Brigham and Women’s 
Hospital, Boston, MA 
Recent studies have found that high-sensitivrty C-reactive protern (hs-CRP) is a potent 
marker of adverse prognosis rn unstable angina and non-ST elevatron Ml. We sought to 
validate this marker in a large cohort of patients and to assess the usefulness of hs-CRP 
in predicting benefit of an invasive vs. conservative strategy. Methods: In the TACTICS- 
TIMI 18 trial patients with unstable angina or non-ST elevation Ml were treated with aspi- 
rin, heparin and tirofiban and randomized to an invasive strategy with routine catheteriza- 
tion and revascularization within 4-48 hours, or to a conservative (i.e., a .‘selective 
invasive” strategy) with catheterization performed only if the patient had objective evi- 
dence of recurrent &hernia or a positive stress test. Hs-CRP (Dade-Behring) was mea- 
sured in all patients who provided a baseline blood sample (N=l804). Results: 
Preliminary results as of August 2000 showed a higher 6-month mortality rate for those 
with hs-CRP> 1.5 mg/dl (99th percentile of normals).(See Table) Similarly, death or MI. 
and the primary endpoint of death, MI or rehospitalization for acute coronary syndrome 
were significantly higher among patients with hs-CRP > 1.5. 
he-CRP <= 1.5 > 1.5 P value 
N= 1398 408 
Mortality (%) 2 08 6.37 <O.OOi 
Death/Ml (%) 6.66 11.03 0.004 
Composite (%) 15.7 20.6 0.02 
Conclusion: In this large cohort of patients with unstable angina, hs-CRP was a signifi- 
cant predictor of 6-month mortaltty, and recurrent cardiac events. Its “se in predrcting 
benefit of a routine invasive vs. “selective invasive” strategies will be presented. 
1052-87 Six Month Prognosis After Hospital Discharge in Patients 
With Acute Coronary Syndromes: The GRACE Project 
Robert J. Goldberg, Frederick Spencer, Joel M. Gore. lmmad Sadiq, Cynthia Sullivan, 
Keith Fox, Gabriel Steg, Kim Eagle, Christopher Granger, Alvaro Avezum. University of 
Massachusetts Medical School, Worcester, MA 
Background: The acute coronary syndromes (ACS) continue to be a major reason for 
hosprtal admissions with significant attendant morbidity and mortality. While significant 
advances have been made in improving the hospital outcome for these patients, consid- 
erably less information is available about the long term prognosis for thus group of 
patients. 
Methods: The Global Registry of Acute Coronary Events (GRACE) Registry is enrolling 
patients with ACS at 94 hospitals in 14 countries. In addition to detailed information on 
inhospital treatment and selected short-term outcomes, patients have follow-up data coi- 
lected at 6 months following hospital discharge assessing the development of subse- 
quent coronary events and medication adherence. 
Results: To date, 2795 patients with ACS have been successfully followed since hospital 
discharge. This includes 1576 patients with myocardial infarction (Ml)(880 wtth ST seg- 
ment elevation [STE) MI and 696 with non-STE Ml), 1067 with unstable angina, and 122 
with other cardiac diagnoses. The 6 month post discharge death rates were highest in 
those with non STE Ml (7.3%) followed by pattents with STE Ml (5.9%), those with 
unstable angina (4.9%) and those with other cardiac discharge diagnoses (4.1%). 
Rehospitalization rates for heart disease were relatively frequent (-20%) in all patient 
groups. Results of a multivariable regression analysis controlling for various demographic 
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1052-84 Cardiac Troponin I Is A Powerful Long-Term Predictor of 
Serious Cardiac Events: Follow-Up of 501 Patients for 35 
Months 
Graham Hillis, Pamela Taggart, Lorraine Hillis, Ning Zhao, Antoinette Mangione. Aibert 
Einstein Medical Center, Philadelphia, PA 
Background: Sensitive and specific cardiac markers are excellent predictors of early 
outcome in patients with chest pain. There are, however, few data regarding the relative 
utility of such markers !n predicting the long-term outcome of such patients. The aim of 
the current study was to assess the relative prognostic ability of clinical factors, cardiac 
troponrn I (cTnl), creatine kinase MBmass (CK-MBmass), myosin light chain 1 (MLC-I) 
and myoglobin (Mgb). Methods: Five hundred and one patrents presenting with chest 
pain were studied prospectively. Eligibility criteria included > 15 minutes of chest pain at 
rest within the prior 24 hours felt clinically to represent myocardial ischemia, but with clin- 
ical and ECG features on admission suggesting a low risk of acute myocardial infarction 
(AMI). Cardiac Tnl, CK-MBmass, MLC-I and myoglobin levels were assayed at presenta- 
tion (0 hours) and at 6 and 12 hours. These were performed by technicians blinded to ail 
clinical data and were not available to the clinicians treating study subjects. Patients were 
followed up a median of 35 (range 9 - 49) months later. The primary study end-point was 
the occurrence of a serious cardiac event (SGE: death, non fatal AMI or coronary ravas- 
cularization) after the index admission. The relative predictive values of different markers 
and clinical factors (age, sex, current smoker, history of hypertension, history of diabetes 
hrstory of coronary revascularisation) were assessed “sing logistic regression. Results: 
Follow-up data ware available on 488 patients (97%) of whom 99 (20%) suffered an SCE 
during follow-up. Ail four biochemicai markers were significant predrctors of the occur- 
rence of an SCE during follow-up. Cardiac Tnl was, however, the most powerful (OR 3.5, 
95% Cl 2.0-6.3; p < 0.0001) and only independent btochemical predictor. In a multivariate 
logistic regression equation, age was the only other independent predictor (OR 1.03 per 
year, 95% Cl 1.01-1.05; p = 0.006). Conclusions: The current data confirm that cTnl is a 
powerful independent predictor of long-term adverse events in patients wrth chest pain. 
In this respect it is superior to other widely available cardiac markers and most clinical 
parameters 
316A ABSTRACTS - Myocardial lschemia and Infarction 
and clinical characteristics revealed that older patient age and failure to receive ACE 
inhibitors at the time of hospital discharge were significantly associated with 6 month 
death rates in patients with AMI and unstable angina. Older patient age and failure to 
receive beta blockers or statins were associated with significantly increased risk of rehos- 
pitalization in patients with ACS. 
Conclusions: Our results from a multi-hospital, multi-country registry suggest that 
patients discharged from the hospital with ACS continue to experience significant morbid- 
ity and mortality over the ensuing 6 months. Targeted interventions need to be directed to 
the elderly and to the Increased use of evidence-based proven theraples to improve 
prognosis after ACS. 
1052-88 Optimal Discriminative Value of Troponin-I for 6 Month 
Cardiac Event Rate in the Evaluation for Suspected Acute 
Coronary Syndromes 
Vincent Roolvink, Hans E. Luijten, Marc A. Brouwer, Gerard J. H. Uijen, Ries de Keljzer, 
Tjeerd van der Weti, Freek W. A. Verheugt. Heartcenter, University Medical Center, 
Nijmegen, The Netherlands 
Background. Troponin-I (cTnl) has proven to be a useful prognostic marker for short- 
term outcome in patients presenting with a suspected acute coronary syndrome. Never- 
theless, a fair amount of patients with a positive cTnl (> 0.20 ngiml) will not develop a 
major ischemic event. This study sought to a?sess ihe optimal discriminative value of 
cTnl with respect to long-term outcome. 
Methods. Between January 1, and October 31. 1999, cTnl-levels were determined 8 
hours or more after symptom onset in 150 patients presenting with acute chest pain at 
the emergency department Clinical charts were reviewed for subsequent events: cardiac 
death(t), (re-)infarctian(reMI), revascularization (revasc.) and recurrent angina (reAP). 
cTnl-levels were assessed by discriminant analysis, with respect to the optimal comblna- 
tion of positive- and negative predictive value (P.PV. ; N.P.V.), sensitivity (SN) and speci- 
ficity (SP). 
Results. Mean follow-up time was 235 * 85 days. Opilmal cTnl levels for the respective 
clinical endpoints are given in the table. The rate of t/reMl was 2% in case of a cTnl < 
0.36 rig/ml (n=liZ): 14% for patients with a cTnl between 0.20 and 0.36 ngiml (n=14), in 
contrast to 0% in patients with a cTnl < 0.20 rig/ml (n=98). 
Conclusions. According to these findings, even a cTnl level slightly higher than 0.20 ngl 
ml carries a markediv increased risk for death and reinfarction within 6 months after the 
index event. 
N (70) cTnl @g/ml) P.P.V. N.P.V. SN SP 
cardiac death (t) 
t/reMl 
tlreMl/revasc. 
tireMllrevasc.lreAP 
3 (2%) 0.42 5% 99% 67% 76% 
10 (7%) 0.36 22% 98% 80% 79% 
38 (25%) 0.23 58% 90% 74% 82% 
52 (35%) 0.20 71% 85% 71% 85% 
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Background: The role of magnesium (Mg) in treating acute myocardial infarction (AMI) 
is controversial. Two major clinical trials (LIMIT 2, 1515-4) which have attempted to exam- 
ine the efficacy of Mg in AMI have produced conflicting results with respect to mortality. 
Experimental studies have however shown that intravenous Mg started before reperfu- 
sion produces beneficial effects by decreasing infarct size and suppressing free radicals. 
Methods: We randomly divided 98 patients with a first AMI (anterior or inferior location) 
into two groups, an Mg (n=48) and a control groups (n=50). All patients were successfully 
rep&used by primary PTCA. Before reperfusion, Patients in the Mg group received a 
bolus injection of 8 mm01 Mg sulphate followed by an infusion of 32 mmal over 24 h. Left 
ventriculograms prior to discharge were used to evaluate ejection fraction (EF) and end- 
diastolic volume index (EDVI) by the area-length method. Regional wall motion (RWM) in 
infarcted segments was analyzed using the cenierline method. Coronary flow reserve 
(CFR) in the infarct-related artery was measured to a.ssess coronary microvascular func- 
tion, using a Doppler guidewire. CFR was expressed as the ratio of maximal hyperemic 
average peak velocily after injectlon of intracoronary papaverine to the baseline value. 
Results: There was no significant difference between the groups in the time to reperfu- 
sion. Distribution of culprit lesion location, diseased vessels, and collateral grade were 
similar between the groups. The frequency of the angiographical no reflow phenomenon 
was significantly higher in the control group than in the Mg group (10% vs 0%). Left ven- 
tricular EF, EDVI and RWM wer& significantly better in the Mg group than in the control 
group (EF:63*9 vs 53?13 %, pcO.001; EDVI:57rl4 vs 72121 mUm2, p<O.OOl; RWM:- 
0.90*1.30 vs 01.83+1 .I5 SD/chord, p=O.O02). CFR was also significantly higher in the 
Mg group than in the control group(2.9t0.8 vs 2.4kO.9, p=O.O36). Conclusions: Intrave- 
nous Mg sulphate started before rep&u&n may preser& left ventricular systolic func- 
tion and suppress dilatation, and result in. better coronary microvascular function 
compared to reperfusion alone in patients with AMI. 
1053-91 Lipid Lowering Drug Therapy Initiated During 
Hospitalization for Acute Ml is Asociated With Lower 
Postdischarge I-Year Mortality 
1053-89 Aspirin Use and All-Cause Mortality Among Patients Being Robert P. Giugliano, Elliott M. Antman, Susan L. Thompson, Carolyn H. McCabe, Eugene 
Evaluated for Known or Suspected Coronary Artery Braunwald. Brigham and Women’s Ho&al, Boston, MA, Nottingham Clfnical Research 
Disease: A Propensity Analysis Group, Nottingham, United Kingdom 
Patricia A. Gum, Maran Thamilarasan, Junko Watanabe, Eugene Blackstone, Michael S. 
Lauer. Cleveland Clinic, Cleveland 
Background: Although aspirin has been shown reduce cardiovascular morbidity, the 
association between its “se and long-term all-cause mortality has not been well defined. 
Methods: We prospectively studied 6527 consecutive adults referred for stress echocar- 
diography at the Cleveland Clinic between 1990 and 1998 for evaluation of known or sus- 
pected coronary disease; 2455 (38%) were taking aspirin. We used propensity analysis 
to identify patients for whom comparisons between aspirin use and no aspirin “se were 
valid and to account for selection biases. Resulb: During 3.1 years of follow-up, 310 
patients (5%) died. After adjustment for age, gender, standard risk factors, “se of other 
medications, coronary disease history, ejection fraction, functional capacity, heart rate 
recovery, and echocardlographic ischemia, aspirin “se was associated with reduced 
mortality (hazard ratio [HR] 0.65, 95% confidence interval [Cl] 0.51-0.84, p=O.OOOS). 
According to a propensity analysis, there were 3916 patients for whom comparisons 
between aspirin users and non-users were valid; among these patients 2149 (55%) were 
taking aspirin. During follow-up there were 243 deaths (6%). Patients taking aspirin were 
at lower risk for death (5% vs 8%, HR 0.71, 95% Cl 0.55-0.91, p=O.O07). See Figure. 
After adjusting for the propensity for using aspirin, as well as all other possible confound- 
ers and interactions, aspirin “se remained associated with a lower risk for death 
(adjusted HR 0.68, 95% Cl 0.52-0.89, p=O.O05). Conclusion: In this propensity analysis, 
Background - The benefit of commencing lipid lowering drug therapy (LLRx) during 
hospitalization for AMI has not been established. 
Methods - We analyzed baseline characteristics, concomitant ireatments, inhospital 
complications, and I-yr mortality among 14,124 patients with AMI surviving the index 
admission in InTIME-II, a randomized double-blind trial comparing tPA and nPA. The 
association between the “se of LLRx with 1-yr mortality, adjusted for baseline character- 
Istics and inhospital complications (recurrent Ml, CHF, shock, stroke), was explored in a 
multivariate model. 
Results _ 34.3% of patients who survived to discharge received LLRx inhospital. Unad- 
justed 1-yr mortality post-discharge was 33% lower among patients receiving inhospital 
LLRx (3.0% vs. 4.5%, p = 0.00005). After multivarlate adjustment, inhospital LLRx was 
associated with 20-36% lower mortality l-year post-discharge: 
Prior Lipid Rx In hospital Lipid Rx OR 95% Cl p-value 
NO NO 1.0 referent group 
Yes NO 1.05 0.61-1.83 0.86 
NO Yes 0.80 0.63-1.22 0.07 
YfYS Yes 0.64 0.43-0.97 0.03 
JACC February 2001 
the use of aspirin among patients undergoing stress echocardiography for evaluation of 
known or suspected coronary artery disease was independently associated with reduced 
long-term all-cause mortality. 
1053-90 Cardioprotective Effects of intravenous Infusion of 
Magnesium Sulphate in Acute Myocardial Infarction 
Hiroshi Nakashima, Toshirou Katayama, Yuklharu Honda, Shin Suzuki. Department of 
Cardiolom Nagasaki Citizens Hospit& Nagasaki, Japan 
JACC February 2001 
Conclusions - LLRx during the Index hospitalization is associated with improved sur- 
vival in this observational study, and provides additlonal support for early Initiation of 
LLRx following acute Ml. 
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Lower Myocardial Infarction Risk in Users of Selective 1053-92 
Serotonin Reuptake Inhibitors 
William H. Sauer, Jesse A. Berlin. Stephen E. Kimmel. University of Pennsylvania School 
of Medicine, Phiiadeiphia, PA 
Background: Depression IS an independent risk factor for myocardial infarcilon (Ml). 
Selective serotonin reuptake inhibitors (SSRls) may reduce this risk via treatment of 
depression and attenuation of serotonin-mediated platelet activation. Methods: A case- 
control study of first Ml in smokers, ages 30 through 65, was conducted among all 68 
hospitals in an E-county area during a 28 month period. Cases were smokers hospital- 
lzed with a first MI, and controls were randomly selected smokers from the Same geo- 
graphic area. Detailed information regarding medication use and other clinical and 
demographic data ware obtained by telephone intervlew. Anxioiyiic use served as an 
alternate exposure group to assess the potential for selection and recall bias. Results: 
653 cases and 2,990 controls participaled. After adjustment using multivariable logistic 
regression, for age. gender, race, education, exercise, quantity smoked/day, body mass 
index, aspirin use for Ml preveniion, family history, and history of coronary disease, dia- 
betes, hypertension. and hypercholeslerolemia, the odds ratio (OR) for Ml among SSRI 
risers compared with non-antidepressant user3 was 0.32 (95% Cl: 0.16, 0.62; P<O.Ol). A 
dose-response relationship towards reduced risk of Ml was seen with increasing doses of 
SSRls (P for trend ~0 01). Non-SSRI antidepressant users had a nonsignificant reduction 
in MI risk v&h wide confidence Intervals (adjusted OR 0.47, Cl: 0.17, 1.29; P=O.l4). How- 
aver, analysis of this group was limited by the small number of exposed subjects. Anxi- 
olytic use was not associated with MI (adjusted OR 0.96; Cl: 0.56, 1.66: P =0.89). 
Conclusion: There is a signiiicani association between SSRI use and MI protection 
This may be due to a reduction in depression-associated Ml risk and/or the inhibitory 
effect SSRls have on serotonin-mediated platelet activation. 
1053-93 Early Use of Beta-Blockers Is Associated With an 
Attenuation of Serum C-Reactive Protein Elevation and a 
Favorable Short-Term Prognosis After Acute Myocardial 
Infarction 
Toshihisa Anrai, Tsutomu Yoshikawa, Toshiyuki Takahashi, Yuichiro Maekawa. Yasushi 
Asakura, Shim Ishikawa, Hideo Mitamura, Satoshi Ogawa Keio Universify School of 
Medicine, Tokyo. Japan 
Background: Peak serum C-reactive protein (CRP) levels in patients with an acute myo- 
cardial infarction (AMI) is known to correlate well with peak serum IL-6 levels, bui not with 
peak creatine klnase (CK) levels, suggesting thal the serum CRP level may reflect the 
process of Infarct healing. We have reported that an extreme elevation of Serum CRP 
level is an independent predictor for cardiac rupture and left ventricular (LV) aneurysmal 
formation after AMI. Bela-blocker is shown to have a protective effect against cardiac rup- 
ture, however, the effect of beta-blocker on serum CRP elevation aft& AMI has not been 
determined. Methods and Results: We studied a total of 105 patients with first Q-wave 
AMI. Patients complicating pump failure (class>Klllip I and/or subset>Forre$ter I) were 
excluded from this study. Forty-eight patients received beta-blocker (metoprolol, atenolol 
or propranolol) treatment within 24 hours from the onset of AMI, while 57 patients 
received no beta-blocker treatment. Peak Serum CK and CRP levels were determined by 
serial measurements (CK, every 6 hours; CRP, every 24 hours) and a prognosis was 
assessed in each group. There was no difference in age, gender, coronary risk factors, 
preinfarction angina, infarct site, the prior use of beta-blocker, the use of ACE inhibitor or 
calcium antagonisis, the use of or success rate of revascularization therapy, and the 
prevalence of multlvessel disease between the groups. Beta-blocker treatment was asso- 
ciated wiih a lower peak CRP level (8.lil .O vs. 11.7t1.3 mgidl, p=O.O4), a shorter dura- 
tion from the onser to ihe peak CRP level (2.510.1 vs. 3.2*0.2 days, p&01) and a lower 
in-hospital cardiac mortality (0 vs. 9%; 4 patients with cardiac rupture and one patient 
wilh ventricular arrhythmia, p=O.O3), despite similar peak CK levels (1829+381 vs. 
1660+195 IU/I, p&67) Conclusion: The early use of beta-blocker is associated with 
decreased serum CRP level and a favorable short-term outcome after first Q-wave AMI, 
suggesring some beneficial effects of beta-blocker treatment on Infarct healing after AMI. 
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1053-94 Cardioprotective Effect of Vasopeptidase Inhibitors in the 
Infarcted and Remodeling Rat Heart 
Nathalie Lapoinie, Charles Blais Jr, Albert Adam, Martin Sirois, Robert Clement, Hugues 
Gosselin, Jean L Rouleau. Toronto General Hospital, Toronto, ON, Canada, Universify of 
Montreal, Montreal, PQ, Canada 
Background: Part of the cardioprotedive effect of angiotensln converting enzyme mhibi- 
tars (ACEI) in the post-myocardial infarction (MI) setting, IS thought to be due io attenua- 
tion of bradykinin (BK) metabolism. Vasopeptidase inhibitors (Vpl), by inhibiting boih ACE 
and neutral endopeptldase (NEP), further reduce BK metabolism and increase natriuretic 
peptides and thus may have better cardioprotective effects than ACEi post-MI. Methods: 
Ml was induced in by coronary ligation (n=514). Rats surviving 4 hours post-Ml (n=255) 
were asslgned to, the Vpi, omapatrilat (80mglkglday), omapatnlat (40 mglkgiday), Ihe 
ACEi captoprll (160 mgikgiday) or no treatment. After 56 days, hemodynamic measure- 
ments were done and rais ware separated into two groups, one for remodeling (diastolic 
pressure-volume relations, morphomeiry) and the other one for biochemistry studies 
(mRNA was assayed by RTPCR). Results: Omapatriiai and captopril resulted in similar 
improvement in survival, hemodynamic measurements, and attenuated ventricular dilata- 
tion. The pattern of ventricular remodeling differed between omapatrilai and captopril, 
despite causing similar reductions in ventricular weights. Bolh interventions reduced 
expression of the pro-fibrotic cytokine TGF, neither effected the antl-inflammatory cytok- 
one inter&kin 10, and only captopril reduced the pro-inflammatory cytokme TNF a. 
Expression of TNF a was in cardiomyocytes. All groups reduced endothelin-1 levels, and 
only omapatrilat increased natriuretic peptides. Conclusion: This study indicates that 
both omapatrilat and captoprii markedly improve post-MI survival, cardiac function and 
cardiac remodeling in the rat. Although minor differences exist between the effects of the 
two drug classes in the post-Ml seitlng, it would appear that the addltlon of NEP inhibition 
to those of ACE Inhibition does not result in significant further benefit. 
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1054-95 Platelet Glycoprotein (GP) Ilb/llla Is Associated With Platelet 
Aggregation in Coronary Lesions Underlying Acute 
Coronary Syndromes 
Takurou Shins&, Takahiko Naruko, Makiko Ueda, Kazuo Haze, Akira ltoh, Masato 
Otsuka, Yuji Sakanoue, Yoshihiro Ikura, Masayuki Ogami. Osaka City GeneraiHOspitai, 
Osaka, Japan, Osaka City University Medical School, Osaka, Japan 
Background : Plaque rupture, hemorrhageand thrombus formation have been impli- 
cated as the mechanisms responsible for iransformation of stable coronary lesions into 
active lesions,leading to unstable angina pectoris (UAP) and acute myocardial infarction. 
Especially platelet aggregation at the site of plaque rupture or erosion is a dominant fea- 
ture in the pathophysiology of plaque destabilization. To elucidate the role of GPllbillla in 
coronary plaque destabilization, we immunohistochemicaily studied the presence of GP 
Ilb/llla in coronary atherectomy specimens obtained from patients with stable angina 
(SAP) and UAP. Moreover we immunohistochemicaliy investigated the presence of P- 
selectin, which is known to be a marker of platelet activation, in these specimens. Meth- 
ods: All these patients underwent atherectomy at primary atheroscl lesions responsible 
for SAP (n=25) and UAP (n=23). Frozen samples were studied with antibodies against 
smooth muscle cells, macrophages (MAC), endothelial cells, GPllb/llla (CD41) and P- 
selectin. Immunoreactive positive areas for GPllbillla, P-s&din. and MAC, respectively, 
ware calculated as a percentage of the total area, using computer-aided planimetry. For 
the identification of cell types which stain positive for GPllb/llla or P-selectln, immunodou- 
ble staining was also performed. Results: The percentage of GPllb/llla, P-selectin and 
MAC positive area was significantly higher (P<O.OOl) in patients with UAP ihan in 
patlents with SAP In patients with UAP, 21 of 23 lesions (91%) contained GPllb/llla posi- 
tive platelet thrombi, and all these platelet thrombi were positive for P-selectin. In con- 
trast, in SAP patients 10 of 25 lesions (40%) showed GPllbillla positive thrombi,and only 
3 lessons (12%) revealed P-selectin positivity in platelet thrombi. Conclusions: These 
findings strongly suggest that platelet activation and aggregation,leading to formation of 
platelet thrombi,play an important role in plaque destabillzatlon in human coronary ath- 
erosclerotic lesions. 
1054-96 Expansion of Interferon-Gamma-Producing Thl 
Lymphocytes as a Mechanism of Progression in Acute 
Coronary Syndromes 
Jijrg Koglin, Heiko Methe, Stefan Brunner, Daniela Wlegand, Wolfgang “on Scheldt. 
Medizinische Klinik 1, Universitfitsklinikum Grosshadern, Mumch, Germany 
Background: The progression from stable coronary artery disease to unstable acute 
coronary syndromes is associated with activation of cellular immune responses. Activa- 
tion and.differentlalion of circulating lymphocytes IS believed to represent part in this pro- 
cess. However, it remains controversial whether these mechanisms are cause or 
consequence of acute coronary syndromes. 
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Methods: To study the temporal relationship between progression of acute coronary syn- 
dromes and activaton of cellular immune responses, we compared lymphocyte activation 
and differentiation towards Thl or Th2 in patients without coronary artery disease (n= 71, 
with stable angina (n=14), with unstable angina (n=il) and with acute myocardial infarc- 
tion (n=lO). Lymphocyte activation was assessed using 3.color flow cytometry to quantify 
CD3+ cells producing IFN-y (Thl), IL-4 (Th2) or both signature cytokines (ThO). 
Results: In patients without coronary artery disease, 7.6521% of peripheral CD3c cells 
stained positive for IFN-p This proportion increased significantly in stable angina 
(13.9+1.3%, ~~0.05) with a maximal expansion in patients with unstable angina 
(33.3+2.6%, p<O.OOOl versus control and stable). In marked contrast in patients with 
acute myocardial infarction, the frequency of IFN-y+/CD3+ cells declined to 7.3+1.6% 
(p<.OOOi versus unstable). The frequency of IL-4+/CD3+ (p=O.64) or IFN-y+lIL-4+/CD3+ 
(p=O.73) cells did not differ significantly between the different groups. 
Conclusion: The present findings suggest that IFN-y-producing Thl cells, but not Th2 or 
ThO cells, promote the progression of acute coronary syndromes. The transient nature of 
the expansion of circulating Thl cells with an abrupt reduction if the instability progresses 
to acute myocardial infarction strongly supports the assumption of lymphocyte activation 
as a cause rather than a consequence of increasing plaque instability. 
JACC February 2001 
1054-99 Oxidative Stress and Redox Equillibrium in Patients With 
Coronary Vasospasm 
Kunihisa Miwa, Toshinori Makita, Katuhisa Ishii, Nobuaki Okuda, Takaharu Saito, Chiharu 
Kishimoto, Hajime Nakamura, Junji Yodoi. Kansai Nectric Power Hospital, Osaka, Japan, 
Kyoto University Kyoto, Japan 
Backgound. Increased oxidative stress has been implicated in the pathogen&s of core- 
nary vasospasm. Thioredoxin is a redox-active protein which is known to be induced by 
oxidative stress and released from cells. The serum thioredoxin level may reflect sys- 
temic oxidative stress or redox equillibrium. In order to determine whether oxidative 
stress is actually accentuated in patlents with coronary vasospasm, serum levels of both 
thioredoxin and antioxidant vitamin E were determined in patients with coronary spastic 
angina. Methods. The serum thioredoxin level was determined using enzyme-linked 
immunosorbent assay in 21 patients with active stage of coronary spastic angina with 
spontaneous angina1 attacks at least twice a week (GSA), in 17 patients with inactive 
stage of coronary spastic angina with diagnosed coronary spasm but without angina for > 
6 months (ICSA), in 26 control subjects without coronary artery disease (Control) and 
also in 26 patients with stable effort angina and a significant organic coronary stenosis 
but without rest angina (SEA). Results. The serum thioredoxin level (mean + SD “g/ml) 
was significantly higher in CSA (64t44) than in iCSA (34?37), in Control (34~15) and 
also in SEA (37+16). I” contrast, the serum alpha-tocopherol (mg/g lipids) level was sig- 
nificantly lower in CSA (2.8eO.7) than in Control (3.6+0.7). Current smoking was signifi- 
cantly more prevalent in CSA (76%) than in iCSA (24%), in Control (35%) and in SEA 
(23%). No significant correlation was found between the serum levels of thioredoxin and 
alpha-tocopherol. In 9 patients of CSA, the serum level of thioredoxi” significantly 
decreased (93+41 to 41+35) and the serum level of alpha-tocopherol significantly 
increased (2.7r0.6 to 3.1+0.6) after a >3-month angina-free period under medication 
with calcium antagomsts and smoking cessation education. Conclusion. Patients with 
coronary spastic angina in active stage had a higher serum thioredoxin level associated 
with a lower serum level of antioxidant vitamin E. Redox equiliibrium appeared to be 
related to the disease activity of coronary vasospasm in these patients. Oxidative stress 
may play a” important role in the genesis of coronary vasospasm. 
1054-I 00 The Circumflex Artery: A Major Contributor in Nonq-Wave 
Myocardial Infarctions 
Anil J. Mani, M. Karatepe, Zoran Lasic, E. Kreps, M. Collins, J. Moses, N. Coplan, I. 
Moussa. Lenox Hi// Heart and Vascular Institute, New York, NY 
Background: In patients presenting with a” acute MI, the EKG has traditionally been uti- 
lized for treatment stratification. However, the EKG has significant drawbacks in evaluat- 
ing events involving the left circumflex artery (LCX). This study was undertake” to 
evaluate the extent of con!ribution by the LCX artery in “on Q-wave MI (NQWMI). Meth- 
ods: Between January 1994 and December 1997, 404 consecutive patients (pts.) with 
NQWMI who underwent coronary angiography for risk stratification at our institution were 
identified. Demographic, in-hospital and angiographic data were collected. NQWMI was 
defined by presentation, EKG and a total CPK above normal with CPK-mb > 5%. A large 
Ml was defined as a peak CPK >5x normal. Results: The mea” age of the study group 
was 65+12.3 years; 65% were male. The infarct related artery (IRA) was identifiable in 
269 pts. (66.6%); 135 pts. had severe three vessel disease which prevented identification 
of the IRA. Total occlusions were present in 95/265 (35%) of IRA. The LCX artery 
accounted for 37.7% of all Ml and 58.13% of all large Ml with an identifiable IRA. Com- 
plete thrombotic occlusion with no collateral supply was significantly higher in the LCX 
artery as illustrated below: 
IRA With Total Occlusion ( n = 95 ) 
LAD(%) LCX(%) RCA(%) LM(%) SVG(%) 
No Collateral(n=48) 25 64.6 8.3 2.1 0 
Collateral(n=47) 31.9 29.8 31.9 0 6.4 
* p values: LCX vs. LAD (O.O5),vs. RCA @.0007), vs. SVG (0.03), vs. all other sites 
(0.0009) Conclusions: The LCX artery is a significant contributor to thrombotic vessel 
occlusions in NQWMI. These patients may benefit from immediate repetfusion therapy. 
cm1tr01s stable 
angina 
1054-97 Incidence of Underlying Coronary Artery Disease Among 
Patients Having Cocaine-Associated Chest Pain 
Michael C. Kontos, Robert L. Jesse, James L. Tatum, Charlotte S. Roberts, Joseph l? 
Ornate. MCV/VCU, Richmond, VA 
Patients who present to the Emergency Department (ED) with chest pain associated with 
cocaine use are a” increasingly recognized problem. The incidence and predictors of 
underlying significant coronary disease (Sig CAD) in patients with and without MI has not 
been well described. Methods: Patients who underwent coronary angiography within 60 
days of a” ED evaluation for cocaine chest pain were included. Sig CAD was defined as 
2 50% luminal stenosis of,a cororary artery or one of its major branches. Results: From 
6194 to 3100, 698 patients were evaluated for myocardial ischemia after cocaine use, of 
whom 84 subsequently underwent coronary angiography. Sig CAD was present in 40 
(48%): 1 vessel in 24, 2 vessel in 8, 3 vessel in 5 and graft stenosis in 3. Sig CAD was 
present in 19/25 (76%) of the pts with acute myocardial infarction (AMI) compared to only 
21159 (36%; p=O.O03) pts without AMI. Only AMI (48% vs 14%, p=<O.OOl), prior Ml (25% 
vs 7%, p=O.O2) and known CAD (prior Ml or revascularization) (40% vs 1 l%, p=O.O03) 
were associated with Sig CAD. There was no significant difference in the age (42+7 vs 
42+9), gender (70% vs 73% male), or risk factors other than diabetes between those with 
and withoui Sig CAD. In the 54 pts without AMI only prior Ml (25% vs 7%; p=O.O2) and 
known CAD (40% vs 11; p=O.O03) were predictive of Sig CAD; ischemic ECG changes 
were not (38% vs 23%; p=O.14). Only 12 pts (14%) of patients without AMI or known 
CAD had Sig CAD. Conclusions: Sig CAD is found in the majority of patients with 
cocaine-associated Ml. I” contrast, only a minority of patients with cocaine associated 
chest pain without Ml have Sig CAD. 
1054-98 Organized Thrombosis in Coronary Arteries of Young 
Sudden Cardiac Death Patients 
Allard C. van der Wal, Rosa Henriques de Goveia, Anton E. Becker. Cardiovascular 
Pathology Academic Medical Center, University oiAm.sterdam, Amsterdam, The 
Netherlands 
Background. To get Informed about plaque instability before the onset of death in young 
sudden coronary death patients. Methods. Eleven patients aged 35 years or younger 
who died instantly or within 6 hours after the onset of symptoms, and in whom coronary 
thrombus was found at autopsy, were enrolled in the study. The thrombosed artery seg- 
ment was serially cut for histology (Haematoxylin and Eosin stain) and immunohis- 
tochemistry with antlbodies reactive with smooth muscle cells (SMC) (anti- smooth 
muscle actin) and endothelial cells (anti- vo” Willebrand factor). Results. Atherosclerotic 
plaques underlying the thrombus showed deep ruptures in 2 cases, and surface erosions 
in 9 cases. Fresh thrombus was found in the culprit plaque of only 3 patients (including 
those with deep ruptures). The remaining 8 patie”ts,all with eroded plaques, showed 
organized thrombus. In 4 of those, thrombus organisation consisted of ingrowth of actin 
positive SMC in the base of the thrombus (a few days old thrombus), in 4 patients there 
was extensive ingrowth of SMC, deposition of collagen and ingrowth of microvessels 
(more than a week old thrombus). Conclusion. Erosions are by far the dominant type of 
plaque complication in young patients who die due to coronary thrombosis. Presence of 
organizing thrombus in the majority of cases indicates plaque instability of at least days, 
up to more than a week before the onset of sudden death. 
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patamts (n=22) with EA and ischemic change on treadmill exercise test were enrolled 
into this study of thiazofidinedione, and randomrzed where they received troglitazone for 
4 months (T-group, n=li) or they were followed without troglitarone ( C-group ). At base- 
kne and at 4 months after medication. we assessed changes of exercise tolerance 
(appearance time of ischemic ST segment change) and noninvasively measured the 
reactive changes in lumen diameter of right brachral artery following transient occlusion 
for 5 minutes (FMD; flow-mediated endothelium-dependent vasodilation), and after sub- 
lingual admrnistration of (300microgram) glyceril trinitrate (TNG; endothelium-indepen- 
dent vasodilation). Results: Exercise trme (minutes) were srgnificantly extended after 
medrcation in T-group (p<O.Ol) but not rn C-group. HOMA index ( product of fasting glu- 
cose and fasting insulin/405 ) and FM0 (%) was improved after medication in T-group 
(pcO.01) but not in C-group. TNG remained unchanged in both groups. Extension of exer- 
case time was correlated to improvement of FMD (Extension of exercise time (y) vs. 
improvement of FMD (x); y=O.72+0.23x. r= 0.79, p=O.O2; and improvement of HOMAin- 
dex (x); y=O.91+1.36~, r= 0.62, p=O.O4). Conclusion: These findings suggest that troglr- 
tazone reverses exercise intolerance partly related to endothelial dysfunction and rnsulin 
resistance in patients with effort-induced angina pectoris. 
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1083-75 Treatment With Folic Acid and Cobalamin Improves 
Coronary Endothelial Function in Hyperhomocysteinemic 
Patients With Symptomatic Coronary Artery Disease 
Frank F. Willems, Win RM Aengevaeren, Godfried HJ Boars, Henk J Blom, Freek WA 
Verheugt. university medical center, nijmegen, The Netherlands, Rijostate hospital, 
arnhem. The Netherlands 
Background: Hyperhomocysteinemia is an independant risk factor for coronary artery 
disease. It is unclear whether lowering homocysteine(HCY)with frolic acid and cobal- 
amine improves coronary endothelial function in patients with hyperhomocysteinemia 
and coronary artery disease.Aim of this study was to evaluate the effect of folic acid and 
cobalamine on coronary endotheltal function in patients with symptomatic coronary 
artery disease. Methods: 17 patients shed&d for elective PTCA with HCY levels above 
16 umolll ware randomised for treatment with follc acid 5 mg and cobalamine daily or pla- 
cebo. Coronary endothelial function was evaluated in a non-PTCA vessel using acethyl- 
choline infusion in an dosage of 10.8M, 10.7M, IO-6M and nitroglycerin POOug.Each 
infusion was followed by coronary angiography. After 6 months of treatment a second 
procedure was performed “sing the same method. Endpoints were the mean changes in 
minimal obstruction diameter(MOD) and mean segment diameter(MSD)of the investi- 
gaied coronary vessel as compared to the initial procedure. Results: Mean HCY level 
was 18,2umol/l [SD 2,34).The mean difference in MOD(%) before vers”~ afier treatment 
with folic acid and cobalamin is 103.6% compared to 87.1% in the placebo treated group 
(p<O.O5). The mean difference tn MSD (%) before versus after treatment with folic acid 
and cobalamin is 106.6% compared to 90.9% in the placebo treated group (~~0.05). 
Conclusion: This is the first randomised placebo controlled intervention study evaluating 
coronary endothelial function in hyperhomocysteinemic patients with symptomatic coro- 
nary artery disease. Our results suggest improvement of coronary endothelkal function 
followrng treatment with folic acid and cob&mine 
1083-76 Evidence of Oxidative Stress in Patients With Angina and 
Normal Coronary Arteries: Role of Statins and Ace- 
inhibitors 
Carmine Przri, Grazia Maria Costa,Barbara Bresciani, Milena Gentile, Carlo Tumscitz, 
Bugiardini Raffaele. Dep cardiology lmola Hospital Universiiy of Bologna, Bologna, f&/y 
Background. It is well known that the endothelial dysfunction plays a key role rn the 
pathophysiology of the angina with normal coronary angiograms. The endothelial dys- 
function is associated with increased oxidative stress (OS] and loss of nitric oxide bio- 
availabiltty. Aim of study was to evaluaie the influence of the therapy with statrns and 
ACE-I on OS production in these pts. Methods. We studied 40 normocholesterolemic pts 
with effort angina (posttive exercise stress teshng and reversible reperfusion defects). In 
order to evaluate OS we measured (T1):plasm.a levels of malondialdhehyde (MDA). a 
marker of liptd peroxidation, by high pressure liquid chromatography (HPLC); superoxide 
dismutase (SOD) and CoQlO. 20 pts (Gl) were treated with atorvastatin (40 mg/day)and 
ramipril (5 mg twice daily) for 6 months in additron to standard antiischemic treatment and 
20 pts (G2) received only standard antiischemic treatment. After 6 months of therapy(T2) 
MDA, SOD and CoQ10 were measured. Changes in OS were correlated with clinical 
response Results. Baseline characteristics (age, gender, risk factors of coronary artery 
disease) were similar in the 2 groups. At Tl MDA, SOD and CoQlO showed no differ- 
ences in Gl vs G2 (MDA:2.5+/-0.8 vs 2.4+/-0.9 nmol/ml; SOD:188+/-47 vs 180+/-51 U/ 
mg Hb; CoQlO it/-O.2 vs 0.9 +I- 0.3 mgldl). At T2 MDA was significantly reduced in Gl 
vs G2 (1.2+/-0.4 vs 2.3+1-l nmol/ml; pcO.001). No changes were demonstrated in SOD 
in Gl vs G2(179+/-52 vs 176+/-62 Uimg Hb). CoQlO’was improved in Gl vs G2 (1.2+/- 
0.2 vs 0.7+/-0.2 mgidl; p<O.OOl).At T2 in exercise stress test there were a significant 
increase !n the exercise time and rnax~mal work capacity and a significant decrease in 
the maximum ST segment depression in Gl. no myocardial perfusion assessed by defect 
tallium tomography (SPECT) in 16 pts of Gl and only 3 pts of G2. Conclusion. Our data 
support the hypothesis that oxygen free radicals production may be an important role in 
microvascular endothelial dysfunction. Administration of antioxidant drugs which reverse 
endothelium dependent dysfunction may be useful in pts with angina and normal coro- 
nary angiograms, independently of plasma total cholesterol levels. 
1083-77 Effects of insulin Resistance and Thiazolidinedione on 
Effort-Induced Angina Pectoris With Type-2 Diabetes 
Mellitus 
Tatsuaki Murakami, Masateru Ohnaka. fukui Cardiovascular Center, Fukcli, Japan 
Background: insulin resistance is thought to be hrghly involved in atherothrombogenic 
processes and effects of an insulin sensttizer on clinical manifestation of ischemrc heart 
disease have marked attention, but few investigations evaluated effects of thiazolidinedi- 
one, and an insulrn sensitizer, on rschemic heart disease. This study investigated 
whether Insulin resistance and its reversal by thiazolidinedione have impacts upon clrn- 
cal manifestations of effort-induced angina pectoris (EA). Methods: Type-2 diabetic 
Baseline T Follow-up T Baseline C Follow-up C 
Exercise Time 4.9+1 .o 6.3el.4 5.1+1.0 5.3*1.4 - 
FMD 4.0~1.6 6.7k3.0 4 222.6 4.4i2.0 
HOMA 2.6+1.4 2.11-1.1 2.551.2 2.5rl.2 
1083-78 Effect of Cholesterol Synthase Inhibitor Treatment on 
Interleukin-6 and CRP in Patients After Myocardial Infarction 
Stephan R. Holmer, Christian Hengstenberg. Hannelors Loewel, Susanne Engel, 
Wolfgang Koenig, Guenter A. J. Aiegger, Heribert Schunkert. University of Regensburg 
Kiinik lnnere Med. II, Regensburg, Germanx GSF- Institute of Epidemiology, Munich, 
Germany 
Background: Levels of cytokines (e.g. tnterleukin-6,lLti) and acute phase proteins (e.g. 
C-reactive protein,CRP) may indicate inflammatory activity in coronary lesions in patients 
with coronary artery disease and have been associated with prognosis. Chronic medica- 
tion with CSE-inhibitors (&tins) improves the prognosis of such patients. It was sug- 
gested that this treatment may modulate the rnflammatory process. 
Methods: We tested in stable patients with previous myocardial infarction (Ml) whether 
IL6 and CRP levels are modulated by chronic statin intake. Patients form the MONICA 
MI-regrster, Augsburg, (n=642; 557 men) were examined l-10 years (mean 5.6 years) 
after Ml including a standardized interview (intake of prescribed medication), anthropom- 
etry, ECG, echocardiography and blood tests (e.g. IL6 hfgh sensitive ELISA). None of the 
patients had signs of acute coronary syndrome. 
Results: Of all Ml patrents, 31% were on statin treatment. Patients with statins showed 
significantly lower IL6 levels compared to those without lipid lowering drugs (2.2kO.l pgl 
mL vs. 2.8iO.l; p<O.OOOl). This was most evident in men (Z.l*O.l vs. 2.8i0.1; 
p<O.OOOl). Simrlarly, CRP was lower in pattents on statins (2.3i0.2 mg/L vs. 3.liO.l; 
p<O.OOOl). Neither IL6 nor CRP levies were related to cholesterol levels. The association 
of statin treatment with IL6 and CRP levels was also highly significant in multivariate 
regression models that included age, body maes index, left ventricular function (EF) and 
cholesterol level as covariates (p=O.O04 and 0.017, resp.). In the small number of women 
with Ml no such association of IL6 or CRP levels with statin treatment was observed. 
Other medication such as ACE-cnhrbrtors, beta-blockers, or vasodilators had no apparent 
effect on IL6 or CRP levels tn this population. 
Conclusion: In this observational study, statin therapy is strongly and independently 
associated with lower IL6 and CRP levels in male patients after Ml. This further supports 
the concept that static therapy attenuates the inflammatory process in atherosclerotic 
patients independently of its cholesterol lowering effect 
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1084-79 Early Defibrillation Through First Responders Doubles 
Sudden Cardiac Arrest Survival in an Italian Community 
Alessandro Capucci, Daniela Aschieri, Massimo F. Piepoli, Efi Iconomu, Maurizio Arvedr. 
cardiology department, Piacenza, ftafy 
Background. The concept that non medical individuals must be allowed to perform early 
defibrillation has been largely endorsed. To improve out-of-hospital survival we devel- 
oped the Piacenza Progetto Vrta project i.e. the first European experience of public 
access early defibrillation. Methods and Results. Thirty-three semi-automatic external 
defibrillators (Heartstart FR) were placed in this Italtar- city (266.531 including the sur- 
rounding region): 15 fixed places, 12 ambulances (laic personnel), 12 polfcemen cars. 
One thousand and twenty-five laic volunteers were trained for defibrillation The volun- 
teers are activated by the Emergency Medical System (“Blue Code” call) to intervene in 
all cases of suspected sudden death. During the first year 197 sudden deaths occurred in 
this area. During this time 198 “Blue Codes” were dispatched: in only 95 of such cases a 
true sudden death (48%) was found. The defibrillator was applied by volunteers in 63 
cases: 36 asystole, 3 pulse-less electrical activity, 4 bradiarrhythmias, 1 supraventricular 
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tachycardia, 3 sinus rhythm, 16 “shackable rhythm”. Seven patients were successfully 
cardioverted and discharged alive. One patient died after 15 days. Survival rate on 
“shockable” rhythm was 43.7% in laic responders system vs. 16.6% in the medical staff 
aid (p< 0.05). Among survivals the proportion having unfavourable neurologic function at 
hospital discharge decreased from 25% to 14%. In 106 “blue codes” the volunteers inter- 
vened before the medical staff (53%) (mean intervention time: 5.30 min + 0.40 min vs. 
6.50 + 1 min, ~~0.05). Conclusions. Preliminary experience of out-of-hospital early 
defibrillation by non-medical volunteers presents encouraging results even if the “3. 
minute response time” (optimal call-to-shock time) was not yet reached. 
Emergency Medical Laic Volunteers p value 
System 
First at the scene 34% 53% 
Shockable Rhythm at the arwe (n” 24 16 
C E S f S )  
Discharged alive (no pts) 4/24 (16.6%) 7/16 (43.7%) pco.05 
Neurologic lesions in pts alive l/4 (25%) 117 (14%) 
Intervention time (min) 6.50+1 .O 5.30+0.40 pco.05 
JACC February 2001 
Conclusions. Prominant increases in the leveis of circulating vasocontraction hormones 
and systemic thrombus formatIon were observed in patients with ACS complicated by 
out-of-hospital cardiac arrest. It was suggested that the managements of hypervasocon- 
traction and hypercoagulopathy in survivors with ACS complicated by out-of-hospital car- 
diac arrest are needed for prevention of postresuscltation syndrome. 
1084-82 Utilization of the Emergency Medical System Among 
Patients With Myocardial Infarction in the Reperfusion Era: 
Results From The NRMI 2 
John G. Canto, Rob Zalenski, Joseph P Ornate, William J. Rogers, Catarina I. Kiefe, 
David Magid, Michael Shllpak, Paul Frederick, Costas G. Lambrew, Hal V. Barron. 
university of Alabama at Birmingham, Birmingham, AL 
Background. National practice guidelines strongly recommend that patients with symp- 
toms consistent with an acute myocardial infarction (Ml) activate the 911 Emergency 
Medical Systems (EMS). We examined the contemporary utrlization of EMS in the US. 
and ascertained the factors which may influence their use. Methods. From April 1994 to 
March 1998, the NRMI 2 has enrolled 772,586 patients. We excluded patients who pre- 
sented in cardiogenic shock, >6 hours from symptom onset to hospital arrival, or who 
were transferred-in. We then compared the baseline characteristics and initial manage- 
ment for patients presenting by ambulance versus self-transport. 
Results 
Ambulance Self-Transport 
N 175,517 153,365 
% 53.4 46.6 
Mean Age, years 68.1 63.7 
Non-White, % 10.5 11.0 
Men, % 60.0 69.0 
HMO, % 11.2 11.8 
Prior MI, % 27.8 24.2 
Prior heart failure, % 15.1 8.2 
Sx Onset to hospital arrival, min 90.0 102.0 
Chest pain, % 78.5 89.9 
Pre-hospital ECG and EMS 6.2 0.0 
Mean time to 1st ECG, min 13.7 15.0 
Mean door-thrombolytic, min 54.7 66.9 
Mean door-to balloon, min 141.7 173.0 
P value < 0.001 for all comparisons. Conclusion. Only 1 of every 2 patients with MI was 
transported to the hospital by ambulance, Use of the EMS was associated with signifi- 
cantly faster receipt of acute repetfusion therapies. Wider use of EMS for patients with 
suspected Ml may offer considerable opportunity for improvement in public health. 
1084-83 Open Chest Defibrillation: Biphasic Versus Monophasic 
Waveform Shocks 
Yi Zhang, Ray Davies, William J. Coddington, Janice Jones, Richard E. Kerber. 
University of lowa, lowa City /A 
Background: Transthoracic biphasic waveform shocks require less energy to terminate 
ventricular fibrillation (VF) compared to monophasic shocks. However, the effectiveness 
of biphasic shocks for intraoperative open chest epicardial defibrillation has not been 
established. Our burpase was to compare biphasic vs. monophasic shocks for open 
chest defibrillation, using a porcine model. Methods: Twenty-five adult swine (15-25kg) 
underwent a midline sternotomy. VF was electrically induced. After 15 seconds VF, each 
pig in Group 1 (n=l6) received in random order damped sinusoidal monophasic shocks 
and truncated exponential biphasic shocks (3 msec positive and 3 msec negative) at 8 
energy levels (2J, 3J, 5J, 7J, IOJ, ZOJ, 30J and 50J) from large (44 cm) hand-held epicar- 
dial paddle electrodes. Pigs in Group 2 (n=9) received simrlar shocks from small paddle 
electrodes (16 cm2). Four shocks at each energy level were delivered to construct energy 
vs. success curves. Results: There was no significant difference in shock success 
between damped sinusoidal monophasic and biphasic waveform shocks at any energy 
level in Group 1 (large electrodes). In Group 2 (small electrodes), swine receiving bipha- 
sic shocks demonstrated a significantly higher shock success than those receiving 
monophasic shocks at 7J (cO.O5), and there was a trend (p=O.O6) in favor of biphasic 
shocks at 1OJ and ZOJ. Conclusion: With small paddle electrodes, biphasic waveform 
shocks demonstrated a higher shock success rate compared to monophasic waveform 
shocks at mid-range energy levels. With large paddle electrodes, biphasic and monopha- 
sic shocks were equally effective. Shocks given from s’mall paddle electrodes may result 
in an inhomogeneous electrical field, allowing the superiority of the biphasic waveform to 
be evident. % Success Comparison. Mean +/- SEE, *p<O.O5 vs. monophasic in small 
electrode group 
1084-80 Different Basic Life Support Compression to Ventilation 
Ratios: Effect on 24-Hour Neurologically Intact Survival 
Karl B. Kern, Robert A. Berg, Ronald W. Hilwig, Arthur B. Sanders, Gordon A. Ewy. 
University of Arizona, Tucson, AZ 
Background: The recently published Guidelines 2000 for CPR and ECC suggests that 
“adult cardiac arrest (CA) victims are more likely to be saved if a higher number of chest 
compressions (CC) are delivered during CPR, even if victims receive fewer ventilations” 
(V). This study prospectively evaluated four different BLS CC:V ratios for the proportion 
of resuscitation time with CC-generated circulation and 24 hr neurologically intact sur- 
vival. Methods: Forty swine (25-35 Kg) were subjected to 3 mm of untreated VF then 
randomized to 1 of 4 different CC:V ratios including 15:2 (standard BLS), 50:5, 100:2, 
and CC-only BLS for 12 min. To mimic real life out-of-hospital resuscitatron results, CPP 
was kept at 12-15 mmHg and previously documented pauses for lay persons to deliver 
ventilations were incorporated into the protocol (i.e 15 set to deliver 2 mouth-to-mouth 
ventilations). Aortic and RA pressures, end-tidal C02, ECG, and exhaled ventilatory vol- 
umes were recorded throughout. Intensive care was provided for 2-3 hrs and neuroiogi- 
cal evaluations were performed on all 24.hr survivors. Results: BLS at 152 resulted in 
only 42% of the resuscitation period with CC-generated circulation. 50:5 produced circu- 
lation 58% of time, 100:2 for 83%, and CC-only for 93%. Standard 15:2 produced O/IO 
neuroiogically intact 24.hr survivors, 50:5 had l/10, 100:2 had O/IO, and CC-only BLS 
had 3110 (l/30 vs 3/10; p=O.O42 via Fisher’s Exact Testing). Conclusion: CC-only BLS 
results in more compression-generated circulation time and better 24-hr neurologically 
intact survival than the other CC:V ratios tested, including the currently recommended 
BLS with a 15:2 ratio 
.- 
1084-81 Postresuscitation Care in Survivors With Acute Coronary 
Syndrome Complicated by Out-of-Hospital Cardiac Arrest 
Ken Nagao, Katsuo Kanmatsuse, Kazuyoshi Satou, lkuyoshl Watanabe, Ken Arima, 
Sumito Oguchi, Satoru Kikuchi, Kimio Kikushima, Sigemasa Tani, Take0 Anazawa, 
Takashi Miyamoto. Department of Emergency & Critical Care Medicine, Nihon University 
School of Medicine, Tokyo, Japan. Department of Cardiology Nihon Universify School of 
Medicine, Tokyo, Japan 
Background : Almost one-half of postresuscitation syndrome deaths that occur take 
place within 24 hours of the event caused by microcirculatory dysfunction from the multi- 
focal hypoxia. There are no convincing clinical data to evaluate the stress response hor- 
mones and coagulative fibrinolytic parameters in patients with acute coronary syndrome 
(Ads) complicated by out-of hospital cardiac arrest. Methods: A total of 252 patients 
whose ACS-related artery could be identified by emergency coronary angtography and 
whose blood test before administration of drugs could be obtained were chosen for this 
study. The stress response hormones and coagulative ftbrinolyytic parameters of 
55patients with ACS complicated by out-of-hospital cardiac arrest were compared with 
those from 197 patients with ACS without this complication. 
Results 
*pco.o5 cardiac arrest without cardiac arrest 
Dopamine *(pgiml) 131 58 
Noradrenaline *(pg/ml) 1843 913 
Adrenaline *(pg/ml) 2096 280 
Angiotensin II *(pg/ml) 47 9 
Brain natriuretic peptide (pgiml) 127 163 
von Wiilebrand factor (%) 257 253 
Free tissue factor pathway inhibitor @g/ml) 46 56 
Prothrombin fragment I+2 *(n molll) 3.5 1.0 
Antithrombin Ill (%) 85 86 85 86 
Trombomodulin (Fuiml) 3.4 3.0 
Activated protein C (%) 68 86 
t PA PAI-I complex 37 15 
c&PI complex 15 9 
FDP *@g/ml) 26 7 
D-dimer ‘@g/ml) 6.3 1.9 
23 3J 5J 7J IOJ 2OJ 3OJ 5OJ 
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108584 C-Reactive Protein and ST Segment Monitoring With 
Continuous 12-Lead Electrocardiogram in Patients With 
Unstable Angina 
Alexander Stefanidis, Michael Zairis, Stavros Manousakis, Evangelos Tsanrs, Thomas 
Matsikas, Maria Thoma, John Hadjissavas, Apostolos Papantonakos, Stelios Handanis, 
Kostas Katsaros, Spyros Argyrakis, Stefanos Foussas. Cardio/ogy De@diwnt, Tzanio 
Hospital, Piraeus, Greece 
Kumamoto City Japan 
Background: Recently, platelet aggregometer using a laser-light scattering is capable of 
monitoring the increase in size of small-sized platelet aggregates (diameter 9-25pm) 
which can not be detected with the conventional methods. Small-sized platelet aggre- 
gates ultimately develop into medium and large-sized platelet aggregates as platelet 
aggregation proceeds, Methods: We examined platelet aggregability, especially small- 
sized platelet aggregates, plasma tissue factor (TF) antigen levels, and plasma plasmino- 
gen activator inhibitor (PAI) activrty levels on admission and after treatment in 22 patients 
with UA. We also compared the results wrth data in 19 patients with stable exertional 
angrna (SEA) and in 17 patients with chest pain syndrome (CPS). Results: The number 
of small-sized platelet aggregates increased signrficantly in the UA group [4.6+/- 
O.BXlOex~(4) (V)] than in the SEA [3.6+/-0,9XlOexp(3) (V), pcO.OOl] and CPS groups 
[2.0+1-0.7XlOexp(3) (V), p<O.OOl]. In the UA group, the number of small-sized platelet 
aggregates after 2 weeks of treatment decreased signrficantly, but was still significantly 
higher compared with the SEA and CPS groups (p<O.Oi). The plasma TF antigen levels 
and the plasma PAI activity levels were higher in the UA group [TF:309+/-28 (pg/ml). 
PAI:12.3+/-2.2 (IUiml)] than in the SEA [TF:215+/-11 (pg/ml), PAI:3.3+/-0.8 (IUiml), 
p<O.Ol] and CPS groups [TF:i91+/-16 (pgiml), PAI:3.4+/-1.3 (lU/mi), p<O.Ol]. Each level 
decreased after 2 weeks of treatment in the UA group (p<O.Ol). There were significant 
correlations among 3 markers. Conclusions: We demonstrated that small-sized platelet 
aggregates, plasma TF antigen levels, and plasma PAI activity levels increased simulta- 
neously in the UA group. Although the blood coagulation and fibrinolysis markers 
decreased after clinical stabilization, platelet hyperaggregability persisted. These results 
confirm that continuous antiplatelet therapy is essentral after stabilizatron of unstable 
angina. 
Background: ST segment monitoring by the continuous 12lead electrocardiogram 
(ECG) has been a useful tool for the quantification of recurrent ischemia rn patients (pts) 
with unstable angina (UA). Addrtronally, high levels of C-reactive protein (CRP) have been 
associated with an unfavorable outcome in these pts. However, the possible relation of 
CAP levels with the incidence and severity of recurrent ischemia in pts with primary UA 
by the use of continuous ECG monitoring was not thoroughly investigated. The arm of 
this study was to evaluate the possible assocration of plasma levels of CRP to recurrent 
ischemia detected by continuous 12-leads ST monitoring. Methods: A total of 111 pts 
with Brawnwald Ill6 UA underwent continuous ST segment monitoring for 48 hours with a 
computer-assisted 12-lead ECG-ischemia monitoring device. An ST ischemic episode 
was defined as a transient ST-segment depression or elevation in any lead of at least 
0.10 mV compared with the reference ECG, lasting for at least 1 min. Vein blood samples 
for plasma CRP values determination were obtained on admission. Pts were classified 
into three groups A. 6, and C according to the tertiles of plasma CRP values. [Mean 
value of plasma CRP: Group A (40 pts)=0.56+0.15, Group B (37 pts)=l.78+0.43, Group 
C (34 pts)=3.16&0.64 mgidl]. Results: Twenty-six out of 111(23.4%) patients had at least 
one ST ischemic episode (6, 8 and 12 pts for the A, B, and C groups respectrvely, 
p=O.ll). However, the group C pts had sigmficantly more ischemrc episodes par patient 
than the group B (3.75rl.l vs. 2.50+1.1, p=O.O3), and than the group A (3.75kl.i vs. 
1.67~0.5, p=O.OOl) pts. Additronally, the total duration of ST ischemic episodes was sig- 
nificantly higher rn the group C than the group 6 (56.41t16.27 min vs. 35.12+23.01 min, 
p=O.O4), and than the group A (56.41r16.27 min vs. 19.50+11.04 min, p=O.OOl). Con- 
clusions: Plasma levels of CRP could predict the total recurrent ischemic burden in pts 
with UA. Thus, plasma CRP levels on hospital admission may serve as an affordable and 
widely available marker for the detection of pts with silent or clinrcal obvious recurrent 
myocardial rschemia. These pts could benefit from more aggressive pharmaceutical or 
invasive treatment. 
108585 Inflammatory Markers in Patients With Acute Coronary 
Syndromes Supressed by Alphatocopherol: Evidence From 
a Randomized Controlled Trial 
R T. Murphy, J B. Foley, N McCarroll, K S. Lee, P Crean, M J. Walsh. Dqxrtment of 
Cardioiog~ St James’s Hospital, Dublin, Ireland 
Background: The acute phase proteins C-Reactive Protein (CRP) and Interleukin-6 (IL- 
6) have been shown to be elevated in Acute Coronary Syndromes (ACS) and are associ- 
ated with an adverse prognosis. Cell Adhesion Molecules are transmembrane glycopro- 
trains which mediate leukocytelendothellal binding, and are elevated in ACS. 
Alphatocopherol has extensive antiinflammatory properties. In a double blind placebo 
controlled trial, we set out to determine the antrrnflammatory effects of alphatocopherol 
on patients presenting with ACS. Methods: 110 patients presenting with ACS were ran- 
domized to alphatocopherol 400 i.u. or matching placebo daily for 6 months. Serum sam- 
ples were drawn at presentation 2, 4, and 6 months. CRP was measured by high 
sensitivity nephelemetry assay. IL-6 and the adhesion molecules soluble Vascular Cell 
Adhesion Molecule-l JsVCAM-I), soluble Intercellular Adhesion Molecule-l(slCAM-1), 
soluble E-Selectin, soluble P-Selectin, were measured using enzyme linked immunosor- 
bent assay (R+D,UK) and alphatocopherol and lipid levels measured by high perfor- 
mance liquid chromatography. A subset of patients underwent flow cytometric analysis of 
monocyte adhesion molecule ligand expression. Results: Alphatocpherolltotal lipid ratio 
rosa in the treated group by 190% and fell in the placebo group by 40%. Mean CRP lev- 
els fell in the aiphatacopherol group (from 21.8~7.1 to 5.2i-0.6 mg/L, pcO.O03), whereas 
CRP levels in the placebo group remained unchanged (17.4i-4.4 vs 10.2t8.2 mg/L, 
p=O.2). Mean IL-6 levels fell in the alphatocopherol group (from 19.513.6 to 5.6_tO.4 pgi 
ml, p<O.OOS) whereas levels ot IL-6 fell nonsigmficantly in the placebo group (17.9c 2.7 
vs 7.751.9 pglmi, p=O.Z). There was no significant difference in soluble Cell Adhesion 
Molecule levels between treatment groups. Flow cytometric analysis failed to show inhibi- 
tion of the monocyte adhesion molecule ligands Mac-l and VLA-4. Conclusion: In 
patients with ACS. alphatocopherol suppressed the expression of CRP and IL-6. These 
observations may be of clinical relevance and justify assessment in a larger clinical trial. 
1085-87 The Leukocyte Count Predicts Future Cardiovascular 
Events in Patients With a Past Myocardial Infarction 
Raef H. Hajj-Ali, Wojciech Zareba, Rana Z. Erreddine, Arthur J. Moss. North Shore 
University Hospital, Manhassef, N,: Universify of Rochesteer, Rochester, NY 
Background: Increasing evidence is accumulating implicating inflammation as a riskfac- 
tar for coronary artery drsease. We thought to determrne whether the leukocyte count is 
an Independent predictor of future cardiovascular events in patients with a past myocar- 
dial Infarction. 
Methods: The study population consisted of 1,294 patients in whom a leukocyte count 
was obtained 6 months after the index Mt. Cardiac events were defined as reinfarction or 
death. The study population was divided into four quartiles, Ql, Q2, Q3 and Q4 based on 
the leukocyte count. 
Results: Over a mean follow-up period of 25 months from the leukocyte count measure- 
ment, 163 patients had cardiac events: 8.7%, 10.9%, 14.0%, and 16.7%, in 01, Q2, 03, 
and 04 respectively (p=O.Oi). After adjusting for potential confounding factors, Cox pro- 
portional hazard analysis revealed a higher leukocyte count to be an independent predic- 
tor of cardiac events (Figure) 
(Hazard Ratio: 1.3 per one quartile rise in leukocyte count; p=O.O03; 95%CI [I .1-l 51) 
Conclusion: The leukocyte count is an inexpensive and readily available independent 
predictor of future cardiovascular events in patients with a history of a myocardial infarc- 
tion. 
1085-88 Ability of the Human Heart Type-Fatty Acid Binding Protein 
to Predict Early Adverse Outcomes in Patients With 
Suspected Acute Coronary Syndrome in Emergency Room: 
A Multicenter Study 
Tomoaki Nakata, Tohru Takahashr, Mamoro Hase, Hitoshi Oh-iwa, Akira Hashimoto. 
Karuhiko Nagao, Takayuki Matsukr, Hiroshi Kobayashi, Kazufumi Tsuchrhashi, Kazuaki 
Shimamoto Sapporo Medical University School of Medicine, Sapporo, Japan 
Background: Human heart type-fatty acid bindrng protein (H-FABP) has been demon- 
strated as a new marker of early myocardial injury rn patients with acute myocardial inf- 
arction (AMI). However, the early prognostic value in acute coronary syndrome (ACS) 
has not been established. The present multicenter prospective study was designed to 
investigate the ability of H-FABP for predicting early clinical outcomes in patients with 
suspected ACS in emergency room by comparing with conventional serum markers. 
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Methods: We measured H-FABP, myoglobin (Mb), troponin T (TnT), and creatine kinase 
MB activity (CK-MB) in 133 patients with acute chest pain suggestive of ACS. The first 
biochemical data obtained at presentation to an emergency room was used to assess the 
ability to predict adverse outcomes that included emergent hospitalization, coronary 
angiography (CAG), ACS, AMI, and early coronary revascularlzation. Results: The first 
samples were obtained within 6 hours from onset (O-6 hrs data) in 74 (56%) patients. The 
diagnoses of ASC and AMI were established in 90 (68%) and 58 (44%) patients, respec- 
tively. H-FABP had the greatest sensitivities for identifying early adverse outcomes and 
the largest ROC areas for detecting AMI and ACS among the markers. Conclusion: H- 
FABP could have the greatest ability among biochemical markers to predict early adverse 
outcomes in patients presenting with suspected acute coronary syndrome in emergency 
room. 
ROC area of each biochemical marker 
H-FABP 
ACS(O-Ghrs) 0.875 
ACS(all) 0.800 
AMI(O-Ghrs) 0.876 
Mb TnT CK-MB 
0.813 0.764 0.851 
0.756 0.776 0.739 
0.837 0.792 0.839 
cardial infarction with a patent infarct artery at angiography < 48 hours with 3 month fol- 
low-up angiography. QCA-analysis was possible in 240 patients: a > 60% stenosis was 
considered significant. An ischemia-guided revasculatization (revasc) strategy was fol- 
lowed. Results: A > 60% QCA stenosis was seen in 43% (103/240) of patients. Median 
clinical follow-up was 858 days (25th.75th percentile: 565.1293). Survival free from death 
or reinfarction (d&hire-MI) was 85% in patients with a < 60% stenosis as compared.to 
82% in patients with a z 60% stenosis (p=ns). lncludlng revasc, the rates were 70% and 
66%(p=ns). At multivariate analysis a > 60% stenosis ‘was not a predictor of deathire-Ml 
or the combination of deathire-Mlirevasc: odds ratios 1.17 (95% Cl 0.58-2.38) and 1.18 
(95% Cl 0.67-2.08). Reocclusion was seen more often in patients with a > 60% stenosis: 
41% (42/103) versus 18% (25/137) (p<O.Oi). Multivariate analysis identified a > 60% 
stenosis as an independent predictor of reocclusion: OR 2.91 (95% Cl 1.60-5.29, p< 
0.01). Conclusions: Long-term clinical outcome following an ischema-guided revascu- 
lad&ion strategy after successful thrombolysis is excellent irrespective of the presence 
of a significant infarct related stenosis. However, a significant infarct related stenosis is 
associated with an increased risk of reocclusion, mainly occurring without death or clini- 
cal reinfarction. The effect of a routine invasive strategy in the prevention of reocclusion 
rsma~ns to be determined. 
AMl(all) 0.907 0.860 0.838 0.826 
1085-89 Heart-Type Fatty Acid-Binding Protein Is More Useful Than 
Cardiac Troponin T and CK-MB lsoforms for Risk 
Stratification in Patients With Acute Coronary Syndrome 
Within 3 Hrs After Onset of Chest Pain 
Junnichi Ishii, Masanori Nomura, Hiroyuki Naruse, Yoshihisa Mod, Toshikazu Ando, 
Hiroshi Kurokawa, Takeshi Kondo, Yoshihiko Watanabe, Hitoshi Hishida. Fuji& Health 
University Toyoake, Japan 
We have previously reported that heart-type fatty acid-binding protein (FABP) is a more 
sensitive and specific marker than myoglobin for the early hiagnosis of acute myocardial 
infarction (AMI). To evaluate the utility of serum FABP for early risk stratification in 
patients with acute coronary syndrome (ACS), we prospectively studied 195 consecutive 
patients (mean age $/- SD: 64 +/- 11 yrs) admitted to CCU for ACS within 6 hrs (4.3 +/- 
2.2 hrs) after onset of chest pain. Serum levels of FABP were measured at admission, 
together with serum cardiac troponin T (TnT) and plasma CK-MB isoforms (MB iso). The 
cutoff values were as follows: FABP, 9 ng/mL; TnT, 0.10 ng/mL; MB iso, MB2 activity, 2.6 
IUiL plus MB2/MBl, 1.7. Results: There were 114 patients with AMI and 81 with unsta- 
ble angina pectoris (UAP). Twelve patients with UAP had cardiac events (1 death, 3 AMI 
and 8 UAP requiring intervention) within 48 hrs after admission. The 126 high-risk ACS 
patients were defined as AMI or UAP with cardiac events. The high-risk ACS patients had 
significantly (pcO.0001) higher levels of FABP (80.8 +/- 108.9 vs 5.9 ci- 4.6 ng/mL), TnT 
(1.38 +/- 2.52 vs 0.05 +/- 0.05 ng/mL), MB2 activity (36.2 +/- 69.0 vs 2.3 +/- 1.8 IUIL) and 
MB2IMBl (3.0 +I- 2.0 vs 1.2 +I- 0.66) than patients without high-risk ACS. The sensitivity 
and predictive accuracy of FABP for the detection of the high-risk ACS in patients with 
ACS within 3 hrs after onset were higher than those of TnT (p<O.OOOl and p=O.O2) or MB 
iso (p=O.O018 and p=O.O3) (Table). Conclusion: These findings suggest that FABP is a 
more useful marker than TnT and MB iso for early risk stratification in patients with ACS 
within 3 hrs after onset of chest pain. 
‘~~0.05 , “*p<O.Ol vs FABP. 
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1086-90 A Significant Infarct Related Stenosis After Successful 
Thrombolysis: Not Associated With Adverse Clinical 
Outcome but a Strong Predictor of Reocclusion 
Peter C. Kievit, Marc A. Brouwer, Gerrit Veen, Johan Karreman, Freek W. A. Verheugt. 
Heartcenter, University Medical Center, Nijmegen, The Netherlands, Free University 
Hospital, Amsterdam, The Netherlands 
1086-91 Safety and Angiography Data of Amediplase, a New Fibrin 
Thrombolytic Agent, Given as a Single Bolus to Patients 
With Acute Myocardial Infarction: The 2K2 Dose Finding 
Trial 
Frank Vermeer, Jurgen P&l, Keith Oldroyd, Stefano Giannelli, Bernard Charbonnier. 
University Hospital Maastricht, Maastricht, The Netherlands 
Background: Amediplase is a new thrombolytic agent with a potent fibrinolytic activity 
and high fibrin specificity. Its innovative structure results from conjugating two parts of the 
human plasmlnogen activators, the kringle 2 domain of t-PA (alteplase) and the catalytic 
chain of scu-PA (saruplase). Methods: This was an open-label, multicenter, randomized, 
dose finding study to evaluate the efficacy and safety of amediplase, given as single 
bolus in the dose range of 20 to 90 mg in patients with suspected acute myocardial inf- 
arction treated with heparin and aspirin within 6 hours from onset of symptoms. Efficacy 
was evaluated by measuring coronary artery patency (TIM1 3 flow grade) at 90 minutes 
angiography performed after amediplase administration. Rescue PTCA was performed in 
patients with TIMI O-2 flow at 90 minutes. Results. 140 out of the 149 randomized 
patients were evaluable for angiographic data. TIMI 3 above 50% was achieved at 2 
70mg amediplase doses. When doses were calculated adjusted to body weight, TIMI 3 
>50% was achieved at > O.bmg/kg body weight. Mortality at 30 days was remarkably low, 
being 3.4% (51149). Thirty-two serious adverse events were reported, mostly related to 
the myocardial infarction. Only one intracranial hemorrhage and one other fatal major 
bleed were reported. Pharmacokinetic analysis showed a plasma half-life value support- 
ing single bolus dosing. Conclusions. 1) TIMI 3 flow at 90 minutes was obtained in more 
than 50% of the patients treated with doses t 70mg corresponding to 2 0.8mglkg body 
weight. 2) Amediplase has a good safety profile with a low incidence of serious bleeding 
complications. 3) Further investigations need to be performed to assess the optImaI dose 
regimen for amediplase. 
1086-92 Comparative Fibrinolytic Activity Profiles of the New Single- 
Bolus Thrombolytics Tenecteplase and Lanoteplase During 
Treatment of Patients With Acute Myocardial Infarction 
Kamal A. Al Shwafl, Antoine de Meester, Bruno Pirenne, Jacques J. Col. University of 
Louvain, Brussels, Belgium 
Background: New t-PA mutants with prolonged plasma half-life allowing a single-bolus 
administration have been tested. Tenecteplase (TNK-tPA) has a half-life of 20 minutes 
(min), lanoteplase (nPA) of 37 min. Efficacy and safty profiles of both agents were com- 
pared to that of the front-loaded t-PA, but no fibrinolytic activity (FA) assessment was per- 
formed. Therefore, a comparison of FA profiles of these agents is of importance to 
evaluate the differences in clinical outcome. Methods: Fibrinolytic activities of whole 
blood samples were assessed immediately after collection by measuring clot lysis onset 
time (LOT) using a bedside thrombolytic assessment system (TAS) before, 10, 60, 90, 
and 180 min after drug administration in 42 AMI patients, 19 were treated wtth 30-40 mg 
TNK-tPA, and 23 recwed 120 kU/kg nPA as a single-bolus. FA is non-detectable when 
LOT >1200 seconds (set); the shorter LOT is, the mare intense the FA. Results: Base- 
line LOT was >1200 set in all patients. LOTwas significantly shortened by the boluses of 
both agents, and was shorter after TNK-tPA than after nPA (median 111 vs 133 set 
respectively). FA after both agents waned gradually, but it was much slower with nPA, the 
half-life of FA was 50 min for TNK-tPA and 69 min for nPA (pcO.005). FA 180 min after 
start of therapy was more intense with nPA than TNK-tPA, it was detected in 87% of 
patients given nPA compared to 59% received TNK-tPA (p<O.OOl). Conclusion: The 
more intense FA achieved immediately after the bolus of TNK-tPA could be translated to 
more rapid reperfusion rate, and the prolonged intense activity beyond 180 min after nPA 
could explain the increased rate of intracranial hemorrhage observed in the In TIME II 
trial. Thus characterizing the FA profiles of thrombolytic regimens might provide an 
insight in explaining the differences in efficacy and safty profiles of existing agents, and 
developing more desirable characteristics in future agents. 
Background: Routine angioplasty of a significant infarct related stenosis early after suc- 
cessful thrombolysis has not been proven superior to a conservative strategy with 
respect to reocclusion related events as mortality and reinfarction. However, in - 60% of 
patients reocclusion occurs without these events while left-ventricular recovery is pre- 
cluded. This analysis addresses the importance of a significant stenosis regarding clini- 
cal events and reocclusion following an ischemia-guided revascularization strategy. 
Methods: In the first Antlthrombotics in the Prevention of Reocclusion In COronary 
Thrombolysis (APRICOT) trial 248 patients had thrombolysis for suspected acute myo- 
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1086-93 Thrombolysis for Acute Myocardial Infarction in Patients 
Older Than 75 Years: Lack of Benefit for Hospital Mortality 
but Improvement of Longterm Mortality: Results of the 
MITRA- and MIR-Registries 
Anselm K. Gitt, Ralf Zahn, Harm Wienbergen, Tobias Hew, Steffen Schneider, Martin 
Gottwik, Martin Gottwik, Jochen Sages, Rudolf Schiele. Herzzentrum Ludwigshafen, 
LudwGshafen, Germanv 
these half received an incorrect weight-adjusted dose. In addition, 7 (2.4%) were ~ncor- 
rectly estimated to weight >=67 kg, and all 7 of them received a full 100 mg dose.(Total of 
4.5% incorrect weight-adjusted dosing.) For TNK, in TIMI IOB and ASSENT I patients 
were randomized to receive a fixed dose of 30, 40 or 50 mg. Only 49/3730 (1.3%) of TNK 
patients received an incorrect dose. There was no difference in mortality or intracranial 
hemorrhage in TNK patients who received an incorrect dose. Conclusion: Errors in esti- 
mating weight are uncommon. especially those that would lead to a dose change. Dosing 
errors were extremelv rare for TNK in the TIMI 106 and ASSENT I trials. and no adverse 
Backgound: Met&analysis of large randomized trials has shown that thrombolysis for 
outcomes were ?.een among patients who received an incorrect dose - suggesting a 
acute myocardial ST-elevation infarction (AMI) reduces 35day-mortality in patients (pts) 
broad safety profile for the new single-bolus agent TNK. 
275 years by 1% which did not reach staiistical significance. Recently published registry 
data even documented a lack of benefit for thrombolysis in AMI-pts 275 years. Methods: 
We analysed the prospective data of 6815 / 25194 (27%) unselected AMI-patients 275 POSTER SESSION 
years of MITRA [Maximal Individual Therapy of AMI Registry) and MIR (Myocardial Inf- 
arction Registry) to identify the impact of reperfusion therapy on hospital and longterm 
outcome (18 months) after AMI. Results: Only 2149 / 6815 AMI-pts 275 years (32%) did 1087 Myocardial Preservation: Experimental 
receive acute reperfusion therapy, 1782 (27%) thrombolysis, 367 (5%) primary PTCA. 
The main determinants of withholding reperfusion lherapv in the elderly were increasing Insights 
age par year (OR 0.90, Cl 0.89.0.92);he&t failure on admission (OR 0165, Cl 0.54-0.78) 
and heart rate ziOO/min (OR 0.66, Cl 0.57-0.77). Hospital and longterm mortality were 
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29.5% / 34.1% in pts without reperfusion therapy, 25.4% / 19.6% in pts with thrombolysis Orange County Convention Center, Hall A4 
and 16.3% / 14.5% in pts with primary PTCA as acute treatment for AMI. After correcting Presentation Hour: 1O:OO a.m.-l I:00 a.m. 
for baseline differences and presence of concomitant diseases thrombolvsis for AMI did 
not influence hospital mortality but did influence longterm mortality (Table). Primary 
PTCA in AMI-pts ~75 years significantly reduced even hospital mortality as well as long- 
term mortality (Table): 
Multivariate Analysis Hospital Mortality OR, 95% Cl 18.Months-Mortality OR, 95% Cl 
Thrombolysis 0.95, 0.81-1.12 0.58, 0.39-0.88 
Primary PTCA 0.39, 0.27-0.57 0.43, 0.20-0.93 
Conclusions: Acute thrombolysis for AMI did not influence hospital mortality in pts 275 
years, but was associated with a 42% lower longterm mortality. In comparison, primary 
PTCA for AMI was associated with a 61% lower hospital mortality and an additional 56% 
lower longterm mortality in pis 275 years. 
1087-96 Brain Natriuretic Peptide Mirrors Left Ventricular 
Remodelling Over 2 Months After First Myocardial Infarction 
Jenifer Crilley, Marty” Farrer. Sunder/and Roy& Hospifal, Sunder/and, United Kingdom 
Background: Brain natriuretic peptide (BNP) has been shown to be a strong predictor of 
moriality after myocardial infarction (Ml). The mechanism may be linked to higher BNP 
levels being associated with adverse left ventricular (LV) remodelling. We investigated 
this in an unselecied cohort of patients having their first MI, all of whom received throm- 
bolysis. Methods: 133 patients who met the entry criteria of first Ml and survival to 3 
days had echocardiography to assess LV volumes and wall motion index (WMI-9 seg- 
ment model) and samples taken for BNP assay at 3-7 days (early) and 2 months (late). 
Patients were followed for 1 year. A WMI cut-off of 1.2 was used to indicate LV dysfunc- 
tion and BNP analysed according to %change in end-systolic volume index (ESVi) 
between the 2 studies. A multiple regression model was constructed to examine the influ- 
ence of remadelling characwistics on BNP levels and 1 year mortality. Data is presented 
as mean (SEM); BNP in pgiml. Results: Mortality was 7%. BNPearly was associated 
with 1 year cardiac mortality (cardiac death: 675 (135) pg/ml v alive: 365 (22) pgiml). 
BNP levels and remodelllng characteristics are seen in the table. Multiple regression 
modelling showed that the significant associations with BNPearly are WMlearly cl.2 
(p<O.OOl) and ES/i dilatation (~~0.028) and with BNPlate, ESVi dilatation (p<O.OOi) and 
WMlearly cl.2 (p<O.O06). Conclusions: BNP is a marker of early post-Ml remodelling 
and initially reflecis the magnitude of the infarct zone but later mirrors progressive LV dila- 
tation. The ability of BNP to predict mortality after Ml is linked to its association with 
adverse LV remodelling characteristics. 
1088-94 Thrombolysis Is Beneficial in Elderly Acute Myocardial 
Infarction Patients 
Ulf Stenestranci, Lars Wallentin, the RIKS-HIA group. Heart Center, Universify Hospital, 
Linkoping, Sweden, Dept of Cardnlogy, University Hospital, L/pp.sa/a, Sweden 
Background: Recent reports have stated that rhrombolysis would noi be beneficial in 
acute myocardiai infarciion (AMI) patients 75 years and older. We sought to investigate 
whether this was true in an unselected Swedish AMI population. 
Methods: From the Swedish Register of Cardiac Intensive Care, which included every 
CCU admitted patient at 58 participating. hospitals 1995-98, we studied 5,428 AMI 
patients >=75 y old admitted wiih ST-elevation or LBBB. Cox regression analysis was 
pelformed evaluaiing the effect of thrombolysis regarding the combined variable cerebral 
bleeding and one-year mor:ality taking into consideration 26 factors known to influence 
survival such as clinical background, medication, interventions and complications. 
Results: There were 0.4% (9) mortal and 0.5% (12) cerebral bleedings in the 2,445 
patients receiving thrombolysis. The combined endpoint of cerebral bleeding plus death 
of any cause within one year proved to have a significantly (pcO.001) lower incidence in 
the thrombolysis treated group 38.3% (699) compared to the conservative group 48.4% 
jl.145 of 2,983)). In Cox regression analysis adjusting for the 26 covariates thrombolysis 
treatment was associated with a risk reduclion of 12% for the combined complications 
RR 0.88 (95% Cl 0.79.0.97), p=O.Oli. 
Conclusion: Even though increased inci- 
dence of severe bleeding complications in 
patients 75 years and older the total one- 
year mortality and cerebral bleedings end- 
point is significanily lower in the thromboly- 
sis treated group. Thus clearly indicating 
that thrombolysls is indicated even in elderly 
patients with ST-elevation or LBBB AMI. 
1086-95 Weight-Based Dosing of Thrombolysis: How Well Do We 
Estimate Weight? How Often Would This Translate Into 
Errors With Administration of Thrombolytic Drugs? A 
Comparison of Single-Bolus TNK With t-PA in TIMI IOB 
Christopher P. Cannon, Michael Gibson, Sabina A. Murphy, Frans Van de Werf, Carolyn 
H. McCabe. Bngham and Women’s Hospital, Boston, MA 
Weight-based dosing of thromboiytic drugs and heparin is recommended, notably for the 
new thrombolyiic agent TNK, but obtaining an actual weight for a patient in the Emer- 
gency Department is difficult and often not done. Few data are available regarding the 
accuracy of esiimated weight, or how often it would lead to a different dose of a throm- 
boiytic drug. With weight-based dosing of TNK, dose increases wiih increments of 10 kg. 
For t-PA patients < 67 kg should receive a weight-based dose. Methods: We compared 
the estimated weight used in the Emergency Department vs. an actual weight obtained 
later in-hospital in 780 patients in the TIMI 106. We then compared the accuracy of dos- 
ing between accelerated t-PA and single-boius TNK in the TIMI IOB patients and 3253 
patients in ASSENT I trials. Results: In TIMI lOB, estimated and actual weight correlated 
very well. R2=0.93 p<O.OOOl. Among TNK patients only 1 (0.4%) had estimated weight 
10 kg under actual weight, and only 4 (1.7%) was the estima@ad weight higher than 
actual.(Total only 2.1% error in weight estimation that would change the dose for TNK). 
For the 290 t-PA patients, 6 (2.1%) were incorrectly esiimated to weight ~67 kg, and of 
BNP (early) 
BNP (late) 
WMI cl.2 (early) WMI > 1.2 (early) 
579 (63)’ 329 (21)* 
517 (65)** 345 (26)‘* 
>lO% rise in ESVi no change >1 0% fall in ESVi 
BNP (early) 454 (46)# 334 (34)# 326 (34)# 
BNP (late) 498 (48)$ 338 (44)$ 269 (28)$ 
‘p=O.OOi; ‘*p=O.O21 by unpaired t-test and #p=O.O34; $p=O.OOl by ANOVA 
1087-97 Aminophylline Improves Regional Function in Chronic 
lschemic Cardiomyopathy: Further Evidence That 
Adenosine Contributes Towards Functional Downregulation 
Elizabeth Le, Howard Leong-Poi, Se-Joong Rim, Tadamichi Sakuma, Nicholas Fisher, 
Sanjiv Kaul. University of Virginia, Charloffesviile, VA 
Background: The neurohumoral mechanisms of reduced left ventricular function in 
chronic ischemic cardiomyopathy are not well understood. One possible regulator is ade- 
nosine, which has been shown to exhibit cardioprotective mechanisms via negative 
inrotropy. We have previously shown that infusion of 8-cyclopentyl I,3 dipropylxanthine, a 
selective Al-adenosine receptor blocker, in the canine model of chronic ischemia 
resulted in improvement in percent wall thickening (%WT) but had no effect in transmural 
blood flow. We therefore hypothesized that infusion of aminophylline, a nonselective and 
competitive inhibitor of adenosine, would similarly result in improvement of myocardial 
function. 
Methods: We placed ameroid constrictors on the proximal LAD and LCx arleries and 
iheir major branches in 7 adult mongrel dogs, which resulted in severe left ventricular 
dysfunction 4-7 weeks later. Closed-chest short-axis images at the low mid-papillary 
level were obtained before and immediately after injection of aminophylline (4mgiKg) 
using 2-D echocardiography. Heart rate and mean blood pressures were also monitored 
during the experiments. % WT and wall thickness in the LAD and LCx regions and end- 
systolic and end-diastolic areas were calculated using custom designed software. 
Results: Aminophylline increased heart rate significantly from 92&7 to 114tll beats/ 
minute (p&05) but did not affect mean aortic pressure (114i9 Versus 107il1 mm 
Hg). % WT and wall thickness were equally reduced in the LAD and LCx beds prior to 
aminophylline infusion. After infusion of aminophylline, % !NT increased from 7.2k2.1 to 
18.4+2.5% in the LAD region (p&001) and from 9.322.3 to 21.74t2.0% in the LCx 
region (p=O.O06). Wall thickness during diasiole did not alter significantly in either region. 
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Conclusion: These results rndicate that adenosine plays a significant role in the down- 
regulation of myocardial function in chronic ischemia and probably serves as a cardiopro- 
tectant, especially during periods of repetitive stress. Aminophylline or a selective Al- 
adenosine receptor agonrst can be used to detect viable myocardium and may be safer 
than dobutamine in severe chronic ischemic heart disease. 
1087-98 Augmented Protein Expression of Neuronal Nitric Oxide 
Synthase in the Atria Parasympathetically Decreases Heart 
Rate During Acute Myocardial Infarction in Rats 
Yoshihito Takimoto, Takeshi Aoyama, Reiko Keyamura, Yoshiki Yui, Shigetake Sasayama. 
Kyofo Universify, Kyofo, Japan 
Background; Vagal stimulation has been reported to be associated with prevention of 
ventricular fibrillation after myocardral infarction (MI). Nitric oxide synthesized within 
sinoatrial cells and neurons has recently been shown to participate in cholinergic control 
of heart rate (HR). However, it is unknown whether nitric oxide in the neuronal cells in the 
heart plays a role in HR regulation after Ml. Methods; One, 3, 7 and 14 days (n=6-10 for 
each group) after ligation of a coronary artery, we examined HR dynamics and neuronal 
nitric oxide synthetase (nNOS) expression in the atria by Western blotting. Results; The 
nNOS protein level in the atria was increased 4.5+0.5-‘, 3.5+0.2-*, 1.7+0.1-* and 
l.O+O.l-fold (‘~~0.01) compared to that in sham-operated rats (SR) one, 3, 7 and 14 
days after MI, respectively. Mean HR at baseline was 470+6 (p<O.Oi vs. SR) and 378+4 
in the Ml group, and 398+13 and 375~4 in SR at 1 and 14 days post-infarct, respectively. 
To examine the role of nNOS on HR, a specific inhibitor of nNOS, I-(2.trifluoromethylphe- 
nyl) imidazole (TRIM), was infused (50mgikg i.v.). Increased HR after infusion of TRIM 
was 66+12’, 59+4*, 32+3’ and 6+4 (‘pcO.01 vs. SR) in MI rats, and 8+4, 6+3, 6+4 and 
4+3 rn SR one, 3, 7 and 14 days after MI, respectively. The effect of TRIM on HR was 
abolished by the prior administration of L-arginine (25mg/kg, i.v.). After the parasympa- 
thetic blockade with atropine (O.dmg/kg i.p.), the administration of TRIM did not signifi- 
cantly increase the ‘HR in both rats with Ml (7+5) and controls (0+4) one day post-infarct. 
Whereas, administration of TRIM with pretreatment of propranolol (imgfkg i.v,) led to sig- 
nificant (~~0.01) heart rate increase in rats with Ml (55+3) compared with that in sham- 
operated rats (14+3) one day post-infarct. There was a strong correlation (rz0.837, 
p<O.OOOi) between the nNOS protein expression and heart rate change after TRIM infu- 
sion. Conclusion; These results indicate that nNOS parasympathetrcally decreased 
heart rate via the production of nitric oxide in rats with acute Ml. Thus, augmented 
expression of nNOS in the atria after acute Ml reduces HR and may have beneficial 
effects on the heart by reducing 02 consumption and preventing ventricular fibrillation. 
1087-99 Myoglobin Sustains Cardiac Function During lschemia and 
Facilitates Oxygen Diffusion in the Beating Heart 
Marc W. Mew, Ulrich Fliigel, Axe1 Godecke, Ulrich K. M. Decking, Jiirgen Schrader. 
lnstitut fijr Herz- und Kreislaufphysiologie, Hewich Heine lJniversit2, Dijsseldorf, 
Germany 
Background: Myoglobin, an intracellular oxygen binding heme protein is considered a 
key player in intracellular oxygen supply with three main functions: facilitating oxygen dif- 
fusion, serving as oxygen reservoir and mediating oxidative phosphorylation. The recent 
generation of myoglobin knockout mice (myo-i-) in our laboratory led to a surprisingly 
benign phenotype, challengrng myoglobin’s functional relevance. Methods: Here we 
explored the effect of acute carbon monoxide (CO) inhibition of myoglobin on isolated, 
Langendorff perfused hearts with hearts from myo-/- mice servrng as appropriate con- 
trols. To closely mimic the in viva situation, myoglobin oxygen saturation was measured 
in the beating heart utilizing 1 H-NMR spectroscopy with arterial buffer-oxygen content 
being adjusted accordingly. Results: Acute myoglobin inhibition had no effect on oxida- 
tive phosphorylation. Partial deoxygenation (13%, determined by 1 H-NMR) of myoglobin, 
being a prerequisite of facilitated diffusion, was achieved at an arterial buffer-oxygen con- 
tent of 65%. Under these conditions we found that acute CO inhibition of myoglobin leads 
to decreased contractility (11% left ventricular developed pressure decrease in wt hearts 
vs. no change in myo-I- hearts, P<O.OOi) and increased coronary venous pO2 (plus 25% 
vs. no change, P<O.OOl), reflecting decreased myocardial oxygen consumption. When 
hearts were subjected to brief, no-flow ischemia both chronic and acute myoglobin inhibi- 
tion resulted in a more pronounced functional decrease compared to wild type (wt) hearts 
(i.e. developed pressure decreased by 8.1r2.9% in myo-I- and CO treated wt hearts vs. 
4.3cO.9’~ in control wt hearts, P<O,OO5). Conclusion: Carbon monoxide is a highly 
selective inhibitor of myoglobin. Oxidative phosphorylation is not mediated by myoglobin. 
During brief periods of ischemia myoglobin’s oxygen reservoir is responsible for sustain- 
ment of cardiac function. Myoglobin is important in facilitating the diffusion of oxygen 
from the vasculature to mitochondrial cytochromes in the beating heart. 
1087-100 Administration of an Adenosine A2A Receptor Agonist 
(ATL-146e) Significantly Reduces Infarct Size in a Canine 
Model of Coronary Occlusion and Reperfusion 
David K. Glover, Mirta Ruiz, Laurent M. Rio”, Kazuya Takehana, Philip W. Smith, Jayson 
M. Rieger, Timothy L. Macdonald, Denny D. Watson, Joel Linden, George A. Belter. 
University of Virginia, Charlottesville. VA 
Background: In recent clinical tn.&, adenosine has been shown to be cardioprotective 
by limiting infarct size when administered durrng reperfusion therapy, however the mech- 
anism for this protection remains unknown. We sought to determine whether low dose 
administration of a highly potent and selective adenosine AaA receptor agonist, ATL- 
146e, might also protect myocardium from infarctron. 
Methods: Accordingly, 7 open-chest dogs underwent 90 minutes of total left anterior 
descendrng (LAD) coronary occlusion with all visible collateral vessels tied, followed by 2 
hours of reperfusion. Both core and heart surface temperatures were monitored and con- 
trolled to maintain a constant surface temperature (37°C). In a subset of these dogs 
(n=3), ATL-146e was infused i.v. at a concentration below that which produces vasodila- 
tation (0.01 pgikglmin) beginning immediately prior to the occlusion and contrnuing 
throughout reperfusion. Regional myocardral blood flow was measured using micro- 
spheres and myocardial risk area and infarct size were determrned by blue dye and his- 
tochemical staining. 
Results: During LAD occlusion, endocardial and transmural flows in the central infarct 
zone were similar in both the control (endo: 0.10 ? 0.01; tm: 0.12 + 0.03 ml/min/g) and 
ATL-146e treated dogs (endo: 0.09 + 0.02; tm: 0.15 k 0.01 mliminlg) (p=NS). After reper- 
fusion, endocardial and transmural flows were also similar confrrming that there was no 
vasodilatory effect of low dose ATL-146e. In addition, the myocardial area at risk was 31 
t 3% and 30 f 5% of the left ventricle in the respective groups (p=NS). Despite a com- 
parable level of flow reduction and similar risk areas, there was a significant 37% reduc- 
tion in myocardial infarct size (% risk area) in the ATL-146e treated dogs (37 + 6%) 
compared wrth the control dogs (59 * 5%) (p<O.O5). 
Conclusion: The adenosine AzA receptor agonist ATL-146e is cardioprotective in this 
canine model of infarction. This finding suggests that the mechanism for the adenosine- 
mediated protectron observed in the clinical setting may involve the adenosine AaA 
receptor pathway. The protective effect does not require the enhancement of blood flow. 
1087-101 The Effect of lnotropic State on the Size of the Mitral 
Annulus 
Joseph H. German, Ill, Robert C. German, Benjamin M Jackson, Martin St.John-Sutton, 
Theodore Plappert, T. Sloane Guy, IV, Sina L. Moainie, L. Henry Edmunds, Jr.. Universify 
of Pennsylvania School of Medicine, Philadelphia, PA 
Introduction: The mitral valve annulus is a dynamic structure whose function is inti- 
mately related to left ventricular (LV) performance. Chronic ischemic LV dysfunctron can 
lead to annular dilatation which contributes to mrtral regurgrtation (MR). Using sonomi- 
crometry array localization (SAL) imaging in sheep, we tested the hypothesis that 
changes in LV inotropic state directly affect the size of the mitral valve annulus. SAL 
accurately determines the three-dimensional spatial relationships of sonomicrometry 
transducers every 5 ms throughout the cardiac cycle. Methods: In 6 sheep, 6 transduc- 
ers were sutured around the mitral annulus. One week after rnstrumentation, animals 
were b-blocked with esmolol (mean infusion 6.7 f 3.5 mglmin) to a rate of 90 bpm and 
were atrially paced: SAL was recorded at heart rates of 120 bpm and 150 bpm. Esmolol 
was discontinued and the animals allowed to return to steady state. An isoproterenol 
infusion was titrated to produce rates of 120 bpm (mean rnfusion 4.6 + 3.9 mg/mrn) and 
150 bpm (mean infusion 5.5 r 4.1 mgimin), and SAL data recorded at both heart rates. 
Thermodilution cardiac outputs (CO) were acquired in triplicate at all physiologic condi- 
tions. All statistical comparisons were made between isoproterenol and atrially-paced 
groups at the same heart rate using paired t-test, and the values reported as mean f 
standard devration. Results: At a rate of 120 bpm, the atrially-paced group had CO of 2.8 
r 0.5 Umrn and end systolic (ES) annular area of 780 f 150 mm2. At the same rate, the 
isoproterenol group had significantly increased (p<O.O04) CO of 4.5 i: 1.0 Limin and sig- 
nificantly decreased (p<O.OOZ) ES annular area of 700 r 160 mm2. At a rate of 150 bpm, 
the atrially-paced group had CO of 3.2 + 0.5 Umin and end systolic (ES) annular area of. 
750 * 130 mm2. At the same rate, the isoproterenol group had significantly increased 
(p<O.O04) CO of 5.8 r 1.5 Umin and significantly decreased (pcO.002) ES annular area 
of 650 * 150 mm2. Conclusions: lsoproterenol increases LV inotropic state and 
decreases mitral valve area rndependent of heart rate. These findings may have implica- 
tions for the treatment of MR due to annular dilatation secondary to ventricular dysfunc- 
tion. 
1087-102 -\ Na+/CaZ+ Exchange May Play an Important Role in 
Ischemia-Reperfusion Injury in In Vivo Heart and Brain 
Teisuke Takahashi, Kenzo Takahashi, Michrhrto Onishr, Yu Tanaka, Tomomi Ota, Kazuya 
Kameo. Jaisho Pharmaceutical, Co., Ltd., Omiya, Japan 
Background: Activation of the reverse mode of Na+/CaP+ exchange may contribute to 
Ca2+ overload during reperfusion after transient ischemra. Role of Na+/Ca2+ exchange 
in in viva myocardial and cerebral ischemia-reperfusion injury was examined by using 
SEA0400, a novel potent and selective Na+/Ca2+ exchange inhibitor. Methods and 
Results: In the rat ischemia-reperfusion arrthymia model, ischemia was induced by 5. 
min occlusion of the left anterior descending coronary artery followed by 1 0-min reperfu- 
sion. SEA0400, administered 1 min before reperfusion, at 1 mgikg i.v. reduced the inci- 
dence of ventricular fibrillation from 80 to 20% (P c 0.05) and mortality from 70 to 20% (P 
< 0.05). In the dog coronary occlusion model, myocardial stunning was caused by 15.min 
occlusion of the left anterior descending coronary artery followed by 4.hr repetfusron. 
SEA0400, administered 1 min before reperfusion, at 1.0 mg/kg i.v. improved recovery of 
myocardial segment shortening of the ischemic region after 4.hr reperfusion perrod. 
77&% compared with vehicle (45&S%) (P < 0.05). In the rat focal cerebral ischemia-rep- 
erfusion model, ischemia was induced by the 2-hr occlusion of the middle cerebral artery 
followed by 24.hr reperfusion. SEA0400, administered after occlusion, at 3 mgikg i.v. 
bolus + 3 mgikglhr i.v. infusion reduced infarction volume: 109+25 mm3 compared with 
vehicle (197+23 mm3)(P < 0.05). Conclusion: These results suggest that activation of 
Na+/Ca2+ exchange play an important role in ischemia-reperfusion injury in in viva heart 
and brain. Thus, inhibition of Na+/CaZ+ exchange may provide a novel therapeutic strat- 
egy to reduce myocardial and cerebral reperfusion in)ury. 
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801-2 
9:30 a.m. 
The Effect of Early Post-infarction Mitral Regurgitation on 
Late Ventricular Remodeling 
Robert C. German, Joseph H. German, III, Benjamin M. Jackson, T. Sloane Guy, IV, Sina 
L. Moainre, Theodore Plappert, Martin St.John-Sutton, L. Henry Edmunds, Jr.. University 
of Pennsylvania School Of Medicine, Phiiadelphia, Pa 
Background: The Question Of How Post-infarction Mitral Regurgitation (Mr) Affects Left 
Ventricular (iv) Function Over Trme is Incompletely Understood. We Studied Two Types 
Of Posterolateral lnfarctrons In Sheep, One Which Produces Mr And One Which Does 
Not, To Examine The Contribution Of lschemic Mr To Lv Remodeling And Congestive 
Heart Farlure (Chf). Methods: Group A (n=5) had infarctron of 25% of the LV mass local- 
ized to the posterclateral ventricle, resultrng in a compensated infarction which does not 
lead to CHF. Group B (n=5) had infarction of 25% of the LV mass localized to the poster- 
olateral ventricle and including the posterior papillary muscle, resulting in acute develop- 
ment of MR and leading to severe CHF. Transdiaphragmatic echocardiograms were used 
to measure end-systolic (ES) LV sphericity (the ratio of minor axis to major axis diameter) 
and ES LV volume, as well as to assess the degree of MR. Results: In group A, no ani- 
mal developed MA, ES LV volumes increased by 71% over 8 weeks, and LV sphericrty 
increased from 0.45 at baseline to 0.50 (NS) at 8 weeks. In group B, the mean degree of 
MR immediately postinfarction was 2.7. The MR progressed to a mean of 3.2 at 8 weeks. 
In this group, ES LV volumes Increased by 140% over 8 weeks, and LV sphericity 
increased from 0.43 at baseline to 0.56 (p c .05) at 8 weeks. At 8 weeks, the two groups 
had srgnificantly different LV volumes and sphencrties (p c .05). Conclusions: These 
results Indicate that significant early post-Infarction MR IS progressrve and greatly exacer- 
bates post-infarction LV remodeling. This data suggest that surgical intervention to treat 
early post-infarction MR may convert an uncompensated infarct destined to result in CHF 
to a compensated infarct consistent with adequate long-term hemodynamic function. 
801-3 
9:45 a.m. 
Macrophage-Colony Stimulating Factor (M-CSP) Induction 
in the Infarcted Myocardium Is Associated With Macrophage 
Differentiation and Proliferation and May Promote Tissue 
Remodeling 
Nikolaos G. Frangogiannis, Leonardo H. Mendoza, Oliver Dewald, Lloyd H. Michael, C 
Wayne Smith, Mark L. Entman. Bay/or Coiiege of Medicine, Houston, TX 
Background: Myocardial infarction is assocrated wrth a rapid induction of mononuclear 
cell chemoattractants, such as Transforming Growth Factor-P and Monocyte Chemotactic 
Protern-i, leading to monocyte infiltration in the mjured area. Effective healing is depen- 
dent on survival and differentiation of Infiltrating monocytes to macrophages. We hypoth- 
esized that the monocyte to macrophage differentiation factor M-CSF may be induced in 
the infarcted myocardium and may modulate monocyte phenotype. Methods: We used a 
canme model of myocardial infarction and an in vitro model of Isolated canine mononu- 
clear cells. Results: Using FIT-PCR we obtained a cDNA clone for canine M-CSF. We 
demonstrated marked induction of M-CSF mRNA in ischemic segments starting after 3 h 
of repedusion and peaiting after 24 h of reperfus~on. M-CSF was predominantly localized 
rn macrophages infiltrating the injured myocardrum. We used staining with the my&id 
cell marker Mac-387 to identrfy newly recruited monocytes and with the anti-macrophage 
antibody PMPK to label mature differentiated macrophages. Abundant Mac-387 positive 
cells were noted in the ischemic myocardium after 24 h of reperfusion (ischemic: 
495.6+148.6 celisisq mm Versus control: 6+1.95; p<O.Ol, n=4) indicating active recruit- 
ment of new myeloid ceils. In contrast, after 7 days of reperiusion the number of newly 
recrurted Mac-387 expressmg cells decreased (74.0518.67, n=4) and the majority of 
inflammatory cells in the healing scar were PM-PK positive, Mac387 negative macroph- 
ages. Dual immunostaining demonstrated significant numbers of proliferating PCNA pos- 
itive macrophages in the scar. Macrophage accumulation was assocrated with marked 
upregulation of Osteopontin(OPN)-I. a marker of monocyte to macrophage differentia- 
tion. In vitro experiments showed that M-CSF induced expression of OPN and matrix 
metalloproternase (MMP)-9 in isolated canrne mononuclear cells Conclusion: We sug- 
gest that the local upregulation of M-CSF in myocardial infarcts may promote macroph- 
age differentiation and proliferation, and modulate monocyte phenotype, allowing them to 
play an actrve role in tissue remodeling through the expression of MMPs. 
801-4 
1o:oo a.m. 
Effects of Angiotensin II Receptor Blockade, Angiotensin- 
converting Enzyme Inhibition, and Their Combination on 
Postinfarction Ventricular Remodeling 
Sunil Mankad. Naihaniei Reichek, Deep& Singh, Walter J. Rogers, Christopher M. 
Kramer. ANegheny General Hospifai, Pittsburgh, PA, University of Virginia He&h System, 
Charlottesvik, VA 
Angiotensin-converting enzyme inhibition (ACEI) attenuates post-infarction LV remodel- 
ing, but effects of angiotensrn II type 1 receptor antagonism (AT,A) alone or in combina- 
tion with ACEI are unclear. Accordingly, we studied the effects of AT,A, standard dose 
ACEI @ACEI), high dose ACEI (hACEI), and combined AT,A + sACEl on post-infarction 
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LV remodeling in a well-characterized ovine model. Methods: Two days after transmural 
anteroapical myocardral infarction by coronary ligation, 62 sheep were treated wrth either 
no therapy (Control, n=12), sACEl (ramipril IO mglday, n=14), hACEl (ramipril20 mglday, 
n=B), AT,A (losartan 50 mg/day, n=13), or combination therapy wrth ATtA + sACEl (CT: 
ramipril 10 mgiday + losartan 50 mg/day. n=15). Magnetic resonance imaging (MRI) was 
performed before and 8 weeks after myocardial infarction to quantify changes in LV end- 
diastolrc volume index (EDVI). end-systolic volume index (ESVi), and ejection fraction 
(EF). Regional % intramyocardial circumferential shortening (%S) in nonmfarcted seg- 
ments adjacent to the infarct (within 2 cm) was measured using tagged MRI. Results: 
Infarct size, mean systolic blood pressure, and left atrial pressure at 6 weeks post-infarc- 
tion ware srm~lar between groups. Heart rate at 6 weeks post-infarction was srgnificantly 
higher m the Control group compared to sACEI, hACEI. ATfA, or CT groups, respectively: 
124+17*, 102z12, 104t15. lllr12, and 107+12; p<O.OOi). Baseline EDVi, ESVi, EF, 
and adjacent %S were similar. CT resulted in the most marked blunting of LV remodeling 
(change from baseline): 
AEDVi AESVi 4EF AAdjacent 
ml/kg) WW (“4 %S (%) 
Control +0.9*0.1 Cl .OiO.l -23+2 -S*l 
sACEl +0.7to.i +0.7+0.1 -18+2 -7*1 
hACEi +0.&O 2 +0.6i-0.19 -14*3\j -5*1 
AT,A +0.9io.1 +0.9*0.1 -i&3 -5*i 
CT +0.4+0.1# +0.4*0.1* -11*2’ -2ai* 
(*p<O.O4 vs sACEI, AT,A and Control; ~~0.05 vs Control; #p ~0.003 vs AT,A and Control; 
ANOVA; mean&E). Conclusion: Compared to sACEI. hACEI, or AT,A. combined 
sACEl + AT,A is superior at attenuating LV remodeling and limiting systolic dysfunction 
following’myocardial infarction. 
801-5 
10:15 a.m. 
ACE Inhibition, ATI- and ETA-Receptor Antagonism: 
Comparison of Structural Reorganization of the 
Myocardium After Infarct in Stroke Prone Spontaneously 
Hypertensive Rats 
Alexander Reinecke, Quingui Xia, Marc Darenkamp, Susanne Pens, Christian Stotz, 
Harm Bitterling, Rijdrger W.R. Srmon and Thomas Unger. Clinic of Cardiology, Universfty 
of Kiel, K&l, Germanl: lnstitufe of Pharmacology, University of Kiel, Kiel, Germany 
Background: The structural organizatron of the myocardral collagen network plays a 
major role in post infarct remodelling and left ventricular (LV) dilation. Methods: We 
investigated the abrlity of the ETA receptor antagonist, Lu 135252 (Lu) (30 mglkgid), to 
reduce fibrosis in the rnfarcted and noninfarcted myocardrum and LV dilatron in stroke- 
prone spontaneously hypertensive rats. Six weeks after induction of myocardial infarction 
(Ml), the effects of Lu were compared with those of the AT1 receptor antagonist, irbe- 
sartan (Irb) (50 mgikgld), the ACE inhibitor, fosinopril (Fos) (20 mgikdld) and placebo 
treated controls. Treatment was started 4 weeks prior to induction of Ml and continued up 
to 6 weeks post Ml. Picrosirius red stained myocardial sections were examined using CII- 
cularly polarized light and a digitized morphometric system. Results: Lu reduced both, 
the total collagen content (3.19 + 0.09 (Lu) vs 3.99 + 0.06 (Irb), 4.72 + 0.16 (Fos),and vs 
6.85 + 0.13 (controls) (% of volume fraction)) and the proportion of thick collagen fibers 
(64.14+5.22(Lu)“s84.66+4.44(lrb), 76.37+6.1 (Fos)and90.01 +7.43(contrOls) (% 
of total collagen content)) to a significantly (p<O.Ol - p<O.OOl) greater extent than Itb or 
Fos. Compared to all other groups, treatment with Lu also markedly increased LV circum- 
ference and dram&r (PcO.05) after Ml. Conclusion: The association of LV dilation with 
a) reduction of total collagen content and b) lower proportion of thick collagen fibers after 
chronic treatment with Lu suggests that balanced myocardial fibrosis IS a prerequisite to 
marntain structural integrity after myocardial infarction. Thus, the adaptive reorganization 
of appropriate collagen fibers after MI was better achieved by treatment with lrb and Fos 
than with Lu. 
ORAL CONTRIBUTIONS 
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820-I 
1l:OO a.m. 
Troponin T and I to Predict 6 Month Mortality and Relative 
Benefit of Invasive vs. Conservative Strategy in Patients 
With Unstable Angina: Primary Results of the TACTICS-TIMI 
18 Troponin Substudy 
Christopher R Cannon, William S. Weintraub, Laura Demopoulos, Ralph Vicari, Martin J. 
Frey. Nasser Lakkis, Debbie Robertson, Paul delucca, Nader Rifar, Eugene Braunwald, 
for the TACTICS-TIM1 18 Investigators. Brigham and Women’s Hospifal, Boston, MA 
Measurement of troponin (Tn) T and I have been useful in assessing prognosis in 
patients with unstable angina. In addition, greater benefit from glycoprotem Ilb/llla inhibi- 
tors is achieved in patients with elevated troponin values than in patients without elevated 
Tn values. Their use in predicting benefit of an invasive vs. conservative strategy has not 
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yet been established. Methods: In the TACTICS-TIM1 18 trial patients with unstable 
angina or non-ST elevation MI were treated with aspirin, heparin and tirofiban and ran- 
domized to an invasive strategy with routine catheterization and revascularization as 
app[opriate within 4-48 hours, or to a conservative (i.e., a “seiectws invasive’ strategy) 
with catheterization performed only if the patient had objective evidence of recurrent 
ischemia or a positive stress test. Both troponin T and I were measured in all patients 
who provided a baseline blood sample (N=l763). Results: Preliminary results as of 
August 2000 showed a graded increase in the 6-month mortality rate for both troponin 
values.(See table) 
TnT <=O.Ol >O.Ol-0.06 20.06-9.1 >O.l-1.0 >1 .o P Trend 
820-4 
II:45 a.m. 
No Beneficial Effect of 24-48 Hours Abciximab Infusion in 
Aspirin and Heparin Treated Acute Coronary Syndrome 
Patients With Elevated Troponin Without Early 
Revascularisation Procedures: a GUSTO-IV ACS Substudy 
S James, B Lindahl, P Venge, P Armstrong, E Barnathan, R Califf, M Sirnoons, E Topol, L 
Wallentin. Dept of Cardiology, Uppsala, Sweden 
In acute coronary syndrome (ACS) elevation of troponin (Tn) level is associated with a 
raised risk of subsequent cardiac evenis. In the GUSTOIV ACS trial ouicome in relation 
to Tn was a predefined substudy. Methods: The multinational multicenter prospectwe 
double-blind trial of the efficacy of abciximab as the primary medical treatment in ACS 
without early revascularization included 7800 patients with chest pain within 24 hours 
and either ST-segment depression or elevation of troponin at entry. The patients were 
randomized to bolus injection followed by 24 hours (n=2590) or 48 hour (n=2612) infu- 
$10” of abciximab or corresponding placebo (n=2598). TnT was measured by the 3rd 
generation Elecsys method at the core laboratory in samples obtained at randomization 
from 6525 patients. Elevated Tn was also reported in the CRF according to local meth- 
ods at each centre. Primary endpoint was death or Ml at 30 days by inteniion-to-treat 
which was related to the predefined cut-off level of 0.1 “g/L for the core laboratory Tn 
Results concerning death or MI% at 30 days 
Local Tn Placebo Abc24 Abc24 Placebo Abc24 Abc48 
Negative n=978 n=925 5.4% 6.8% 7.5% 
Positive n=1329 “=1361 n=1351 10.0% 9.1% 9.3% 
TnT Placebo Abc24 Abc24 Placebo Abc24 Abc48 
co.1 “g/L n=l094 n=i 082 n=1090 5.3% 5.9% 6.0% 
.=O.l ug/L fl=1066 n=1099 n=i 094 9.7% 10.2% 11.7% 
Conclusion: In accordance with previous reports elevated troponin levels identify 
patients with higher risks of subsequent death or Ml. However, the present prospective 
study does not confirm the concept that elevated troponin levels will identify responders 
to treatment with Gpllbillla inhibitors. 
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820-5 Risk Stratification in Unstable Angina: Incremental Analysis 
of Clinical, Electrocardiographic, Autonomic and 
Biochemical Markers 
Simon R. 0. Kennon, Heather Clarke, James Hooper, Jackie Cooper, Adam D. Timmis. 
Batis and the London NHS T&t, London, United Kingdoin 
Background: The positive predictive values of tests used for risk stratification in non-ST- 
elevation acute coronary syndromes are generally low. Incremental analysis has the 
poteniial to enhance predictive value but there have been few reports of its application in 
this group of patients. In this study the incremental value of clinical data, troponin T, ST 
segment monitoring and heart rate variability for predicting outcome in patients with non- 
ST-elevation acute coronary syndromes has been evaluaied. 
Methods: Prospective cohort study of 304 consecutive patients admitted with non-ST- 
elevation actite coronary syndromes. Baseline clinical and electrocardiographic data 
Were recorded, serial blood samples obtained for troponin T assay, and 48 hour Halter 
monitoring performed for ST segment and heart rate variability analysis. End-points were 
major ischaemic events (cardiac death, non-fatal myocardial infarction) during follow-up 
for 12 months. 
Results: After 12 months, 7 patients had died and 21 had had non-fatal myocardial inf- 
arction. The risk of an event was increased by troponin T rO.l~g/l (odds ratio 6.33; 95% 
confidence intervals 1.9-21 .OS), T wave inversion on the presenting ECG (5.75: 1.48. 
22.25), Halter ST elevation (4.41; 1.51-12X12), Halter STdepression (3.24; l.ll-9.43), 
and a decrease in the standard deviation of 5 minute mean RR intervals (0.53; 0.29. 
0.96). Positive predictive values of individual multivariate risk markers for cardiac death 
and non-fatal infarction in the first year were low, however, incremental analysis of all mul- 
tivariate risk markers permitted calculation of a cumulative risk score which increased the 
positive predictive value to 46.9% while retaining a negative predictive value of 96.9%. 
Conclusion: An incremental approach to risk stratification in non-ST-elevation coronary 
syndromes, utilising a range of widely available risk markers, was powerfully predictive of 
outcome, successfully identifying a group in whom the risk of cardiac death or non-fatal 
myocardial infarction approached 50% during the first 12 months. 
N= 808 150 81 527 197 
Mortality (%) 1.9 3.3 2.5 3.8 5.1 0.009 
Tnl co.1 z-o.1 -0.4 >0.4-1 .o >l.O-1.5 A.5 P Trend 
N= 394 79 70 37 1183 
Mortality (%) 1.3 0 5.7 13.5 3.3 0.034 
Conclusion: Both TnT and I were significant predictors of 6 month mortality. Their use in 
predicting benefit of a routine invasive vs. “selective invasive” sirategies will be pre- 
sented. 
820-2 
11:15 a.m. 
Troponin-T 0.03 ug/L Is the Most Appropriate Cut-Off Level 
Between High and Low Risk Acute Coronary Syndrome 
Patients: Prospective Verification in a Large Cohort of 
Placebo Patients From the GUSTO-IV ACS Study 
6 Lindahl, P Venge, P Armstrong, E Barnathan, R Galdf, M Sirnoons, E Topol, Lars 
Wallentin. Depariment of Cardioiogl: Uppsala, Sweden 
The prognostic value of troponin T (tnT) in unstable coronary artery disease (UCAD) is 
well esiablished. A 3rd generation tnT assay using human recombinant cardiac tnT for 
calibration has been developed improving precision and modifying the measuring range. 
The upper reference level of healthy controls with this new assay is below the detection 
limit 0.01 “g/L. Considering the precision of the assay a new cut-off value of 0.03 ug/L 
was recently recommended based on retrospective analysis in relation to outcome in 
2156 noninvasively managed patients in the FRISCII trial. In order to prospectively verify 
this new cut-off we tested iis relation to the 30 days rate of death or Ml in a large cohort of 
placebo patients in the GUSTO-IV-ACS trial. Methods: Plasma sample obtained at inclu- 
sion in 2160 of the 2598 enrolled in the placebo group of the GUSTOIV ACS trial recruit- 
ing patients within 24 hours after the last episode of chest pain and with ST-segment 
derpession or elevation of a biochemical marker of myocardial damage. All placebo 
patients were treated with aspirin and heparin or ImW heparin. The primary end-point 
was death or MI at 30 days. Serum samples were obtained at entry and analysed in the 
core laboratory with the 3rd generation tnT assay (Roche Diagn.) with a detection limit of 
0.01 “g/L and a functional sensitivity (CV<ZO%) of 0.03 “g/L. 
Results concerning death or MI% at 30 days 
Troponin-T ug/L co.03 0.03.<O.l 0.1.<0.3 >=0.3 
Patients 818 276 388 678 
Death 1.6% 2.5% 4.6% 6.8% 
Death or Ml 4.0% 9.1% 9.5% 9.7% 
Conclusion: The results confirm that a cut-off level Troponin-T 0.03 “g/L is the most 
appropriate for identification of patients with minor myocardial infarction and a raised risk 
for subsequent events. 
820-3 
II:30 a.m. 
Are There High-Risk Patients Who Are Troponin Negative? 
Further Risk Stratification With the TIMI Risk Score in 
Patients With Acute Coronary Syndromes: Results From 
OPUS-TIM1 16 
Christopher P. Cannon, Carolyn H. McCabe, Elliott M. Antman, Jane Bentley, Nader Rifai, 
Eugene Braunwald. Brigham and Women’s Hospital, Boston, MA 
While patients who are troponin (Tnl) positive are al high risk of mortality and recurrent 
cardiac events, debate has emerged about patients who are troponin negative. Are they 
all low-risk? We hypothesized that clinical risk factors can identify patients at high risk of 
mortality even among patients who are troponin negative. Methods: In the OPUS-TIM1 
16 trial, patients with acute coronary syndromes (ACS) were treated with aspirin and ran- 
domized within 72 hours of symptom onset to the oral Ilb/llla inhibitor orbofiban or pla- 
cebo. In a case-control study of the composite endpoint of death, MI, uigent 
revascularization, recurrent ischemia requiring rehospitalization or stroke, Tnl (Bayer) 
was measured in 2241 patients at study entry, and the TIMI Risk Score was calculated 
for each patient using 6 of the 7 criteria. Results: Patients with Tnl z 0.1 nglml had 
increased relative risk (RR) of 10 month mortality RR=1.6, p=O.O3, Ml RR=1.82, p=O.OOl, 
death or MI, 10 months RR=1.7, p=O.OOOZ, urgent revascularization RR=1.56, p=O.O04, 
and death/Ml/urgent revascularization RRzl.82, p<O.OOOl, but only weakly for the com- 
posite including angina requiring rehospitalization: RR=1.17, p=O.O43. Among patients 
with a negative troponin <= 0.1 “g/ml, the TIMI Risk Score identified a graded increase in 
the relative risk of the composite endpoint to 10 month follow-up (TRS 0, RR=l, TRS 
1,2,3,4, 5-6 Rel Risk: 1.3, 1.4, 1.8, 2.3, 2.6, p trend = 0.002. Conclusion: In this broad 
ljopulation of patients with acute coronary syndromes, Tnl was a significant predictor. of 
long-term mortality and ischemic events. Most importantly, however, among patients with 
a negative troponin, formerly considered to be low-risk patients, the TIMI Risk Score was 
able further risk stratify patients into high and low risk. These data indicate that additional 
risk stratification should be carried out beyond just assessment of troponin in order to 
identify high-risk patients who warrant aggressive therapy. 
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ORAL CONTRIBUTIONS 
821 Stabile lschemic Syndrome: Clinical 
Aspects 
Monday, March 19, 2001, II:00 a.m.-l 2:15 p.m. 
Orange County Convention Center, Valencia A 
821-l 
11 :oo a.m. 
Improvement in Health Status at 3 Months in the COURAGE 
Trial: Seattle Angina Questionnaire Results 
William S. Weintraub, John Spertus, Emir Veledar, Cheryl Lewis, Elizabeth Mahoney, 
Pamela Hartigan, David J. Maron, Koon Tao, Paul Gasperson, Karen Potter, Sandra B. 
Dunbar, Robert A. O’Rourke. William E. Boden. Emory University At/an@ GA, West 
Haven Veterans Adminisrration Hospital, Wesi Haven, CT 
Background: The uillity of percutaneous coronary intervention (PCI) to treat angina is 
being evaluated in COURAGE, a multicenter randomized trial in 3260 patients treated 
with best possible medical care and randomized to medicine vs medicine plus PCI. 
Methods: COURAGE includes a detailed health related quality of life (QOL) study. with 
angina measured using the Seattle Angina Questionnaire (SAQ). COURAGE also 
includes aggressive treatment goals for angina (angina free), blood pressure, exercise, 
diabetes control and lipid lowering, all according to ACCIAHA guidelines. The SAQ 
Includes domains for physical limitation, angina stability, angina frequency, treatment sat- 
isfaction and QOL. Scores can range from 0 to 100, with higher scores reflecting belter 
sIa1us. 
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821-3 Protective Effects of Angiotensin Converting Enzyme 
Inhibitors in African American Men With Coronary Artery 
Disease 
Vasilios Papademetriou, Andreas Pittaras, Peter Kokkinos, Puneet Narayan. VA Medica/ 
Center, Washington DC, DC, Georgebwn Universify Washingion, DC 
Background: Angiotensin converting enzyme inhibitors (ACEI) are underutilized in Afri- 
can-Americans (AA) because of their perceived lesser efficacy in the control of hyperten- 
sion. However, the potential protective effect of ACEI in AA has not been evaluated 
Methods: We assessed the effects of ACEI therapy in 810 AA men who underwent diag- 
nostic cardiac catheterization at the Washington VAMC. 
Results: Of those, 237 (29%) received ACEI therapy and 573 (71%) did not. All patients 
received adjunctive therapy (BB, CCB, diuretics, and cholesterol lowering agents) as 
needed. Both groups were of similar age at entry (6&10 Vs 68+9 yr.) had similar lipid 
profiles and blood pressure. Patients on ACEI however were heavier (84516 Vs 81+14 
kg; p <0.02), had higher blood glucose (132f37 Vs 123+32 mg/dl; p<O.OOl, had higher 
LVMI (166+49 Vs 156+49; p<O.Ol) and lower EF (49% Vs 58%; pcO.000). More patients 
cn the ACEI group had diabetes meliitus (43% Vs 27.5%; p<O.OOO), severe CAD (36% Vs 
28%; pcO.O3), history of hypertension (75% Vs 64%; pc0 004), complex arrhythmias 
(21.8% Vs 14.4%; p<O.Ol), and CHF (26.7% Vs 9.5%; p<O.OOO). Over a period of 
lZOr28 months, 74 patients (31%) in the ACEI group and 212 (37%) in the non-ACE1 
group died. After adjusting for confounding faciors (Cox Regression), patients not receiv- 
ing ACEI had 80% higher mortality compared to patients on ACEI (RR=1.8; Cl: 1.3-2.6, 
p<o.ooo). 
Conclusion: These data indicate a strong protective effect of ACEI in AA men with coro- 
nary heart disease. 
Results: Baseline and three month SAQ scores are available for the first 195 patients 
randomized in COURAGE: 
Baseline 3 Months P Value 
Physical Limitation 63+27 72+26 0.0008 
Angina Stability 48+33 76&28 <0.0001 
Angina Frequency 64?28 80124 <0.0001 
Treatment Satisfaction 8&i 8 91212 0.0012 
Quality of Life 47*26 68+26 <0.0001 
The physical limitation, angina1 stability, angina1 frequency and QOL scales all improved 
significantly. SAQ scores were correlated with treatment goal variables. Physical Ilmita- 
tlon at 3 months correlated with targels for no angina (p=O.OSl), regular exercise 
(p=O.O038) and LDL ~85 mg/dl (p=O.O75). Angina stability correlated with target for no 
angina (p=O.O004). Angina frequency correlated with target for no angina (p=O.OOOl), 
systolic pressure <I30 (p=O.O48) and diastolic pressure ~80 (p=O.O25) QOL correlated 
with target for no angIna (p=O.OOOl). 
Conclusions: Patients with coronary disease and significant angina can be expected to 
improve over a period of several months wiih aggressive treatment options including PCI 
and medical management. The Seattle Angina Questionnaire offers a detailed assess- 
meni of angina1 burden on health related QOL and correlates with other measures of 
outcome. The importance of intensive medical therapy as an adjunct to PCI in symptom- 
aiic CHD patients can be demonstrated to improve health outcomes using the SAQ in a 
large randomized trial 
821-Z 
Ii:15 a.m. 
Percutaneous Myocardial Laser Revascularisation (PMR): Is 
the Symptomatic Benefit Maintained to 2 Years? 
Richard J. Allen, Simon R. Redwood, D J. Coltart Guy‘s and St Thomas‘ Hospifai Trust, 
London, United Kingdom 
How to manage totally asymptomatic diabetic (TAD) patients in whom a myocardial per- 
fusion defect has been documented by stress SPECT imaging performed as a screening 
test remains debated. A follow-up (F-U) registry recruited, from 03192 to 03197. 383 TAD 
pts (age 61 i10 years, 192 males) without history of heart disease who underwent a rest 
Thallium 2lOistress Tc-99m sestamlbi SPEGT imaging screenmg because of a diabetes 
duration > 10 years plus at least one additional risk factor. Among the 383 pts, 124 had at 
least one myocardial perfusion defect at SPECT and were managed at physician discre- 
tion either with conservative medical treatment (Gl 1x60) or invasively with immediate 
coronary catheterization followed by revascularization whenever possible (G2 n=64). The 
mean F-U was 39 months (range 21.57). Results. At inclusion in the registry, the 2 
groups did nd differ regarding age, gender, duration of diabetes, number of risk factors; 
the extent of SPECT defects was greater in G2 (1.65) than in Gl (1.4, p = 0.04). The 
pharmacologic treatment during F-U was similar between the 2 groups. Dtmng F-U in 
Gl, 15 pts (25 %) underwent coronary angiogram and 6 were revascularized (IO %); in 
G2, 2 pts underwent repeat coronary angiogram leading to revascularization in one. At F- 
U, cardiac death and combined major cardiac events (cardiac death, heart failure, acute 
myocardial infarction, unstable angina) rates were higher in Gl than in G2, relative risk 
(RR) 0,31(p=O.O7; 95% Cl 0,084 to 1,13) and RR 0,37 (p=O.O085; 95% Cl 0,18 to 0,78), 
respectively. By univariate analysis, age, gender, diabetes duration, number of risk fac- 
tors and extent of SPECT defect were not prognosis predictors whereas the non-inva- 
sive/invasive approach was. Thus, immediate wasive strategy may wnpiova the 
prognosis of selected totally asympiomatic diabetic patients in whom myocardial perfu- 
sion defect has been documented by SPECT imaging performed as a screemng test. 
Between May ‘98 and September ‘99, patients with Canadian Cardiovascular Society 
(CCS) class Ill or IV angina were entered into a longitudinal study inio the effects of 
PMR. All patients were unsuitable for more conventional methods of revascularisation. 
Method. PMR was performed on 27 patients (22 male) using the CardioGenesis PMR 
system. At follow up patients were assessed for CCS angina class, exercise treadmill 
testing (Naughton protocol) and completed the Seattle Angina Questionnaire to assess 
impact on quality of life. Nuclear myocardiai perfusion scanning was performed at base- 
line and 6 months follow up. Results. Angina class improved from 3.45 & 0.3 (mean f 
SD) to 2.09 t 0.6 at 3 months (p<O.OOl). There was at a P+class improvement in 67% of 
patients ai 3 months. The improvements were lmaintalned to 6 months (pcO.OOl), but 
thereafter a gradual return of symptoms was reported. At 1 year there was still a signdi- 
cant improvement in angrna (~~0.05) but at 2 years angina levels (3.16 i- 0.4) have virtu- 
ally returned to baseline (p=NS). Exercise capacity increased from 342 + 202 seconds to 
470 * 252 seconds at 3 months (p<O.OOi). The improvements were maintained to 1 year, 
432 t 232 seconds (PcO.01) but were agaIn reduced at 2 years (p = NS). Quality of life 
measures were signiiicantly improved at 3 months (p<O.Oi) with the benefits maintained 
to 2 years (p<O.Ol). No significant improvements were deiected on nuclear perfusion 
821-4 
ii:45 a.m. 
What Strategy in Totally Asymptomatic Diabetic Patients 
With Myocardial Perfusion Defect at Stress SPECT Imaging 
Performed as a Screening Test? 
Alexis Cerisier, Valerie Bruiport-Cerisier, Bruno Estour, Antoine Da Cosia, Karl Isaaz. 
umversity of saint Etlenne, sainr mmne. France 
821-5 
Noon 
Are Women at Increased Risk of Death After PCI? Results 
From the ACC-NCDR Database 
Vernon Anderson, William S. Weintraub, Richard Shaw, Charles McKay, Ralph Brindls. 
On Behalf of fhe ACC-NCDR(TM)/ACC Database Commitlee, Bethesda, MD 
Background: Women are ai increased risk after percutaneous coronary Intervention 
(PCI). However, there are llttle data to quantify this increased risk from contemporary, 
nationally based, multisite registries. The ACC-NCDR is a major registry activity of the 
American College of Cardiology which is designed to assess outcome of PCI. 
Methods: Outcome of PCI in men (n=l1508) and women (n=5800) was examined in the 
ACC-NCDR database. 45 Institutions (l/1/98-6/30/99) with acceptable complete da& 
used standardized definitions and identical reporting standards. 
Results: Women were older, more symptomatic, had more co-morbidity, but less objec- 
tive severity of disease (see table). 
Mall Women P Value 
scanning at 6 months (p=NS). Conclusions. PMR offers hope to a group of patients who 
have ilttle in the way of therapeutic options. Our findlngs suggest significant initial symp- 
Age 
tomatic benefits lasting to 6 months, after which there is a gradual return in symptoms. Hypertension 
with no significant anginal improvement 2 years after the procedure. The findings are Diabetes 
interesting with regards to the potential mechanism of action of PMR and Cal! into ques- Heart Failure 
tion how worthwhile ihe treatment is long-term. Class Ill-IV Angina 
Prior CABG 
Ejection Fraction 
stent 
Angiographic Success 
6&12 
59% 
23% 
9.6% 
60% 
21% 
51i14 
70% 
66+12 <0.0001 
70% co.ooo1 
30% co.ooo1 
14.4% <0.0001 
64% <0.0001 
15% <0.0001 
54*15 <0.0001 
68% 0.003 
93% 0.23 
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Q Wave MI 0.45% 0.47% 0.99 
CABG 2.14% 2.51% 0.14 
Death, All Cases 1 .38% 2.23% 0.0001 
Death, Elective Cases Only 0.46% 0.86% 0.01 
stay (days) 2.3+3.1 Z&3.8 <0.0001 
wliill 
corrected for baseline differences, ihere was only a trend toward increased mortality in 
women (OR = 1.27, 95% Cl 0.97-1.65). 
Conclusion: In the ACC-NCDR, women had higher in-hospital mortality than men, but 
primarily due to older age and greater co-morbidity. The broadly representative nature of 
the ACC-NCDR offers a nationally based registry to examine in-hospital outcome of PCI 
in the United States. 
Results: PCI candidates undergoing EECP were older with more previous intervention 
and higher risk profile: 
Baseline Presentation 
EECP (n=148) PCI (n=411) 
Mean age ** 65.8 yrs 62.4 yrs 
Female ** 18% 30% 
Prior PCI *** 60% 31% 
Prior CABG *** 38% 15% 
Prior myocardial infarction *** 57% 13% 
History of congestive heart failure ** 17% 8% 
HIstory of diabetes *** 43% 22% 
Baseline angina severity: CCSC l/llllll/lV (%) ** 13/30/39/l 8 514514515 
**pc.o1, **p<o.o01. 
At one-year follow-up, mortality was comparable (2.1% EECP vs. 2.2% PCI) as were 
rates of subsequent CABG (5.2% EECP vs. 5.1% PCI). During follow-up, 9.6% of those , 
initially undergoing EECP had repeat course(s) of EECP, while 5.3% had subsequent 
PCI. Of the patients initially undergoing PCI, 17.0% underwent repeat PCI during follow- 
up. Angina was reported at one year in 60% of EECP pts vs. 26% of the PCI cohort 
{p<O.OOl). However, reported rates of severe angina (Class III, IV, or unstable symptoms) 
were 11% among EECP pts and 8% among PCI pts (p=ns). 
Conclusions: PCI candidates undergoing EECP for stable symptoms have a markedly 
higher risk profile than patients with stable angina who undergo PCI. While angina is sub- 
stantially more prevalent one year post EECP, more severe symptoms are reported rela- 
tively infrequently with each of the two treatments. 
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1117-101 Enhanced External Counterpulsation for Chronic Angina Is 
Associated With Improved Outcome at 6 Months 
Gregory W. Barsness, Theresa Schnell, David R. Holmes, Jr.. Mayo Clinic, Rochesfer, 
MN 
Background: There is a growing population of patients with severe ischemic chest pain 
(CP) who are not amenable to traditional revascularization strategies. EECP is a non- 
invasive, outpatient treatment that promotes diastolic augmentation and may reduce 
angina symptoms. Methods: 35 patients with severe angina (CCS angina class 3 or 4) 
despite optimal medical therapy underwent 35 one-hr EECP treatments over a 7.week 
period. Clinical characteristics, symptoms and follow-up events were recorded at base- 
line, at the end of treatment, and at 3, 6 and 12 months. The DASI score, a prospectively 
validated, semiquantitative assessment of cardiovascular functional status, was also 
measured via a self-administered questionaire. Results: Patients were elderly (media” 
69 yrs), primarily me” (83%), with a history of diabetes (31%), hypertension (76%), 
tobacco use(67%), heart failure (16%), Ml (48%), PCI (69%) and CABG (92%). 4 
patients had prior TMR (3) or heart transplantation (1). Adverse treatment effects 
included local ski” irritation I” 2 patients. Angina measures improved during treatment 
with persistent benefit to 6 months (below). Throughout treatment and follow-up there 
were 13 clinical events, Including 4 CP hospitalizations without MI, 2 NQWMI, 1 CHF, 5 
PCI and 1 CVA, but no deaths. 
Median (25,75) Pre-EECP Post-EECP B-month p (g-month) 
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1117-75 Are the Initial Benefits of Enhanced External 
Counterpulsation Sustained at One Year? 
William E. Lawson, John C. K. Hui, Elizabeth D. Kennard, Richard Holubkov, Sheryl F. 
Kelsey. SUNY Stony Brook, Sfony Brook, NL: University of Pittsburgh, Pittsburgh, PA 
Background: Enhanced external counterpulsation (EECP) has been shown to be a safe 
and effective treatment of angina in several small University hospital case series, with 
clinical benefits lasting up to five years in follow-up. However, there is no data on the long 
term effectiveness of EECP in routine clinical practice. 
Methods: The International EECP Patient Registry (IEPR) was initiated in January 1998 
at the University of Pittsburgh to sequentially track angina patients (pts) treated with 
EECP for up to 3 years across a broad spectrum of providers and practice settings. The 
registry records: pt demographics, Canadian Cardiovascular Society (CCS) Angina 
class, adverse cardiovascular events (MACE-including: hospitalization, death, infarctlon 
(MI). revascularization (PC1 and CABG)). The IEPR first year follow-up is analyzed. 
Results: The IEPR Includes 734 angina pts one year post EECP, with completed foliow- 
up available on 589 pts. Patients were predominately male (75%) with a mea” age of 68 
years. Pre treatment history was sigmficant for: multivessel disease- 77.6%, prior angio- 
plasty - 58.3%, prior CABG 56.5%, prior Ml - 63.5%, history of Congestive Heart Failure 
- 26.1%. The pts received a mean 34 hours of treatment with 83% completing the full 
course of treatment. Events occuring during the treatment period included: unstable 
angina in 2.5%, MI in 0.4%, death O.l%, CABG 0.5%, PTCA in 0.1%. CCS Angina class 
immediately post EECP improved in 73.4% of pts and 61.6% of pts discontinued nitro- 
glycerin use. The improvement in angina was maintained at 6 and 12 months (table). 
Cumulative MACE at 12 months included: death 5.0%, Ml 4.2%, CABG 3.0%, PTCA 
4.2%, cardiac hospitalizations 17.2% (mean “umber 1.5 and duration 5.5 days). By 12 
mos, 22.8% of pts had undergone additional hrs of EECP treatment. 
Conclusions: In a cohort of high risk cardiac pts, EECP produced immediate and sus- 
tained improvement in CCS angina class in the majority of pts with MACE comparable to 
historical treatment trials. 
EECP effect on CCS Angina Class 
Angina Class BaSeline lmmedlate Post EECP 
NO 0 % 17.6 % 
I 6.4 % 33.7 % 
II 27.2 % 30.8 % 
Ill 46.9 % 12.7 % 
IV 19.5 % 5.3 % 
6 Mos Post EECP 
27.8 % 
33.7 % 
24.1 % 
9.9 % 
4.6 % 
12 Mos Post EECP 
34.1 % 
24.7 % 
24.5 % 
12.2 % 
4.4 % 
1117-76 Intervention for Stable Angina: A Multicenter Comparison of 
Consecutive Patients Undergoing Enhanced External 
Counterpulsation (EECP) and PCI 
Richard Holubkov, Elizabeth D. Kennard, Sheryl F. Kelsey, Ozlem Soran. David R. 
Holmes, Jr.. Universi~ of Pittsburgh, Pittsburgh, PA, Mayo Clinic Foundation, Rochester, 
MN 
Background: Many patients with CAD and stable symptoms who are treated with EECP 
are also suitable for percutaneous coronary intervention (PCI). Assessment of EECP out- 
come in these pts requires comparison of risk profile as well as follow-up status to 
patients with comparable symptoms who undergo PCI. 
Methods: We compared baseline presentation and one-year outcome in two interna- 
tional multicenter cohorts of consecutive pts with stable angina: 148 PCI candidates 
undergoing EECP (International EECP Registry) and 411 pts undergoing nonemergent 
PCI in the NHLBI Dynamic Registry. 
Angina Class (CCS) 3(3,4) 2R2) 2(1,2) <0.0001 
#CP/wk 10(2.8,16.3) 2(0,3) 2(0,5) 0.0002 
#NTG/wk 3(1,10) oc4 0.5(0,4) 0.009 
DASI Score 7.2(4.5,13.5) 15.2(10.0,27.2) l&8(10.5,26.8) 0.003 
Conclusions: Non-invasive EECP treatment was associated with significant improve- 
ment in angina and functional status with few adverse eflects in this high-risk cohort. 
These benefits were maintained at 6 months. Clinical event rates remain low through 6 
months. Further evaluation of mechanism and longer-term durability of effect are war- 
ranted. 
1117-102 Spinal Cord Stimulation for Refractory Angina Pectoris 
Patients: Data on Clinical Outcome From the Prospective 
Italian Registry 
F Di Pede, G Zuin, S Grew, D Rap&i, M Romanb, G Neri, A Circa, A Capucci, G Lanza, 
P Stritoni, GM Actis Data, E Marangoni, M Maritano, M Barbiero, G Dragagno. Cardiology 
Dept. Mestre-Venice, Italy 
The Prospective Italian Registry of Spinal Cord Stimulation [SCSI for severe refractory 
angina was designed to evaluate the immediate and long term clinical outcome of 
patients treated with SCS. From May 1998 to April 2000 87 patients (62 male, mea” age 
69 yrs) were implanted in 15 centers with a” ltrel Ill Medtronic device. All pts implanted 
were followed up after l-3-6-12 months. Results: Baseline clinical characteristics: diabe- 
tes 24%, hypertension 47% dislipldemia 54%. CAD family hystory 24%, smokers 34%, 
mea” duration of angina 7.6 yrs, CCS II 15%, CCS Ill 27%, CCS IV 58% previous myo- 
cardial infarction [Ml] 66%, CABG 47%, PTCA 37%, mea” EF 0.48, triple vessel disease 
82%. Stimulation was bipolar in 80% and continuous in 88% of pts. The mea” follow up 
duration was 7.2 months. Complications: pocket infections in 5 pts, lead dislocation in 1 
pt. Clinical events during follow up: Ml in 1 pt, “on sudden cardiac death I” 3 pts, sudden 
death in 2 pts, “on cardiac death in 2 pts. The CCS improved from a mea” value of 3.39 
+ 0.7 to 1.84 ?. 0.7, the mea” number of rest angina1 attacks/week decreased from 5.3 e 
4.7 to 0.4 + 0.7, the mea” number of effort angina1 attacks/week decreased from 4.5 f 
3.8 to 1.1 f 1.1 and the mea” number of dose nitrate consumption/week decreased from 
8.6 + 7 to 1.3 k 1 after 12 months. Eighv-four percent of pts experienced more than 30% 
reduction of the number of angina1 attacks and 51% had at least 2 CCS reduction. The 
need of hospitalization was analyzed in 47 pts with minimum period of 6 month follow up: 
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the number of patients admitted to the hospital for angina decreased from 35 (75%), dur- 1118-79 Cardioproterction After Experimental Myocardial Infarction 
ing the 6 months period before SCS, to 8 (17%) during the 6 months period after SC!?; in in Stroke-Prone Spontaneously Hypertensive Rats. 
consequence the mean number of days in hospital per patient decreased from 21.5 * 3.2 
to 3.2 i 5.5. Conclusion. SCS seems useful in reducing the number of anginai attacks, 
Comparison Between Antihypertensive Treatment With 
the nitrate consumption and the rate of hospital admission. 
ACE-Inhibitor, ATI-Receptor Antagonist and Combination 
Therapy 
POSTER SESSION 
Alexander Reinecke, Marc Dorenkamp. Quingul Xia, Harro Bitterllng, Susanne Penz. 
Christian Storz, Rtidiger W.R. Simon and Thomas Unger. lnsfitute of Pharmacology, 
University of Kiel, Kiel, Germany C/!mc of Cardioiogy, University of Kiel, Kiei 
1118 Measurement of Infarct Size and 
Myocardial Protection 
Monday, March 19,2001, Noon-2:00 p.m. 
Orange County Convention Center, Hall A4 
Presentation Hour: 1:00 p.m.-2:OO p.m. 
i 118-77 Sonomicrometry Myocardial Tagging Quantifies Regional 
Remodeling After Anteroapical Infarction 
Background: We compared the cardioprotective effects of the ACE inhibitor, fosinopril 
(Fos), the ANGII AT1 receptor antagonist, irbesartan (Irb), and the combined therapy with 
both substances (Comb) after experimental myocardial Infarction (MI) in male stroke- 
prone SHRs (SHRSP) (n=88-235). Methods: To obtain strictly comparable hemody- 
namic conditions, treatment was started with equipotent antlhypertensive doses 4 wks. 
prior to induction of Mill and continued up to 6 weeks post MI. Sham operated and pla- 
cebo treated infarcted rats served as controls. We investigated mortality, survival in rela- 
tion to infarct size (IS), mean IS, cardiac dimensions, hemodynamics and myocardial 
collagen content. Results: In all investigated parameters, Irb was highly significant supe- 
rior to Fos or Comb. Under treatment with Irb, rats significantly showed the lowest mortal- 
ity after MI and survived the largest MIS. Moreover, Irb improved dP/dtmax in infarcted 
rats to a 2.2 and 2.6 fold higher extent than with Comb or Fos, respectively (p<O.OOl). 
Furthermore, myocardial collagen content six wks. after Ml was 1.5 fold lower under Irb 
treatment compared to Fos (p<O.OOl). Combination treatment exerted no synergistically 
beneficial effect compared to Irb as a single drug treatment. Conclusion: When applied 
at equally antihypertensive doses, the cardioprotective effects of the AT1 receptor antag- 
onism were significantly diminished in all parameters investigated when combined with 
an ACE inhibitor. The superior cardloprotection of Irb could be explained by its lack of 
kinin potentiation, second by lower myocardial catecholamine release and third by lower 
incidence of fatal arrhythmias after Ml. 
Benjamin M. Jackson, Robert C. German, Joseph H. German, III, T. Sloane Guy, IV. Sina 
L. Moainie, Theodore Plappert, Martin St.John-Sutton, L. Henry Edmund& Jr.. Univewty 
of Pennsylvania School of Medicine. Philadelphia. PA 
Background: The relative contributions of infarcted, borderzone (normally perfused but 
hypocontractile). and remote myocardlum to chronic left ventricular (LV) remodeling after 
myocardial infarction (Ml) are uncertain. Echocardiography and MRI cannot quantify 
regional dilatation because they depend on anatomic landmarks susceptible to distortion 
with remodeling. We used sonomicrometry array localization (SAL), which allows Identifi- 
cation of discrete locations within the myocardium throughout the remodeling process, to 
assess regional remodeling after anteroapical Ml. Methods: Anterioapical infarctions 
ware performed in 6 sheep with placement of 16 epicardial SAL piezoelectric transduc- 
ers. At baseline (pm-infarction) and 30 min., 2, 5, & 8 weeks post-infarction, end-systolic 
chord lengths between SAL transducers were measured. Borderzone was assumed to 
be myocardium immediately adjacent to the infarct zone (but perfused) which did not 
contract after infarction (as measured by SAL). Results: At 30 min, the infarct dilated sig- 
nificantly, the borderzone slightly, and the remote segments did not dilate. From 30 min to 
8 weeks, however, all regions dilated at approximately the same rate. % Expansion Rela- 
tive to Baseline Segment Length Region 30 min 2 weeks 5 weeks 8 weeks Net (8 wks) 
Infarct 2726 * llrt6 t 614 lo-c9 54+11 * Borderzone 726 * 8+4 7+5 lo+5 t 32i5 * 
Remote 0+2 * 6*2 8i3 5t4 19i4 ’ * Significant difference between all pairs of groups 
(p&5). t Significant difference between indrcated group and “Remote” at same time 
point (pc.05). Conclusions: Tl?ese data show that while early LV dilatation in anteroapi- 
cal Ml is predominantly due to infarct expansion, chronic remodeling is the result of bal- 
anced dilatation in all LV regions, including ContractlIe segments. These results imply that 
mechanical stress is increased throughout the LV. The various determinants of wall 
stress likely act to d&ring degrees in each raglo”. In the infarct, decreased wall thick- 
ness increases stress; in the borderzone, geometric changes (increased endocardial 
radius of curvature) increase stress, m remote myocardium, series contractile resistance 
increases stress. 
1118-80 Biosense N6GA Mapping for Detection of Myocardial 
Ischemia: Comprehensive Assessment in 74 Pigs 
Gilbert P. Beran, Mark Post, Michael Simons, Dietmar Glogar, Roger J. Laham. B/DMC/ 
Harvard medical School, Boston, MA 
Introduction: Biosense NOGA-mapping has been used to detect myoca@al Ischemia. 
This, however, is based on older software versions, small series, and limlted experimen- 
tal studies. The purpose of this study was to comprehensively and systematically evalu- 
ates NOGA maps as a tool for myocardial ischemia detection. Methods: 87 normal and 
ischemic (3-4 weeks after placement of a 2.25-2.5 mm ameroid constrictor on the left cir- 
cumflex artery, LCX) Yorkshire pigs, which underwent NOGA mapping, were considered 
for the study. Angiograms ware analyzed in ischemic animals to document LCX-occlu- 
sion. NOGA maps on all animals were assessed quantitatively (data for each acquired 
point) and semiquantitatively (O-6 scale) for linear local shortening (LLS, regional myo- 
cardial function) and unipolar (UPV) and bipolar (BPV) voltage. Results: 74 animals had 
maps and coronary status adequate for analysis [38 ischemic pigs and 36 non-ischemic 
animals]. By semi-quantitative analysis, with moderate to severe (grade 3-6) impairment 
I” LLS as a cutoff for ischemia, sensitivity of NOGA mapping was 82% and specificity 
was 61% (positive predictive value: 68%; negative predictive value: 76%). In the quantita- 
tive analysis, 5423 points (72.4kl4.4 per animal) were measured. Given species differ- 
ences. the rotatlonal anale (theta) was shifted 40° clockwise to adiust for anatomical 
I _  
1118-78 Endocardial Mapping Accurately Predicts the Transmural position. UPV and BPV were preserved in both normal and ischemic animals. LLS, how- 
Extent of Myocardial Infarction 
ever was impaired in the lateral wall.of ischemic compared to normal pigs [8.9%*1.40 
(SE) vs. 11.2%~1.44, pcO.001) lschemic animals had lower LLS in the mid (8.4all.60 
Tamir Wolf, Lior Gepstein, Gal Hayam, Rona Shofti, Asaph Zaretrky, Gideon Uretzky, Uri vs. i1.6%i1.59 pcO.001) and basal (8.3%+1.44 vs. 10.7%+1.34. pcO.005) but not in the 
Oron, Shlomo A. Ben-Haim. Cardiovascular System Labor&q The Bruce Rappaport apical lateral wall (pzO.14). Interestingly, LLS of the septal wall was higher in ischemic 
Faculfv of Medicine. The Technion-/.I. T. Haifa. lsrael than normal animals (12.0%+1.44 vs. 10.1%+1.34, p<O.O05), possibly secondary to 
Background: The degree of iniarct transmural extent has previously been linked to 
compensatory hypercontractility. There was a good correlation between semi-quantitative 
patient prognosis and may have significant impact on therapeutic strategies. We hypoth- 
and quantitative analysis (r=0.81; p< 0.001). Conclusion: NOGA mapping in this large 
eszed that catheter based mapping of infarcted tissue, and interpretation of endocardial 
study can detect &hernia with reasonable accuracy. The average LLS I” ischemic myo- 
electrophysiological information, is capable of delineating infarcts of various transmural 
cardium of 8.4% warrants increasing the detection threshold for clinical NOGA maps. 
subtypes. 
Methods: I” 13 dogs, electromechanical mapping was performed 4 weeks following LAD 
ligation, enabling a 3D reconstruction of the LV chamber. A concomitant reduction in 
bipolar electrogram amplitude (SEA) and local shortening (LS) indicated the infarcted 
region. In addition, impedance, unipolar electrogram amplitude (UEA) and slew rate (SR) 
were quantified. Subsequently, the hearts were excised: TTC stalned. and sliced trans- 
versely. The mean transmural extent of the necrotic tissue in each slice was determined 
and infarcts were divided into (1) ~30%; (2) 31.60%; and (3) 61.100% transmural sub- 
types to be correlated with the corresponding electrical data. 
Results: Ail four indices delineated Infarcted tissue. However, BEA (2.li-0.5mV, 
1.2+0.2mV, 0.8fO.lmV in the three groups respectively, PcO.05 between each group) 
and SR (1.5iO.5mV/msec, O.SiO.2mV/msec, 0.7?0.lmV/msec in the three groups 
respectively, PcO.05 between each group) proved superior to both UEA and impedance 
which could only differentiate between the first (~30%) and third (61.100%) transmurality 
subgroups 
Conclusions: The degree of infarct transmural extent can be derived from the endocar- 
dial properties of the tissue using electromechanical mapping. Utilization of such infor- 
mation may be helpful in determining the therapeutic approach and prognosis of patients 
suffering from myocardial infarction 
1118-81 No Impact of an AGE-Crosslink Cleaving Agent Found in 
Rat LV Infarct 
Paul S. Hees, David E. Bush, Michelle H. Leppo, Edward P. Shapiro. Johns Hopkins 
University, Baltimore, MD 
Background 
The advanced glycation endproduct (AGE)-crosslink cleaving agent ALT-711 reduces 
vascular stiffness in animal models, and IS currently being studied in humans. However. 
the ‘de-stiffening’ effect of the drug could reduce scar formation and promote Infarct (MI) 
expansion, a deleterious effect. Alternatively, new evidence suggests that the drug also 
mutes the proliferative response to myocardial overload, ie, has a neuro-hormonal effect 
analogous to that of ACE inhibition, which might improve post-Ml remodeling. We there- 
fore studied post Ml remodeling folIowIng ALT-711 in a rat model of MI. 
Methods 
Treated animals (“=14) received ALT-711 (10 mgikgida IP) for 1 mo prior to infarct, 
while 15 controls received placebos. Animals underwent thoracotomy and LAD Ilgation. 
lschemia was confirmed by visual observation of blanching in the LAD bed and ST eieva- 
tion. The chest was closed and the animal recovered, continuing AL%71 1 Animals were 
sacrificed 2 wk after MI, and the hearts fixed at end-diastole. sectioned, and examined 
histologically to assess morphology after expansion. 
Results 
Results tabulated for 9 ALT-71 l’s and 8 controls surviving Ml and post-Ml period. 
Conclusions 
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ALT-711 had neither a deleterious nor beneficial effect on post-MI remodeling, with no POSTER SESSION 
evidence for an alteration in infarct expansion, wall thinning, or hypertrophy. A trend 
toward reduced infarct size (MI) and wall thickness in the remote zone (LVWT) with ALT- 
711 reouires continuina stud”. 1119 Surgical Strategies for Patients With 
Heart Failure 
”  I  
Morphometric Results in Treated and Control Rats Following Infarct 
BW,S LVMIBSA, LVVIBW, Mb MI% MIWT, LVWT, 
gikg cc/kg mm mm 
ALT-711 321*29 1.432.34 .28+.08 .l lk.05 25+9 1.65+.45 2.56t.22 
Control 357+42 1.55r.21 .29+.06 .16+.04 30+7 1.60?.31 2.72i.13 
P-“&E 0.05 0.41 0.94 0.04 0.22 0.78 0.09 
BW=Body weight; LVM=LV mass: LVV=LV cavity volume; MI=mass of infarcted zone; 
MI%=lOO*Ml/LVM; MIWT=wall thickness in Ml zone; LVWT=remote zone WT 
111882 Apstatin, a New Inhibitor of Aminopepticlase P, Reduces 
Myocardial Infarct Size by a Kinin-Dependent Pathway 
Sebastian Wolfrum, Andreas Dendorfer, Klaus Tempel, Gert Richardt. Medical Clinic II, 
Universiiy of Lijbeck, Liibeck, Germanl: Institute of exp. and c/in. Pharmacology and 
Toxicologfi University of LObeck, Lfibeck, Germany 
Background: Inhibitors of the angiotensin converting 
enzyme (ACE) have been shown to exert their cardiopro- m”mr~K4pwa~mi)n 
tective actions through a kinin-dependent mechanisms. 
,mnt511e 
ACE is not the only kinin degrading enzyme in the rat 
heart. Since aminopeptidase P (APP) has been shown 
to participate in myocardial kinin metabolism to the same 
extent es ACE, in the present study we investigated 
whether inhibition of APP by its specific inhibitor apstatin 
leads to a reduction in myocardial infarct size after acute 
ischemia and reperfusion. Methods: Anesthetized, 
open-chest rats were instrumented for measurement of systemic hemodynamics. Ani- 
mals were subjected to 30-min left main coronary artery occlusion followed by 3-h reper- 
fusion. Apstatin (1 mg/kg), a selective inhibitor of APP or saline were administered 5min 
before ischemia, and rats receiving HOE 140 (0.5 mg/kg), a specific bradykinin-B(2)- 
receptor-antagonist, were pretreated 2min prior to apstatin. After reperfusion, myocardial 
infarct size (IS) was determined by tetrazolium staining and expressed as a percentage 
of area at risk (AR). Results: As given in figure 1, IS/AR% was significantly reduced in 
rats that received apstatin (18 +/- 2%, p < 0.05) as compared with those receiving saline 
(40 +/- 2%) or apstatin plus HOE 140 (49 +/- 4%). Conclusion: Apstatin reduces infarct 
size in an in viva model of acute myocardial ischemia and reperfusion. Cardioprotection 
achieved by the new inhibrtor of Aminopeptidase P is mediated by bradykinin. lnhibion of 
other kininases than ACE could therefore open additional therapeutic strategies for the 
treatment of acute myocardial infarction. 
1118-83 Na+/H+ Exchange Inhibition Protects lschemic Myocardium 
Independent of Potassium-ATP-Channels 
Marie-Luise “on Briihl, Claudia Strohm, Wolfgang Schaper. Department of Experimental 
Cardiology, Max-Planck-Institute for Physiological and Clinical Research, Bad Nauheim, 
Germany 
Background: It has been shown that several N&H+ exchange (NHE) inhibitors protect 
against myocardial injury following ischemialreperfusion. We investigated the role of ATP 
sensrtive potassium (KATn) channels and of the p38-mitogen activated protein kinase 
(MAPK) in cardioprotection induced by BllB722CI, a new NHE inhibitor in a porcine 
model of myocardial ischemia and repeffusion. We have reported that BIIB significantly 
reduced infarct size (IS = infarct area / risk area) in ischemia (coronary occlusion) fol- 
lowed by reperfusion. We now investigated, whether the cardioprotective effect of BIIB is 
preserved during KATp-channel blockade by glibenclamide. 
Methods: Landrace pigs were treated with BIIB prior to left anterior descending artery 
(LAD) occlusion. BIIB (in NaCIIDMSO) was administered either intravenously at a dose 
of 1.5 mgikg (n=4, group A) or 3 mgikg (n=5, group B) for 15 min. The control group 
received only the solvent. BllB was also given via intramyocardial (50mM in NaCI/DMSO) 
microinfusions into the prospective area at risk for 60 min (n=3, group C). For group D the 
protocol of group C was used with the simultaneous systemic application of glibencla- 
mide (0.5mg/kg) (n=3). In all animals the LAD was occluded for 60 minutes followed by 
60 minutes of reperfusion. The amount of dual-phosphorylated ~38.MAPK (Thrl80i 
Tyr182) was measured by Western blot analysis at various timepoints of ischemia. 
Results: Treatment with BIIB significantly decreased IS (PcO.05) in group A and B when 
compared to the control group (35.4t3.9%, 40+7.5%, 62.2+6.%, respectively). In group 
C and D a marked myocardial protection was shown by the presence of viable (triphe- 
nyltetrazolium chloride stained) myocardium around mkxinfusion needles delivering 
BIIB that was not seen around needles with solvent. Treatment with BIIB was associated 
with a decrease of phosphop38MAPK. 
Conclusion: The preservation of the protective effect of BllB722CL in the presence of 
glibenclamide suggests a survival pathway independent from the KATn-pathway but may 
be mediated by its effect on the p38-MAPK signal transduction pathway. 
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1119-84 Hybrid Gene Therapy in Patients Turned Down for Coronary 
Bypass Surgery: an Option for No Option Patients? 
S Kassam, M Kutryk, A Campbell, N Camack, D Latter, L Erret, R Chisholm, D Fitch@ D 
J. Stewart. St Michael’s Hospital, Toronto, Canada 
A significant proportion of patients with severe symptomatic coronary artery disease are 
considered unsuitable for either coronary bypass grafting (CABG) or percutaneous coro- 
nary intervention (PCI), and many are being referred for non-conventional revasculariza- 
tion procedures, including gene therapy. We describe the initial experience of a newly 
established gene therapy program for myocardial angiogenesis. From January to August 
2000, 127 patients with ?.evere angina, considered to be unsuitable for CABG or PTCA 
were evaluated by a team of interventional cardiologists and cardiac surgeons. In 19 
(15%) a standard revascularization procedure was recommended (12 CABG; 7 PCI). In 
this group, there was an operative mortality of 8% (l/12). 96 patients were found to be 
ineligible for the clinical trials: CCS angina class ~3, 29; LVEF < 25% 16; LBBB, 12, 
ischemia-symptom mismatch, 8; history of or active malignancy, 7; miscellaneous rea- 
sons, 24. After successful screening, 12 patients (10%) were entered into a trial. 6 had 
CABG with adjuvant intramyocardial plasmid DNA for VEGF165, 2 were given plasmid 
DNA for VEGF165 with the Biosense NOGA needle injection catheter delivery system 
and 4 were randomized into controlled trial (2 assigned to active treatment with adenovi- 
ral VEGFlPl via minithoracotomy). All patients survived to 90 days post procedure. Of 
the 10 patients treated with VEGF165 gene therapy + CABG, the mean CCS class was 
reduced from 3.56 + 0.50 to 0.88 + 0.83 (p<O.OOOl) and mean global perfusion score in 
segments receiving VEGF was improved from 8.00 + 4.00 to 4.13 + 3.36 segments 
(p<O.Ol). Therefore, we conclude that only a small proportion of patients referred for 
myocardial angiogenesis with “moperable” coronary disease are suitable candidates for 
VEGF gene therapy. However in this observational study these patients appear to bene- 
fit. 
1119-85 Surgical Reconstruction of the Left Ventricle (Dor 
Procedure) in Postinfarction Patients With Moderate to 
Severe Congestive Heart Failure: An Observational Study 
Marisa DI Don&, Anna Toso, Michel Sabatier, Vincent Dar, Mauro Maioli, Gian France 
Gensini, Gerald Buckberg. Dpt of Critical Care Medicine, Florence, l&/y, CardioThoracic 
Center, Monaco, Monaco 
Background: The long term effects of surgrcal reconstruction of the left ventricle (Dor 
procedure) in p&infarction patients with heart failure are only partially known, yet. Meth- 
ods: The study reports early and late results in 179 consecutive patients (59+9yr) oper- 
ated by Dor procedure at the Cardiothoracic Center of Monaco, retrospectively selected if 
they had EF<40% and NYHA class II and Ill. Hemodynamic study before and early after 
surgery was performed in all pts;l year study was done in 94 pts. Results: There were 
114 dyskinetic and 65 akmetic scar. Delay from myocardial infarction was 52r66 months. 
Clinical signs of cardiac failure were present in 133. Urgent operation was performed in 
17. The extent of non contractile myocardium was 58r14 % of the LV perimeter. Mild to 
moderate mitral regurgitation was present in 40. Associate procedures were: CABG in 
all, mitral repair in 12, replacement in 6 and aortic replacement in 2. Perioperative mortal- 
ity rate was 5.6% (101179). Two were transplanted in the perioperative period. Mean fol- 
low-up*was 4Oi20 months; there were 19 late deaths; 2 patients were transplanted (1 
died 1 year after) and 4 were in a transplant list. The table shows hemodynamic data 
before and after surgery (*vs basal; # vs early postop). Conclusion: In pts with postinf- 
arction large ventricular volumes, depressed ventricular function, and moderate to severe 
clinical status Dor procedure has an acceptable operative risk, improves functional class 
and pump function and has a favorable impact on late survival (89% of surviving patients 
and 83% of the overall population, are alive during our observational period). A random- 
ized trial is needed to confirm our results in a larger population and at different Institu- 
tions. 
EDVI ml/m2 ESVI ml/m2 EF % CWP ml/m2 Cl L/minim2 NYHA 
PREOP 183i86 131+65 29i7 1627 2.61.7 2.6&5 
EARLY POSTOP 98*43* 55%30* 45r11* 11+7* 2.6*.6 
1 YEAR 122i49*# 71*32*# 42~11’ 18*10# 2.7k.6 1.5+.7’ 
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1119-86 Real-Time Three-Dimensional Echocardiographic Follow-Up 
d Patients With lschemic Cardiomyopathy Undergoing 
Infarct Exclusion Surgery 
Jian Xin Qrn. Takahiro Shiota, Patrick M. McCarthy, Neil L. Greenberg, Fabrice Bauer, 
Marta Sitges, Jeanne K. Drinko, Xi-Yi Hang, Vong Jin Kim. Kathy J. Hoercher, Tiffany 
Buda, Nicholas G. Smedira, James D. Thomas. The Cleveland Clinic Foundation. 
Cleveland, OH 
Background: We have previously shown the immediate efficacy of infarct exclusion sur- 
gery (IE) for reducing left ventricular (LV) volumes and increasing ejection fraction (EF) in 
patients with ischemic cardiomyopathy using real-time three-dimensional echocardio- 
graphy (RTSDE). The purpose of this study was to evaluate whether this benefit persists 
after the surgery during a mid-range follow-up. 
Methods: Forty-six patients (mean age 63 f 9 yr) who had undergone IE surgery were 
studied. The surgical procedures included infarct exclusion, coronary bypass and mitral 
valve repair (23 patients) when associated with significant mitral regurgitation (MR). 
Transthoracic RT3DE was performed before IE, before discharge (average 7_t4 days after 
IE) and during follow-up (average 922 months). The LV volumes were determined using 
multi-parallel 7-11 short axis planes with Simpson’s method. 
Results: No significant MR was found after the IE surgery. LV end-diastolic (EDV) and 
end-systolic (ESV) volumes were signrficantly decreased and LV EF (EF = (EDV - ES/)/ 
EDV x 100) and forward stroke volume (FSV) (FSV = EDV-ESV-MR volume) significantly 
increased before the discharge after the IE surgery, At the average g-month follow-up, 
LV EF and FSV remained higher than before IE. LV volumes remained lower (164 f 56 
ml for EDV and 97 f 48 ml for ESV. both p > 0.05) in 38 patients. but 8 patients showed 
recovered LV dilation (> 50% in comparison with that before discharge) (Table). 
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EDV (ml) ESV (ml) FSV (ml) EF (%) 
Before IE 227 f 82 162+66 22%12 29*10 
Discharge 152t57’ 94?46 58 f 20’ 40*9 
B-month 183i64ii 103+46# 79 * 35# 43+ 12 
* vs before IE, p c 0.001; # vs before discharge, p < 0.05. 
Conctusion: RT3DE demonstrated sustained benefit in LV ejection fraction and forward 
stroke volume in patients undergoing IEsurgery after a follow-up of 9 months. 
1119-87 Beta-Blocker Attenuates the Development of intramural 
Small Coronary Vessel Disease in Chronic Hibernating 
Myocardium Subtending a Severe Epicardial Coronary 
Stenosis 
Huashan Hong, Seigei Aksenov, Joseph Marak, John Falion, David Waters, Chunguang 
Chen.. Newark Sefh Israel Medical Center, Newark 
Recovery of LV dysfunction after revascularization is often both incomplete and delayed 
in hibernating myocardium. We have previously shown that chronic myocardial ischemia 
induces significant wall thickening of intramural small coronary vessels with reduced 
lumens, preventing complete restoration of myocardial perfusion/flow reserve after revas- 
cularization. To test the hypothesis that a beta-blocker attenuates wall thickening and 
lumen narrowing of small vessels distal to epicardial coronary stenosis (CS), we studied 
21 pigs in 3 groups: Group 1: 9 pigs with 4-week severe proximal LAD CS to reduce cor- 
onary flow (CF) by -30% with LV dysfunction; Group 2: 6 pigs with severe CS as in 
Group 1 + metoprolot (100 mg x 2 /day) for 4.weeks; Group 3: 6 pigs as controls. CF 
reduction(%) by implanted flowmeter, LV ejection fraction (EF,%) and LV wall thickening 
(WTm,%) were monitored. Quantitative microscopic study of arterial wall thickness 
(WTa), lumen diameter (LDa) and WT/LDa ratio of small coronary vessel (30-90 urn) and 
myocardial fibrosis were performed. Results: CF (33+/-6% reduction), WTm (12+/-5%) 
and LV EF (37+/-7%) were significantly reduced in Groups 1 and 2 compared to control 
Group 3 (p<U.Ol). Significant wail thickening of small intramural vessels with reduced 
luminal diameters was found in Group 1 (WTa=l7.2+/-3.2 urn, WTa/LDa=1.34+/-0.15) 
and in Group 2 (WTa=l3.3+/-1.5 urn, WTa/LDa=0.38+/-0.03) compared to controls 
(WTa=9.8+/-2.5 urn, WTa/LDa=0.34+/-0.03,both pcO.05). Metoprolol signifrcantiy 
reduced WTa with increased LDa in Group 2 compared to Group 1 (both pcO.01). Con- 
clusion: Chronic myocardial ischemia induces significant arterial wall thickening with 
reduced vessel lumens in small intramural coronary vessels. Beta-blocker signrficantly 
attenuates, but did not completely prevent, the development of this small vessel disease 
in chronic ischemic, hibernatrng myocardium distal to epicardial coronary stenosis. Thus, 
the preoperative administration of a beta-blocker may enhance the improvement of myo- 
cardial perfusion/flow re.serve aiter revasculariration via this mechanism. 
1119-88 Relative Advantage of a Comprehensive Logistic- 
Regression Model for Preoperative Estimation of the Risk of 
Aortocoronary-Bypass Surgery 
Alan D. Bernstein, Victor Parsonnet. Newark Beth lsrael Medical Cenfer, Newark. NJ 
Background. Risk-adjusted outcome evaluation of aortocoronary-bypass surgery is an 
important resource for assessing the quality of care at regional, hospital, and surgeon 
levels, and in discussions with patients who are considering surgery as a possible thera- 
peutic option. Several existing logistic-regression models used for this purpose incorpo- 
rate only a limited number of preoperative risk factors, excluding (and treating as absent) 
many factors that in individual patients may Increase the likelihood of operative 
mortality. Methods. We developed a logistic-regression model (ROC area 0.792) com- 
prising 25 distinct risk factors and 30 covariates from data encompassing 16,246 isolated 
aortocoronary-bypass procedures performed at 13 New Jersey hospitals in 1996 and 
1997. This model, in which more liberal standards of statistical significance were 
accepted, was compared with a previously published 9.factor, 13.covanate model (ROC 
area 0.781) derived from an earlier version of the same dataset. Results. Risk- 
adjusted mortality rates (RAMRs) derived from the comprehensive model were more 
consistent with observed mortality rates. In contrast, the S-factor model underestimated 
the operative risk seriously in half of the 30% of patients with >4 risk factors (see plots), 
giving those 2,408 patients an erroneously inflated and potentially misleading RAMR 
(5 91%, vs. 3.56% with the 25factor model). Conclusions. A risk-estimation model that 
incorporates many objective, reliably determrned rusk factors affords risk stratification that 
is farrer and closer to reality than a more limited model can provide. The limited model 
was specifically detrimental to surgeons who treated many high-risk patients. RAMRs 
calculated using a more complete model do not penalize hospitals or surgeons that 
accept high-risk patients. 
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1120-89 Clinical Risk Stratification Predicts Extent of Coronary 
Artery Disease in Patients With Unstable Angina 
Verghese Mathew, Michael E. Farkouh, Lynn Urban, Diane Grill, David R. Holmes, Jr., 
Bernard Gersh. Mayo Clinic, Rochester, MN 
Background: The Agency for Health Care Policy and Research (AHCPR) guidelines for 
unstable angina stratify patients into low, intermediate, and high risk subgroups accord- 
ing to the short-term risk of death or myocardial infarction (Ml). Whether these guide- 
lines are useful in predicting the severity of ooronary artery disease by angiography is 
unknown. 
Methods: From 1985.1992, 892 patients in the Olmsted County Acute Chest Pain Study 
with unstable angina underwent angiography within 7 days of index presentation; 64 
(7.2%) were low risk, 641 (71.9%) intermediate risk, and 187 (21%) high risk patients 
according to AHCPR criteria. 
Results: Normal or mild disease (~50% stenosis) was more likely in low risk patients, rel- 
ative to both high risk (OR 13.6, 95% Cl 6.9-26.8) and intermediate risk patients (OR 5.4, 
95% Cl 3.194). Signrficant 1,2,3 vessel (270% stenosis) or left main (350% stenosis) 
disease was more common in high-risk patients relative to low (OR 9.9, 95% Cl 5.2-19) 
and in intermediate relative to low risk patients (OR 4.9. 95% Cl 2.8-8.5). Three vessel 
or left main disease was common in high relative to intermediate risk patients (OR 1.5, 
95% Cl 1.03-2.2) and in high relative to low risk patients (OR ii, 95% Cl 2647.7). 
Conclusion: Among patients with unstable angina undergoing coronary angiography 
within 7 days of presentation. short-term risk stratification according to AHCPR gurde- 
lines correlates with the angiographic extent of coronary artery disease. 
1120-90 Risk Stratification in Patients After Myocardial Infarction 
Using Demographic Risk Factors: A Powerful Prognostic 
indicator 
Yee Guan Yap, Trinh Duong, Martin Bland, Marek Malik, Christian Tarp-Pederson, Lars 
Kober, Stuart Connolly, Robin Roberts, Bradley Marchant, A. John Camm. St. George’s 
Hospital Medica/ School, London, Unifed Kingdom 
Background:Risk stratification of patients after myocardial infarction (Ml) at high risk of 
mortality remains expensive and disappointing. Demographic features may provide use- 
ful prediction but contemporary information is lacking on their effect on the specific mode 
of mortality after MI rn the thrombolytic era. We report the clinical value of a powerful 
prognostic indicator using demographrc information. Method: We combined individual 
patient data from the placebo arms of EMIAT, CAMIAT, TRACE & DIAMOND-MI with 
LVEF/= 45 days after Ml. Risk factors for mortality up to 2.years were examined (Cox 
regression). Risk scores were derived from the equation of a Cox regression model con- 
taining only the significant variables. The prognostic index was the sum of the individual 
contribution from their risk factors. Result: 2707 patients were pooled (age: 66(23-92) yr, 
2132M) wrth 480 deaths at 2 yrs (213 arrhythmic 8 171 cardiac deaths). Variables pre- 
dicted mortality were age, sex, previous MI, previous angina, hypertension, diabetes, 
systolic blood pressure, heart rate 8 Q-wave. Drstinct survival curves were obtained for 3 
risk groups based on the median 8 Inter-quartile range for the prognostic index (figure). 
In the high risk group, up to 40% of patients died of all-cause mortality and 33% died of 
arrhythmic and 32% died of cardiac mortality at 2.year. Conclusion: Our prognostic 
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index provides a simple powerful bedside risk stratification tool using baseline informa- 
tion for the prediction of various modes of mortality. Furthermore, we proposed that such 
information should be considered when designing risk stratification or survival studies. 
Risk Score Low risk Medium risk High risk 
All-cause mortality 4.8 16.4 39.6 
Arrhythmic mortality 2.2 8.1 19.1 
Cardiac mortality 0.9 6.1 18.2 
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1120-93 Prognostic Significance of Conduction Disorders 
Complicating Acute Myocardial Infarction in the Elderly 
Saif S. Rathore, Bernard J. Gersh, Wrlliam J. Oetgen, Allen J Solomon. Georgetown 
University Medical Center, Washington, DC, Delmarva Foundatkx for Medical Care, 
Easton, MD 
Background: Although disorders of cardiac conduction are common in patients present- 
ing with acute myocardial infarction (Ml), patient characteristics and outcomes remain 
poorly defined in the elderly. 
Methods: We evaluated 106,720 Medicare beneficiaries age 65 years and older who 
presented with MI between 1994 and 1996. Subjects who were not transferred during 
hospitalization with valid electrocardiographic data were evaluated to determine the pres- 
ence of right bundle branch block (RBBB), left bundle branch block (LBBB), fascicular 
block (FAS), or bifascicular block (BIF) at time of admission. The influence of RBBB, 
LBBB, FAS, and BIF on mortality was evaluated by logistic regression modeling of 30-&y 
mortality and Cox proportional hazards modeling of long-term mortality (mean follow- 
up=575 days). 
Results: 22,181 (20.8%) subjects had a conduction drsorder documented at admission: 
7,678 (7.2%) presented with LBBB, 6,419 (6.0%) with RBBB, 5,428 (5.1%) with FAS, and 
2,657 (2.5%) with BIF. Patients with conduction disorders had a higher crude in-hospital 
(LBBB 22.4%: RBBB 26.8% BIF 24.6%; FAS 18.3%; no disorder 16.8%, p=O.OOl), 30. 
day (LBBB 26.7%; RBBB 30.0%; BIF 29.0%; FAS 22.2%; no disorder 19.9%, p=O.OOi), 
and one-year (LBBB 49.9%; RBBB 45.6%; BIF 46.8%; FAS 37.2%; no disorder 33.8%. 
p=O.OOl) mortality. Multivariable adjustment for patients’ clinical and demographic char- 
acteristics confirmed hrgher risk of 30.day mortality among patients with LBBB (RR 1.08, 
95% Cl:1.03,1.13), RBBB (RR 1.28, 95% CI:1.22,1 34) and BIF (RR 1.23, 95% 
CI:l.15,1.32) block; FAS was not associated with increased rrkxtality (RR 1.04, 95% 
CI:O.98,1.10). Similar findings were obtained for risk of long-term mortakty among 
patients with LBBB (HR 1.25, 95% Cl:l.22,1.29), RBBB (HR 1.24, 95% CI:l.20,1.29), 
and BIF (HR 1 24, 95% Cl:1 18,1.30); FAS block had limited prognostic significance at 
long-term follow-up (HR 1.04, 95% CI:1.00,1.08). 
Conclusion: Conduction disorders are a common complicatron of Ml in elderly patients. 
Lefi bundle, right bundle, and bifascicular blocks are associated with increased short and 
long-term mortality, while a solitary fascicular block is not of prognostic significance. 
1120-94 The Management and Investigation of Elderly Patients With 
Acute Coronary Syndromes Without ST Elevation: An 
Evidence-Based Approach? Results of the Prospective 
Registry of Acute lschaemic Syndromes in the United 
Kingdom (PRAIS-UK) 
Julian R. Collinson, Marcus D. Flather, Ameet Bakhai, Marcelo C. Shibata, Diego Perez, 
Erwin A. Rodrigues, lain Findlay. Royal Brompton and Harefield NHS Trust, London. 
United Kingdom 
Background: In the elderly, acute coronary syndromes (ACS) without ST elevation are a 
frequent and important cause of admission. In the United Kingdom, practice patterns and 
outcomes in these patients need to be assessed. Methods: We enrolled 1046 patients 
admitted with ACS without ST elevation to 56 UK centres (20 consecutive patients per 
centre) and followed them for 6 months. We compared baseline characteristics, out- 
comes and treatments in Group 1: those aged over 80 (n=ll9, 11%) Group 2: from 70 to 
80 (n=301, 29%) with Group 3: those below 70 (n=572, 60%). Results: The proportion of 
males was 40% 52%, and 69% respectively (pcO.001). There were no differences in the 
proportion of patients with diabetes (17% overall), treated hypertension (38%) or prior Ml 
(48%). The proportion with ST depressron or bundle branch block on the admission ECG 
were 40%, 39% and 22% (pcO.001) respectively and a normal admission EGG was seen 
in 13%, lo%, and 19% (p<O.Ol) respectively. Median length of stay was 6, 5, and 4 days 
(p=O.O3). The rate of the composite endpoint of death or new Ml at 6 months was 13% 
18%, and 8% (p<O.OOl) respectively. Any heparin was used in 61%, 70%, and 75% 
(~~0.01) respectively and aspirin in-hospital in 83% 84% and 89% (~~0.03) respec- 
tively. Lipids were measured in 49%. 58%, and 68% (p<O.OOi) and total cholesterol found 
to be greater than 5.0 mmolil (190 mgidl) in 44%, 43% and, 41% (no difference). At 6 
months, beta blockers were used rn 29%, 38%, and 45% (p<O.OOl) and statins in 32% 
40%, and 55% (p<O.OOl) respectively. Rates of angiography were 18%, 21%, and 36% 
(p<O.OOl) and of revascularisation 9%, 12%, and 18% (p=O.Oi). in-hospital stress testing 
was performed in 2%. 9%, and 16% /p<O.OOl) respectively. Conclusion: In this large 
population based registry of UK patients admitted to hospital with ACS without ST eleva- 
tion, those aged over 70 are at substantially hrgher risk of adverse events than younger 
patients. However, they are less likely to receive treatments of proven benefit or to be 
investigated with a view to revascularisation. A more aggressive approach to these 
patients is likely to result in substantial benefits. 
1120-91 Acute Myocardial lschemia and Alternative Diagnoses in 
Low-Risk Patients for Coronary Event Presenting to the 
Emergency Department 
Alberta Conti, Barbara Paladini. Maurizio Zanobetti, Stefano Grifoni, Stefania Sartini, 
Sabrina Maseth, Chiara Gallini, Paolo Fern Egidio Costanzo, Maria Matteini, Giacomo 
Trallori. AZIENDA OSPEDALIERA CAREGGI, FIRENZE, k/y 
Background. The evaluation of patients with chest pain (CP) and non-dragnostic ECG 
doesn’t generally go beyond the exclusion of acute coronary events. Thus, the underlying 
presence of depression and gastroesophageal disease is often neglected and of 
unknown proportions. In this study, we addressed this issue in a population of 214 con- 
secutive patients presenting at the Emergency Department with chest (CP) pain and non 
diagnostic ECG. Methods. All patients had CP lasting .lO minutes within 24 hours 
before admission, and a negative first line evaluation based on serial EGGS, cardiac 
enzymes, echocardiography and chest X rays. Patents underwent restSPET (~3 hours 
from CP and exerciseSPET (z-3 hours) followed by coronary angiography when positive. 
All patients without documented coronary artery disease, underwent: 1) psychiatric 
screening using the Hospital Anxiety and Depression Scale questionnaire (HAN); all 
patients with a HADS score >8 were submitted to psychiatric interview for final diagnosis, 
according to the Diagnostic and Statistical Manual IV; 2) gastroesophageal endoscopy. 
Results. Of the 214 patients, 27 patients (13%) had documented coronary artery dis- 
ease and 74 patients (35%) had CP of parietai origin. Among the remaining 48% (n=ll3 
patients), HADS > 6 was founded in 54 patients (25%) and depression or panic disorders 
were detected in 22 patients (10%). Gastroesophageal pathology was documented in 59 
patients (27%; peptc ulcer and HLO in 17% and esophageal reflux in 10% of patients). 
Conclusions. In one half of patients with non-diagnostic EGG, chest pain was associ- 
ated with psychiatric or gastroesophageal disorders that usually may be grossly underes- 
timated in the emergency department. Detection of alternative diagnoses and correct 
related management for patients without coronary artery disease could reduce readmis- 
sion visits at the Emergency Department, 
1120-92 Predictors of Heart Failure Development After Non-ST 
Elevation Acute Coronary Syndromes 
Eric J. Velazquez, Douglas A. Criger, David Hasdai, Robert M. Califf, Robert A. 
Harrington. Duke University, Durham, NC 
Heart failure (HF)after ST-segment elevation acute myocardiai infarction portends a 
worse prognosis. Most patients with an acute coronary syndrome (ACS) present without 
persistent ST elevation yet HF development in this broader patient group is poorly char- 
acterized. Methods: Patients in a large international trial of ACS without ST-segment ele- 
vation ware categorized by the in-hospital development of HF or not. Univariable 
regression analysis was done on baseline factors and in-hospital and 180.day endpoints. 
A multivariable Cox proportional hazards model was built using variables found signifi- 
cant in the univariable analysis to determine which factors contributed to HF develop- 
ment. Results: Of the 9461 patients randomized to high-dose Eptifibatide or placebo in 
the PURSUIT trial, 495 patients (5,2%)had an episode of HF in the hosital. The following 
baseline variables, presented as odds ratios with 95% C.I., were related to in-hospital HF 
development: previous HF 2.49 (2.03-3.05) previous MI 1.42 (1 .I 8-l .71), smoking 1.38 
(1.14-l .69), hypertension 1.32 (1.09-l .61), diabetes melktus 1.27 (1.05-l .47), age 1.06 
(1.05-l .07), heart rate 1.02 (1.02-l .03), systolic blood pressure 0.99 (0.98-l .OO), Eptifi- 
batrde therapy 0.93 (0.78-i .ll), and previous percutaneous coronary intervention 0.62 
(0.45-0.85). The mortality rate at 180 days after the ACS event was 39% in the HF group 
compared with 5% in the group without HF (p<O.OOl). Conclusion: HF develops in a 
minority of patients presenting with a non-ST elevation ACS but is predictive of a marked 
excess in 6-month mortality. Investigation of strategies that help identify this patient group 
for appropriate risk stratification and more aggressive therapies is warranted. 
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1121-97 Frequency and Clinical Significance of Angiographic 
Evidence of Distal Embolization During Primary 
Angioplasty for Acute Myocardial Infarction 
Felix Zijlstra, Jan Paul Oitervangec Menko Jan de Boer, Henk Eenhuizen, Dirk Dijkstra, 
Jan C. A. Hoarntje, Harry Suryapranata, Arnoud W. J. van ‘t Hoi, /se/a lil,nieken. hospital 
De Weezenlanden, Zwolle, The Netherlands 
Background: Although recognized as an important feature of atherosclerotic coronary 
disease, little is known about the frequency and prognostic importance of distal embo- 
lization during primary angibplasty for acute myocardial infarction. Methods: As part of a 
randomized trial of thrombolysis versus primary angioplasiy, 194 patients with acute 
myocardial infarction were treated with primary angioplasty. None of the patients was 
treated with Ilb/llla inhibitors or thrombolytics. Clinical information was collected for a 
mean of 5 years. Emboliration was defmed as a distal filling defect with a” abrupt ‘cutoff 
in 1 of the periferal coronary artery branches of the infarct-related vessel, distal to the site 
of angloplasty. Enzymatic infarct size was estimated from cumulative release of lactate 
dehydrogenase (LDH 072). Results: Distal embolization was present in 27 patients 
(14%). Mean age and gender were not different between the two groups. Patients with 
distal embolieatlon had a larger enzymatic Infarct size (mean LDH Q72 1612 vs 847, p < 
005) and a lower left ventricle ejection fraction at discharge (42% vs. 51%, p c 0.01). 
Long-term mortality was significantly higher in patlents with distal emboliration (44% vs 
9%, p c 0.001). Conclusions: Distal embolization during primary angioplasty can be 
see” on the coronary angiogram in 14% of patients. It is a predictor of a large myocardlal 
infarction and a worse prognosis. Additional pharmacologic interventions and/or mechan- 
ical devices should be studied to prevent distal embolization. 
1121-98 Use of a Protection Device Offsets the Delay in Reperfusion 
on the Recovery of Angiographic Parameters in Primary 
PTCA 
Gabor Sutsch, F. Wolfgang Amann, Sabina Murphy, 6. Michael Gibson. Cardioiogl: 
University Hospital Zurich, Zurich, Switzerland, UCSF; San Francisco, CA 
Background: There is evidence that prolonged symptom-onset-to-balloon time (SBT) for 
primary PTCA is associated with a” increased mortality and lower rates of TIMI flow 
grade (TFG) 3, in particular with stenting. Possibly, sienting further aggravates the bur- 
den of ongoing myocardial ischemia by causing additional downstream emboiization. 
Methods: In 34 patients (mean age 56i-11) with acute Ml (SBT < 12 hours, h) PTCA with 
stenting of the occluded infarct-related artery was performed in combination with the Per- 
c&urge@ distal protection device. Patients were divided according an arbitrary cut-off of 
4 hours in two groups with fast (SET < 4 h, n=lZ, group 1) or delayed (SBT > 4 h, “~22, 
group 2) PTCA. Groups were comparable with respect to gender, age, hemodynamics, 
patter” of the infarcted vessel (LAD: 25% and 36%, respectively), ejection fraction, and 
use of glycoproteln 2bi3a inhibitlo” (75% and 64%, respectively). An angiographic core 
analysis assessed pre-post TFG, correc&d TIMI Frame Counts (CTFCs) and tissue level 
perfusion (TIMI Myocardial Periusion Grade; TMPG) Results: 
Group 1 Group 2 P’ 
SBT in min (range) 193i;50 (85.240) 472*157 (250.740) 0.0001 
TFG pre / post 0.17*0.4 / 2.9&l .4 0.18t0.4 / 2.98+0.1 n.s./n.s 
CTFC pre / post 100 125.3i10.8 100 / 22.3r8.2 n.s./n.s 
TMPG ore / vast O.&O.9 / 2.Oil.i 0.721.1 / 2.0*1.2 n.s./n.s 
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1121-95 Kinetics of Myocardial Perfusion in the Setting of ST 
Segment Elevation Acute Myocardial Infarction vs Unstable 
AnginaINonq-Wave IVlI 
Matthew H. C. Otten, Sabina A. Murphy, Brad Angela, Colin A. Hynes, Jessica S. Lim, 
Lily L. Luu, Sarah R. Kermgard, Susan J. Marble, Chistopher t? Cannon, Eugene 
Braunwald. C. Michael Gibson. Univers!ty of California. San Francisco, San Francisco, 
CA, Brigham and Women’s, Bosion, MA 
Background: The goal of this study was to compare the kinetics & appearance of myo- 
cardial perfusion (blush) in the setting of ST elevation myocardial infarction (STEMI) & 
Unstable Angina / no” Q-Wave Ml (UA). We hypothesized that dye filling of the myocar- 
dium would be delayed in patlents with STEMI vs UA. Methods: STEMI data were 
obtained from 775 pts in the TIMI 1OB trial comparing TNK vs. tPA & from 248 pts in the 
LIMIT trial comparing tPA+ rhuMab CD18 (a WBC antibody) vs tPA + placebo. UA data 
were draw” from TIMI 18 patients randomized to either conservative or invasive manage- 
ment of UA who underwent PCI or diagnostic angiography & had TIMI myocardial periu- 
sion grade (TMPG) data available (n=560). Blush was assessed using the TMPG. Grade 
1 TMPG is a stain of the myocardium (dye remains in the myocardium on the next injec- 
tion). To assess the kinetics of blush, the number of frames required for blush to 1st 
appear &the number of frames for dye to reach peak intensity were counted & converted 
to 30 frames per second. The blush was characterized as heterogenous (patchy) or dif- 
fuse. Results: When adjusted for location of Infarct, a” increase of myocardial staining 
(TMPG 1) occurred in the setting of STEMI vs UA (O.R. of 2.6; pcO.001). After controlling 
for flow in the epicardial artery (Corrected TIMI frame count). the frame for 1st & peak 
appearance of blush boih remained significantly slower in STEMI. Conclusions: A two- 
fold increase in both the incidences of myocardial staining (TMPG 1) & heterogenous, 
hyperintense regions of blush was observed in STEMI when compared to UA. It took 
longer for dye to reach ihe myocardium & to reach peak intensity, eve” when adjusting for 
epicardlal flow. T&s, independent of impaired epicardial flow, perfusion of the myocar- 
dium is delayed in the setting of STEMI compared with UA. These results may explain in 
part the poorer early outcomes observed in ihis group of patients. 
UAI Non Q-!&we Ml STEMI p-value 
% of pts w/ TMPG 1 5.92% n=31/560 ii ,049~ n=11 i/l 005 <O.OOi 
Hetetogenous Blush 13.8% n&6/479 22.6% n=43/190 0.005 
Frame Blush 1st Appears 44.7 f 26.5 i-1=540/560 51.ii25.7 “=184/248 0.0044 
Frame for Peak Blush 104&k 42.5 “=445/560 122.5 ? 44.4 n=187/248 <O.OOi 
1121-96 The Kinetics of TIMI Myocardial Perfusion Grades 2 & 3 in 
the Setting of Acute Ml: A LIMIT Substudy 
Matthew H. C. Otten. Sabina A. Murphy, Brad Angeja, Lily L. Luu, Sarah R. Kermgard, 
Jessica S. Lim, Colin A. Hynes, Je” Kliris, Susan J. Marble, Kent Dauterman, Priscilla 
Hsue, 6. Michael Gibson. University of Caiifornia. San Francisco, San Francisco, CA 
Background: We have previously shown thai TIMI Myocardial Perfusion Grade (TMPG) 
2 is associated wth a two- fold increase in mortality rates in the setting of Acute Ml in 
comparison with TMPG 3 (4.4%, 2.0%, respectively). The goal of this study was to objec- 
tively characterize the kinetics of myocardial perfusion in TMPG 2 vs TMPG 3. Methods: 
We hypothesized that dye inflow into the microvasculature is slower in TMPG 2 in com- 
parison with TMPG 3. Data were drawn from 116 acute Ml patients in the LIMIT AMI trial 
of tPA + rhuMAb CD18 (a WBC antibody) vs tPA + placebo. These 116 patients were 
assessed to have either a TMPG 2 (pewstent dye stain at end of injection that fades by 
next injection) or a TMPG 3 (normal blush). The number of frames required for dye to 1st 
enter the myocardium & for dye to reach peak intensity in the myocardium were counted 
and converted to 30 frames per second Results: There was no significant difference in 
the time for dye to first enter the myocardium; however the peak intensity of TMPG 2 
occurred 41.6 frames or 1.5 seconds later. This delay held true when corrected for the 
Core&d TIMI Frame Count(p=<O.OOl). Conclusion: While the time io initial appear- 
ance of dye in the microvasculature does not differ between TMPG 2 and 3, the time to 
peak intensity is delayed in the TMPG 2. The delay I” peak intens@ may be secondary to 
distal mlrco-embolizatmn. vasospasm or damage in Ihe microvasculature. This may 
explain in parl the poor outcomes among patients with TMPG’s of 2. 
TMPG 2 TMPG 3 p-value 
Frame Blush Isi Appears 49.3 zk 22.7 “=18 51.4 + 23.4 n=95 NS 
Frame of Peak lniensity of Blush 161.3 t 36.44 n=18 119.7 t 44.5 n=97 0 003 
Diastole Blush 1st Appears 2.31 t 1.15 “=18 2.27 k 0.93 “=96 NS 
Diastole of Peak Intensity 6.97 i 2.01 “=I8 5.21 i 1.61 n=98 0.0001 
(mean i- SD; p for unpaired comparison between the groups) 
Conclusions: I” this pilot study, the recovery of epicardial and myocardial perfusion is 
equally improved in fast and delayed reperfusion using distal embollzaiion protection in 
PCI wiih stenling for acute Ml. Clinical benefit and survival advantage need to be deter- 
mined in adequately designed trials. 
1121-99 Validation of Myocardial Perfusion Grades Using Digital 
Subtraction Angiography (DSA) 
C. Michael Gibson, Lily L. Luu, Sarah R. Kermgard, Colin A. Hynes, Matthew H. C. Otten. 
Jessica S. Llm, Mark Appleby, Andrew Michaels, Susan J. Marble, Sabina A. Murphy, Hal 
V. Barron. University of California San Francisco, San Francisco, CA 
Background: Previously we demonstrated that a semiquantiiative visual scheme of 
grading tissue level perfusion (Myocardlal Perfusion Grade, MPG) is related to mortality 
in AMI. We hypothesized that the different MPGs (MPG O=little or no blush;MPG l=stain 
that persists on next injectlon;MPG P=stain that fades by next injection; MPG 3 = normal 
blush) w&Id be related to tissue level perfusion when analyzed quantitatively using digi- 
tal subtraction angiography (DSA). Methods: Data were drawn from 161 consecutive pts 
in the LIMIT AMI trial of IPA + rhuMAb CD18 (a WBC antibody) vs tPA + placebo & 88 
normals (no AMI). The MPG & DSA were assessed 90 min. after lytic administration. 
DSA was performed ai end dlastole by aligning images before dye filled the myocardium 
with those at the peak of dye filling the myocardium to subtract spine, ribs, diaphragm & 
artery. Conclusions: Overall, AMI is associated with less myocardial perfusion on DSA 
(p<O.OOOl for all), increased peak Gray (brightness), decreased rate of rise in Gray&c, 
increased blush circumference, & lower rate of growth of circumference (cmisec). HOW- 
ever, these data validate quantitatively thai in AMI, myocardial perfusion for MPG 3 (nor- 
mal blush related to lower mortality) is similar to that in normal pts, & is associated with 
increased tissue level perfusion on DSA compared to MPG 0. Whlie entry appears “or- 
mal for MPG 1 & 2, dye exit from the myocardium is delayed. 
MPG* n DSA Peak Growth in Gray Circumference Circumference 
Gray I se0 (cm) Growth (cm) I set 
OinAMI 71 2.5 f 4.9 0.75 i 1.6 7.2 * 7.9 2.2 r 2.4 
1 inAMI 19 13.0 f 12.8 3.8 * 4.4 17.8 i 7.0 5.4 i 4.2 
2inAMI 11 19.9 i 10.8 4.0 t 1.9 190+11.8 4.2 r 3 1 
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3inAMI 60 10.3 s 6.0 2.9 i- 1.9 18.8 f 10.4 5.0 c 2.4 
All AMI 187 7.8~ 8.9 2.1 i 2.5 13.6 + 10.7 3.7 k 2.0 
No AMI 88 10.9 + 5.7 2.8 r 1.4 19.4 ,. 5.4 5.2 + 2.0 
L way 0 spc= y rus a 
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1121-l 00 Effects of Early ACE-Inhibition in Nonthrombolyzed Diabetic 
Patients With Acute Myocardial infarction 
Claudia Borghi, Stefano Bacchelli, Daniela Degli Esposti, Eugenio Cosentino, Ettore 
Ambrosloni. Department of Medicine-University of Bologna, Bologna, f&/y 
Background. ACE-inhibitors (ACEI) have been demonstrated to be largely effective for 
the treatment of patients with either diabetes and coronary artery disease. MethodsThe 
present study was carried out as a post-hoc analysis of the SMILE trial to evaluate the 
influence of diabetes on the efficacy of 6-week treatment with the ACEI zofenopril given 
early (< 24 hours from symptoms) in 1514 patients with non thrmbofyzed acute anterior 
myocardial infarction (AMI). The main oucome measures were B-week combined occur- 
rence of death and severe refractory CHF as well as 1 year mortality rate. Results. The 
diabetic population (D+, n.183) was significantly older and showed a greater proportion 
of females and hypertensive subjects than non diabetics (D-~11331). These variables 
have bee used as co-variates to adjiust statistical analysis. After 6 weeks of the double- 
blind treatment a greater proportion of the D+ patients reached the primary end-point 
(18.3% vs 9.6%, 2p=O.O01). The effects of zofenopril over the primary end-point were 
significantly enhanced in D+ (absolute red.: -9.7% vs -2.1, 2p=O.O01). Cumulative mortal- 
ity was greatly reduced in D+ (absolute red.-3.0% vs -1.5% 2p=O.O1) as did early mortal- 
ity (~24 hours) (absolute red:6.1% vs -0.7%, 2p=O.O13). The incidence of S-CHF was 
increased in D+ where we observed a greater reduction in absolute event rate after ACEI 
when compared to D- (-7.3% vs -0.9%, Zp=O.OOl). i-year mortality was increased in Dc 
(15.2 % vs 11.4%). Surprisingly, the survival rate after 1 year was greatly improved by 
ACEI in D- (13.8 vs 9.1%, 2p=O.OOi) than in D+ (16.5% vs 13.7% 2p=O.O3) and these 
findings have been confirmed by the Kaplan-M&r approach. Conclusions. The results 
of the present study confirm the pivotal role of ACEI for the teratment of patients with dia- 
betes. They also suggest that the benefit of ACEI in patients with diabetes is strictly 
related to active drug treatment that should be maintained irrespectively of post-MI LV 
function. 
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2:oo p.m. 
Stunning Reduction in Death and Myocardial Infarction 
Observed With Early Lipid Lowering Therapy After Acute 
Coronary Syndromes 
Herbert D. Aronow, Penny L. Houghtaling, Katherine E. Wolski, Eric J. Topol, Michael S. 
Lauer. Cleveland Clinic Foundation, Cleveland, OH 
Background: Whether lipid lowering agents (LLA) reduce death or myocardial infarction 
(Ml) when administered soon after an acute coronary syndrome (ACS) is unclear. 
Methods: We compared the incidence of death and Ml after an admission for ST eleva- 
tion MI, non-ST elevation MI or unstable angina among patients from the GUSTO Ilb and 
PURSUIT trials who were (n=3,653) or were not (n=17,156) discharged on LLA. A pro- 
pensity analysis was used to match patients on the probability of receiving LLA at dis- 
charge. The resulting propensity score was entered into Cox models. 
Results: Overall, there were 668 deaths. Treatment with LLA was associated with a 
marked mortality reduction by 30 days that was even greater at 6 months [Figure]. After 
adjusting for hyperlipidemia, other cardiac risk factors, type of ACS on presentation, dis- 
charge medications and other potential confounders, treatment with LLA was associated 
with a marked reduction in the incidence of death (Risk Ratio = 0.67, 95% Cl 0.48-0.95), 
p = 0.023) and the composite death or MI (Risk Ratio = 0.80, 95% Cl 0 660.99) p = 
0.036) at 6 months. 
Conclusion: In the largest international cohort study of this type to date, early lipid low- 
ering therapy was associated with reduced death and MI after all types of ACS. Early ini- 
tiation of LLA should be considered in all oatients after an ACS. 
- 
831-2 
2:15 p.m. 
Early Statin Therapy Is Associated With Markedly Lower 
Mortality in Patients With Acute Coronary Syndromes: 
Observations From OPUS-TIM1 16 
Christopher i? Cannon, Carolyn H. McCabe, Jane Bentley, Eugene Braunwald. Brigham 
and Women$ Hospital, Boston, MA 
While statin therapy reduces mortality in patients with prior MI, few data are available on 
their early effects in patients with acute coronary syndromes (ACS). Methods: In the 
OPUS-TIMI 16 trial, patients with ACS (ranging from ST elevation Ml to high-risk unsta- 
ble angina) were treated with aspirin and randomized within 72 hours of symptom onset 
to the oral llbillla inhibitor orbofiban or placebo. In-hospital use of lipid-lowering therapies 
was assessed and mortality rates compared, with multiple Cox regression to adjust for 
baseline characteristics. Results: In 10,288 patients, lipid-lowering therapy was pre- 
scribed during hospitalization in 3883 (38%) of patients: 94% received statins, 7% 
received fibrates (with or without statins), cl% received niacin or resins. By 10 months, 
90% of remained on lipid-lowering therapy and 34% had newly started therapy (97% 
statins). Treated patients were younger (age 59 vs. 61 years for non-treated, p<O.OOOl), 
but more often had prior Ml (32% vs. 24%), Prior CABG 15% vs. 8%, ot prior angina 
(30% vs. 25%)and more frequently received prior aspirin, beta-blocker, and other medical 
treatments, each pcO.0001. Mortality was significantly lower in patients treated with lipid 
lowering therapy: at 30 days 0.7% vs. 2.4% (pcO.0001). No differences in mortality were 
observed by which statin agent was used. The mortality difference persisted at 10 
months 3.1% vs. 5.3% (p<O.OOOl).(Figure) Adjusted relative risks of mortality were 0.31 
and 0.50 respectively each p<O.OOOl. This benefit was present in both placebo- and 
orbofiban-treated patients. Conclusion: In patients with acute coronary syndromes, we 
observed an significantly lower mortality that emerged early in the course of treatment 
among patients treated with statin therapy. If confirmed in randomized trials, these results 
provide further evidence of the benefit of early initiation of statin therapy in ACS. 
I’ In.hospital Lipid-Lowering Rx 
0 50 100 150 200 250 300 
Time (days) 
831-3 
2:30 p.m. 
Effects of Acute Hormone Therapy on Recurrent lschemia 
in Postmenopausal Women With Unstable Angina 
Steven P. Schulman, David R. Thiemann, Pamela Ouyang, Nisha C. Chandra, Douglas 
S. Schulman, Steven E. Reis, Michael Twin, Susan N. Townsend, Sandra Forman, Gary 
Gerstenblith. Johns Hopkins Medical Institutions, Baltimore, MD, Maryland Medical 
Research lnstifute, Baltimore, MD 
Background: Endothelial vasodilator dysfunction occurs in atherosclerotic coronary 
artery disease and may contribute to the pathophysiology of unstable angina. Acute 
estrogen administration improves endothelial function in postmenopausal women with 
stable coronary artery disease. We conducted a randomized, double blind placebo con- 
trolled trial to determine whether acute hormone therapy reduces the incidence of ambu- 
latory electrocardiographic (AECG) ischemic events over 48 hours in postmenopausal 
women with unstable angina. Methods: 293 patients were randomized to receive intrave- 
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nous followed by oral conjugated estrogen (E) plus medroxyprogesterone (MPA) for 21 
days. intravenous followed by oral E for 21 days, or placebo (PLBO). The primary end- 
point was the number of AECG ischemic events over the first 48 hours compared by t- 
tests.Clinical events were also determined over 6 months of follow-up. Results: The sub- 
iects were well matched in clinical characteristics and standard anti-ischemlc medica- 
tions were used. The AECG and clinical outcomes are shown below, ail nonsignificant. 
The duration of AECG ischemia was also not different. 6.month events, including death. 
myocardfal infarction, hospitalizations for recurrent angina. or need for revascuiarization 
also did not differ significantly among the 3 groups. Conclusion: Acute hormone therapy, 
when added to standard anti-ischemic therapy, does not reduce the number or duration 
of lschemic events, or the proportion of patlents experiencing such events in postmeno- 
pausal women with unstable angina. This study adds to the growing evidence that hor- 
mone therapy may not benefit postmenopausal woman with known coronary artery 
disease. 
E+MPA E+PLBO PLBO 
Mean #AECG ischemic events148 hrs 0.86 0.74 0.74 
% of patients with AECG &hernia 14.1% 9.8% 10.9% 
In-hospital symptomatic ischemia 52.1% 39% 42.4% 
In-hospital myocardial infarction 3.2% 3.0% 5.1% 
In-hospital death 5.3% 5.0% 3.0% 
831-6 
3:15 p.m. 
Is Initial Treatment With Enoxaparin Beneficial in Unstable 
Angina/Non-ST Segment Elevation Patients Who Later 
Undergo Percutaneous Coronary Intervention (PCI)? 
Keith A. A. Fox, Ell~otl M. Antman, Marc Cohen, Frederique Bigonzi, David Radley, On 
behalf of the ESSENCE & TIMI 11 B investigators. The Royal infirmary of Edinburgh, 
Edinburgh, United Kingdom 
831-4 
2:45 p.m. 
Low-Dose Urokinase and Enoxaparin Reduces the 
Incidence of Acute Myocardial Infarction in Patients With 
Unstable Angina or Non-qwave Myocardial Infarction 
Ji-Lln Chen, Collaborative Research Group of National Project Beijing China. 
Cardiovascular fnsfitute & Fu Wai Hospital, Beijing, Peopled Republic of China 
Background: Previous studies have shown increased rates of acute myocardial infarc- 
tion (AMI) when high-doses of thrombolytic agents are used in the treatment of unstable 
angina. However, low-dose urokinaso (UK) has been shown to be an effective anti- 
ischemic and anti-angina1 therapy for patients with refractory anglna pectoris, in combina- 
tion with unfractionated heparin and aspirin. The aim of this study is to assess if the addi- 
tion of low-dose UK to enoxaparln and aspirin therapy provides added benefits. 
Methods: This study was a multicenter, single-blind, placebo-controlled. randomized 
clinical trial, conducted in 40 hospitals in Chlna. Entry criteria ware effort angina signifi- 
cantly aggravated within 5 days and angina at rest within 24 hours. 791 patients with 
unstable angina or non-Q wave myocardial infarction received either placebo or 5OOOlUi 
kg UK admimstered for 3 consecutive days. All patients also received aspirin 300 mg and 
enoxaparin 30 mg intravenous bolus plus lmglkg subcutaneous given in the hour before 
low-dose UK thrombolytic or placebo therapy on the first day of therapy; and subcutane- 
ous enaxaparin 1 mg/kg 912 hours for 6 days and aspirin 300 mg/day for 6 days, then 
100 mglday (administered prior to UK on the second and third days of therapy). The pri- 
mary endpoint for the comparison between the low-dose UK and placebo groups was 
death and AMI (cardiac event) within 30 days of enrollment. 
Results: Although the combined endpoint of death and AMI was not significantly 
reduced in the low-dose UK group (2.0% vs. 4.0% placebo group, p = 0.147) the rate of 
AMI (0.05% vs. 2.5% placebo group, p=O.O37) and the number of patients with frequent 
recurrent angina (first week results; 29.3% vs. 41 .l% placebo group, p=O.OOl; fourth 
week results; 5.9% vs. 11.2% placebo group p=O.Ol) was significantly lower. 
Conclusions: The addition of low-dose UK to a regimen of enoxaparin and aspirin 
appears to reduce the frequency of AMI and recurrent angina in patients with unstable 
angmalnon-Q-wave myocardiai InfarctIon remarkably 
Background. Combined analysis of ESSENCE and TIMI 11 S demonstrated that enox- 
aparin is superior to unfractionated heparin (UFH) in patients with unstable angina (UA)/ 
non-ST-segment elevation myocardial infarction (Ml): 7.1% vs 8.6% (~~0.02) death/Ml at 
43 days Decisions to proceed to revascularization ware independent of trial randomiza- 
tion. 
Methods We analyzed a population comprising 6098 patients for death or MI at 43 days 
using chi-squared tests; 983 patients undergoing coronary artery bypass grafting ware 
excluded. Clinicians were blinded to enoxaparin vs UFH (unfractionated heparin). 
Results PCI was not randomized but was performed at the discretion of the treating phy- 
sician. Results are shown in Table 1. 
Conclusion Patients undergoing PCI (compared with those who were not) sustained 
more events, including events prior to PCI, consistent with a higher risk population. Enox- 
aparin treatment, when compared with UFH treatment, beneflted both patients treated 
solely medIcally, and those patlents who underwent PCI following an initial penod of med- 
ical stabilization. 
Table 1. 
Patients undergoing PCI within 12 hrs of final dose: 
UFH n/N (%) Enoxaparin n/N (%) RR (+/-95CI) 
Patients with PCI: 
Death/Ml past-PC1 14 / 237 (5.9%) 7 / 198 (3.5%) 0.60 (0.25, 1.45) 
All Death/Ml 25 / 237 (10.5%) 20/198(10.1%) 0.96 (0.55, 1.67) 
Patients without PCI: 
All Death/Ml 196 / 2783 (7.0%) 167 / 2880 (5.8%) 0.82 (0.67,1.01) 
All patients undergoing PCI during hospitalization: 
UFHn/N(%) Enoxaparin n/N (%) RR (+/-95CI) 
Patients with PCI: 
Death/MI post-PC1 34/482 (7.1%) 18 / 424 (4.3%) 0.60 (0.34.1.05) 
All Death/MI 56 / 482 (11.6%) 43/424(10.1%) 0.87 (0.60,1.27) 
Patients without PCI: 
All Death/Ml 165 / 2538 (6.5%) 144 / 2654 (5.4%) 0.83 (0.67,1.04) 
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The Effects of Beta Blocker Therapy in Patients With Acute 
Coronary Syndromes Undergoing Percutaneous 
Intervention: EPIC, CAPTURE, and RAPPORT Data Bases 
1150-79 TIMI Risk Score to Predict B-Month Mortality, Recurrent 
Cardiac Events, and Relative Benefit of Invasive vs. 
Conservative Strategy in Patients With Unstable Angina: 
Results From TACTICS-TIM1 16 
Byron K. Ellis, A. M. Lincoff, Shelly Sapp. C/eve/and Clinic Foundaiion, Cleveland, OH 
Background: Various clinical trials have shown the beneficial effects of beta blockers in 
patients with coronary artery disease and congestive heart fajlure. This study evaluates 
the effects of beta blockers in patients undergoing percutaneous intervention (PCI) in the 
setting of unstable angina or myocardial infarction (MI). 
Methods: Using data bases from the EPIC, CAPTURE and RAPPORT randomized pla- 
cebo-controlled trials, a total of 2,163 patients ware studied. Only a subset of patients 
ware studied from the EPIC trial, consisting of those patients presenting with unstable 
angina or acute Ml. These trials evaluated the glycoprotein lib/llla inhibitor, abciximab, 
during coronary intervention. Beta blockers were administered to 1405 patients either 
prior to or at the time of enrollment, and 758 patients did not receive beta blocker therapy. 
The end points ware death, Ml and urgent revascularization at 30 days and 6 months. 
Results: Death was significantly reduced at 30 days and 6 months in patients receiving 
beta blocker therapy. 
End Points Follow Up No Beta Blocker Beta Blocker p-value 
Christopher P Cannon, William S. Weintraub, Laura Demopoulos, Peter DiBattiste, 
Debbie Robertson, Paul deLucca:Carolyn H. McCabe, Elliott M. Antman, Eugene 
Braunwald, for the TACTICS-TIM1 18 Investigators. Brigham and Women’s Hospi@J, 
Boston. MA 
The Thrombolysis In Myocardial Infarction (TIMI) Risk Score for acute coronary syn- 
dromes has been shown in several studies to predict both prognosis and response to 
new therapies such as low-molecular weight heparin or glycoprotein llbillla inhibitors. We 
sought to validate the TIMI Risk Score and assess its usefulness in predicting benefit of 
an invasive vs. conservative strategy. Methods: In the TACTICS-TIM1 18 trial patients 
with unstable angina or non-ST elevation Ml were treated with aspirin, heparin and 
tirofiban and randomized to an invasive strategy with routine catheterization and ravascu- 
larization as appropriate within 4-48 hours, or to a conservative (i.e., a “selective inva- 
sive” strategy) with catheterization performed only if the patient had objective evidence of 
recurrent ischemia or a positive stress test. We used the TIMI risk score by calculating 
the number of the 7 predictor variables each patient had: age >65 years, at least 3 risk 
factors for coronary artery disease, prior coronary stenosis of >=50%, ST deviation on 
ECG, severe angina, prior aspirin, and elevated cardiac markers. We then compared 
mortality and outcomes acroSs the TIMI risk scores. Results: Preliminary results as of %I 
2000 showed among the 2220 patients, there was a gradient in B-month mortality for 
Death 30 days 161758j2.1) 12 / 1405(0.9) 0.013 
6 months 31 / 758(4.2) 30/ 1405(2.2) 0.009 
MI 30 days 30 / 758(4.0) 49 / 1405(3.5) 0.554 
6 months 44 l758(5.9) 86 / 1405(6.2) 0.832 
Revasc. 30 days 27 / 758(3.8) 61 / 1405(4.4) 0.411 
6 months 154 / 758(21.2) 344 / 1405(25.1) 0.048 
Conclusion: The use of beta blockers in patients undergoing PCI with acute coronary 
syndromes is associated with a statistically significant reduction in short term mortality. 
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1150-82 The Effect of Clopidogrel vs Aspirin on Recurrent Clinical 
Events and Total Vascular Mortality: Results From the 
CAPRIE Study 
James J. Ferguson, Rollo P. Villareal, Edward K. Massin. Texas Heart Institute, Houston, 
TX 
Background: The CAPRIE.study compared the thienopyridine cfopidogrel with aspirin in 
patients with atherothrombotic disease; the primary outcome cluster was a composite of 
new first events. However, since recurrent events are also a significant contributor to sub- 
sequent overall clinical outcomes, we analyzed total events (Initial and recurrent) and 
total vascular mortality (fatal Ml, fatal stroke, and other vascular death) in CAPRIE. 
Methods: A retrospective analysis of the CAPRIE patient cohort (n=19,185), Including 
both initial events (fatal/non-fatal MI, fatal/non-fatal stroke, other vascular death) and sub- 
sequent vascular events. 
Results: 
increasing TIMI Risk Score.(See Table) Similarly, the primary (composite) endpoint of 
death. Ml or rehosoitalization for acute coronarv svndrome was sionificantlv hiaher as , I - _” 
TIMI Risk Score increased. 
TIMI Risk Score O/l 2 3 4 5 617 P trend 
N= 161 450 735 576 233 53 
Mortality (%) 1.9 1.6 2.0 5.2 4.6 11.9 <O.OOl 
Composite (%) 7.45 13.8 16.2 19.4 22.6 32.2 co.oo1 
Conctusion: The TIMI Risk Score was a srgnificant predictor of 6 month mortality, and 
recurrent cardiac events. Its “se in predicting benefit of a routine invasive vs. “selective 
invasive” strategies will be presented. 
1150-80 Percutaneous Coronary Intervention Versus Coronary 
Bypass Graft Surgery: Outcome of Diabetics in the 
AWESOME Randomized Trial and Registry 
Steven P. Sedlis, Douglass A Morrison, Gulshan Sethi, Jerome Sacks, William 
Henderson, Frederick Grover, Rick A. Esposito, for the Investigators and Patients of VA 
cooperative #385 (AWESOME). New Yor!i VA Medical Center, New York, NY 
Background: Prior studies indicate that coronary bypass graft surgery may be superior 
to percutaneous coronary intervention for diabetics, but coronary bypass graft surgery 
has not been previously compared to percutaneous coronary intervention for diabetics at 
high risk for surgery. This study compares the three year survival of diabetics with coro- 
nary bypass graft surgery versus percutaneous coronary intervention in a randomized 
trial and registry of such high risk patients. Methods: AWESOME was a five-year (1995. 
2000) sixteen site, Veterans Affairs, prospective, randomized trial and registry experi- 
ence comparing coronary bypass graft surgery to percutaneous coronary intervention in 
patients with medically refractory unstable angina and one or more high-risk factors (prior 
heart surgery; myocardial Infarction within 7 days; left ventricular ejection fractionc.35; 
age>70 years; intra-aortic balloon required to stabilize). percutaneous coronary interven- 
tion could include both stents and glycoprotein Ilb/llla receptor blocking drugs and 
bypass surgery could include off-pump or innovative myocardial protection. Of the 454 
patients in the AWESOME randomized trial, 144 (32%) had diabetes; of the 327 in the 
patient refused registry 89 (27%) had diabetes; and of the 1650 patients in the phvsician _ 
assignment registry, 525 (32%) had diabetes. Results: 
6 month 36 month log-rank 
diabetic CABG PCI CABG PCI 
Random 86% 91% 73% 80% p=o.40 
Patient refused 85% 97% 85% 91% p=o.o.35 
Physician assignment 87% 86% 72% 73% p=o.40 
non-diabetic CABG PCI CABG PCI 
Random 92% 36% 80% 79% p=o.so 
Patient refused 92% 96% 81% 88% pzo.30 
Physician assignment 90% 91% 78% 79% p=o.40 
Conclusions: We conclude that percutaneous coronary intervention is a relatively safe 
alternative to bypass surgery for diabetic patients with medically refractory unstable 
angina who are at high risk for coronary bypass graft surgery. Patients and physicians 
are able to choose between these two very different revascularization options for these 
patients. 
1150-81 Comprehensive Analysis of Death and Nonfatal Myocardial 
Infarction During the First Twelve Months Following Acute 
Nonq-Wave Myocardial Infarction: Comparison of Invasive 
Versus Conservative Strategies in the VA Non Q-Wave 
Infarction Strategies In-Hospital (VANQWISH) Trial 
Arun K. Kolli, Michael J. Wade, Robert A. O’Rourke, Alvin S. Blaustein, William E. Boden. 
Veterans Affairs Medical Center, Syracuse, NY; Harfford Hospital, Hartford, CT 
Background: The overall results of the VANQWISH Trial indicate that long-term (mean: 
23 months; range: 12-44 months) clinical outcomes for the composite primary end point 
(death or non-fatal [NF] myocardial infarction [Ml]) were similar in patients (pts) random- 
ized to an early ischemia-guided (IG) strategy compared to a “routine invasive” (R-INV) 
strategy. However, in the first 12 months, pts randomized to the R-INV strategy had signif- 
icantly worse outcomes than those in the IG strategy, with a significantly higher rate of 
combined events (death or Ml) and death alone. In order to better elucidate these find- 
ings, we performed a comprehensive analysis of all deaths and Mls that occurred in pts 
randomized to the two management strategies during the first post-Ml year. Methods: 
920 pts were randomized to either an IG strategy (n=458) or a R-INV strategy (n=462). 
The IG strategy group was further divided into 2 groups: a) pts who remained without cor- 
onary angiography during 12 months of follow-up (“conservative arm”[CON], 11~236) 
and; b) pts with inducible ischemia who met pre-defined criteria for coronary angiography 
followed by revascularization if coronary anatomy was feasible (“selective invasive” arm 
[S-INV], w222). Results: Multivariate analyses revealed that the R-INV arm had worse 
12.month outcomes than the CON arm (hazard ratio [HR]=2.2; P<O.OOl for combined 
events; HR=i 3; P=O.O4 for death alone; HRz2.2; P=O.Ol for NFMI alone). Compared to 
the CON arm, pts in the S-INV arm had significantly more composite events (HR=2.3: 
P&001) and NFMI (HR=3.2; P<O.OOl), but no difference in l-year survival (HR=1.2; 
P=O.52). When clinical outcomes between the S-INV and R-INV arms were compared, 
there was no difference in composite events (HR=I .l; P=O.6), mortality (HRz0.7; 
P=O.21) or NFMI (HR=1.5; P=O.O52). Conclusion: Better outcomes at 12 months were 
achieved in the early IG strategy in VANQWISH, particularly those in the CON subset 
who remained low-risk. An initial “ischemia-guided” approach to the management of 
NQMI permits appropriate risk stratification of patients into distinct subsets resulting in 
improved i-year clinical outcomes that can be tailored to the level of risk. 
Aspirin (n=9586) Clopidogrel (n=9599) % Decrease 
Initial Events 1021 939 8.2 % * 
[ * primary outcome cluster: 8.7% RRR by Cox Proportional Hazard Model ] 
Subsequent Events 
Ml 43 33 23.4 % 
Stroke 84 71 15.6 % 
Other vascular death 35 34 3.0 % 
Total 303 256 15.6 % 
TOTAL Events 1324 1195 9.9 % 
Initial vascular death 321 308 4.2 % 
Recurrent vascular death 57 42 26.4 % 
Total vascular death 378 350 7.4 % 
The net reduction in total events (both initial and recurrent) with clopidogrel was 14 
events/l000 patients; the net reduction in total vascular death (both initial and recurrent) 
was 3/l 000. 
Conclusions: In CAPRIE, clopidogrel was significantly superior to aspirin in preventing 
both initial and subsequent vascular events. The total events prevented (1411000 
patients) and total vascular deaths prevented (311000) may be more representative of the 
potential clinical benefits of clopidogrel over aspirin. 
1150-83 Safety of Abciximab in Addition to the Lmw Heparin 
Dalteparin as the Primary Treatment of Acute Coronary 
Syndromes (ACS) 
S James, M Pfisterer, S Husked, F Kontny, M Nieminen, L Wallentin. Deparlment of 
Cardiology, Uppsala, Sweden 
The combination of aspjrin and Imw heparin is at present the routine initial treatment of 
acute coronary syndromes in many patients. So far the safety and efficacy of the addition 
af abciximab to Imw heparin as the primary medical treatment in acute coronary syn- 
drome (ACS) has not been evaluated. Methods: As a substudy within the multi-national 
multicenter prospective double-blind trial of the efficacy of abciximab as the primary med- 
ical treatment in ACS without early revascularization 974 of the 7800 patients used sub- 
cutaneous treatment with dalteparin 120 IUiKg b.w. (max. dose 10.000 IU)for 5 - 7 days 
instead of the routine 4% hoursheparin infusion. The patients were randomized to bolus 
injection followed by 24 hours (n=315) or 48 hour (n=331) infusion of abciximab or corre- 
sponding placebo (n=328). The primary endpoint was safety at 30 days follow up. As in 
the main trial there were no significant differences in efficacy by the addition of abcix- 
imab. 
Results Dalteparin Heparin Results Dalteparin 
n=328 n=646 n=2270 n=4556 
Any stroke 1.2% 1 .I % 0.6% 0.6% 
Intracranial haemorrhage 0 0.31%(2) 0.1%(2) 0.15%(7) 
lschemic stroke 1.2%(4) 0x!%(5) 0.4%(9) 0.44%(20) 
Any Bleeding (non-CABG) 
Major (TIMI) 0.7% 1 .3% 0.2% 0.8%” 
Minor 1 .3% 4.0%* 1 .6% 3.2%**’ 
Platelet count (c50KimL) 0% 0.8% 0% 1.6%*** 
*p<o.o5, **p<o.o1, ***p<0.001 
Conclusion: Combination of abciximab with full dose LMWH (dalteparin) seems as safe 
as its combination therapy with reduced dose standard heparin. In both cases there is a 
slight excess in bleeding with combination therapy. 
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CFLD-M (%g-1) 0.89*0.89 4.4111.45# 24.85+10#-$ 
CFM-LD (%g-1) 5.4922.35 3.88k2.34 9.5*2.6#$ 
-p<u.us vs. I;;#p<u.us vs. CuM;+p<u.u!J vs. MI;*p<u.us”s.MI+ti”Nl 
Conclusion: Cardiotiyoplasty Improved left ventricle function after myocardial infarction. 
In this setting, VEGF treatment may offer an alternative route to myocardial revascuiar- 
ization. 
1151-86 Effects of Angiotensin II Type 1 Receptor Blockade and 
Angiotensin Converting Enzyme Inhibitor on the Ventricular 
Remodeling After Myocarclial infarction- With Special 
References to Sarcoplasmic Reticulum and Its mRNA 
Eiichi Geshl, Takashi Katagiri. Third Department of internal Medicine, Showa University 
School of Medicine, Tokyo, Japan 
We clarified the role of win-angiotensin system and its relation with ventricular remodel- 
ing after myocardial infarction with the influences of Ca-ATPase activity of the sarcoplas- 
mic reticulum (SR) and its mRNA (SERCA2a) using angiotensin type 1 receptor blockade 
(ATIB) and anglotensin converting enzyme inhibitor (ACEI). Material and method: Myo- 
cardial infarction was induced by the ligation of the LAD in 40 SD rats. They were divided 
into 4 groups: 1) V group, vehicle treated; 2)ATlB group, Candesartan treated; 3)ACEI 
group. Captopril treated; and 4) C group, sham operated. After 4 weeks, hemodynamic 
measurements (HR, LVP and left ventricular end diastolic pressure (LVEDP)) and bio- 
chemical (Ca-ATPase activity of SR and SERCA2a) and histological analyses (trans- 
verse diameter of myocyte and % of interstitial fibrosis) of the non-ischemic portion were 
performed. Result: There were no significant changes in HR and LVPs between each 
group. While LVEDP was significantly higher in the V group than in the C group, it was 
maintained at low levels in both the ATIB and ACEI groups. Ca-ATPase activity of SR was 
significantly lower in the V group (3.06 micromoles Pl/mg proteinihr) than in the C group 
(5.82), but the values in the treated groups were significantly higher (ATIB, 5.10. ACEI; 
5.04). In the northern blot analysis, the SERCA2a/beta-actin was significantly lower in 
the V group (1.88) compared to the C group (3.38). while values in ATIB (3.08) and ACEI 
(2.86) groups were higher. In the histological observations, hypertrophy of myocytes and 
interstitial fibrosis were observed more in the V group (transverse diameter, 8.16 
micrometer, and interstitial kbrosis, 11.21%) than in the C group (7.03 and 9.69), and 
these changes were diminished similarly by treatments with ATIB (7.18 and 10.02) and 
ACEI (7.29 and 9.98). Conclusion: Treatments of ATlB and ACEI showed similar bene- 
ficlal effects on the infarcted heart. We concluded that renin-angiotensin system acts as 
one of the key factors in the ventricular remodeling after myocardial infarction. 
1151-87 Induction Of Transforming Growth Factor beta And 
Connective Tissue Growth Factor Expression During 
Myocardial Ischemia-Reperfusion Injury 
Bysani Chandrasekar, Gary R. Grotendorst, Gregory L. Freeman. University of Texas 
Health Science Center, San Antonio, TX, Universify of Miami School of Medicine. Miami. 
FL 
Background: The growth factors involved in post-infarct tissue healing and subsequent 
left ventricular remodeling are not fully known. Hence, the goal of the present study was 
to evaluate the expression and localization of transforming growth factor beta (TGF b) 
and connective tissue growth factor (CTGF) followng myocardial ischemia-reperfusion 
injury. Methods: In 32 WKY rats, the LAD coronary artery was occluded for 45 min, and 
reperiused (R) for 15, 30 ml”, 1, 2, 3, and 6, 24 hours, and 7 days (n=4/group). Sham- 
operated animals served as controls (n=4). Following reperfusion, part of the tissue con- 
taining ischemic and adjacent non-ischemic tissue were embedded in OCT for immuno- 
histochemistry (IHC). For mRNA and protein analyses the ischemic portion was 
separated from the non-ischemlc zone, and was snap frozen. Results: Northern blot 
analysis revealed TGF b mRNA in controls. In rep&used animals, levels of TGF b fell at 
1 h R, and increased significantly at 3 h R, and remained elevated until 7 days. Protein 
levels followed a similar pattern as that of mRNA. In contrast, CTGF mRNA was not 
detected in controls. It was detected in rep&used animals at 2 h, and remained elevated 
thereafter. However, CTGF protein was detected at 3 h, increased further at 6 h, and 
remained at these high levels until 7 days. IHC revealed intense but diffuse TGF b immu- 
noreactwty throughout the myocardium In controls. In reperfused myocardium, intensity 
of TGF b immunoreactivity was much higher in the non-ischemic tissue at 6 and 24 h R. 
At 7 days. TGF b was detected in both ischemic and non-ischemic zones at similar levels. 
While CTGF immunoreactivity was not detected in controls or in rep&used myocardium 
until 2 h, weiker but diffuse staining was present in both the ischemic and non-ischemic 
zones. Its mtensity increased by 3 h, and remained at these high levels until 7 days. Con- 
clusions: Following ischemia-reperfusion, both TGF b and CTGF are expressed. How- 
ever, TGF b is expressed earlier than CTGF, indicating that TGF b might have induced 
CTGF expression. Together, these growth factors may participate in the deposition of 
extracellular matrix and subsequent remodeling. 
1151-88 Different Origin From Elevated Hepatocyte- and Vascular 
Endothelial Growth Factor Serum Levels in Patients After 
Myocardial Infarction. Role of Leukocyte Activation 
Achim Gutersohn, Jr., Ahmet H. Elmaagacli, Thomas Budde, Jochen Buchholr, Ulnch W. 
Schdfer, Raimund Erbel. University of Essen, Essen, Germany: ALfried Krupp Hospitai, 
ESS& 
Background: Leukocytes play an important role in inflammation yet it remains unclear 
how they interact during myocardial ischemia. Hepatocyte Growth Factor (HGF) and Vas- 
cular Endothelial Growth Factor (VEGF) are involved in angiogenesis, wound healing, tis- 
sue differentiation and vasorelaxation. They are both supposed to be cardioprotectwe 
After acute myocardial infarction (AMI) serum HGF and VEGF levels are elevated 
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1151-84 Angiotensin Converting Enzyme Inhibitor Reduces VEGF 
Expression by Cardiac Myofibroblasts in Healing Infarct 
Scar Tissue and Attenuates Ventricular Remodeling 
Samuel A. Wickiine. Qingyan Zhu, Heather Lewis, Christopher Hall. John Allen, Michael 
Scott, Gregory Lanza. Washington Universi& St, Louis, MO 
To define the time course of expression of VEGF in cardiac remodeling after infarction, 
the cell types involved. and the role of the renin-angiotensin system in VEGF regulation, 
myocardial infarction was Induced by left coronary artery occlusion in 33 Sprague-Daw- 
ley rats. Ramipril (1 mg/kg/d) was admimstered in drinking water starting 3 days after inf- 
arction and continued for 1,12 or 24 weeks in 5, 8; and 5 infarct rats, and placebo was 
administered to 4, 7, and 4 infarct rats, respectively. VEGF was quantified by immunocy- 
tochemical analysis of the averaged number of positive cells in 8-10 contiguous high 
power fields. The Flgure demonstrates prominent VEGF expression early after infarction. 
which declines thereafter (~~0.05 for time dependence, by ANCOVA to control for infarct 
size). Ramlpril significantly reduced VEGF expression at later time periods (p&O5 for 
treatment effects at 12 and 24 weeks). Ramipril also limited ventricular remodeling: rela- 
tive heart mass decreased by 17% a1 12 weeks and 20% at 24 weeks as compared with 
values for untreated rats (~(0.05 each). lmunocytochemical analysis of cells containing 
p-smooth muscle actin (#-E&IA), a marker for myofibroblasts, indicated that the majority 
of cells expressing VEGF at all time periods were tissue myofibroblasts, which was con- 
flrmed by double immunostalning for VEGF and p-SMA. We conclude that: 1) VEGF 
expression in healing infarct scars is time dependent and is regulated by the renin-angio- 
tensin system; 2) myofibroblasts are the predominant cell types that express VEGF in 
chronic cardiac wound healing after infarction; and 3) ACE inhibitors coordinately reduce 
remodeling and scar tissue VEGF expressIon independent of infarct size. These data 
suggest that ACE inhibitors alter the natural history of scar tissue wound healing after inf- 
arction, including obligate angiogenic responses attributable to cell types such as the 
myofibroblast. 
TIME PERIOD 
1151-85 Cardiomyoplasty and Treatment Improve Left Ventricular 
Function and Myocardial Revascularization After 
Myocardial Infarction in Rats 
Katia L. D. De Angeiis, Maria Claudia Irigoyen, Adolfo A. Leiner, ldrigene A. Cestari. 
Biengineering Division, Heart Institute (lncor), Medical School. Federal University of Seiko 
Paula, .%o Paula, Brazil 
Background: Myocardiai infarction can cause complex architectural changes that have 
an important bearing on ventricular function. We tested the hypothesis that cardiomyo- 
plasty (CDM) combined with VEGF treatment in the setting of experimentally induced 
myocardial Infarction (Ml) would stimulate angiogenesis and reduce the hemodynamic 
deficit. Methods: Male Wistar rats were divided in five experimental groups: intact (6, 
n=6), CDM (n=s), Ml (left coronary artery ligation: n=5), CDM performed 14 days after Ml 
(MI+CDM, n=6) and MlcCDM associated to VEGF treatment (MI+CDM+VEGF, n=5) 
Recombinant human VEGF165 was Infused (25 mg) Into the left latissimus dorsi (LD) 
main artery immediately before CDM. End-diastolic pressure (EDP) was obtained by left 
ventricle cannulation. Regional flows and cardiac output (CO) were measured by the 
injection of colored microspheres into the left ventricle (300.000, blue) at day 56. Collat- 
eral blood flow (CF) from LD to the myocardium (CF LD-M) was determined by the ratio 
of yellow microspheres (50.000 injected into the LD main artery) counted in myocardlum 
to that counted ln LD, whereas the CF from the myocardium to the LD (CF M-LD) was 
determined by the ratio of blue microspheres counted in LD to that counted in the myo- 
cardium. Results: The ratio of left ventricle to body weight (LVIBW) and end-diastolic 
pressure (EDP) were reduced after CDM I” MI rats. No differences were found between 
groups in CO and coronary flow. VEGF treatment was associated with an increase in the 
CFLD-M in Ml rats submItted to CDM. CF M-LD was greater In VEGF group compared to 
CDM and MI+CDM. 
C CDM Ml Ml+CDM MI+CDM +VEGF 
LVIBW 2.5+0.05 2.8t0.08 3.4+0.12*# 2.9iO.O8*+ 3io.14*+ 
EDP (mmHg) -0.14+0 5 -0.44+1.2 15.3553 3”# 4.77*1.8+ 3.9+2+ 
CO (mLmin-1) 62.5i6.6 7454.6 49.5k4.5 71 Sill 8 76t9.6 
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although the origin remains unknown. Methods: Blood was obtained from patients sub- 
mitted to the hospital with diagnosis of AMI before any intervention and 24 hours after. 20 
healthy volunteers were recruited consecutively. Concentrations of HGF and VEGF m- 
RNA transcripts in human leukocytes were measured quantitatively using the newly 
established real time polymerase chain reaction (PCR). Results: A 95 fold increase in 
HGF m-RNA concentration at admission (412.03%) and an addltional increase after 24h 
compared to control group (4.32%) was measured. VEGF m-RNA concentrations in leu- 
kocytes were low at admission (1085.9%) and 24h after AMI compared to control group 
(23652.5%). Conclusion: Early increase of HGF after AMI is due to an upregulation of 
HGF m-RNA in leukocytes. Though HGF m-RNA concentrations remained elevated 
VEGF m-RNA decreased. Serum VEGF therefore may originate from myocardium itself. 
Both mitogens are important in post AMI repair regulation and repetfusion. Our results 
undermine that leukocytes take an active role in reperfusion and myocardial repair. 
Conclusion: Cine FLASH MRI proved to be a valuable tool for non-invasive characteri- 
sation of little known small animal models. Induction of coronary stenosis led to worsen- 
ing function of the associated myocardial segment with consecutive impairment of global 
LV function. Regional SWT was improved by dobutamine stress but did not reach control 
values This model of chronic ischemia is well suited for tests of novel therapies 
1151-89 Pharmacokinetics and Efficacy of Intravenous Vascular 
Endothelial Growth Factor (rhVEGF) in Porcine Hibernating 
Myocardium 
Shankha S. Biswas, Patrick W. Domkowski, Luis H. Diode@ Anne M Pippen, Kevin P 
Landolfo, Brian H. Annex. Duke University Medical Center, Durham, NC 
Background: In porcine hibernating myocardium, we have demonstrated changes in 
myocardial blood flow (MBF) and function with laser and anglogenic therapies. The pur- 
pose of this study was to examine the pharmacokinetics (PK) and long-term efficacy of 
intravenous (IV) rhVEGF (total 30 g/kg) in hibernating myocardlum. Methods: Eight mini- 
swine with 90% left circumflex artery (LCX) stenosis and documented hibernating myo- 
cardium by positron emission tomography (PET) and dobutamine stress echocardio- 
graphy (DSE) were randomized to IV rhVEGF (50 nglkgimin for 200 minutes at 3 72 hour 
intervals, n&) or IV vehicle (n=Z). As an additional control, 6 pigs had 30 intramyocardial 
vehicle (IM) injections. PK parameters were calculated using non-compartmental analy- 
sis and compared to published human data. After 3 and 6 months, PET and DSE were 
repeated. DSE detects ischemia by changes in regional wall motion score index (WMSI) 
where 1 normal, 2 hypokinetic, 3 akinetic, and 4 dyskinetic. Results: The plasma clear- 
ance (14.8 mliminikg) was biphasic with a large volume of distribution (Vss 1530 mUkg) 
and a terminal half-life of 71 minutes after IV rhVEGF. The rapid clearance and large Vss 
suggests extensive tissue binding and is similar to the PK parameters reported in 
humans (Cl 22 mllminikg; t112 77 men; Vss 1690mlikg). With IM and IV vehicles, MBF 
did not increase significantly over baseline at 3 months (6.7&2% and 8.6&Q%) or 6 
months (6.9?6.7% and 0.54~059%). With rhVEGF, MBF increased by 4.7?3.8% over 
baseline at 3 months (p=O.25), and by 22.0*5.8% at 6 months (p=O.O03). At 3 months, 
restmg and peak stress LCX WMSI trended towards less ischemia with rhVEGF 
(2.1kO.20 and 1.6+0.20 vs 2.2+0.21 and f&O.24 at baseline, p=O.lO for both). At 6 
months, resting and peak stress WMSI demonstrated significant reduction in ischemia 
(1.9+0.25, pzO.02 and 1.5*0.18, p=O.O4 vs baseline). No ischemic changes were seen 
with IM or IV vehicle. Conclusions: Using a dosing regimen yielding a similar PK profile 
to humans, IV rhVEGF significantly improved regional MBF, as well as resting and stress- 
induced ischemia in porcine hibernating myocardium. 
1151-90 Characterisation of a Model of Chronic Coronary Artery 
Stenosis in the Rat by Cine-MRI 
Matthias Nahrendotf, Karl-Heinz Hiker, Kai H”, Christiane Walker, Axel Haase, Georg 
Ertl, Wolfgang Ft. Bauer. Wueuburg University, Wuerzburg, Germany 
Background: Chronic coronary artery stenosis is a disease with a high mcidence. Aim of 
the study was to non-invasively characterize a model of chronic artery stenosis in the rat, 
which could be a research tool for the search of novel therapies of this condition. Meth- 
ods: Stenosis was induced by a ligation including a 3OO”m wire placed next to the left 
coronary artery. The wire was taken away immediately after the suture was closed. MRI- 
.scans were done 2 weeks after induction of stenosis in a 7 T-scanner using an ECG-tng- 
gered Cine-FLASH-sequence: 16 short axis slices, slice thickness 1 mm, echo-time 1.2 
ms, resolution 200 urn. Left ventricular (LV) mass, LV volumes, cardiac output (CO), 
ejection fraction (EF), end-diastolic wall thickness of the area associated to the stenosis 
(ST) and a remote region (EDW) and systolic wall thickening of both regions (SWT) were 
determined in 7 wistar rats and compared to 11 controls. Occlusion of the coronary was 
excluded by SD-MR-Angiography of the isolated perfused heart. Results: There was no 
difference in LV mass and heart rate between groups. 
control stenosis 
EDV (14 169.7+/-8.5 196.2+/-32.3 
sv (IN 124.7+/-6 83.2+/-9.1* 
Cl (ml/kglmin) 142.5+/-6 97.5+/-12,5* 
EF % 74+/-2 44.3+/-3.0* 
EDW (mm) 2.1+/-0.05 2.1+/-O.O5/ST: 1.6+/-0.1’ 
SWT (%) 62.5+/-4.1 54.3+/-5.41 ST:18.6+/-10.3* 
mean+/-SEM. *p<O.Ol vs control. 
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1152-92 Comparative Antianginal Efficacy and Tolerability of 
Ranolazine in Diabetic and Nondiabetic Patients: Results of 
the MARISA Trial 
Vincent DeQuattro, Sandra Skettino, Bernard R. Chaitman, Peter C. Ha&y, Petr Jansky, 
J. K. Kuch, John 0. Parker, J. J. Nelson, David Hebert, Andrew A. Wolff. University of 
Southern California, Los Angeles, CA, CV Therapeutics, Palo Alto, CA 
Background: Ranolazine is a partial fatty acid oxidation (pFOX) inhibitor that shifts ATP 
production away from fatty acid oxidation toward more oxygen-efficient glucose oxidation. 
Because of the metabolic shift toward glucose oxidation, data from diabetic patients were 
examined. Methods: The MARISA (Monotherapy Assessment of Ranolazine In Stable 
Angina) study randomized patients to ranolazine 500 mg, 1000 mg and 1500 mg bid and 
placebo in a double-blind, 4-period crossover design study. All patients performed a mod- 
ified Bruce exercise test at the time of trough and peak drug levels on each treatment; 42 
patients with diabetes were compared to 133 non-diabetic patients. Results: Exericse 
duration (see table), time to angina and time to 1 mm ST segment depression were pro- 
longed by ranolazine at the time of both peak and trough drug levels (treatment p-values 
<O.OOl) and generally increased with dose. At peak and trough, ranolazine effects were 
similar tn diabetic and non-diabetic patients (treatment by diabetes interaction p-values 
>O.iO). In diabetic patients, at least one adverse event occurred in 16%, 23%, 23% and 
33% of patients on placebo, ranolazine 500 mg, 1000 mg and 1500 mg, respectively; in 
non-diabetic patients the analogous values were 15% 13%, 21% and 34%, respectively. 
Mean changes (*SE) from baseline to the end of the study in glucose and triglyceride 
levels were similar between diabetics and non-diabetics (change in glucose: diabetics 
lo+-11 mg/dL, non-diabetics 31-2 mg/dL [NS]; change in triglycerides: diabetics 
10+17mg/dL, non-diabetics -7?6 mg/dL INS]). Conclusion: Patients with chronic angina 
and diabetes appear to tolerate and to respond to ranolazine, a pFOX inhibitor, as well as 
patients without diabetes. 
Exercise Duration’ (seconds) 
Treatment 
Diabetics n=42 
Non-diabetics 
n=l33 
Placebo Ranolazine Ranolazine Ranolazine 
500 mg bid 1000 mg bid 1500 mg bid 
troug peak trough peak trough peak trough peak 
h 
499 498 520 527 526 550 530 547 
503 500 528 530 539 550 554 557 
‘Values are given as least squares means. Treatment p-values: trough <O.OOl, peak 
<O.OOl; treatment by diabetes interaction p-values: trough p=O.768, peakz0.953 
1152-93 Prolonged Statin Therapy and the Arterial Elasticity in 
Stable Coronary Artery Disease 
Magorzata Kurpesa, Ewa Trzos, Micha Kidawa, Maria Krzemihska-Pakua. Zbigniew M 
Bednarkiewicz. Medical Academy, fdd? Poland 
Background: Hypercholesterolemia and atherosclerosis are known to influence the 
mechanical properties of the arterial tree. Statins may alter the arterial distensibility 
because they decrease plasma cholesterol level and inhibit the progression of athero- 
sclerosis. Pulse wave velocity (PWV) provides an indirect, non-invasive measurement of 
mechanical properties of the arteries. The aim of the study was to evaluate the influence 
of statin therapy on arterial elasticity in pts with coronary artery disease(CAD). Methods: 
Study group consisted of 46 pts with angiographically documented, clinically stable CAD 
and with high-normal plasma cholesterol level(l90-210 mgidl). They were randomised 
into Group l-23 pts who received placebo and Group II-23 pts who received statin ther- 
apy Groups were comparable according to age, gender, risk factors and treatment of 
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CAD. Before and following 6 months of treatment PWV was evaluated using a computer was established in 88% at a mean of 61 min after RNS arrival. Treatment included: stent- 
system COMPLIOR. In each patient carotid-femoral PWV was measured. For automatic ing 63%, PTCA 9%, emergency CABG IO%, in-hospital CABG 8% and no intervention 
measurement of PWV pressure waveforms were digitized at rate 500Hz for carotid-femo- 10%. Reopro was used in 33% and intraaortic balloon pumping in 27%. In-hospital mor- 
ral distance.10 healthy volunteers constituted a control group. Results: After 6 months tality was 8.3% with reMI, CVA and target lesion revascularisation in 1.7%, 2.5% and 
the plasma cholesterol level was 205t21mgidl in Group1 and 168r15 mgidl in Group 8.3% respectively. Mean total D/R+RNS hospital stay was 8.3 k I,1 days. Conclusion: 
Il(p<O,Ol). Results of PWV are shown in the table.*p<O,Ol 
Pulse wave velocity m/s 
Emergency transfer of MI patients from D and R hospitals with FT failure or C/l to a ter- 
tiary centre for immediate CA + revascularisation results in an excellent short-term out- 
Group I Group II controi come despite a high-risk population and long transport delays. 
Initial 12,i f I,3 12,3 i 0,s 7,OA 0,6 __ 
After 6 months 12‘4 + 2,0 8,9 * 0,7* 
1153-96 
7,2 +0,4 - 
Relation Between Time-to-Pharmacologic Reperfusion and 
After &month therapy with statin a significant decrease of PWV was observed. This 
the Probability of Achieving Complete ST-Segment 
result may be explained by beneficial effect of statins on the degree of plaque growth. 
Resolution in ST Elevation Myocardial Infarction 
The alternative explanation may be the influence of statins on vascular remodeling. Con- Howard A. Cooper, James A. de Lemos, Sabina A. Murphy, Carolyn H. McCabe, Kristin 
elusion: Statin therapy may improve arterial elasticity in patients with normal plasma C. Schuhwerk, Elliott M. Antman, Eugene Braunwald. Brigham and Women’s Hospital, 
cholesterol and stable CAD. Boston, MA 
1152-94 Relation Between Self-Efficacy and Diet/Exercise Adequacy 
Background: ST-segment resolution reflects myocardlal reperfusion and predicts mor- 
in Cardiac Rehabilitation 
tality following ST elevation MI. The relation between time-to-pharmacologic reperfusion 
and ST-seament resolution is unknown. 
Sammy Chan, Kor~ Kingsbury, Frances Johnson, Anka Brozic, Wolfgang Linden. Sandra 
Barr, Jiri Frohlich. Andrew Ignaszewski. University of British Columbia, Vancouver, BC, 
Canada 
Background: Self-efficacy (SE) lhas been shown to influence health behavior. To deter- 
mine the role of SE in cardiac rehabilitation (CRP), we correlated SE with measures of 
diet/exercise compliance in participants of CRP Methods: 47 subjects (age 61+13, 19% 
female, 68% CAD) were evaluated. SE was judged in 2 domains (diet, exercise) with a 
SE questionnaire (SEQ) using Likert scales. Adequacy of diet was assessed with body 
mass index (BMI). Adequacy of exercise was assessed with age adjusted fitness classifi- 
cation (FIT) (l-7, most to least fit) based on treadmill results. SEQ was tested prior to 
CRP. BMI and FIT were measured prior to and at completion. All subjects completed a 4 
month CUP with supervised exercise conditioning and outpatient diet counseling. 
Results: Subjects were divided rnto 2 groups based on their SEQ scores. At initial evalu- 
ation, subjects with high dietary SE had a significantly lower BMI (figure). The indices did 
not change in either group at completion. Exercise SE was evaluated in subgroup with 
negative stress test. At start of CRP, subjects with high exercise SE were significantly 
more fit (figure). However, subjects with low SE improved significantly during CRP while 
there was no change in FIT in subjects with high exercise SE scores. Conclusions: (1) 
diet and exercise SEQ scores correlate wth initial BMI and FIT suggesting that these 
scores are useful in predicting behavior in a” ambulatory setting; (2) a supervised exer- 
cise CRP improves FIT especially in subjects with low SE; (3) dietary counseling only has 
a minimal impact on BMI regardless of SE. 
Methods:-Data were pooled for 544 patients randomized to various combinations of 
reteplase, alteplase, and abciximab (TIMI 14 trial) and 763 patients randomized to full- 
dose ianoteplase or alteplase (InTIME II trial). Multivariable logistic regression was used 
to assess the independent relation between time from symptom onset to the start of 
pharmacologic reperfusion and the probability of achieving complete (270%) ST-segment 
resolution at 90 minutes. Other variables in the model were infarct location (anteriodnon- 
anterior), abciximab use in TIMI 14 (yes/no), and fibrinolytic agent (aiteplaseireteplasei 
lanotepiase). 
Results: Time-to-treatment was inversely related to the probability of achieving complete 
ST-segment resolution at 90 minutes (per hour OR 0.94, 95% Cl 0.89-0.99, p=O.OS). 
Patients with “on-anterior infarcts were more likely to achieve complete ST-segment res- 
olution (OR 2.81, 95% Cl 2.21-3.57, p<O.OOl). The probability of achieving complete ST- 
segment resolution was not significantly different among the 3 fibrinolytic agents (p=NS), 
but was greater if abciximab was part of the reperfusion regime” (OR 2.05, 95% Cl 1.51. 
2.78, p<O.OOl). 
Conclusion:While the effects of abciximab and infarct location predominate, time-to- 
treatment also has a significant impact on the probability of achieving reperfusion at the 
myocardial level. This may be one mechamsm by which earlier pharmacologic reperfu- 
$1~” results in reduced mortality in ST elevation Ml. 
POSTER SESSION 
1153-97 
‘I 153 Time to Treatment in Acute Myocardial 
Prehospital Infarction Angioplasty Triage (PHIAT): Results 
From the Zwolle Myocardial Infarction Study Group 
Infarction Nicolette Ernst, Menko Jan de Boer, Arnoud W. J. van ‘t Hof, Frans Hollak, Jan C. A. 
Monday, March 19, 2001, 3:00 p.m.-5:OO p.m. 
Orange County Convention Center, Hall A4 
Presentation Hour: 4:00 p.m.-5:OO p.m. 
Hoorntje, Harry Suryapranata, Jan Henk E. Dambrink, Felix Zijlstra. /sala Klinieken 
hospital De Weezenlanden, Zwolle, The Netherlands 
Background: Time from onset of symptoms to reperfusion therapy is of paramount 
importance for the clinical outcome in patients (pts) with acute myocardlal infarction 
(AMI). Prehospital identification of pts with AMI may result in a reduction of total ischemic 
1153-95 Emergency Transfer of District and Rural Hospital Acute time when considering primary angioplasty (PA) treatment. Methods: Between Novem- 
Myocardial Infarct Patients for immediate Angiography 2 
ber 1998 and July 2000, 17 ambulances were equipped with 12.lead EGG computers 
Intervention Is Associated With Excellent Clinical 
using a” algorithm to Identify large AMI. When pts were Identified as having large AMI. 
Outcomes Despite a High Risk Population and Long 
immediate transfer and preparation of cath lab and personnel were initiated. Results: 
During the study period in 213 pts the indication for PA treatment was made. The mea” 
Transport Delays age was 60.4 years (range 16.90). One patient died before arrival in the hospital. 
Peter Hansen, Yutaka Koyama, Michael Ward, Helge Rasmussen, Greg Nelson. Roya/ Clinical characteristics (11~212): 
North Shore Hospital, Sydney, Ausfraiia N % 
Background: District (D) and rural (R) hospital patients (pts) with acute myocardiai inf- 
arction (Ml) in whom fibrinolytic therapy (FT) fails or is contraindicated (Gil) have a high 
in-hospital morbidity and mortality Limited information is available on emergency transfer 
to a tertiary centre for immediate coronary angiography (CA)/lntervention. Methods and 
Results: Between 711997.g/2000 we prospectively examined in-hospital outcomes of 
142 consecutive Ml pts from D and R hospitals with FT failure (75%) or C/I (25%) 
urgently transferred to Royal North Shore (RNS) a tertiary centre for immediate CA/inter- 
vention. Average transfer distance k SD was 68 km t 19 km. Pt arrival was “out of hours” 
in 66%. Mean age was 63r13 yrs (range: 28-88 yrs) and FM ratio 4:9. Previous MI, per- 
cutaneous transluminal coronary intervention (PTCA), coronary artery bypass grafting 
(CABG), cerebrovascuiar accident (CVA) and diabetes was present in 18%, 6%, 8%, 8% 
and 15% respectively and 30% of pts were Killip class Ill/IV. Mean time from diagnostic 
ECG to RNS notificatioon and from RNS notification to pt arrival was 294 and 115 mi” 
respectively. At CA 75% had TIMI 0, 1 or 2 flow in the infarct related artery. TIMI 3 flow 
Male 160 75 
Previous Ml 23 11 
Immediate angiography 210 99 
Anterior Ml 89 45 
No AMI, other diagnosis 12 6 
PA (N=191) success 177 93 
Urgent bypass surgery 2 1 
Bvpass suroerv later 17 8 “, 
The median tlrne from symptom onset to admission and from admission to first balloon 
inflation were 122 and 38 mmutes respectively. The total mortality with a mea” follow-up 
of 6 months was 6%. Conclusion: Pre-hospital triage in the ambulance is a feasible, 
effective and safe way to identify patients with large AMI in order to transfer then- directly 
340A ABSTRACTS - Myocardial lschemia and Infarction 
to a center for primary angioplasty. A considerable amount of patients (6%) do not have a 
myocardial infarction and this is definitely more than is reported from prehospltal throm- 
bolysis trials. 
1153-98 Delayed Is Better Than Early Elective Intervention After 
Acute Myocardial Infarction Treated With Thrombolytic 
Therapy 
Abid R. Assali, Ali Moustapha, Stefana Sdringola, Joseph Salloum, Mohammad Ghani; 
Sangeeta Saikia, Susan Hale, Goerge Schroth, Oscar Resales, Vernon H. Anderson, 
Richard W. Smalling. UNIVERSITY OF TEXAS MEDICAL SCHOOL AND HERMANN 
HOSPITAL, HOUSTON, TX 
Background:- Optimal timing of elective percutaneous coronary intervention (PCI) after 
acute myocardial infarction (Ml), especially those treated with thrombolytic therapy (TT), 
is unknown. &!x&x We compared the results of early (6-24 hours) and delayed (>24 
hours) elective PCI in acute Ml patients (pts) treated with TT Methods: We performed a 
retrospective analysis of 231 consecutive pts with acute Ml undergoing elective PCI after 
successful TT (pts undergoing emergency PCI or hemodynamic instabllity were 
excluded): Group I = 86 pts (37%), 6.24hours; Group II = 145 pts (63%), r24hours. Each 
group was analyzed according to TT All major adverse cardiac events (MACE: death, 
non-fatal MI, and re-intervention) were recorded. 
GROUP I (24>TIME>6 hours) Group II (Time, 24 hours) P-value 
Tr+ TT Tr+ TT- 
# Patients 12 74 30 115 
AGE (YRS) 57.It13 %-/+I 2 59./+13 58:/+1 4 0.4 
DM 3 (25%) 25 (34%) 5 (17%) 37 (32%) 0.1 
1 -Vessel disease 10 (83%) 53 (72%) 22 (73%) 84 (73%) 0.6 
Anterior Ml 3 (25%) 32 (43%) 9 (30%) 43 (38%) 0.3 
stent 7 (58%) 30 (41%) 29 (97%) 90 (78%) 0.005 
GP2bi3a 3 (25%) 38 (51%) 7 (21%) 32 (28%) 0.8 
In-hospital death 1 (8.2%) 0 (0%) 0 (0%) 2 (1.2%) 0.5 
In-hospital MACE 3 (25%) 5 (7%) 0 (0%) 11 (10%) 0.02 
Conclusion: Early (6-24 hours) elective PCI after acute Ml is associated with higher rate 
of in-hospital MACE especially when thrombolytic therapy was given. 
1153-99 Influence on Outcome of Time From Myocardial Infarction 
Onset to Primary Angioplasty 
Thierry Lefevre, Christophe Loubeyre, Marie-Claude Morice, Yves Louvard, Fran@ 
Gobeil, Rajpal Abhaichand, Jean-Franqois PiBchaud. /CPS, Massy. France 
Background: Time from Ml onset to thrombolysis has been shown to be a predictive fac- 
tor of procedure failure and mortality. The same influence of time to primary PTCA 
(TIME) on patient outcome still remains controversial. 
Methods: We retrospectively assessed from our AMI database (January 1995 to Decem- 
ber 2000) the influence of TIME on angiographic results and in-hospital outcome. All pts 
admitted for acute MI were included. The strategy was as follows: direct admission to the 
cath-lab for immediate coronary angiogram. PTCA and stent implantation when indicated 
and feasible. 
Results: During this penod, 1030 pts were admltted 5 12 hours. Time from admission to 
reperfusion was 41.9k44.6 min. The main pts characteristics and results according to 
TIME are summarized below 
Time 3.1-6 6.1-g 9.1-12 p 
(hours) 
Patients (%) 39 39 13 10 - 
Female Gender (%) 20 21 17 28 ns 
Previous Ml (%) 18 11, 6 6 <O.Ol 
Age (~0 59+/-14 64+/-14 60+/-14 62+/-16 <0.05 
Anterior Ml (%) 49 45 42 49 “.S 
Prehospital Thrombolysis (%) 14 19 24 13 ns 
Killip 30r 4 (%) 14 14 12 15 ns 
Stent used (%) 90 89 92 86 ns 
Final TIMI 3 (%) 94 91 89 80 <O.Oi 
Angiographic success (%) 97 98 99 95 ns 
Death (%) 66 6.7 10.2 10.1 <0.05 
Conclusion: In this observational study including all AMI pts 5 12 hours, the majority 
were admitted less than 6 hours after MI onset. Patients admitted earlier were younger 
and had more frequently a previous MI. In our series this earlier treatment led to higher 
final TIMI 3 rate and lower mortality. 
1153-100 Time to Treatment Influences the Impact of ST Segment 
Resolution on One Year Prognosis: Insights From ASSENT- 
2 
Yuling Fu, Shaun Goodman, Wei-Ching Chang, Padma Kaul, Frans Van de Werf, 
Christopher B. Granger, Paul W. Armstrong. for the ASSENT2 Investigators. University 
of Alberta, Edmonton, AB, Canada 
Rapid resolution of ST-segment elevation at 90 and 180 min following fibrinolytic therapy 
is related to early coronary artery patency and improved clinical outcomes in patients 
with acute myocardial infarction(AMI). However the prognostic value of later ST resolu- 
tion assessed at 24 hours in predicting l-year mortality is unknown. Moreover the impact 
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of time to treatment on extent of 24.hour ST resolution has not been previously evalu- 
ated. Accordingly, we studied these issues using Schrijder’s method in ASSENT-2 where 
13045 patients had both baseline and 24-hr EGGS free of confounders (LBBB, ventricular 
rhythm, reinfarctlon). Of these patients, 50% had complete resolutlon(>70%), 36% had 
partial resolution(30-70%), and 14% had no ST resolution(< 30%). The overall l-year 
mortality rates for these patients were 5.1%, 8.1%, and 9.5%, respectively (p< 0.001). 
Analysis according to pre-specified time windows revealed complete ST resolution in 
54.7 % of patients treated wlthin 2 hours, in 50.6% treated between 2 4 hours, and in 
42% treated between 4 6 hours (p < 0.001). The figure shows l-year mortality partl- 
tioned according to extent of ST resolution and time to treatment. The extent of ST reso- 
lution was inversely associated with time to treatment. Indeed, within each category of 
ST resolution, the sooner the patients were treated, the lower their mortality. Hence irre- 
spective of the extent of ST resolution, incorporating time to treatment provides additlonal 
prognostic value. These results further emphasize the importance of early treatment for 
AMI. 
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1154-75 Diabetes Mellitus Prevents lschemic Preconditioning by 
Prodromal Angina in Patients With a First Anterior Wall 
Acute Myocardial Infarction 
Masaharu Ishihara, Hikaru Sate, Takuji Kawagoe, Yuji Shimatani, Satoshi Kurisu, Kenji 
Nishioka, Yasuyuki Kouno, Takashi Umemura, Shuji Nakamura. Hiroshima Crry Hospifai 
Hiroshima, Japan 
Backgrotind: Prodromal angina occurring shortly before the onset of acute myocardial 
infarction is associated with favorable outcome by the mechanism of ischemic precondi- 
tionlng. However, little is known about impact of diabetes on ischemic preconditioning. 
Methods: We studied 620 consecutive patients with a first anterior wall acute myocardial 
infarction who underwent emergency catheterization with 12 hours after the onset of 
chest pain. Prodromal anglna was defined as angina episode(s) occurring within 24 
hours befoie the onset of acute myocardial infarction. Serial contrast left ventriculograms 
were obtained in 505 patients at the time of acute and predischarge catheterization. 
Results: In 490 patients without diabetes, prodromal angina was associated with lower 
peak creatine kinase value (3,068?2,6471lJ/L vs 3,601r2,462lU/L, p=O.O37), more 
improvement of left ventricular ejection fraction (9.7r13.2% vs 5.6r13.6%, p=O.O095) 
and lower in-hospital mortality (3.4% vs 9.3%, p=O.O15). On the contrary, in 130 diabetic 
patients, there was no significant difference in peak creatine kinase value 
(3,382+2,52OlU/L vs 3,233~2,4121U/L, p=O.75), the change in left ventricular ejection 
fraction (7.2+14.0% vs 8.2?15.1%. ~~0.76) and in-hospital mortality (8.8% vs 11.0 %, 
~~0.68) between patients with and those wlthout prodromal angina. Conclusion: Pro- 
dromal angina occurring shortly before the onset of acute myocardial infarction was 
associated with llmited infarct size, enhanced recovery of left ventricular function and 
improved survival. However, such beneficial effects of prodromal angina were not 
observed in diabetic patients, suggesting that diabetes might prevent ischemic precondi- 
tioning in patients with acute myocardial infarction. 
1154-76 Association of Chronic Renal Insufficiency With Adverse 
Cardiovascular Outcome After Acute Coronary Syndrome: 
A Study From the Michigan Cardiovascular Outcomes 
Research and Reporting Program 
Rosario V. Freeman, Rajendra H. Mehta, Jeanna Cooper, Eva Kline-Rogers, Kim A. 
Eagle. University of Michigan, Ann Arbor, MI 
Background: In order to address the association of chronic renal insufficiency (CRI) 
(serum creatinine >I.5 mgidl) with known cardiovascular risk factors and mortality 
among patients admitted with acute coronary syndromes, 925 consecutive patients pre- 
senting with an acute coronary syndrome to a tertiary academic medical center in 1999 
were studied. Methods: Demographic, procedural, and outcome data were collected 
prospectively on a standardized data collection form. Predictors of in-hospital mortality 
were identified by univariate.analysis. Odds ratios (OR) and 95% confidence intervals 
(Cl) for in-hospital mortality were calculated Multivariate logistic regression was used to 
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assess the independent association of CRI with in-hospital mortality. Results: 176 
patrents (19.0%) had CRI. Overall, there were 43 in-hosprtal deaths (4.6%), of which 27 
were in CRI patients. Patients with CRI were older and had more prior congestive heart 
failure, diabetes, hypertension and myocardial infarction (table) CRI patients had longer 
hospital stays, were less likely to have a normal angiogram and were more likely to have 
a failed procedure if coronary interventron was attempted. CRI was an independent pre- 
doctor of m-hospital mortalrty.(OR 7.02, 95% Cl 3.5 to 13.9 pcO.OOOl), after adjustment 
for older age, presence of congestrve heart failure and diabetes. Conclusions: CRI is 
prevalent in patients presenting with an acute coronary syndrome and is an under-appre- 
ciated independent risk factor for in-hospital mortality. Recognition of the increased risk 
burden of CR identrfies a patient subset at substantially higher risk of adverse cardiovas- 
cular outcome. 
CRI NON-CR1 p-value 
DEMOGRAPHICS N=l76 N=749 
Age 67+1-14 63+/-l 4 <0.0001 
Male(%) 115(65) 481(64) 0.57 
Hypertension(%) 135(77) 455&i) <0.0001 
Diabetes Mellitus(%) 87(43) 192(X) <0.0001 
CHF(%) 83(47) 98(13) <0.0001 
PreviousMI(%) 98(56) 325(43) <0.0001 
Ejection Fraction 41+/-16 50+/-17 <0.0001 
OUTCOMES 
Days Admitted 5.9+/-5.2 4 9+/-6.0 0.01 
Failed Procedure 4’Of 41 PCIS 11 Of 295 PCIS 0.04 
Non Q-wave MI 66(38) 233(31) 0.05 
Major Bleeding 24(14) 76(10) 0.09 
Normal Angiogram 5(3) 455(61) <0.0001 
In-Hospital Death 27(15) 1W) <0.0001 
regarding ST-segment deviation (Xl 05mV) and the summed ST-segment deviation in 11 
leads (except aVR) was calculated. Patients with bundle branch block, fascicular block 
and left ventricle hypertrophy constituted a separate subgroup of 514 patients. 
Summed ST Non-invasive Invasive strat- D Trooonin T Ptts w. LMS. 
segment 
deviation 
strategy egy Death, MI (ChiP) (ug/L)median 2VD or 3 VD 
Death, MI 1 1 year values (only invasive 
O-2 5mm 
pat 
9.3% 11.7% 0.45 0.09 
group) 
43.9% 
3.5.5mm 
>&mm 
ECG con- 
founders 
13.3% 6.2% 0.004 0.15” 54.3%* 
19.4% 9.5% 0.002 0.23’* 68.3%** 
15.5% 13.4% 0.57 0 21 61.7% 
“p<O.O5 or ‘*pcO.Oi compared with group above. Results:An invasive treatment strategy 
reduced the risk of death or AMI by 1 year follow up significantly in the subgroups with 
the highest degree of ischemia.There was a gradual increase in Troponrn T values by an 
increasing level of ischemic burden as well as the patients with the most ST-segment 
deviation had more severe coronary artery disease by 5-7 days angiography. Conclu- 
sion: In patients with unstable coronary artery disease the rschemrc burden determined 
by ECG is related to poor outcome in patients treated non-invasively An invasrve treat- 
ment strategy provides a significant risk reduction in these patientsIn addition, ischemic 
burden rn the ECG IS also correlated to Troponin T level and to the severity of coronary 
artery drsease by angiography 
1154-101 Emergency Department Rest Myocardial Perfusion Imaging 
Results in More Effectve Utilization of Coronary 
Angiography in Low Risk Chest Pain Patients 
Michael C. Kontos, Rakesh K. Shah, Kristin L. Schmidt, Robert L. Jesse, Joseph P. 
Omato, James L. Tatum. MCV/VCU, Richmond, VA 
Background: Previous studies have shown that using myocardial perfusion imaging 
(MPI) with sestamibr in Emergency Department (ED) patients (pts) with chest pain IS cost 
effective. This may result from more effective utilization of invasive testing, with a reduc- 
tion of coronary angiography in low-risk pts. Methods: We compared a consecutive 
group of pts prospectively evaluated according to a protocol using MPI in low risk pts 
(ACT) to a control group (CON) evaluated during the year prior to rmplementation of the 
protocol. CON patients were retrospectivety assrgned a pre-defined risk level based on 
the ED admissron record and ECG. Hugh risk (High) unstable angina pts were compared 
to lower risk pts (Low), who underwent ED MPI in the ACT group but not in the CON 
group, to assets the relationship of MPI to the use of coronary angiography (Cath), pres- 
ence of signrficant disease (Sig Dz [,70% stenosrs]). and revascularization (Rev) in tests 
performed within 30 days of ED evaluation. Results: There was no difference in the pro- 
portion of pts who were High and Low rusk between the two groups (table). High risk CON 
pts underwent stress testing more frequently (~~0.05) than did High risk ACT pts. Cath 
was performed as frequently in High risk CON and ACT pts, with no difference in the inci- 
dence of Sig Dz and Rev. In contrast, Cath was performed less frequently rn Low risk 
ACT pts (p<O.O5), but the yield was higher, with more Srg Dz (p<O.O05) and Rev 
(pcO.05). There was no significant difference rn costs between the ACT and CON groups, 
either in the High risk ($9435 vs $10,425) or Low risk (S2800 vs 2896) pts 
Conclusions: The higher proportion of Sig Dz and Rev in ACT pts suggests more 
approprrate invasive test utilrzation rn Low rusk chest pain pts. ED MPI improves cost 
effectiveness of Low risk pts by increasing the yield of invasive testing 
1154-77 Atrioventricular Nodal Block in Acute Myocardial Infarction 
Treated With Thrombolytic Therapy Is Common and 
Portends Poor Prognosis: Results From Large Trials of 
Thrombolytic Therapy 
Sana M. Al-Khatib, E. Magnus Ohman, Harvey D. Whrte, Christopher B. Granger, Robert 
M. Califf, Rakhi Kilaru, Eric J. Topol. Duke Clinical Research Insfifute, Durham, NC 
Background: In the pre-thrambolytic era, atrioventrrcular nodal block complicating acute 
myocardiai infarction was associated with a poor prognosis. The incidence and prognoses 
of atrioventrrcular nodal block in the setbng of acute myocardial mfarction treated with 
thrombolytic therapy are less well defined. We examined the incidence, predictors, and 
outcomes of second and thrrd degree atrioventncular nodal block in 76,002 patients with 
ST-segment elevation myocardial rnfarction treated wrth thrombolytic therapy enrolled in 
the GUSTO-I, GUSTO-lib, GUSTO-III. and ASSENT-II trials. Methods: We compared 
baseline characteristics and 30.day mortality of patier?ts wrth atrioventncular nodal block 
(5,273) to those without it (70,729). Results: The incidence of atrioventricular nodal 
block was 7.5%. Significant predictors of atrioventricular nodal block were inferior myo- 
cardial infarction location (Odds Ratio [OR] 2.9, 95% Confidence Interval [Cl] 2.7-3.1) 
history of congestive heart failure (OR 2.4, 95% Cl 2.3-2.6) female gender (OR 1.5, 95% 
Cl 1.4-l .6), Killip class at presentation (OR 1.4, 95% Cl 1.4-l .5), and older age (OR t .2, 
95% Cl 1.2-l .3). In a time-dependent analysis, patrents wrth atnoventricular nodal block 
had a srgnificantly hrgher 30.day mortalrty (20% versus 6%, p-value 0.001). Conclusion: 
Atrioventricular nodal block is a relatively common and understudied complication of 
acute myocardial infarction and is associated with a poor prognosis even when throm- 
boiytrc therapy is used. The related use of treatments, including pacemakers and beta- 
blockers, needs further study. 
i I 54-78 lschemic Burden in the Standard ECG Identifies Patients 
Who Benefit Most From an Early Invasive Strategy in 
Unstable Coronary Artery Disease: A FRISCS Substudy 
Lene Holmvang, Peter Clemmensen, Bertil Lindahl, Bo Lagerqvrst. Per Venge. Lars 
Wallentin. Peer Grande. The A!afiona/ University Hospifaai, Copenhagen, Denmark. 
Uppsala university Hospifai, Uppsala, Sweden 
Background:lschemic burden, defined as amount of ST-segment depression in the ECG 
has been shown to relate to prognosis in patients with acute coronary syndromes. Meth- 
ods:We evaluated the influence of the iscemic burden on the effects of an early invasive 
versus a conservative treatment strategy in the FRISC 2 trial as well as the relationship 
between ischemic burden and Troponin T values and angiographic findings at day 5-7 
2210 patrents with chest pain and signs 01 ischemra (ST-depression. T-wave inversion 
and/or elevated brochemical markers) were included. The rnclusion ECG was evaluated 
CON, High (n=i75) 
ACT, High (n=198) 
CON, Low (n=464) 
ACT, Low (n=597) 
% Pts % stress % Cath % Sig Dz % Rev 
27 24 45 72 59 
25 16* 50 59 45 
73 21 19 31 22 
75 53 ** 13 * 51 ** 38 * 
* =p<o.o5: ** =p<o.o05 
1154-102 Outcome of Patients With Acute Coronary Syndromes With 
and Without Prior CABG: Results From the PURSUIT Trial 
Marina Labinaz, Rakhi Kilaru, Karen Pieper, Steven P Marso, Lisa Berdan. Michael Kitt 
Maarten L. Sirnoons, Robert M. Califf, Eric J. Topol, Robert A. Harrington, Paul W. 
Armstrong, for the PURSUIT Investigators. Universify of Olfawa Heart Insfifuie, Offawa. 
ON, Canada, Duke University Medical Center, Durham, NC 
Coronary Artery Bypass Grafting (CABG) signifincantly improves the morbidity and mor- 
tality of patients (pts) with advanced coronary artery disease. However, it is unclear 
whether prior CABG protects pts presenting with acute coronary syndromes (ACS) from 
adverse events. Furthermore, the effect of glycoprotein (GP) Ilb/llla blockade in pts with 
prior CABG presenting wrth ACS is also unknown. The purpose of this study was to eval- 
uate the baseline characteristics and outcomes of pts presenting with ACS with and with- 
out prior CABG. Methods: PURSUIT randomrzed pts presenting with ACS to 72 hrs of 
treatment with the GP llb/illa antagonist eptifibatide (ept) vs placebo. Results: In PUR- 
SUIT, 1134 pts (12.0%) had prior CABG. Pts with prior CABG were older, heavier, had 
significantly more cardiac risk factors, more prior MI, stroke, PVD and PTCA compared to 
pts without prior CABG. The use of asprrin, beta-blockers, calcium channel blockers, ACE 
inhibitors and nitrates were higher rn the 2 wks prior to presentation in pts with prior 
CABG. The incidence of death and death/MI rn prior CAEIG compared to non-prior CABG 
at 30 days was 5.2 vs 3.4% and 15.7 vs 14.8% and at 6 months it was 8.1 vs 6.1% and 
20.7 vs 18.1%. The table shows adjusted hazard ratios (95% Cl) for death and death/Ml 
by prior CABG. Comparing ept vs placebo in pts with prior CABG, the 30 day mortality 
was 4.1 vs 6.3%, 30 death/Ml was 15.0 vs 16.5%. Conclusions: Pts presenting with 
ACS and prior CABG have significantly worse baseline characteristics than non-prior 
CABG pts Prior CABG pts have significantly higher mortality at 30 days and 6 months 
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despite adjusting for differences in baseline characteristics and treatments. The treat- 
ment effects of ept among prior CABG pts were consistent with the overall PURSUIT 
trial. 
Outcomes in Patients with prior CABG vs No prior CABG 
Event Adjusted Hazard Ratio (95%CI) P-Value 
Death (30 day) 1.45 (1.06-1.98) 0.019 
Death (6 mos) 1.32 (1.04-1.67) 0.021 
Death/Ml (30 day) 0.95 (0.80-1.13) 0.55 
Death/Ml (6 mos) 1.02 (0.88-l .19) 0.78 
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duration without cardiogenic shock were randomized to primary PTCA, PTCA + Abx, 
stenting with the MultiLink or MultiLink Duet stent, or stenting + Abx. DM was present in 
346 pts (16.6%). The primary clinical endpoint was the 6 month composite incidence of 
death, disabling stroke, reinfarction and ischemia requiring NR. Results. Compared to 
non-DM pts, the 6 month rate of MACE was increased in the diabetic (17.1% vs. 12.3%. 
p<O.O2). Considering the individual components of the primary endpoint, death occurred 
in 4.9% of pts with DM vs. 2.9% of pts without DM(pz0.06); disabling stroke occurred in 
0.3% vs. 0.2% respectively (p=O.99); reinfarctio” 2.0% vs. 1.7% (p=O.70); and ischemic 
TVR 11.9% vs. 10.2% (p=O.O37). The outcomes in DM and non-DM stratified by treat- 
ment appear in the table: 
6 Month Results 
Diabetics All PTCA All Stent No abciximab Abciximab 
(“=162) (n=i 84) (n=162) (rl=l84) 
Death 3.7% 6.0% 3.7% 6.0% 
Disabling stroke 0% 0.5% 0.6% 0% 
Reinfarction 2.5% 1 .6% 1.9% 2.2% 
lschemic NR 17.3% 7.1%* 13.0% 10.9% 
MACE 20.4% 14.1%‘* 17.3% 16.8% 
Non-diabetics All PTCA All Stent No abciximab Abciximab 
(rl=883) (“=853) (“=866) (“=870) 
Death 3.2% 2.6% 3.5% 2.4% 
Disabling stroke 0.1% 0.4% 0.1% 0.4% 
Reinfarction 1 .7% 1.8% 1.3% 2.2% 
lschemic NR 12.1% 5.9%t 10.2% 7.9%tt 
MACE 15.5% 9.O%/,t 13.9% 10.8%$ 
*p=O.O003 vs. all PTCA; *‘p=O.12 vs. all PTCA: tp<O.OOOl vs. all PTCA; ttp=O.ll vs. 
no Abx; Sp=O.O53 vs. no Abx. 
Conclusions. Stent implantation in pts with AMI, compared to PTCA alone, significantly 
reduces ischemic TVR within 6 months in both pts with diabetes (31% relative risk reduc- 
tion) and non-diabetes (51% reduction). A potential benefit of abciximab in reducing 
MACE at 6 months was evident in non-diabetic pts, but not in those with diabetes. 
838-3 
4:30 p.m. 
Effect of Stent Implantation and Glycoprotein llb/llla 
Receptor Blockade on TIMI Flow and Mortality After Primary 
PTCA in Acute Myocardial Infarction: Final Results of the 
CADILLAC Trial 
Cindy L. Grines, David A. Cox, James E. Tcheng, Eulogio Garcia, Thomas Stuckey, John 
Carroll, Giulio Guagliumi, Barry Rutherford, Paolo Esente, Alexandra J. Lansky, John 
Griffin, Gregg W. Stone. The Cardiovascular Research Foundation and Lenox Hi// Heart 
and Vascular Institute, New York City, NY, William Beaumont Hospital, Royal Oak, MI 
Background. Long-term mortality after repetfusion therapy in AMI is directly related to 
the early achievement of TIMI- flow. In the randomized Stent PAMI Trial, post procedural 
TIMI -3 flow rates we”? reduced in Palmaz-Schatz stented pts compared to those under- 
going PTCA only, which resulted in a strong trend toward increased mortality after stent- 
ing, offsetting the benefit of reduced restenosis. However, GP Ilb/llla inhibitors were 
rarely used in Stent PAMI, and lower profile, better performing stents have since bee” 
infroduced. Methods. To determine the optimal reperfusion strategy in AMI, 2,082 pts of 
any age with symptom duration ~12 hrs without cardiogenic shock were randomized at 
76 international centers in a 2x2 factorial design to primary PTCA alone (n=516), PTCA + 
abciximab (n=529), stenting with the MultiLink or MultiLink Duet stent (n=512), or stent- 
ing + abciximab (n=525). Results. By core lab analysis, TIMI- flow was restored in 
95.6% of pts, TIMI- flow was present in 3.0%, and TIMI- was present in 1.4%. Mortal- 
ity at 6 months occurred in 68 pts (3.3%); 2.9% of pts with post procedural TIMI- flow 
died, vs. 6.7% with TIMI- flow and 7.1% with TIMI-O/l flow (~~0.04). TIMI flows and 6 
month mortalities by treatment arm appear in the table: 
ORAL CONTRIBUTIONS 
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838-l A Prospective, Multicenter, International Randomized Trial 
Comparing Four Reperfusion Strategies in Acute 
Myocardial Infarction: Principal Report of the Controlled 
Abciximab and Device Investigation to Lower Late 
Angioplasty Complications (CADILLAC) Trial 
Gregg W. Stone, Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, 
Thomas Stuckey, John Carroll, Giulio Guagliumi, Barry Rutherford, Gary Johnson, Mark 
Effro”, Paolo Es&e, Alexandra J. Lansky, John Griffin. The Cardiovascular Research 
Foundalion and Lenox Hi// Heart and Vascular Instifufe, New York City, NY 
Background: Prior studies have show” that stent implantation in AMI, while reducing 
recurrent ischemia and restenosis compared to PTCA alone, may degrade antegrade 
blood flow and result in increased mortality. These studies were done with first generation 
stent technology, and without the routine use of GP llbillla inhibitors. Methods: To deter- 
mine the optimal reperfusion strategy in AMI, 2082 pts of any age with AMI cl2 hrs with- 
out cardiogenic shock were randomized at 76 sites to primary PTCA alone (n=516), 
PTCA with abciximab (n=529), stenting alone (n=512), or stenting with abciximab 
(n=525), and followed for’12 mos. The stent used was the MultiLink and MultiLink Duet. 
Angiographic inclusion criteria included native ref. vessel dia. >2.5 mm or ~4.5 mm, Isn 
length ~65 mm, non-ostial location, and absence of major side branch involvement. The 
primary endpoint was the 6 mo composite Incidence of death, disabling stroke, reinfarc- 
tion, and ischemic TVR. Protocol 6 mo angiographic follow-up was performed in a 962 pt 
subset to assess myocardial recovery and restenosis. Results: Mean age was 60 + 12 
yrs (range 21-95), 27% were female, 17% had diabetes, and 37% had anterior Ml. 
Median time from symptom onset to ER was 1.8 hrs, and from ER to PTCA 2.0 hrs. By 
core lab analysis, TIMI- flow was restored in 95.3% of pts after PTCA, 96.3% after 
PTCA + abciximab, 94.6% after stenting, and 96.1% after stent + abciximab (all p=NS). 
The primary clinical endpoint data appear in the table 
6 Month Events 
PTCA PTCA + Abciximab stent Stent + Abciximab 
Death 4.3% 2.3% 2.7% 3.8% 
Disabling stroke 0.2% 0% 0.2% 0.6% 
Reinfarction 1 .6% 2.1% 1.2% 2.3% 
lschemic TVR 14.0% 11 .9% 7.2%t-t 5.0%** 
MACE 18.4% 14.2%* 10.4%7 9.5%* 
‘p=O.O6 vs. PTCA alone; tp=0.0002 vs. PTCA alone; $p=O.O2 vs. PTCA c abciximab; 
ttp=0.0005 vs. PTCA alone; #p<O.O001 vs. PTCA + abciximab. 
Conclusions. Compared to primary PTCA alone, MultiLink stent implantation during AMI 
results in a marked reduction in ischemic TVR and MACE at 6 mos, without adversely 
affecting TIMI flow or survival. The outcomes tend to be further improved with abciximab, 
especially in pts undergoing PTCA alone. Complete 12 mo clinical results, and 6 mo 
angiographic data will be presented for the first time in March. 
8389 
4:15 p.m. 
Does Stenting and Glycoprotein llblllla Receptor Blockade 
Improve the Prognosis of Diabetics Undergoing Primary 
Angioplasty in Acute Myocardial Infarction? The CADILLAC 
Trial 
Thomas Stuckey, Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, John 
Carroll, Barry Rutherford, Giulio Guagliumi, Paolo Esente, Alexandra J. Lansky, John 
Griffin, Gregg W. Stone. The Cardiovascular Research Foundation and Lenox Hill Heart 
and Vascular Institute, New York City N): Moses Cone Memorial Hospital, Greensboro, 
NC 
Background. Although the prognosis of pts with AMI and diabetes mellitus (DM) is 
improved with primary PTCA compared to thrombolytic therapy, long-term outcomes are 
still poor compared to non-DM. Patients with DM undergoing elective PCI may benefit by 
stent implantation (reduced TVR) and abciximab (Abx; prolonged survival). Methods. To 
examine whether similar benefits of stems and Abx are conferred in an AMI population, 
we examined the CADILLAC database. in which 2,082 pts of any age with AMI ~12 hrs in 
PTCA PTCA + stent stent + 
TIMI- flow 
6 month death 
6 month cardiac 
death 
95.3% 
4.3% 
4.1% 
Abciximab 
96.3% 
2.3% 
2.3% 
94.6% 
2.7% 
2.3% 
Abciximab 
96.1% 
3.8% 
3.2% 
TIMI- flow’ 
6 month death 
6 month cardiac 
All 
PTCA 
95.8% 
3.3% 
3.2% 
All 
stent 
95.4% 
3.3% 
2.8% 
NO 
Abciximab 
95.0% 
3.5% 
3.2% 
All 
Abciximab 
96.2% 
3.0% 
2.8% 
death 
There were no statistically significant differences between any groups. Conclusions. 
Coincident with improved stent technology, post procedural TIMI flow rates are no longer 
reduced by stent implantation in AMI, and survival is excellent with all mechanical reper- 
fusion strategies in patients without cardiogenic shock. 
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4:45 p.m. 
Abciximab Use During Percutaneous intervention in 
Patients With Acute Myocardial infarction Improves Early 
and Late Clinical Outcomes: Final Results of the CADILLAC 
Trial 
James E. Tcheng, Mark Effron, Cindy L. Grines, Eulogio Garcia, Dawd Cox, Thomas 
Stuckey. John Carroll, Giulio Guagliumi, Barry Rutherford, Alexandra J. Lansky, Paolo 
Esente, John Griffin, Gregg W. Stone The Cardiovascular Research Foundation and 
Lenox Hi// Heart and Vascular Insfitute, New York City, NY, Duke Univers~fy Med~cai 
Center, Durham, NC 
Background. Abcixrmab (Abx) improves clinical outcomes in pts undergoing elective 
percutaneous intervention. We hypothesized that the adtunctive use of Abx during prw 
mary PTCA and stenting in AMI would improve the early safety profile of the procedure 
and reduce late adverse events. Methods. In the CADILLAC trial, 2082 pts of any age 
with AMI ~12 hrs onset without cardiogenic shock were prospectively randomized in a 
2x2 factorial design to primary PTCA or MultrLink stenting, and to Abx or no Abx. The pri- 
mary endpoint was the 6 month composite occurrence of death, disabling stroke, reinf- 
arcticn, or ischemia requrring TVR. Results. A total of 1,054 pts were assigned to Abx 
(529 to PTCA and 525 to stent), and 1,028 pts were assigned to no Abx (516 to PTCA 
and 512 to stent). By core lab analysis: TIMI-3 flow was restored in 96.2% of pts 
assigned to Abx vs. 95.0% assigned to no Abx (p=O.18). Results by intention to treat 
appear in the table: 
No Abciximab Abciximab P Value 
30 day death 23 (2.2%) 19 (1.8%) 0.48 
30 day drsabling stroke 2 (0.2%) 2 (0.2%) 0.99 
30 day reinfarciion 6 (0.6%) 7 (0.7%) 0.81 
(9%) TIMI 2 and 106 (31%) TIMI O-.1 flow. Rescue PTCA was attempted in 91/106 (86%) 
lytic failures and achieved TIMI 3 flow in 81191 (89%). Long-term follow-up (up to 10 
years) was available in 96% of this cohort. Results: IO-year actuarial survival was 
81+3%, 85+3% without cardiovascular death, 76&3% without cardiovascular death or inf- 
arction, 58+4% without death. infarctron or revascularization (event-free survival). 
Kaplan-Meier analysis shows srmilar event-free survival among patients in whom TIMI 3 
when achieved by lysis alone vs lysis+rescue PTCA (p=O.65). Likewise, survival was sim- 
ilar among patients with successful lytic therapy (TIMI 3 flow) or attempted rescue PTCA 
(p=O.85). Muftivanate analysis of predictors of event-free survival demonstrated that fail- 
ure of lytrc therapy to achieve patency was not a predictor of long-term survival rn this 
cohort with a high rate of rescue PTCA. Conversely, final (i.e. post rescue) TIMI flow, sex, 
age, number of diseased vessels and left ventricular function were uni- and multivariate 
predictors of survival and event-free survival. 
Chi-Square P 
Nbr diseased vessels 62.6 <0.0001 
LV function 6.4 <O.Ol 
Male gender 8.9 0.003 
Interaction TIMI flow-Nbr Diseased vessels 6.1 0.01 
Interaction TIMI-LV function 62 0.01 
TIMI 1.1 0.28 
Conclusion: Routine rescue PTCA of patients with failed lytic therapy achieves Similar 
long-term survival to successful lysis for acute myocardial infarction. 
ORAL CONTRIBUTIONS 
30 day rschemic TVR 
30 day MACE 
30 day severe bleed 
43 (4.2%) 25 (2.4%) 0.02 
69 (6.7%) 45 (4 3%) 0.01 
4 (0.4%) 6 (0.6%) 
846 New Aspects of Glycoprotein Ilb/llla 
0.75 Inhibitors in Acute Coronary Syndromes 
6 month MACE 148 (14.4%) 125 (11.9%) 0.09 
The reduction in the 30 day MACE rate with abciximab was more pronounced in pts 
Tuesday, March 20, 2001, 8:30 a.m.-IO:00 a.m. 
assigned to PTCA (4.3% vs. 8.1%, relative reduction [RR] 47% p=O.Ol) than in those Orange County Convention Center, Room 230D 
assrgned to stenting (4.2% vs. 5.3%, RR 21%, p=NS), as was the reduction in 6 month 
MACE (14.2% vs. 18.4% RR 23%. ~~0.06, and 9.5% vs. 10.4%, RR 9%, p=NS, respec- 
tively.) Conclusion. In patients without cardiogenic shock undergoing mechanical reper- 
fusion therapy for AMI, abciximab use during intervention improves early and late clinical 
outcomes, especially after primary PTCA, without increasing complications 
838-5 
500 p.m 
Early Stenting Versus Conservative Treatment After 
Thrombolysis in Acute Myocardial infarction 
Bruno Scheller, Benno Wennen, Bernd Hammer, Hans-Peter Stall, Torsten Markwirth, for 
the SIAM Ill study group. University of Sax/and, Internal Medicine 111, Homburg/S&q 
Germany 
Objectives: Thrombolysis in acute myocardial infarction (AMI) is limited by TIMI Ill-flow 
rates of 60% and reocclusion of the infarct related artery. Prior studres showed no benefit 
of PTCA following thrombolysis compared to thrombolytic therapy alone in AMI. Recent 
studies, however, have demonstrated superiority of primary stenting versus PTCA alone 
in AMI. The objective of the SIAM Ill study (South West German Interventional Study rn 
Acute Myocardial infarction) is to compare the strategy of early coronary stenting [group 
I) witn a conservative treatment (group II) following thrombolysis in AMI. Methods: SIAM 
III is a multicenter. randomized, prospective, controlled study. Inclusion criterion is throm- 
bolysis within 12 hours from the onset of symptoms in AMI. Patients of group I are trans- 
ferred to the interventional center within 6 hours after thrombolysis for coronary 
angiography including stenting of the infarct related artery. Group II has elective coronary 
angiography aiter two weeks with stenting of the infarct related artery at this time. Prr- 
mary endpoint is a combined endpoint of death, reinfarction, and target lesion revascuiar- 
izatron. Findings: So far (august 2000) 166 pts have been randomzed. During a mean 
follow-up time of 159t97 days, early stenting was associated with a significant reduction 
of the combined end point (22.1% vs 37.7%, p=O.O35) of death (5.9% vs 11.6%, ns), 
reinfarctron (2.9% vs 2.9%, ns), and target lesion revascularization (16.2% vs 24.6% ns) 
The incidence of ischemic events leading to unplanned rehosprtalization or angiography 
was significantly reduced in group I (2.9% vs 34.8%, p=O.Ol). Bleeding complications 
occurred in 10.3% of pts in group f vs 7.2% in group II (ns). TIMI III flow rates at the two 
week angiography were 98.5% in group I vs 59.0% in group II (p=O.Ol). Left ventricular 
ejectron fraction two weeks after AMI was 56.7ili .5% in patrents undergoing early stent- 
ing compared to 52.5+13.4% in the conservative group (p=O.O6). Conclusions: Early 
stenting after thrombolysis in AMI is safe. This preliminary data indicate a clinical benefit 
by thus approach compared to conservative treatment after thrombolysis in AMI. 
838-6 
5:15 p.m. 
Long-Term Survival After Routine Rescue PTCA for Failed 
Thrombolysis is Similar to That of Successful Thrombolysis 
846-i 
8:30 a.m. 
Immediate Reduction of Microvascular Resistances 
Following Abciximab Administration in Unstable Angina. 
Insight Into the Mechanism of Action of GPllb/llla Inhibitors 
Mario Marzilli, Gianmario Sambuceti, Roberto Testa, Silvio Fed&. Cardio Thoracic 
Depf, Universify of Piss, Piss, /tail: lnsfitute of Clinical Physiology, CNR, Piss, l&/y 
Background: Platelet glycoprotein Ilb/llla blockers have been proven to be beneficial in 
acute ischemic syndromes. Their favourable effects have been attributed to passivation 
of the active plaque and reduction of the thrombus burden.However~ recent studies have 
shown that benefits from GP Ilbillla blockers are independent from the presence of 
thrombus and from plaque morphology. The purpose of this study was to investigate the 
mechanism of action of GP llbillla blockers by srmultaneous assessment of their effects 
on the stenotic coronary segment and the distal coronary vasculature. Methods:Nlne 
patients with refractory unstable angina underwent cardiac catheterization and angio- 
plasty. The resistances to flow of the stenotic segment and of the distal coronary vascula- 
tune were measured at baseline, during hyperventilation, and during intracoronary 
adenosine, before and after abciximab administration. Measurements were repeated 
after PTCA. Results: Hyperventilation consistently induced an ischemic attack and 
increased trans.stenotic (14.91-i 98.2 mmHglml/min vs 6.327.0 mmHg/ml/min, p&05) 
and drstal (11.2&8.3 mmHg/ml/min vs 8.0+7.2 mmHg/ml/min, ~~0.05) coronary resis- 
tances to flow. Abciximab had no significant effect on stenosis resistance while it 
promptly reduced distal coronary resistance under all study conditions, includrng base- 
kne (6.0+5.9 mmHg/ml/min, pcO.O5), hyperventrlation (5.9k5.6 mmHg/ml/min, p<O.Ol), 
and adenosine-induced vasodrlation (3.7i3.8 mmHg/ml/min vs 5215.4 mmHg/mVmin, 
~~0.05). Moreover,the hyperventrlation test became negative in all patients after abcix- 
imab administration, prior to PTCA. Conclusion: The observations of this study demon- 
strate that abciximab administration result in an immedrate reduction of coronary 
microvascular resistance to flow and prevents active coronary vasoconstriction Improve- 
ment of micro&cular function may play a prominent role rn the beneficial effects of 
abcrximab rn acute rschemic syndromes. 
846-2 
8:45 a.m. 
Optimal Dosing of a Glycoprotein Ilb/llla Antagonist With a 
Simplified Renal-Based Algorithm: Pharmacodynamic and 
Clinical Findings From PARAGON B 
Christopher K. Dyke, Kenneth W. Mahaffey, Lisa G. Berdan, Magnus Ohman, Kristin 
Newby. Rodney A. Sparapani, Peter B. Berger, Neal S. Kleiman, Harvey D. White, Judith 
S. Hochman, Frans van de Werf, Paul W. Armstrong, Robert M. Califf, Robert A. 
Harrington. Eric J. Topol. Duke C/in&/ Research Insfifufe, Durham. NC 
Philrppe G. Steg, Laurent Francois. Bernard lung, Patrick Gharlier. Pierre Aubry, 
Dominrque Himbert, Hakim Benamer. Laurent J Feldman. Jean-Michel Julrard. Hop&/ 
B/chat Paris, France 
Background: PARAGON A and PARAGON B evaluated the glycoprotein llbillla antago- 
nist lamifrban in patients with non-ST elevation ACS. In a post hoc analysis, PARAGON 
A demonstrated a relationship between plasma concentration and clinical outcomes. 
The plasma concentration of lamifiban in a range of 18-42 ngiml was associated with 
Background: Failed thrombolysis is associated with decreased short- and long-term sur- marked reductions in ischemic outcomes. Methods: PARAGON B was designed to pro- 
vival. Rescue PTCA has been tested in small clinical trials, but no information is avarIable spectively test that a renal-based dosing algorithm could provide an optimal lamifiban 
on the long-term outcome after rescue PTCA for failed thrombolysis. Methods: 362 con- concentration that would be associated with an accentuation of small molecule glycopro- 
secutive Pts with acute myocardial infarction receiving fytic therapy for acute infarction tein llbillla benefit The primary endpoint was a composite of death, MI, or severe recur- 
were studred. 95% underwent 90 min angiography and 208 (60%) had TIM 3 flow. 31 rent ischemia (SRI). Results: Steady state concentrations were reported in 1272 of 2628 
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Methods: The PURSUIT risk score was calculated for 313 consecutive Olmsied County, 
MN patients presenting to our insiitution with non-ST elevation AMI between 1988 and 
1998. The predicted mortality was then compared with the actual mortality. 
Results: 
PURSUIT risk Number of Estimated 30-day mortality, by Actual 30-day 
SCOV? patients PURSUIT risk ?.core (%) mortalitv I%) 
patients who received lamiflban. Target conceniration was achieved in 919 (72%). Base- 
line differences associated with a significant likelihood of being out of range included age, 
sex, and renal Insufficiency (CRI).,There were no significant statistical differences in the 
primary endpoint but in a subset of troponin positive patients, an increase in events was 
seen in the ~18 nglml group. No stalisticai differences were s?en in bleeding. 
<18 18-42 >42 Placebo 
(n=i 10) (n=919) (n=243) (n=2568) 
% Total PK Data 8.7 72.2 . 19.1 NA 
Death/Ml/SRI (%) 11.9 10.7 9.1 12.8 
TnT+ Death/Ml/SRI* (%) 19.7 8.7 7.9 19.4 
Age>80 (%) 2.7 5.7 9.1 7.2 
Female (%) 23.6 33.4 46.1 34.3 
CRI (%) 0 0.8 4.5 1.9 
*For lamifiban-treated patients with PK and trooonin data. Conclusions: Renal-adiust- 
merit of the lamifiban infusion rate was successful in achieving target conceniration in the 
majority of patients. However. age>80, female sex, and CRI remained predictors for 
higher than anticipated serum concentrations despite formula corrections. High-risk 
patients (troponin positive) with sub-target lamifiban concentrations experienced more 
frequent adverse ischemic events and had similar outcomes as placebo. These findings 
highlight the imporiance of adequate dosing of a glycoprotein llbillla antagonist. 
Marco Roffi, L. Kristin Newby, Robert A. Harrington, Harvey D. White, Christian W. 
Hamm, Eric J. Topol. Cleveland Clinic Foundation, Cleveland, OH 
Background: Previous trials have shown that GP llbillla are particularly beneficial in the 
medical management of non-ST elevation acute coronary syndromes (&iCS) patients with 
elevated troponin. However, ihis benefit could not be reproduced in GUSTO IV ACS. We 
therefore performed a systematic overview. Methods: We included in a m&a-analysis 
the troponin positive populations of the so far periormed non-interventional GP Ilb/llla tri- 
als assessing troponin status systematically, namely PRISM (tirofiban for 48 hours), PAR- 
AGON B (lamifiban for up to 72 hours), and GUSTO IV ACS (abciximab for 24 or 48 
hours). The diagnostic threshold for troponin positivity was troponin-I level of 1 .O UgiL in 
PRISM, and troponin-T level of 0.1 pg/L in PARAGON B and GUSTO IV ACS. Results: 
As shown in the figure, the Incidence of death/Ml in troponin positive patients was highly 
significantly reduced by GP Ilb/llla inhibitors in PRISM and PARAGON B (p<O.OOl and 
p<O.O16, respectively) but not in GUSTO IV ACS (p=O.26). Driven by the latter trial, the 
m&-analysis showed no overall benefit (~~0.16). The impact of GP llblllla blockade was 
strikingly heterogenous across the trials (as documented by Breslow-Day test p<O.OOl). 
Unlike the previous trials, m GUSTO IV ACS troponin positivity was per se an inclusion 
criteria. This led to a different patient population enrollment with a clearcut lower event 
rate (9.7 vs. 13-19 % in the placebo group), less responsive to GP llbillla inhibition. Alter- 
natively or additionally, the different benefits may be due to variable drug action. 
846-3 
9:oo a.m. 
An Integrated Clinical Approach to Predicting the Benefit of 
Tirofiban: Application of the TIMI Risk Score for Unstable 
Angina/Non-ST Elevation MI in PRISM-PLUS 
David A. Morrow, Elliott M. Amman, Carolyn H. McCabe, Eugene Braunwald, Pierre 
Theroux. Brigham & Women’s Hospital, Boston, MA, Mmtreal Heart Instifufe, Montreal, 
PO, Canada 
Risk assessment at presentation may guide selection of patients (pts) for whom effective 
but expensive theraples are most beneficial. The TIMI Risk Score for UAINSTEMI identi- 
fies pts who benefit from treatment with enoxaparin but has not been evaluated for ther- 
apy with intravenous GPllbilla inhibitors. Methods: The TIMI Risk Score is a simple 
integer ?.core for predicting the risk of death and recurrent ischemic events based on the 
sum of 7 clinical characteristics at presentation (age=< 65, >=3 cardiac risk factors, 
severe angina1 symptoms, documented CAD, ST deviation z-0.5 mm, elevated cardiac 
markers, prior ASA use). We evaluated Ihe risk score in 1570 pts with UAINSTEMI 
treated with tirofiban + heparin vs. heparin alone in PRISM-PLUS for predictmg both the 
risk of recurrent events and the benefit of tirofiban. In addition, we assessed the prognos- 
tic capacity of the 6 remaining variables in pts with negative cardiac markers. Results: 
By 14 days, 288 pts (18.4%) had experienced death, new MI, or refractory ischemia (Di 
MI/RI). Stratification by the TIMI Risk Score, revealed both a highly significant gradient of 
inwasing risk for D/Ml/RI (Fig A), and a strong pattern of increasing benefit of tirofiban 
with rising risk score (P,,teract = 0.05, Fig B). Among pts with normal cardiac markers 
(N=lO60), the risk ?.core established a similar 3.5.fold gradient of increasing risk for D/Ml/ 
RI (p < 0.001). Further, the risk score (>= 4) identified a population with normal cardiac 
markers that derived significant benefit from tirofiban (RR 0.73, p = 0.027). Conclu- 
sidns: Applied in pts from PRISM-PLUS ihe TIMI Risk Score: 1) showed a strong prog- 
nostic capacity and revealed an increasing benefit of tirofiban wth rising risk score; 2) 
performed well as a simple clinical tool to aid in the early identification of pts without ele- 
vated cardiac markers who should be considered for therapy with more potent antiplate- 
let therapy. 
846-4 
9:15 a.m. 
Use of the PURSUIT Risk Score Can Provide Accurate Early 
Risk Stratification in a Nonselected, Community-Based 
Population With NonST Elevation Acute Myocardial 
Infarction. 
Emmanouil S. Brilakis, Stephen L. Kopecky, Brent A. Williams, Jason Vinar, Ian P. 
Claments. Mayo Clinic, Rochester, MN 
Background: In a recent post-hoc analysis of the PURSUIT (Platelet glycoprotein llbi 
llla in Unstable Angina: Receptor Suppression Using lntegrilin (eptifibatide) Therapy) 
trial, a risk stratification scheme was proposed. Using 7 clinical parameters [age, gender, 
worst CCS (Canadian Cardiovascular Society) class in past 2 weeks, heart rate, systolic 
blood pressure, signs of heari failure, and ST-depression on presenting ECG] a risk score 
was calculated, which showed strong association with 30.day mortality. However, 
patients included in the PURSUIT trial had to fulfill specific inclusion criteria. The goal of 
our study was to examine the predictive accuracy of the PURSUIT risk score in a com- 
munity-based population with non-ST elevation acute myocardial infarction (AMI). 
o-3 40 0.5 0.0 
4-7 66 2.0 00 
8-11 94 4.5 6.5 
12-15 69 8.0 8.7 
16-20 44 19.0 20.7 
Conclusion: In a community-based population with non-ST segment elevation AMI the 
PURSUIT risk scow allowed an excellent prediction of 30.day mortality. The PURSUIT 
risk score can be used in non-selected patient populations with non-ST elevaiion AMI for 
accuraie early risk stratification. 
846-5 
9:30 a.m. 
Striking Heterogeneity of Responsiveness to Glycoprotein 
Ilb/llla Inhibition in Patients With Acute Coronary 
Syndromes and Positive Troponin 
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Conclusions: The data in aggregate demonstrate substantial heterogeneity in troponin 
positive ACS patients for response to llbillla blockade. Troponin responsiveness to llblllla 
blockade has only been validated by retrospective assessment in ACS trials; further trials 
prospectively assessing the value of troponln in ACS are warranted. 
846-6 
9:45 a.m. 
Reversibility of Platelet Inhibition Associated With Small 
Molecule, Competitive GPllb/llla Antagonists: An In Vitro 
Model for Clinical Management Strategies 
Richard C. Becker, You Fu LI, Frederick A. Spencer. University of Massachusetts Medical 
School, Worcester, MA 
Background:Platelet surface glycoprotein (GP) Ilb/llla (p Ilbib,) receptor inhibition, by 
preventing fibrinogen binding, attenuates hemostatic potential. Because small molecule 
antagonists have relatively low GPllb/llla receptor affinity (and high circulating plasma 
concentrations), it has been assumed that: 1)platelet transfusions would not effectively 
restore physiologic aggregability, and 2) alternative substrates would be required to man- 
age hemorrhage events. Methods: Washed platelets from 24 healthy volunteers were 
suspended in tyrodes buffer and incubated with steady state concentrations (in viva) of 
tirofiban or eptifibatide prior to activation with TRAP (15bM). In a separate series of 
experiments, platelet inhibition 290% (in response to 5pM ADP) was achieved with 
tiroflban or eptifibatide. Recovery of platelet aggregation was determined following fibrin- 
ogen and/or platelet supplementation. Results: Platelet inhibition was reversed by the 
addition of fibrinogen in a concentration-dependent manner. Recovery of platelet aggre- 
gability toward a physiologic level was achieved with fibrinogen (0.76-0.80 g/L), platelets 
(2.4 x lO”/L) or their combinaiion. The finditigs are summarized below: 
Recovery of Platelet Aggregation (%) 
Treatment FgN (0.75 g/L) Pit 1 (1.2 x 1o”ii) FUN + PI,. Pll P 2.4 Y 10”/1) FgN + Pit. 2 
(A) (6) (C) (W (E) 
Mean +,- so 30 8 f 12.4 28.9 ii- 10.5 405+,-11.0 54.4 +,- 12.9 67.3 +,- 12 1 
(A) vs. P=O.S9 P<O.OS P<0.00003 P<O.O001 
(B) “S PC005 P<0.0001 P<O.O001 
(0) “S P&O5 P<O 0001 
(0) “S P<O.O5 
JACC February 2001 
Conclusions: Effective reversibility of small molecule. competitive GPllb/llla antagonlsts 
and restoration of platelet-mediated hemostatic potential can be achieved with either 
fibrinogen supplementation (equivalent of 8 units fresh frozen plasma) or platelet transfu- 
Zion (equivalent of 8 units pooled platelets). Combined administration should be consld- 
ered in the setting of life-threatening hemorrhage or when hemostasis is comprised in 
association with major surgery. 
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1182-81 Off-Pump Versus On-Pump CABG Surgery: Determinants 
and Surgical Outcomes Among 51 Surgeons Doing Both 
Procedures 
Michael J. Mack, April W. Swnon, Edmund Ft. Becker, Steven D. Culier, Lynn G. 
Tarkington, Salvatote Battaglia, Michael P. Macris, Sameer Mehta. Medica/ City Dallas, 
Da//as, JX, Emory University Rollins Schooi of Pub/k Heaifh, Atlanta, GA 
Background: The growth !n off-pump CABG (OPCAB) raises questions about when it is 
appropriate versus an on-pump (OnP) approach. Of those surgeons who use both 
OPCAB and OnP techniques, what factors influence their decision? We compare sur- 
geons who perform both OPCAB and OnP surgery to evaluate differences in patient 
characteristics and surgical outcomes. Methods: The 1999 HCA Case Mix Database 
contains data from 75 facilities and 17,609 CABG surgeries (DRGs 106, 107, and 109). 
For surgeons who performed 10 or more OPCAB and 10 or more OnP surgeries in 1999, 
we compared their OPCAB and OnP performance for 19 patlent characteristics and 14 
surgical outcomes. Results: The 51 surgeons performed 5,508 CABGs, an average of 
30 OPCAB and 78 surgeries OnP OnP use increased for surgeons as the number of 
bypassed vessels increased (see table) Patients with preop AMI were significantly more 
likely to be OnP and OnP patlents were more likely to have neurological complications. 
POSTER SESSION 
1182 Coronary Bypass Operation Without 
Extracorporeal Circulation 
Tuesday, March 20, 2001, 9:00 a.m.-l I:00 a.m. 
Orange County Convention Center, Hall A4 
Presentation Hour: 1O:OO a.m.-l 1:OO a.m. 
1182-79 Beating Heart Versus Conventional Coronary Artery 
For these surgeons, death rates OnP were more than double their OPCAB rates. Of the 
Bypass: Early Versus Late Postoperative Neurological 
remaining 33 variables analyzed, none were statistically significant (p=O.O5). However. 
acute renal failure and percentage of patients discharged directly home without further 
Complications structured medical support were trending toward significance. Conclusion: For surgeons 
Garrett K. Peel, Sotiris C. Stamou, Peter C. Hill, Ammar S. Bafi, Mercedes K. C. Dullum, 
Albert J. Pfister, Steven W. Boyce. Jorge M. Garcia. Paul J. Corso. Washington Hospiiai 
Center, Washington, DC 
performing both OPCAB and OnP, there are significant differences in both mortality and 
neurologic complications. Given these results, further research is needed to determine 
which patients are best suited for this surgical approach. 
OPCAB OnP 0 Value 
Background: Coronary artery bypass grafting without cardiopulmonary bypass (Off- 
diovascular disease study group estimated risk of cerebrovascular accident was 1.9% for 
pump CABG) has been associated with comparable or lower rates of postoperative neu- 
rological complications compared to the conventional approach (On-pump CABG). It is 
both groups. Results: The rate of neurological complications was 4.9 % (n=l94) for the 
unknown, however whether the timing of occurrence of neurological complications is dlf- 
ferent between these two approaches. Methods: New neurological complications were 
On-pump group Vs. 2.7 % (n=42) for the Off-pump group and stroke rate was 2.3% 
considered as a single end point and were categorized with respect to whether they were 
detected withln the first 2 days after surgery (early) or more than 3 days, after an initial, 
(n=93) Vs. 1.3% (n-21), respectively. Of patients who had neurologic complications the 
uneventful neurological recovery from surgery (delayed). We compared the occurrence 
of early and delayed neurological complications after On-pump (n=3980) Vs. Off-pump 
CABG (n=1563) between January 1998 and July 2000. The two groups were similar with 
respect to baseline characteristics and risk stratification; the Northern New England car- 
#of Bypass Vessels 2.51 3.43 <O.OOl 
PreOp AMI 23.12% 25.60% 0.036 
Acute Renal Failure 2.72% 4.05% 0.071 
Neuro Compilcations 0.66% 1.81% 0.031 
Discharge Home 87% 84% 0.065 
Mortalitv 1.39% 3.06% 0.001 
1182-82 Outcome in Patients Undergoing Redo CABG With and 
~ I. Without Cardiooulmonarv Bvoass 
Martin Czerny, Daniel Zimpfer, Vedat Sahin. Harald Baumer, Juliane Kilo, Andreas 
Zuckermann, Ernst Wolner, Michael Grimm Department of Cardiothoracic Surgery 
University of Vienna, Vienna, Austria 
incidence of early or delayed events between on and off-pump CABG is summarized in 
table (ail analyses were significant at the level of p<O.OOi). Conclusions: Among 
patients experiencing neurological complications after surgery, Off-pump CABG patients 
are at a iower risk of immediate but are at a higher risk of late postoperative neurological 
complications than On-pump CABG. Different mechanisms may be implicated in the 
pathogenesls of neurological adverse events between the two approaches. 
All Neurological complications 
Stroke (deficit> 72 hours) 
On-pump (n=194) Off-pump (n=42) 
Early Delayed Early Delayed 
118 (61%) 76 (39%) 6 (14%) 36 (86%) 
52 (56%) 41 (44%) 3 (14%) 18 (86%) 
1182-80 A Large Unselected Series of Consecutive OPCAB Patients 
Demonstrates Reduced Hospital Morbidity and Mortality 
Mark W. Connolly, Valavanur A. Subramanian, Nilesh U. Patel, John C. McCabe, Mark H. 
Genovesi, Didier F Loulmet, Rita M. Considine, Archana Maini. Lenox Hi// Hospital, Mew 
York, NY 
Objective: To assess the potential benefits of multivessel CABG without cardiopulmo- 
nary bypass (OPCAB), a committed, intentlon-to-treat OPCAB program was begun for all 
patients requiring multivesssel primary CABG. Methods: In a retrospective analysis 430 
unselected, consecutive OPCAB patients (July 1999-July 2000) were compared to 453 
conventional CABG patients (July 1997.July 1998). The OPCAB patients were slgnifi- 
cantly older (66.7 yrs. vs. 64.5 yrs.) and had a higher incidence of more than one previ- 
ous MI (10% vs 6%), diabetes mellitus (39% vs 34%), HTN (77% vs 70%), CHF (81% vs 
45%), and renal failure (8.4% vs 2.6%). The mean number of grafts performed was less 
in OPCAB (3.2 + 0.9 vs 3.4 + 0.9, p< 0.0001). Conversion to CPB occurred in 11 patients 
(2X%, one death). Results: Compared to conventional CABG, OPCAB including CPB 
COnverSiOn patients had a significantly less overall complication rate (451430, 11% vs 861 
453, 19%, pcO.OOl), deep sternal infection (51430, 2.3% vs 161453, 5.3%, p&03), reop 
for bleeding (101430, 1.2% vs 241453, 3.5%, pcO.O2), percentage of patients transfused 
(50% vs 67%, pcO.OOOl), mean number of PRBC’s units transfused per patient (3.1 + 3.2 
vs 1.8 + 5.5, p<O.O002), and operative mortality (8/430, 1.9% vs 20/453, 4.4%, p<O.O3). 
Approaching significance (p<O.O7), OPCAB had a lower stroke rate of 1.4% (61430) com- 
pared to 3.1% (141453) for CABG. As OPCAB had a higher risk profile. risk-adjusted 
operative mortality (NYSCSRS) was 1.3% compared to 3.9% for CABG. Mu&regression 
analysis demonstrated age, ejection fraction, calcified aorta, and conventional CABG as 
significant factors for operative mortality (p<O.OOOl). Length of stay was also less in 
OPCAB (6.1 days vs 7.5 days, p&0001). Conclusion: Even including conversion to 
CBP patients, this large, retrospective series of consecutive, unselected OPCAB patients 
achieved significantly lower hospital complications and mortality compared to conven- 
tional CABG. Methods to prevent conversion to CPB may further improve results. 
Background: The aim of this study was to compare morbidity, mortality and functional 
status after redo coronary artery bypass grafting (CABG) with and without cardiopulmo- 
nary bypass in a retrospective study design. Methods: We compared morbidity, mortality 
and functional status in 53 elective patients having undergone redo CABG between Jan- 
uary 1998 and April 2000. Twentyfour patients underwent redo CABG with and 29 
patients underwent redo CABG without CPB. Mean EURO score was 7.5+/-0.7 in 
patients with and 7.0+/-0.6 in patients undergoing CABG without CPB (ns). Parsonnet 
score was 15.4+1-l .2 and 15.0+/-1.4, respectively. Follow-up was defined by means of 
survival, freedom from recurrence of angina (Canadian Cardiovascular Society Score), 
freedom from rehospitalisations and reinterventions as well as need for antianglnal medl- 
cation. Patient follow-up was performed either by telephone or a mailed questionnaire. 
Follow-up was complete in all patients. Results: There were 3 perioperative deaths in the 
group with CPB and 1 perioperative death in the group wlthout CPB (ns). Those 4 
patients who died, had a significantly higher EURO score than the survwors- EURO 
score 10.3+/-0.5 “s 7.0+/-3.3 (P=.OOOl). Parsonnet score l&8+/-6.7 “s 14.9+/-6.7 (ns). 
In the group of patients operated with CPB, 83% of patients received complete revascu- 
larization. In the group without CPB, 14% received complete revascularization 
(P=.OOOOl). The mean follow-up period in patients with CPB was 19 months and 14 
months in patients without CPB (ns). During follow-up, death was not observed. At the 
time of follow-up, mean CCS score in patients having undergone redo CABG with CPB 
was 1.4+/-0.8 and in patients without CPB 1.6+/-0.8 (ns). Patients after redo CABG with- 
out CPB had a higher use of nitrates at follow-up (P=.O13). Conclusions: Myocardial 
revascularization without cardiopulmonary bypass may represent a safe and effective 
therapeutic modality for patients requiring redo CABG, resulting in lower hospital morbid- 
ity and mortality. Despite the lower number of bypass grafts and the higher use of nitrates 
in p&ants without CPB, medium-term outcome is well comparable to patients having 
undergone redo CABG with CPB. 
1182-83 Minimally Invasive Direct Coronary Artery Bypass Versus 
Off-Pump Coronary Artery Bypass: A Study in Clinical 
Appropriateness in 226 Patients 
Kevin A. Richardson, Robert E. Michler, Randall K Wolf, David A. Brown. Ohio State 
University Medical Center, Columbus, OH 
Background: Coronary artery bypass without the aid of extracorporeal circulatory sup- 
port is gaining popularity as an alternative to conventional on-pump techniques. These 
techniques include minimally invasive direct coronary artery bypass (MIDCAB) and 
median sternotomy, off-pump coronary artery bypass (OPCAB). This study evaluated 
these two surgical methods and compared climcal outcomes for patients with single ves- 
sel left anterior descending artery (LAD) disease. 
Methods: Outcomes were analyzed for patients with LAD disease who underwent MID- 
CAB (n=l58) vs OPCAB (n=70) between January 1, 1997 and June 30, 2000. These 
groups were similar in risk stratification and patient characteristics. Data was collected 
prospectively and analyzed using Chi-Square and Fisher Exact tests. 
346A ABSTRACTS - Myocardial lschemia and Infarction 
Results: During this time period, 1537 bypass procedures were performed, 303 were 
done without cardiopulmonary bypass. Of these, 226 were performed for isolated LAD 
disease. The incidences of postoperative complications for MIDCAB vs. OPCAB were as 
follows: reoperation rate, 1.92% vs 1.43% (p=O.OS), graft occlusion, 2.56% vs 0 (p=O.33); 
myocardiai infarction, 0.64% vs 0 (p=O.17); atrial fibrillation, 3.21% vs 4.29% (~~0.08); 
infection, 1.28% vs 0 (p=O.O3): neurologic events, 0.64% vs 2.86% (p=O.22); renal failure, 
0.64% vs 1.43% (pzO.09); prolonged ventilation 0 vs 1.43% (p=O.17); chronic pain syn- 
drome, 3.21% vs 0 (0.29): mortality, 0.64% vs 2.86% (p=O.OS). The postoperative length 
of stay for the MIDCAB “s OPCAB groups was 3.91 +/- 3.34 days “s 4.45 +I- 2.24 days. 
Conclusion: Our experience with minimally invasive surgery shows there is no cllnically 
significant difference between MIDCAB and OPCAB approaches. Although some have 
claimed an advantage with the MIDCAB technique with respect to patient recovery and 
cosmetics, our raw data would suggests a trend toward less morbidity with the OPCAB 
method. Prospective randomized trials will further delineate this issue. 
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total lactate production was increased in Ml-Control vs. Sham-Control (28+5 vs. 16?3 
mm/gLV; ~~0.05). After blockade of glycolysis lactate production was almost absent and 
identical between Sham-Glyc and MI-Glyc (2il vs. 2il; ns). 
Conclusion: Chronically infarcted hearts exhibit an increased tolerance towards subse- 
quent ischemtc injury compared to normal hearts. Our results suggest that increased gly- 
colytic activity in the non-infarcted myocardium contributes to the improved ischemic 
tolerance of chronically infarcted hearts. 
1183-86 Cyclosporin A Inhibits Cytochrome c Release and Prevents 
Myocardial Cell Death Induced by IschemialReperfusion 
Zhe Jiao, Olena M. Gorodnya, Xi-Ming Yang, Tal-Hwang M. Fan. University of South 
Alabama, Mobile, AL 
Background: The mitochondrial permeability transition pore (MPTP) plays a pivotal role 
in both apoptosis and necrosis. Persistent MPTP opening causes swelling and uncou- 
pling of mitochondria and results in necrosis. TranSient MPTP opening may lead to apop- 
tosis via release of cytochrome c. The present study examined whether cyclosporin A 
(&A), a calcineurin inhibitor and a potent MPTP inhibltor, could attenuate the release of 
cytochrome c and prevent myocardial cell death induced by ischemiaireperfusion. Addi- 
tionally, we tested whether FK506, another immunosuppressive drug that acts via cal- 
clneurin inhibition while havmg no effect on the MPTP, could also protect the heart. 
Methods: Adult rabbit hearts perfused in the Langendorff fashion were subjected to 30 
min of global ischemia followed by 2 h of reperfusion. CsA or FK506 were given as a 15- 
min infusion prior to the onset of global ischemia. Infarct size was determined by com- 
puter morphometry of TTC s!ained sections. Cytosolic cytochrome c levels were deter- 
mined by Western blot analysis in a separate series of hearts, in which serial biopsies 
were taken at baseline and at 5, 10, 20, 30, 60. SO, 120 min of ischemia. Results: Com- 
pared to the control group, the CsA and FK506 groups demonstrated significantly better 
preserved contractile function following reperfusion. The infarct size was significantly 
smaller in the CsA group (7rl%, n=6) as compared to the control group (50*5%, n=6) 
and the FK506 group (19r5%, 1x8). In the control hearts, ischemia caused a progressive 
rise in the cytosolic cytochrome c levels during the initial 30 min of Ischemia, reaching a 
peak of 4.5.fold the pre-ischemic level. CsA completely abolished the rise in cytosolic 
cytochrome c levels. In contrast, FK506 had little effect on cytochrome c release induced 
by ischema. Conclusion: The calcineurin inhibitors CsA and FK506 are excellent car- 
dioprotective agents against ischemiaireperfusion injury. The apparent superiority of CsA 
over FK506 may be attributable to the unique inhibitory action of CsA on the MPTP. 
Drugs that interfere with cytochrome c release may be good targets for screening for clin- 
ically useful anti-Infarct agents. 
1183-87 Cardioprotection by an Adenosine A2A Receptor Agonist in 
a Canine Model of Myocardial Stunning Produced by 
Multiple Episodes of Transient lschemia 
David K. Glover, Mlrta Ruiz, Kazuya Takehana, Frank D. Petruzella, Jayson M. Rieger, 
Timothy L. Macdonald, Denny D. Watson, Joel Linden, George A. Belier. University of 
Virginia, Charlottesville. VA 
Background: Stimulation of adenosine ApA receptors on inflammatory cells is inhibitory. 
We hypothesized that infusion of a highly potent and selective adenosine Azn agonist, 
ATL146e, would inhibit post-ischemic cardiac inflammation and therefore improve left 
ventricular (LV) function in a canine model of myocardial stunning. 
Methods: Accordingly, 22 open-chest dogs underwent either 4 or 10 cycles of 5 minute 
left anterior descending coronary artery (LAD) occlusions (OCC) interspersed by 5 or 10 
minutes of reperfusion (REP). Left ventricular thickening was measured with ultrasonic 
crystals beginning at baseline and continuing for 180 minutes after the last occlusionlrep- 
erfusion cycle. Regional flow was measured with mlcrospheres. In 11 of the 22 dogs, 
ATL-146e was infused i.v. prior to occlusion #l and continued throughout reperfusion at a 
dose below that which produces vasodilatation (0.01 pgikglmin). 
Results: Myocardial flow was similar between control and ATL-146e treated animals at 
all times, confirming the absence of vasodilatation. During occlusion, there was severe 
dyskinesis with marked LAD zone thinning in all animals. As shown in the table. there 
was significantly greater recovery of LAD zone thickening after reperfusion with ATL- 
146e in both the 4 (56% vs Sl%)and 10 cycle (-5% vs 59%) occlusion-reperfusion 
groups. 
Recovery of LAD Zone LV Thickening During Reperfusion (% Baseline) 
OCC-REP Treatment # Dogs 5 min REP 180 min REP 
4 cycles’ Control 6 35+8t 56*12t 
4 cycles’ ATL-146e 6 57*9t 91t7t* 
10 cycles’ Control 5 6*12t -5+11t 
10 cycles2 ATL-146e 5 4711 oy 59&t 
t p < 0.01 vs Baseline; 7 p < 0.05 Control vs ATL-146e. 
Notes:’ OCC=5 min;REP=lO mm *OCC=5 min;REP=5 min 
Conclusion: The striking amount of functional recovery obs’erved with ATL-146e sup- 
ports its further evaluation for the attenuation of post-ischemic stunning after reperfwon 
therapy in patients. 
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1183-84 Protective Effects of Adenosine on Myocardial &hernia and 
Reperfusion in the Dogs 
Hela Aschour, Ali Denktas, Abid Ass&, James Amirian, Patty Felli, Maximilan Buja, 
Margaret Uthman, Richard W. Smalling. University of Texas Medical School, Houston, TX 
Background: Although intracoronary adenosine has been shown to improve angio- 
graphic evidence of coronary blood flow post repetius~on in humans, its physiologic and 
mechanism of action is unknown at the present time. 
Objective: To evaluate the effect of intracoronary adenosine boius prior to repetfusion 
and its effect on white blood cell (WBC) activation, Icam-l expression, end diastolic wall 
thickness (EDWT) and infarct size. 
Methods: Fourteen open chest dogs were subjected to two hour occlusion of mid-left 
anterior descending (LAD) artery followed by four hours of reperfusion. 
The dogs were instrumented with sonomicrometer crystals to measure EDWT in the LAD 
artery and circumflex (CX) regions. Hemodynamic measurements were done at baseline, 
ten minutes after occlusion, and then at one hour intervals until the end of the experi- 
ment. Twenty-four micrograms of adenosine were injected over two minutes distal to the 
cuff occluder just prior to reperfusion in the treated animals and an equal volume of 
saline in the control ammals. 
The findings were compared using analysis of variance. 
Results: Ten minutes after caperfusion, there was an abrupt increase in the EDWT in 
both control and adenosine groups that is a sign of irreversible reperfusion injury. The 
Icam-l measurements by immunohistochemistry were significantly higher in the control 
group compared to the adenosine group (P=O.OOOl). Myeloperoxidase production (WBC 
activation) was reduced significantly in the infarct and ischemic regions with the adenos- 
ine compared to saline(P<O.OS,P<O.Ol respectively). A trend towards a reduction in mf- 
arct size was noted when expressed as a percentage of the area at risk (control 
48.04%+9.24%, adenosine 58.20%~13.37%,P<O.O7). 
Conclusions: In this study, we demonstrated that 24ug of intracoronary adenosine injec- 
tion prior to reperfusion provides an intermediate benefit in infarct size reduction com- 
pared to saline administration. This can be due in part to a suppresion of neutrophil 
activation and adhesion (reperfusion injury) to endothelial cells. 
1183-85 Protective Effect of Increased Glycolysis in Chronically 
Infarcted Hearts 
Franz R. Eberli, Regina Berchtold, Gert Printzen, Thomas Schaffner, Bernhard M&r. 
Swiss Cardiovascular Center Bern. Bern, Switzerland 
Background: Following a myocardial infarction (Ml) hearts increase their capability to 
generate energy via the glycalytic pathway in the non-infarcted myocardium. We hypoth- 
esized that this metabolic remodeling might convey an increased tolerance towards a 
subsequent ischemia-reperfusion injury. 
Methods: 8 weeks after Sham operation or experimental infarction isolated, blood per- 
fused rat hearts were exposed to 30 min of ischemia (10% of initial flow) and 30 min of 
reperfusion. Hearts with intact glycolysis and normal substrates (glucose, lactate, palmi- 
tate) (Sham-Control [n=lO] and Ml-Control [n=lO]) were compared to hearts with blocked 
glycolysis (Sham-Glyc [n=l l] and MI-Glyc [n=7]). Glycolysis was blocked by infusing 
100 $M iodoacetate over 15 min after pretreatment with glucagon during glucose free 
periwon. 
Results: Infarct size in Ml-Control vs. MI-Glyc was similar (30+3% vs 28+3% of LV; ns). 
Ml-Control hearts exhibited less ischemic diastolic dysfunction than Sham-Control hearts 
(LVEDP at end ischemia 30+5 vs. 46+7 mmHg; p<O.O5). In contrast, when glycalysis was 
blocked, ischemic diastolic dysfunction was increased in MI-Glyc compared to Ml-Control 
(~~0.05) and similar to Sham-Glyc (52+3 vs. 54-i5 mmHg; ns). Recovery of LV developed 
pressure was similar in Sham-Control vs. Ml-Control (73-t4% vs 77?2%; ns), and 
reduced to similar level in Sham-Glyc and MI-Glyc (52i-3% vs. 42+9%; ns). The improved 
tolerance towards ischemia of Ml-Control hearts could not be explained by differences in 
residual coronary flow and oxygen consumption. However, glycolytic flux, as indexed by 
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118388 Pretreatment With Delta-Opioid Receptor Blockade 
Attenuates the Reduction of Apoptosis Associated With 
lschemic Preconditioning or Morphine-Induced 
Cardioprotection in Rabbit IschemiaKleperfusion Model 
Shlnji Okubo, Yujirou Tanabe, Nakaba Fujioka, Noboru Takekoshi, Rakesh C Kukreja. 
Kanazawa Medical University, Uchinada, Japan 
We have proposed that myocardiai protection associated with ischemic precondition- 
ing&PC) in rabbit hearts involved in the delta-opioid receptor. We examined whetherlPC 
attenuates irreversible ischemic reperiusion injury in part by decreasing apopiosis and 
whether the delta-opioid receptor can regulate ihe apoptosis formation in cardloprotec- 
tion. SIX groups of rabbits were studied All rabbits underwent susialned coronary artery 
occiu$ion(CAO) for 30 min followed by 180 min of reperfusion. IPC was elicited with 4 
cycles of 5 min regional ischemia plus 10 min reperfusion before sustained GAO. i)Con- 
trol(C)(n&), 2)IPC(n=8), 3)Morphine (treatment with 3 mgikg, iv, 15 min before sustained 
ischemia)(Mor) (we), 4)Naioxone( treatment with 10 mg/kg, iv, 10 min before 
IPC)(Nal+lPC) (n=8). To determine If the delta-opioid receptor has a role in IPC and mor- 
phine-induced cardioprotection, naltrindole(NTI), a selective delta-opioid receptor antag- 
onist was utilized: 5)NTl(treatment with 10 mg/kg. iv, 10 min before IPC)(NTI+IPC) (x8), 
and 6)NTl(lO mg/kg. iv)+Mor(3 mgikg, iv) were given 15 min before sustained CAO(n=8). 
Infarct size(infarct size as a percent of the area at risk ) was significantly(p<O.Ol) reduced 
in preconditioned and Mor treated group compared with control, Nal+lPC, NTI+IPC and 
NTi+Mor group (C:46% “s PC:12% “s Mor:15.3% “s Nal+iPC:48.5% vs. NTl+lPC:44.5% 
vs NTl+Moc49.3%). The percentage of Apop Tag-labeled cells(DNA fragmentation) was 
determined with a microscope containing an eyepiece grid@200 magnificalion).The per- 
centage of apoplotic cells was calculated for the ischemic region. The findings of DNA 
fragmentation were significantly(p<O.Ol) decreased in ischemic preconditioned group 
and Mor treated group compared with control, Nal+lPC, NTI+IPC and NTI+Mor group 
(C:22% “s PC:7.2% “s Mor:l0.2% “s Nal+lPC:18.5% “s NTl+lPC:20.3% “s 
NTl+Mor:lB%). This study suggests thai IPC reduces lethal ischemic injury in part by 
decreasing apoptosis(DNA fragmentation) after ischemiaireperfusion and activation of 
the delta-oploid receptor may play a crucial role in IPC or morphine-Induced myocardial 
protection in the rabbit. 
1183-89 Intravenous Use of Dimethylsulfoxide to Improve Outcome 
of Acute Myocardial lschemia in a Porcine Model 
Dennis W. Dunning, George Eyster, Kevin L. K&o, Echo Hansen, Earl T. Hawkins, 
Shirley Siew, Lynn Cronin, William W. O’Neiil. Wiam Beaumont Hospifai, Roya/ Oak, Ml, 
Michigan State Universify - College of Veterinary Medicine, East Lansing, M/ 
Background: Relief of ischemia by tissue reperfusion is the mainstay of therapy to 
reduce necrosis in an acute myocardial infarct (AMI). Blood and 02 returning to injured 
tissue can lead to further cellular damage and lethal arrhythmias. We hypothesrzed that 
treatment with dimethylsulfoxide (DMSO), an antioxidant, anti-inflammatory, and mern- 
brane stabilizer, would improve outcome in AMI. Methods: We caused myocardial 
ischemla in 3 groups of pigs by 30.minute inflation of an intra-coronary balloon in the dis- 
tal LAD. One group served as controls and 2 treatment groups received intravenous (IV) 
DMSO as a pre-treatment (early group) or 15 minutes after the start of balloon inflation 
(late group). ECG and arterial BP were monitored during the procedure. Two-D echocar- 
diagrams were done before the cath and ~30 minutes after balloon deflation. After 48 
hours the hearts were harvested and stained with triphenyl tetrazolium chloride (TX) to 
determine areas of necrosis and myocardium at risk. Routine H&E staining was done. 
Results: The pre-treatment group had less necrosis (8.3% +I- 6.7), as a percentage of 
area at risk, compared to controls (24.3% +/- 10.2, P= 0.0367). The late group (30.6% i/ 
- 9.1) was not significantly dlfferent from controls. Histology validated TTC staining. The 
combined end-point of VF or VT during reperfusion was higher in controls (77.8%) vs 
either treatment group (early 28% and late O%, P=O.O18). Further analysis showed the 
difference 10 be most significant in the late group (P=O.OZl). ST segment change in the 
early group was less vs controls (2 mm vs 4.22 mm, P~O.043). Wall motion index was 
increased similarly in early and control groups, but less in the late group (P=O.O23). 
Blood pressure did not decrease with DMSO. Conclusions: IV DMSO may be useful in 
limiting myocardial necrosis and arrhythmia’s during tissue reperfusion. The potection 
against cell death is greatest when given as a pre-treatment before the onset of 
&hernia, bul benefits extend to late treatment as well. 
1183-90 Diazoxide Preserves Oxidative Phosphorylation and the 
Structural Integrity of Cardiac Mitochondria From Anoxic 
Injury 
Cevher Ozcan, Ekhson L Holmuhamedov, Arshad Jahangir, Andre Terzic. Mayo C/ink, 
Rochester, MN 
Background: Myocardial energetics, which primarily rely on oxidative phosphorylation, 
are highly vulnerable to anoxia. Mitochondrial ATP-sensiiive potassium channel (mito- 
KATP) openers have emerged as powerful cardioprotective agents, yet direct evidence 
demonstrating the ability of mite-KATP openers to preserve mitochondria against anoxic 
injury is lacking. Methods: Mitochondria ware isolated from rat hearts, subjected to 20 
min anoxia followed by reoxygenation, and mitochondrial function and structure 
assessed using selective-minielectrodes. fluorometry, HPLC, and electron microscopy. 
Results: in the absence of a potassium channel opener, anoxia/ reoxygenation 
decreased the rate of ADP-stimulated oxygen consumption, inhibited ATP production and 
disrupted mitochondrial membrane Integrity On average, anoxia inhibited ADP-stimu- 
lated respiration from 291+1-14 to 141 +/-I5 “g-atoms 02lminlmg pritein and decreased 
the rate of ATP production from 752+/-14 to 414+/-34 “moles ATPlminimg protein. Fol- 
lowing anoxia, ihe majority (88%) of mitochondria were damaged or swollen with only 
12% remaining intact. Diazoxlde (iOOuM), added prior to anoxia, maintained ADP-stimu- 
lated respiralion at 255+/-7 “g-atoms 02/min/mg protein and ATP production at 640+/-39 
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nmoles ATPlminimg protein. Diaroxide also preserved mitochondrial structure, so that 
following anoxia 67% of mltochondria remained with an intact morphology and adenylate 
kinase confined to the mitochondria. Conclusion: The present study demonstrates that 
diazoxide prevents anoxia- Induced functional and structural deterioration of isolated car- 
diac mitochondria. By directly protecting mitochondria, the prototype mite-KATP channel 
opener could maintain myocardial energetics under condiiions of reduced oxygen avail- 
ability, with powble implications in myopreservation. 
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1184-91 Right Ventricular Performance Is Preserved During Stress in 
Patients With Chronic Proximal Right Coronary Occlusion 
Soo-Terk Lim, Pamela Marco& William W O’Nelll, James A. Goldstein. WiNiam 
Beaumont Hospital, Royal Oak, MI 
Introduction: In patients with proximal right coronary artery (RCA) occlusion and right 
ventricular (RV) infarction, resting RV performance typically improves over time, even 
without reperfusion. However, whether exercise RV performance during stress is pre- 
served in patients with chronic total proximal right coronary artery (RCA) occlusion is 
unknown. Methods: In 20 patients with angiographically documented chronic proximal 
RCA occlusion, RV free wall (FW) wall motion (lznormal, Pzhypokinetic, 3=akinetlc, 
4=dyskinetic) was analyzed at rest and peak exercise during stress echocardiography. 
Anglograms were analyzed for the location of total occlusion relative to the RV branches, 
as well as the presence of collaierals. Results: The RCA was 100% occluded proximal to 
the RV branches in all cases. Prominent collaterals to the occluded RCA were noted in 
19120 (95%) patients. Resting RVFW motion was normal in 16120 (80%) pts. whereas 
mild abnormalities were present in 4 others. For the entire group, RVFW motion was 
intact (RVFW motion score = 1.13+/-0.31). At peak stress, RVFW motion increased 
appropriately in 18/20 (90%) of cases, including all 4 pts with resting RVFW abnormall- 
ties. However, 2 (10%) patients with normal resting RVFW motion developed exercise 
induced wall motion abnormalities. Nevertheless, for the entire group, overall RVFW 
motion score improved during stress (r&=1.13+/-0.31 to 1.06+/-0.18, ~~0.05). Conclu- 
sion: In patients with chronic proximal RCA occlusion, RV free wall performance is typi- 
cally maintained at rest and responds physiologically to stress, undoubtedly reflecting the 
beneflclal effect of collaterals. The few patients in whom RVFW contraction abnormalities 
developed during exercise likely reflect collateral insufficiency. Given the importance of 
RV performance under conditions of severe LV dysfunction, these findings may have 
implications for patients with chronic multivessel ischemic heart disease and severe 
ischemic cardiomyopathy. 
1184-92 Exercise Thallium-201 Myocardial Image Is Useful for 
Predicting Adverse Outcomes in Patients With Vasospastic 
Angina 
Akihiro Nakagomi, Satoshi Aoki, Yoshito Yamane, Takeshi Yamamoto, Nobuhiko Fujita, 
Chikao Ibuki, Yoshiki Kusama, Morimasa Takayama, Kouichi Nagasawa, Teruo Takano. 
Nippon Medical School, Tokyo, Japan, Tama-Nagayama Hospital, Nippon Medical 
School, Tokyo, Japan 
The usefulness of exercise thallium-201 myocardlal image (ETM) for predicting adverse 
outcomes in patients (pts) with vasospastic angina (VSA) was examined. Ninety pts with 
VSA were enrolled in this study. VSA was defined as typical chest pain at rest and on 
exertion and positive for intracoronary acetylcholine provocation testing and normal coro- 
nary angiogram (~25% luminal stenosis) after the intracronary administration of nitroglyc- 
erin (NTG). Multiple factors including ETM findings, clinical characteristics, blood 
chemical variables and coronary flow reserve (CFR) using a Doppler flowwire were ana- 
lyzed in a prospective study fashion. Sever&en segments of the left ventricle were seml- 
qualitatively scored on ETM study on a scale ranging from 0 (normal) to 4 (absent) 
uptake, and the sum of each segment was defined as defect score (DS). Seventy-three 
patients were stabilized by Ca antagonist and/or nicorandil, however, 17 patienis did not 
respond to these medications and need sublingual NTG during angina1 attacks and 2 
patients suddenly died probably due to fatal arrhythmia. The relation between DS, clinical 
characteristics, blood chemical variables, CFR and adverse outcomes (refractory to anti- 
angina1 therapy and death) was analyzed using univariate and multiple logistic regression 
analysis. Univariate analysis mdicated that white cell count (p=O.Ol), plasma fibrinogen 
level (p<O.Ol) at presenatation, delta BS (30 minutes blood sugar value-fasting blood 
sugar value, p=O.O2) and delta IRI (30 minutes insulin value- fasting Insulin value. 
~~0.04) during 75g of glucose tolerance test, CFR (p<O.Ol) and DS (p<O.OOl) were 
associated with adverse outcomes. However. the only variable independently associated 
with adverse Outcomes in multlvariate analysis was DS (p=O.Ol). These data indicated 
that ETM is useful for seleciing therapeutic strategy and predicting adverse outcomes in 
patients with vasospastic angina. 
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1184-93 Electromechanical Left Ventricular Mapping With 
Dobutamine Stress for Detection of Myocardial Viability 
Khaled R. A. Nour, Julian P. J. Halcox, Shmuel Fuchs, Vandana Sachdev, Julio A. Panza, 
Vasken Dilsizian, Rita Mincemoyer, Ran Kornowski, Arshed A. Quyyumi. Cardiology 
Branch, National lnstitubs of Health, Bethesda, MD, Washington Hospital Center, 
Washington, DC 
6ackground:NOGA left ventricular (LV) electro mechanical mapping (EM) has been 
used to detect viabillty in hypoperfused dysfunctional myocardial regions by’demonstrat- 
ing preserved voltage (unipolar UpV) in segments wth reduced local shortening (LS). We 
hypothesized that “lability defined by echo and radio nuclide testing can be detected by 
EM during dobutamine stress. 
Methods:We performed detailed EM (mean 81 points) in 6 patients with normal coronary 
arteries (NCA), and 31 with coronary artery disease (CAD): 14 with normal LV and 17 
with impaired LV function (EF<45%). 26 patients underwent repeat EM during dob- 
&mine infusion (5 to15 mcglmin, mean 7.1). Ectopy was more frequent during dob- 
u&mine, but adequate EM was performed (mean 71 points in < 18 min). Using 
echocardiography and stress-redistribution-reinjection thallium scintigraphy, 533 seg- 
ments (16imap) were Independently defined as: A= normal contractility without inducible 
ischemia, B= normal contractility with inducible ischemia, C= asynergic with preserved 
thallium uptake (viable/hibernating), or D= asynergic with severely reduced thallium 
uptake (scar). 
Results: (see Table) Compared to patients with NCA, UpV and LS in ischemlc and viable 
segments (B,C) were significantly lower. Furthermore, normal segments in CAD (A) had 
lower UpV than NCA patients. Compared to viable/hibernating segments (C), UpV 
iended to be lower, p=O.O8 in scarred segments (D). Dobutamine increased LS in NCA 
patients, in non-ischemlc (A), reversibly ischemic (B), and hibernating (C) segments (Indi- 
eating contractile reserve), but not in scars (D). UpV increased with dobutamine in all 
segments in CAD patients and did not help discriminate viabillty. 
Conclusion: UpV is lower in normally contracting segments in CAD compared to NCA 
patients, perhaps indicating subtle myocardial injury. Low-dose dobutamine mapping is 
feasible and may hblp discriminate hibernating from scarred myocardium. Table: 
*=pcO.O5 compared to NCA, #=p<O.O5 compared to baseline. 
NCA CAD 
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UPV (mV) 
LLS (%) 
Change in LLS (%) 
A B C D 
19.5*7 13.7+6* i3a* 8.8~4’ 7.1*4* 
12.2+8 11.2~7 9.li6* 7.4r6’ 4.&6* 
3.5# 2.5# 2.6# 1.8# -0.4 
1184-94 ST Segment Slope Alone Detects Exercise-Induced 
Myocardial lschemia in Bddy Surface Potential Mapping 
Helena Hanninen, Pan” Takala, Petri Korhonen, Lasse Oikannen, Juha Montonen, 
Markku Makijarvi, Jukka Nenonen, Kim Simeiius, Toivo Katila, Law To~vonen. Helsinki 
University Centrai Hospital, Helsinki, Finland, Helsinki University of Technology Espoo, 
FhlH7d 
Background: Horizontal or descending conflguraiion of the ST segment is an additional 
indicator of myocardial ischemia in stress ECG. We studied the capability of the ST slope 
to detect exercise-induced ischemia in body surface potential mapping (BSPM). Meth- 
ods: BSPM with 123 channels was recorded in 24 single vessel coronary artery disease 
(CAD) patients with no previous myocardial infarction and in 17 healthy controls during 
supine bicycle exercise &sling. Of 24 patients 11 had a stenosis in left anterior descend- 
ing, 7 in right, and 6 in lefl circumflex coronary artery. The ST segment was defined as 
the second quarter from QRS offset to T wave apex. The ST slope was calculated I” 
each recording location by fitting a regression line to the signal averaged ST segment 
data immediately after stress. Discriminant index, indicating the capability of each sensor 
site to separate a patient subgroup from other patients and controls, was calculated in 
each measurement location. First, the mean slope of the control group was subtracted 
from the mean slope of the patient subgroup. The difference was then divided by the 
standard deviation of the slope in all subjects. Results: In the CAD group and in patient 
subgroups the most sensitive locations for ischemia were at lefi inferior side below stan- 
dard EGG leads V5 and V6 (ST slope CAD “s Controls 285*310 “s 1060+340 uV/s: 
p<O.O005), and in the middle of superior back (ST slope CAD vs controls -230+250 vs - 
940+340 “V/s; p<O.O005). The ST slope was more horizontal in the CAD group and in 
the patient subgroups than in the control group (all pcO.005). In the control group the ST 
slope was mole rapidly ascending in the anterior and more rapidly descending in the 
posterior thorax compared with the patient groups. With ihe cut off value 800 “V/s, the 
slope at left side separated the CAD group from controls with sensitivity of 96% and 
specificity of 76%. Over the back at cut of value -600 uV/s the corresponding values were 
92% and 94%, respectively. Conclusion: In BSPM, the ST segment slope alone, without 
information on ST segment level, is a sensitive indicator of transient myocardial ischemia. 
The indicator is best exploited with BSPM, covering areas outside the conventional 12 
lead EGG. 
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1185-95 The Smoker’s Paradox: Angiographic Findings and 
Outcome of Patients With Acute Coronary Syndromes with 
Respect to Smoking Status 
Christopher Heeschen, Eric Boersma, John i? Cooke, Christian W. Hamm, Maarten L. 
Simoons. Stanford University School of Medicine, Stanford, CA, Kerckhoff Heart Cenfeer. 
Bad Nauheim, Germany 
Paradoxically, tobacco use is independently associated wiih iower mortality in patients 
with acute coronary syndromes. It is assumed that this difference is due to lower plaque 
burden and less complex lesion characteristics in smokers. Accordingly, we invesrigated 
the database of the CAPTURE trial, which enrolled patients who had a functional single 
vessel disease, for angiographic findings and the clinical outcome with respect to smok- 
ing status. Results: 42% of the 1265 CAPTURE patients were smokers that were 
younger (61.0 vs. 65.1; P<O.OOi) and more often male (71.9 vs. 60.5%; P<O.OOl). During 
the first 24 hours prior to scheduled coronary intervention, smokers had significantly 
fewer coronary events (death, Ml; age and gender adjusted OR 0.26; P=O.OOZ). In con- 
trast, their risk for PTCA-associated complications was significantly hrgher (adjusted OR 
2.15; P<O.OOl). Results were similar for the 3232 PRISM patients: cardiac risk of smok- 
ers (69%) was lower during the initial 48.hour treatment period (with interventions being 
discouraged; adjusted OR 0.32; P<O.OOi) whereas in patients that were then treated 
interventionally, cardiac risk for smokers was elevated at 7-day follow-up (adjusted OR 
3.94; P<O.OOi). This difference was maintained during 30.day follow-up. Baseline Iropo- 
nin T levels were consistently lower in smokers (0.27 vs. 0.41 IgiL; P<O.OOl). For the 
CAPTURE patients, the characteristics of the target lesions did not differ between smok- 
ers and non-smokers (P&86). However, baseline TIMI flow was higher in smokers with 
73.5% showing TIMI 3 flow compared to 62.1% for non-smokers (P<O.OOl). Further, 
smoking status was an Independent predictor of cbllateral flow (partial or complete retro- 
grade filling; 16.4 vs. 8.0 %; smokers vs. non-smokers; P<O.Ol). Conclusions: After 
adjusting for other risk factors, smokersremained to be at lower risk during acute coro- 
nary syndromes. Despite similar lesion characteristics, they appear to have less troponin 
elevation, better preserved TIMI flow and a higher collateral Index. The recently reported 
proangiogenic effect of nicotine may explain these paradoxical findings in smokers. 
1185-96 The Effect of Aspirin on C-Reactive Protein as a Marker of 
Risk in Unstable Angina 
Simon R. 0. Kennon, Chris P Price, Kulasegaram Ranjadayalan, Jackie Cooper, Heather 
Clarke, Peter G. Mills, Adam D. Tim&. Barts and the London NHS Trust, London, 
United KIngdam 
Background: C-Reactive Protein release in acute coronary syndromes may be a 
response to myocardial necrosis or may reflect the inflammatory process that drives 
atherogenesis and predisposes to plaque rupture. Aspirin has the potential to influence 
C-Reactive Protein release, either directly by its antiinflammatory activity or indirectly by 
reducing myocardial necrosis. The clinical significance of this potential interaction has not 
previously been assessed. 
Methods: Prospective cohort study of 304 consecutive patients admitted wth non-ST- 
elevation acute coronary syndromes. Baseline clinical data were recorded and serial 
blood samples obtained for C-Reactive Protein and troponin I assay. End-points were 
cardiac death and non-fatal myocardial infarction during follow-up for 12 months. 
Results: 174 patients (57%) were taking aspirin before admission. Patients taking aspirin 
had lower troponin I concentrations throughout the sampling period, only 45 (26.0%) hav- 
ing concentrations >O.lmg/l compared with 48 (37.8%) patients not taking aspirin 
(p=O.O3). Maximum C-Reactive Protein concentrations were also lower in patients taking 
aspirin (8.16 mgil (3.24-24.5)) than in patients not taking aspirin (11:3 mg/l (4.15-26.1)) 
although the difference was not significant. However, there was significant interaction 
(p=O.O4) between prior aspirin therapy and the predictive value of C-Reactive Protein 
concentrations for ischaemic events (7 deaths and 21 nonfatal myocardial infarctions) at 
12 months. Thus odds ratios (95% confidence intervals) for events associated with an 
increase of 1 standard deviation in maximum C-Reaciive Protein concentration were 2.64 
(1.22 - 5.72) in patlents not pretreated with aspirin compared with 0.98 (0.60-i .62) in 
patients pretreated with aspirin. 
Conclusion: The association between C-Reactive Protein and cardiac events in patients 
with non-ST-elevation coronary syndromes is mfluenced importantly by pretreatment with 
aspirin. The effect of aspirin on iroponin release suggests that modification of acute 
phase inflammatory responses to myocardial injury is the major mechanism of this inter- 
acmn. 
1185-97 Elevated Troponin I Levels and Lesion Morphology in 
Unstable Angina 
Jose Arias, Tien H. Nguyen, Randy Gould, Ramy Doss, Pedro Mego, Marian Hawkey, 
John A. Ambrose. Saint Vincents Hospital, New York, NY 
Background: Elevated troponln levels (a sensitive marker of myocardial necrosis) in 
unstable angina have been shown to independently predict an adverse outcome and may 
be a marker for embolization to distal vascular beds. Positive correlations between ek- 
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vated troponin and rntracaronary thrombus have been reported but thrombus was 
present in no more than 20% of positive individuals. Complex lesions (eccentric, irregu- 
lar, overhanging edges, filling defects or ulcerations) are found in 50 to 70% of culprit 
lesions in unstable angma. Thus, this classificatron represents a more sensitive method 
for examining the relationship between an elevated troponrn and a disrupted/thrombotic 
(complex) lesion. Methods: 162 consecutive patients undergoing coronary angiography 
for unstable angina with an identifiable culprit lesion and troponin I values ware analyzed 
blindly to troponin levels obtarned prior to angrography. All patrents had normal creatine 
kinase levels. Lesions were classified according to whether or not complex or non-corn- 
plex by the same angiographer who analyzed all lesions in orthogonal views blinded to 
clinical information. Troponin I measurements ware based on MEIA technology. Results: 
See Table 1. An elevated troponin I as a predictor of a complex lesron had a sensitivity of 
71%, a specificity of 70%, a positive predictive value of 71% and a negative predictive 
value of 70%. Conclusion Thus, an elevated troponin I is a sensitive but only moderately 
specific marker for the presence of complex lesions confirmrng a relationship between 
thrombotic-appearing lesions and elevated troponrn. However, 24 of 82 complex lesions 
(29%) are not associated with an elevated troponin. These data expand on prior studies 
suggesting that an elevated troponin may be a marker of either drstal embolizatron of 
thrombotrc material andior other mechanisms resulting in transient reductions in myocar- 
dial oxygen supply leading to myocardral necrosis. Why some complex lesions do not 
elevate troponin requires further Investigation. 
syndrome than stable angrna. Conclusions; Coronary thrombi exsisted in nonischemic 
related vessels as well as culprit lesions in patients with acute coronary syndrome. These 
results indicate that acute coronary syndrome is not a local vascular accident, but a pan- 
coronary process. Infection and/or rnflammation play an important role in the outbreak of 
acute coronary syndrome. 
1185-I 00 Antibiotics Against Chlamydia Pneumoniae and 
Helicobacter Pylori Reduce Further Cardiovascular Events 
in Patients With Acute Coronary Syndromes 
Adam F. M. Stone, Michael Mendail, Juan-Carlos Kaski, Sandy Gupta, John Camm, 
Timothy Northfield. St George’s Hospital Medical School, London, United Kingdom 
Background: Infection with Chlamydia pneumoniae (Cp) and Helicobacter pylon (Hp) 
has been associated with coronary heart disease (CHD). We conducted a randomized, 
placebo-controlled Intervention trial to determine the effects of antibiotrcs (effective 
against Cp and Hp) on serum inflammatory markers and major adverse cardiac events 
(MACE) in patients with ac&! coronary syndromes (ACS). Methods: The study enrolled 
325 subjects presenting with ACS. Patients were randomized to one of 3 treatment rag)- 
mens, each lasting 1 week: 1). Aztthromycin 500mg od, Omeprarole 20mg bd, Metron- 
rdazole 400mg bd. (Anti-Cp) 2). Amoxycillin 500mg bd, Omeprazole 20mg bd, 
Metronidazole 400mg bd. (Anti-HP) 3). Placebo Changes in serum antibody titres of Cp 
and Hp, inflammatory markers (CRP, fibrinogen and white cell count) and MACE (read- 
mrssion wrth ACS, ooronary revascularisation or cardiac death) were recorded. Follow-up 
period extended to 12 months. All patients recerved standard treatment for CHD. 
Results: All three groups were matched for age and classical risk factors. There was no 
difference in frequency or timing of MACE between either the azithromycin or the amoxy- 
cillin treated groups compared with placebo. However, when combined, subjects receiv- 
ing either one or other actrve anttbiotic treatment regimens had a 40% reduction in MACE 
compared with placebo (p=O.O34). The full benefit was observed by 12 weeks and per- 
sisted to 1 year. No differences in mflammatory markers were noted Cp or Hp infection 
status had no effect. Conclusion: Short courses of combination antibiotics, given to 
patients presenting with ACS. are assocrated with better clinical outcome for up to 1 year, 
independent of infectron status. A larger trial is now merited to confirm these novel find- 
ings and to evaluate whether the benefits are related to ‘antimicrobial’ or ‘anti-inflam- 
mtory’ properties of antibiotrcs. 
Elevated Troponin I Normal Troponin I P-Value 
N 82 80 
Complex 58 (71%) 24 (30%) < 0.0001 
Non-Complex 24 (29%) 56 (70%) < 0.0001 
1185-98 Soluble Thrombomodulin is Elevated in Postmenopausal 
Women with Acute Coronary Syndromes but Is Not 
Associated With Adverse Outcomes nor Affected by Short 
Term Estrogen Therapy 
Eric T. Chou, Steven P Schulman, David Ft. Thismann, Michele F Bellantoni, Jeffrey J. 
Rade. Johns Hopkrx School of Medicine, Baltimore, MD, Weill Medical &liege of 
Cornell Univemfy, New York, NY 
Soluble thrombomodulin @TM) IS a marker of endothelial injury and may predict future 
adverse coronary events. Short term estrogen replacement therapy (ERT) has been 
shown to restore endothelial cell function to postmenopausal women with coronary 
artery drsease as well as to decrease sTM levels in women without coronary disease We 
retrospectively studied the effects of short-term ERT on sTM in postmenopausal women, 
not receiving ERT, who presented with erther unstable angina or non-Q Ml. Serum sTM 
levels were determined by ELISA in 70 postmenopausal women (mean age 69 years) 
wrth serum creatinine ~2.0 mgldl, who ware randomized to receive erther placebo or IV 
conjugated estrogen (1.25 mg) followed by oral conjugated estrogen (1.25 mg I progest- 
erone daily) for 21 days. Baseline sTM was compared to a cohort of 32 healthy post- 
menopausal age-matched controls rnot receivrng ERT. Paired baseline and day 21 sam- 
ples were available for 27 patients who were randomized to placebo or short term ERT. 
All patients were followed clinically for SIX months. Results: Baseline sTM in pabents with 
acute coronary syndromes was signrficantly elevated compared to healthy age-matched 
controls (4.8 r 2.4 vs. 3.1 * 0.9 rig/ml, pcO.001, respectively). Baseline sTM did not cor- 
relate with recurrent ischemia, as assessed by halter monitoring, nor was it associated 
inlith the combined endpoints of death, recurrent MI, or need for revascularization over a 
six month follow-up period. Furthermore, short term ERT did not significantly alter sTM 
levels compared to baselrne (delta sTM= 0.2 + 1.4 nglml for the estrogen group (n=16) 
vs. -0.2 i 1 .O nglml for placebo (n=l l), p=O.3). Conclusion: Soluble thrombomodulin is 
elevated in postmenopausal women with acute coronary syndromes but IS not associated 
with adverse cardiac outcomes nor significantly altered by short term estrogen therapy. 
1185-99 Acute Coronary Syndrome Is Not Local Vascular Accident, 
but Pan-Coronary Process 
Takayoshi Ohba. Kyoichi Mizuno, Kouji Seimiya, Masamichi Takano, Shinya Yokoyama, 
Ryuta Uemura, Shunta Sakai, Yoshrkr Kusama, Takeshi Ino, Noritake Hata, Takurou 
Shinada, Yasuhiro Hiarasawa, Jun Tanabe, Kenichrrou Tajtka, Hiroyuki Kamon. 
Cardiovasciar Medicine, Chiba Hokusou Hosp~tal,Nippon Medical School, lnba Chiba, 
Japan 
Background; Recently it has been suggested that infection and/or inflammation cause 
plaque disruption or endothelial damage that result in thrombus formation and lead to 
acute coronary syndrome. Therefore, we hypothesized that the pathophysiologic process 
e.g. coronary thrombi, exsisted in pan-coronary arteries if the infectron and/or inflamma- 
tion induced the acute coronary syndrome. As angioscopy is more sensitive method to 
identify coronary thrombr than angiography, we performed coronary angioscopy to clarify 
this hypothesis. We also studied patients recent history of infection. Methods; Coronary 
angioscopy was performed in both culprit lesions and non-ischemic related vessels rn 33 
patients with acute coronary syndrome and 29 patients with stable angina. All patients 
were questioned about infectious conditions presenting one month before angioscopy 
and tested for WBC, including its segment, and CRP levels on admission. Results; Cor- 
onary thrombi in culprit lesions were observed more frequently tn patients with acute cor- 
onary syndrome than in those with stable angina (76% vs 24%,p<O.O1). Moreover, 
thrombi in non-ischemrc related vessels were more common in patients with acute coro- 
nary syndrome than in those with stable angina (61% vs 28%,p<O.O5). There was no sig- 
nificant difference in the percent diameter stenosis in non-ischemic related lesions 
between this two groups. The frequency of patients who had inflammatory symptoms 
before angioscopy was higher in patients with acute coronary syndrome than in those 
with stable angina (42% vs 21%,p<O.l0). On the other hand, plasma CRP levels and 
plasma WBC count, especially neutrocyte and monocyte, were higher in acute coronary 
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Ii 86-75 Thrombolytic Therapy and the Future Risk of Stent 
Thrombosis 
Raef H. Hajj-Ali, Stephen Green, Rana Z. Ezreddine, Barry Kaplan, Donna Marchant, 
Larry Ong, Stanley Katz. North Shore University Hospital, Manhasset, MY 
Background: Thrombolflic therapy has made a significant difference in the manage- 
ment of patients with acute myocardial mfarction. Nevertheless, there is some concern 
regarding a rebound hypercoagulability state following its administration. In this era of fre- 
quent use of stents in rescue percutaneous revasculanzation, an increase rate of stent 
thrombosis following thrombolytic therapy IS a concern. We thought to investigate 
whether patients undergoing stent implantation have an increased risk of stent thrombo- 
sis if they received thrombolytic therapy within 24 hours prior to their intervention. 
Methods: The study population consisted of 5978 patrents that underwent stent implan- 
tation at our instrtution between January 1, 1998 and June 30, 2000. Patients were fol- 
lowed for at least one month following their procedure and information regarding repeat 
hosprtalizatron and cardiac procedures was collected. All patients were placed on aspirin 
and ticlopidine or clopidogrel. The primary endpoint of the study was angiographically 
documented stent thrombosis. 
Results: The incidence of stent thrombosis in the 188 patients who received thrombolytic 
therapy within the 24 hours preceding their stent procedure was 4.3% (8 patients) corr- 
pared to 1 2% (67 patients)in the 5790 patients that did not (p=O.OOl). After adjusting for 
post acute myocardial infarction status using logistic regression analysis the association 
between thrombolytic therapy and stent thrombosrs was not statistically sigmficant. Post 
myocardial infarction status was a strong independent predictor of stent thrombosis 
(OR:25 p=O.O02). 
Conclusion: The risk of stent thrombosis IS increased in patients havrng their stent pro- 
cedure within 24 hours of thrombolytic therapy. The increased risk in these patients is 
attributable to their post myocardial Infarctron status. 
1186-76 Risk of Major Bleeding in Patients Treated With PTCA Early 
Following Thrombolysis With TNK vs. t-PA 
John H. Alexander, Xin Li, Richard Chin, Hal Barron, Christopher B. Granger, Paul W. 
Armstrong, Frans Van de Werf. Duke University Medical Center, Durham, MC 
Background: Although often unavoidable, PTCA following thrombolysis is associated 
with a risk of bleeding and ICH. This risk may be even greater with the “se of glycopro- 
tein llbillla Inhibitors. We investigated risk of bleeding associated with PTCA in the set- 
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1186-101 Both Stent and Abciximab Use During Primary Angioplasty 
Independently Improve Outcomes in Diabetics With 
Myocardial Infarction 
Satyendra Gin, Joseph Mitch&, Jeffrey A. Hirst, Daniel B. Fran, Michelle Fitzpatrick, 
Daniel I. Simon, Francis J. Kieman. Brigham and Women’s Hospital, Boston, MA, 
Hartford Hospital, Hartford, C J 
Stent and abciximab use during primary angioplasty (PA) can reduce MACE (Major 
Adverse Cardiac Event = death, MI, target vessel revascularization [TVR], which is par- 
ticularly high in patients with adult-onset drabetes [DM]). To identify the independent 
effect of adjunctive therapies, we prospectively studied (01/96-OliOO) 810 Ml patients 
(DM=151) who underwent PA ~12 hours of symptoms and an ECG diagnostic of Ml. 
Quantitative coronary analysis was performed by 2 angiographers. Pie-specified clinical 
variables were entered in a dedicated database. Risk of explanatory variables was quan- 
tified by logistic regression modeling. 
Results: The DM patients ware more likely to be women (38 vs 29%) hypertensive (65 
“s 43%) obese (43 “s 30%), sedentary (78 vs 65%) age >65 years (49 “s 38%) with 
peripheral vascular disease (16 “s 7%) and 3.vessel disease (42 vs 34%); but less smok- 
ers (32 “s 51%) or family history of premature coronary disease (20 “s 38%) “s nonDM 
patients (all p ~0.05). 
Of 15lDM patients, 46 (30.4%) suffered 52 (35%) MACE (17 death, 9 MI, 26 TVR) in 6 
months compared to 23.7% MACE in nonDM patients. See table for multivariate predic- 
tors. Other univariate predictors of MACE in CM patients were u-albuminuria (70 “s 
51%) renal failure (16 “s 22%) and age >65 years (61 vs 44%). DM patients with MACE 
also presented with higher serum glucose, potassium, BUN and HbA,, levels. 
Conclusion: During PA, a minimal lumen diameter-MLD >2 mm, stent and abciximab 
use independently provide decrease MACE, which persrsts even after adjusting for other 
potent risk factors prevalent in the DM population. 
Independent Predictors Wald Odds Ratio 95% Cl 
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ting of thrombolysis and to determine whether this risk differs with different thrombolytic 
regimens. Methods: ASSENT 2 was a randomized, double-blind, 16,949 patient trial that 
compared the safety and efficacy of the thrombolytics TNK and t-PA in the treatment of 
acute myocardial infarction. We investigated the incrdence of SO-day mortality, intracra- 
nial hemorrhage (ICH), major bleeding and transfusion in patients who underwent PTCA 
(with or without stentrng) within 1 day of TNK compared to t-PA. Results: The patient 
populations were balanced with respect to age, Killip class on presentation, heart rate, 
blood pressure, and weight. Anterior infarcts were slightly more frequent in the t-PA 
group. 
TNK n=640 tPA n=598 p-value 
30-day Mortality 5.3% 4.5% 0.60 
ICH 0.47% 0.33% 1.0 
Major Bleeding 10.6% 11.7% 0.41 
Transfusion 8.8% 9.4% 0.76 
Conclusion: Major bleeding and transfusion rates are relatively high in patients who 
undergo PTCA within 1 day of thrombolysis, however, ICH is rare. TNK is not associated 
with a higher bleeding risk than tPA. These results are consistent with the lower overall 
rata of bleeding with TNK seen in ASSENT-P. 
118677 Impact of Stent Use Following Thrombolytic Administration 
on the TIMI Myocardial Perfusion Grades in Acute MI 
C. Michael Grbson, Kenneth W. Baran, Michael Nguyen, George R. McKendall, Costas T. 
Lambrew, Gary Dykstra, Sebastian Palmeri, Lily L. Luu, Colin A. Hynes, Steve G. 
Gourlay, Hal V. Barron. University of California San Francisco, San Francisco, CA, Rhode 
Island Hospital, Providence, RI 
Background: Stenting has been shown to increase epicaridal flow in AMI, & the goal of 
this study was to quantitate improvements in myocardial perfusion. Methods: Data are 
from the LIMIT trial of rhuMAb CD18 (anti WBC ab) rn AMI. Adjunctive stenting was done 
at the discretion of the investigator. The Myocaridal Perfusion Grade (MPG) was 
assessed & digital subtraction angiography (DSA) was used to quantify brightness of the 
myocardial blush. Results: TIMI 3 flow was 54.2% (641118) pre stent, & 87.2% post (1021 
117)(pcO.O01) & TIMI frame counts decreased from medians of 37.6 to 21 (pcO.001). By 
DSA, there was a trend toward brighter blush post&ant than pre (8.4 f 8.7 Gray, n=68 vs 
6.8 + 8.5, n=68, p=O.16). However, post-stent blush was not as bright as blush in normal 
pts without coronary syndromes (10.9 ? 5.7, n=65, p=O.OOl). Conclusion: Adjunctive 
stenting in AMI improves epicardial TIMI 3 flow & TIMI frame counts as well as dye inflow 
into the myocardium: MPG 0 is reduced & myocardial blush measured quantitatively by 
DSA tends to be brighter. However, dye outflow is impaired (more MPG 1 or dye staining 
present on next injection), possibly due to embolus, spasm or capillary leak. 
TIMI Myocardial Perfusion Grade Pre and Post-stem 
Pre-PCI post-stew p-value 
MPG 0 25.2%, 291118 i4.3%, 16/118 0.03 
MPG 0.5 19.3%, 23/118 21.9%, 261118 NS 
MPG1 13.5%, 16/118 28.6% 341118 0.004 
MPG 2 5.9%, 7/l 18 6.7%, 81118 NS 
MPG 3 36.1%,43/118 28.6%, 341118 0.21 
5 way p-value = 0.02. MPG O=no blush; MPG 0.5=minimal blush; MPG l=stain on next 
injection: MPG Z=blush intense at injection end, gone next injection; MPG3= normal 
blush or ground glass appearance of myocardium. 
1186-78 Adjunctive Thrombolytic Therapy With or Without 
Glycoprotein Ilb/llla Inhibition Prior to Percutaneous 
Coronary Intervention in Acute Myocardial Infarction 
Steven B. H. Timmrs, Gerald C. Timmis, Michael S. Flynn, Mark C. Pica, Simon R. Dixon, 
Robert 6. Tober, William W. O’Neill. WiNam Beaumont Hospitaal, Royai Oak, MI, Naples 
Community Hospital, Naples, FL 
Background: While percutaneous coronary intervention (PCI) following thrombolytic 
therapy has produced mixed and unsatisfying results, the adjunct& administration of 
glycoprotein (GP) Ilb/lla inhrbitors with half-dose retwase may rmprove subsequent pri- 
mary PCI outcomes. 
Methods: 160 patients admitted to one of three community hospitals in Naples, Florida 
with acute Ml were enrolled into this registry. Forty-seven patients were treated with half- 
dose retavase and IV GP Ilb/llla inhibitors (operator’s choice) while 113 subjects 
received IV GP Ilb/llla inhibitors alone. Patients subsequently underwent urgent cardiac 
catheterization. 
Results: Baseline demographics were similar for both groups. Time from treatment to 
cardiac catheterization was unaffected by group assignment (-140 min). Preliminary 
angiographic data demonstrated TIMI 2-3 patency in 61% of patients treated with corn 
bined retavase/GP llbillla inhibitor compared to 44% of those who received GP Ilb/llla 
inhibitors alone before PCI (p = ,147). Following PCI, 100% of patients in both groups 
achieved TIMI 2-3 patency. The final percent stenosis was 9.5% in the group receiving 
combined therapy compared to 11.4% in the cohort treated with GP Ilb/llla inhibitor alone 
(p = ,442). Left ventricular ejection fraction was 51% vs. 52% respectively (p = ,458). 
Conclusions: This initial experience suggests that combined half-dose thrombolytic 
therapy and GP Ilb/llla inhibition before primary PCI for acute myocardial infarction 
enhances early repetfusion compared to pretreatment with GP llbillla inhibitors alone. 
The final angiographic results after primary PCI were equally good with both treatment 
strategies. 
MLD >2 mm 4.51 0.25 0.07-0.89 
Abciximab use 9.03 0.25 0.10-0.62 
stent Use 3.93 0.36 0.13-0.98 
% Diameter Stenosis 7.72 1.11 1.05-1.17 
Total &hernia Time 17.81 1.37 1.10-l .71 
1186-102 Safety and Feasibility of Abciximab Treatment in Rescue 
Angioplasty 
Giuseppe Musumeci, Anna Sonia Petronio, Roberto Baglini, Ugo Limbruno, Giovanna 
Mengozzi, Gwanni Paterni, Paolo Caravelli, Mario Mariani. CardioJhoracic Dpt 
University of Pisa, Piss, Italy 
We evaluated the feasibility and safety of abciximab administration in patients (pts) with 
acute myocardial infarction (AMI) already submitted to intravenous thrombolysis (IT) and 
its influence on clinical outcome. Methods:Seventy-seven out of 83 consecutive pts (58 
male; mean age 62.5i10.6 yrs) with AMI and unsuccessful IT, submitted to rescue coro- 
nary angioplasty (PTCA) within 24 hours, were studied. Thirty pts (Group A: 38.9%) were 
treated with abciximab before the procedure according to the standard protocol (0.25 
mcgikg bofus plus 12.hour infusion at 0.125 mcgimin) while forty-seven pts didn’t recive 
abciximab therapy (Group B). In Group A an intravenous heparin bolus, not followed by a 
continuous intravenous infusion, was administered based on body weight (70 U/kg). 
Major bleeding and minor bleeding were taken into account. Major adverse cardiac 
events (MACE) studied during the hospital stay and the 6-month foll&up were death, 
reinfarction, congestive heart failure, target lesion revascularization, and recurrent 
ischemia. Results: Time to repetfusion was 10.5+8 hrs; mean time interval from IT to 
receiving abciximab was 8.2 hrs (range 2.9 to 22); in 54 pts (70%) a stent was deployed. 
Rescue PTCA was successful in 96.1% of pts (96.6% in Group A and 95.7% in Group 8) 
In-hospital death occurred in 9.09% of pts. No difference in baseline parameters was 
observed between the two groups. Major bleeding occurred in two pts who didn’t undergo 
abciximab therapy. Minor bleeding complications occurred in four pts of Group A (13.3%) 
and in four of Group B(8.5%; p = ns) At 30-day follow-up, only 3.3% of Group A pts pre- 
sented MACE compared with 21.2% of Group B pts (p < 0.01). At 6.month follow-up, 
10% of Group A pts had MACE versus 48.9% of Group B pts (p < 0.001) At l-month fol- 
low-up, the PD-echocardiographic evaluation showed a reduction in wall motion ?.core 
index (WMSI) in 26 abciximab-treated pts (86.6%)and in only 22 Group B pts (46.8%; p < 
0.05). Conclusions: Treatment with abciximab and low-dose heparin after IT is safe, fea- 
sible and improves the outcome of pts submitted to re?,cue PTCA. 
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11:oo a.m. 
National Trends in the Use of Beta Blockers for the 
Treatment of Older Patients After Acute Myocardial 
Infarction 
JoAnne M. Foody, Deron H. Galusha, Jennifer M. Lewis, Dale R. Burwen, Martha J. 
Radford, Harlan M. Krumholz. Quahd!gm, Mfddletown, CT; Healfh Care Ffnanancing 
Adnnnisfration, Baitimore, MD 
Background: Despite the importance of beta blockers for secondary prevention after 
acute myocardial infarction (AMI), they are substantially underutilized, particularly in &he 
elderly HCFA’s quality performance measurement program provides a unfque oppartu- 
nity to describe current natlonal trends of beta blocker prescription at hospital discharge 
among older patients with AMI. 
Methods and Results. We identified two national cohorts of 30,795 and 3873 Medicare 
AMI cases discharged alive without contraindications to beta blocker in 1994-1995 and 
1998.1999 respectively. In the 1998-1999 cohort; 71% were prescribed a beta blocker 
as a discharge medication compared with 50% in the 1994.1995 cohort. There was sig- 
nificant variation by age ranging from 60% to 75% ( p < 0.001 for trend). In general, the 
very old (285) are less likely to be prescribed beta blockers (60% vs. 73% p < 0.001 for 
trend). 
Conclusions. Currently, more than one quarter of ideal elderly patlents do not receive 
beta blockers as part of their discharge medications. Patients t 85 free from contraindr- 
cations continue to be less likely to receive beta blockers than their younger counter- 
parts. While there has been an absolute Improvement in beta blocker use across all age 
groups nationally, this improvement relative to the opportunity was the smallest in those > 
85. Despite continued improvement in national beta blocker usage following AMI, many 
ideal older patients do not receive this Important and effective therapy. 
National Trends in the Use Of Discharge Beta Blockers In Older Patients After 
AMI 
AGE 1994.1995 Prescribed/Ideal 1998.1999 Prescrlbedildeal Change in 
(%) (%) Rate 
~65 140812660 (52.9) 303/403 (75.2) 22.3 
65-74 7633/14078 (54.2) 1130/1529 (73.9) 19.7 
75-84 5025/10497 (47.9) 964/1346 (71.6) 23.7 
,I= 133913560 (37.6) 3571595 (60.0) 22.4 
85 
ALL 15405/30795 (50.0) 275413873 (71.1) 21.1 
ORAL CONTRIBUTIONS 
a55 Secular Trends in the Management of 
Acute Myocardial Infarction 
Tuesday, March 20, 2001, IO:30 a.m.-Noon 
Orange County Convention Center, Room 230D 
855-l 
10:30 a.m. 
Medication Errors and Outcomes With Fixed Double-Bolus 
r-PA Versus Bolus Plus Weight-Adjusted Infusion t-PA 
Fibrinolysis: The GUSTO-III Experience 
Shaun G. Goodman, Aiala Barr, C,hristopher Granger, Magnus Ohman, Anatoly Langer. 
Paul Armstrong, Brian Gibier, Eric Topoi. Canadian Heart Research Cenfre. Toronto, ON, 
Canada, Duke University Medical Center, Durham, NC 
Background: It has been suggested that fibrinoiytic dosing errors result in higher rates 
of intracranial hemorrhage (ICH) and death and use of bolus lysls may reduce errors and 
lead to Improved outcome: however, the relationship between doslng error and outcome 
has also been reported to be primarliy due to confounding factors rather than to the dos- 
ing error itself. A small retrospective review (r&00) comparing r-PA (fixed double-b&s) 
and t-PA (boius + weight-adjusted infusion) found fewer errors with r-PA, but a similar 
comparison derived from the only large randomized trial (GUSTO-III; n=15,059) examin- 
mg patient (pi) outcomes has not been reported. 
Methods: Medication errors in pts who received study lytic (n=14,766) in GUSTO-III 
were defined for (1) r-PA = early discontinuation (discont.); or, duration between the 1” 
and 2”d boluses <25 minutes (min) or >35 min: (2) t-PA = early discont.; or, dose admin- 
l&red either less than or greater than dose expected (based on pt weight. maximum 100 
w). 
Results: Adverse outcome was higher in patients with early discont.. incorrect dose (with 
t-PA), or incorrect duration between boiuses (with r-PA)@ Table). While medication 
errors occurred more frequently in the t-PA vs. r-PA group (26.8% vs. 7.4%, p<O.OOOl), 
the rates of stroke (2.2% vs. 2.4%), ICH (0.7% vs. 1.0%). in-hospital (10.5% vs. 9.9%) 
and 30.day mortality (11.4% vs. 10.7%) were similar between the two lytic treatment 
error groups (t-PA vs. r-PA, all comparisons p>O.6). 
Medication Error* t-PA (n=4,834) r-PA (n=9,932) 
Yes’ (n=,.294) No* Yes- (n=737) NO’ 
Early dlSco*tln”atlon* 30 day death 38 5% 6 3% 49 4% 7.0% 
Stroke 8.8% 1.6% 7 8% 1 .6% 
incorrect dose/duration‘ 30 day deaih 11 1% 5 5% 105% 7 1% 
StidG 2 1% 1 7% 2.3% 1 6% 
Conclusions: While medical error analyses are confounded (e.g. early discont. in pts 
who die is not really a medical error), randomized trial data remains the best way to 
examine the impact of different lytic strategies on clinical outcomes. In GUSTO-III, 
regardless of which iytlc was used, medication errors were associated with worse out- 
comes. However, increased rates of errors seen with t-PA were not associated with 
higher adverse event rates when compared with r-PA. 
855-2 
IO:45 a.m. 
High-Risk Direct infarct Intervention Using IABP Support: 
Does It Make a Difference? 
Robert M. Siegel, Ambika Bhaskaran, Warren Breisbiatt. Barbara Barker, Alvin Nuttail, 
Deborah Frazier, Jennifer Vermililon, Greg Etts, Scott Olson, Jennifer Carson Advanced 
Cardiac Specialists, GIlbert /Phoenix, AZ 
Background: Clinical outcomes 1-1 acute Ml have shown encouraging improvement since 
the advent of direct coronary interveniion (d-PTCA). The challenge of d-PTCA in high- 
risk clinical subsets persists. Adjunctive IABP use for mechanical circulatory support in 
high-risk d-PTCA may improve outcomes by decreasing pm- and after-load, prom&g 
hemodynamic stabilization and diastolic augmentation of flow through the infarct-related 
artery, leading to reduced remodeling and improved LV function in the long term. Meth- 
ods: We compared acute and long-term clinical outcomes in 1,037 high-risk (TIMI crite- 
rla) patients who underwent d-PTCA within 12 hours of onset of acute MI. Of them, 430 
(41%) received IABP and 607 did not (non-IABP group). The incidence of cardiogenic 
shock was higher (20% vs 1.5%; pcO.0001) and mean global LVEF was lower (38.1% vs 
46.4%; p<O.OOOi) in the IABP group. Hypertension (p=O.O09) was more frequent in the 
non-IABP group. Both groups were well-matched for all other clinical and angiographic 
variables. Results: Procedural success was higher in the IABP group (99% vs 96%; 
p=O.O04). In-hospital complications were lower in the IABP group (p<O.OOl), although 
mean hospital stay was longer (4 3 vs 2.6 days; p<O.OOi). During follow-up (mean 11.3 
months), target lesion revascularization rates were comparable (11.6% IABP vs 9% non- 
IABP; p=O.39). Mortality was significantly lower (2.3% vs 6.1%; p=O.O2) and cardiac 
event-free survival significantly higher (86% vs 80%; ~~0.045) in the IABP group. Mean 
rise rn LVEF was higher in the IABP group (8% vs 4%; p=O.OlZ). Conclusions: In this 
series of d-PTCA in a high-risk subset, patients with more severe/unstable presentation 
received IABP support. Despite this. the IABP group demonstrated significantly higher 
procedural success, lower in-hospital complications and lower incidence of MACE during 
long-term follow-up. This translated into significantly greater survival in the IABP group. 
These findings may have Important implications for future management strategies in 
high-risk d-PTCA. The myriad benefits of IABP appear to be critical not just for Improved 
in-hospital outcomes, but also for long-term absolute and event-free survival. 
855-4 
II:15 a.m. 
Higher Coronary Intervention Following Acute MI 
Associated With Lower Rates of Evidence-Based Medical 
Therapy in Regions of North America: Results From 
ASSENT II 
Maria Cecilia Bahit. John H. Alexander, Gudaye Tasissa, Paul W. Armstrong, Robert M. 
Califf, Christopher B. Granger. Duke Climcal Research instituufe, Durham, NC 
Background: Randomized clinical trials and clinical practice guidellnes have provided 
clear evidence that certain medications improve surwal in patients with ST elevation 
myocardial infarction (Ml). The aim of this study was to determine whether the use of evi- 
dence based medications and procedures differ across North America (NA) for patients 
with ST elevation Ml. Methods: Using the database of the ASSENT II trial, which com- 
pared TNK vs t-PA in patients with MI, we selected patients enrolled in N.A. We exam- 
lned the use of aspirin, beta-blockers (bb), ACE inhibitors, coronary angiography and 
angioplasty, length of stay (mean LOS, days) among census regions across United 
States (US) and Canada. Results: Of the 16949 patients in ASSENT II, 4806 (28 %) 
patients were enrolled in North America between October 1997 and November 1998. 
Baseline characteristics were similar across the regions. The use of aspirin was uniformly 
high (from 95% to 97%). The use of cardiac procedures generally was mversely related 
to the use of evidence-based medicatlons.For example, the central US had the highest 
rate of PCI. lowest use od beta-blockers and ACE-I, and shorter LOS.On the other hand, 
Canada and New England had the highest use of ACE-I and beta-blockers, respectively. 
PC, 53% 49% 48% 47% 45% 35% 13% 0.001 
bb 82% 89% 92% 87% 84% 92% 85% 0 001 
ACE-I 45% 42% 51% 48% 50% 47% 52% 0 001 
ioways 5.9 5.8 7.8 65 6 6.3 7.8 0.001 
Conclusion: There was wide variation in both coronary Interventions and the use of evi- 
dence-based medicine in North America in the treatment of acute MI, and regions with 
higher intervention rates had both shorter hospital length-of-stay and lower use of proven 
medical therapies 
II:30 a.m. 
855-5 National Trends in Quality of Care for Acute Myocardial 
Infarction (AMI) Between 1994-1995 and 1998-1999 
Dale R. Burwen, Deron H. Galusha, Jennifer M. Lewis, Harlan M. Krumholz. Marjorie Ft. 
Bedinger, Martha J. Radford. Health Care Financing Administrafion, Balffmore. MD, 
Qualidigm, Middietown, CT 
Background: Many studies have documented underuse of recommended theraples for 
AMI patients. Information about the change in use of these therapies over time IS critical 
to evaluate and target quality improvement efforts. We report the first national trend data 
for AMI care from the Medicare Health Care Quality Improvement Program. 
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Methods: A national sample of medical records of Medicare AMI hospitalizations during 
an 8.month period tn 1994-1995 (n=234754) and a 6-month period tn 19981999 
(n=35713) was abstracted. We determined the percent of cases receiving key therapies 
(after excluding patients with contraindications), the change in use over time (from 1994. 
1995 [baseline] to 1998-1999), and change relative to the opportunity for improvement 
(100% - baselfne rate). 
Results: Median utilization (25th,7+ p rcentile) 
Quality Indicator 1994.1995 % Absolute change % Relative change % 
utilization 
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Early administration of aspirin 77 (7660) - 7- (5,Q) 31 (23,39) 
Aspirin prescribed at discharge 79 (7682) 67 C&8) 27 (1635) 
Early administration of beta- 50 (43,56) 19 (1422) 39 (32,44) 
blocker 
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Beta-blocker prescribed at dis- 50 (42,54) 22 (1828) 44 (36,52) 
charge 
ACE inhibitor for systolic dys- 63 (60,68) 7(3,1f) 20 (7,32) 
function 
1216-75 Impact of Gender on the Improvement in Left Ventricular 
Systolic Function Following Coronary Artery Bypass Graft 
Surgery for lschemic Cardiomyopathy 
Mohammad Bashir, lmran Afridi, lbrahim Abdalla, Nicholas G. Smedira, Eugene 
Blackstone, Michael S. Lauer. The C/eve/and Clinic Foundation, Cleveland, OH 
Smoking cessation counseling 43 (39,49) --3 (-8x4) -5 (-14,8) 
Conclusions: Over a 4 year period, varied progress was made across cane processes 
(beta-blockers > aspirin LACE inhibitors; no improvement in documented smoking 
advice) and states. Important advances were made, however, diffusion into practice can 
be a slow process. In the meantime, a significant proportion of Medicare patients hospi- 
talized with AMI are not receiving optimal, evidence-based therapies to reduce mortality. 
855-6 
ii:45 a.m. 
Higher Early Mortality Among Younger African Americans 
After Myocardial Infarction: Analysis of the National 
Registry of Myocardial Infarction-2 
A~ay Manhapra, John G. Canto, Viola Vaccarino. Len Parsons, Hal V. Barron, Nathan R. 
Every, Catarina A. Kiefe, William J. Rogers, W Douglas Weaver, Steven Borzak. Henry 
Ford Heart and Vascular Institute, Detroit, Ml, University of Alabama at Birmingham 
Medical Center; Birmingham, AL 
Background. Young African Americans with acute myocardial infarction reportedly have 
higher short-term mortality than Whites of similar age. However, the relationship of 
younger age with increased short-term mortality in African Americans, and the influence 
of demographic, clinical and treatment factors on this relationship have not been explored 
in detail. Method. We analyzed the patient characteristics and mortality data of 558,272 
patients enrolled in the National Registry of Myocardial Infarction-2 who were 90 years or 
younger and had confirmed myocardial infarction (40,903 African Americans and 
501,995 Whites). Results. The overall mortality was slightly lower among African Ameri- 
cans compared to Whites (10.9% in blacks and 12.0% in whites, p<O.OOOl). The mortal- 
ity of African Americans younger than 65 years of age was significantly higher compared 
to Whites of similar age groups (figure). Logistic regression analysis showed that 
younger age had a negative influence on the mortality of African Americans compared to 
Whites (p value for age-African American race mteraction on mortality <O.OOOl). Each 5 
year decrement in age was associated with 7.2% higher odds of death in African Ameri- 
cans (95% confidence intervals 5.7% 7.6%) compared to Whites. Although there was 
substanttal variation between African Americans and Whites in different patient charac- 
teristics, these variations were found to account for only a quarter of the higher risk of 
death in African Americans on multivariate analysis (5.4% increased odds for death after 
adjustments, 95% confidence intervals 3.6% - 7.2%). Conclusion. Younger African 
Americans have a higher short-term mortality compared to Whites of similar age foilow- 
ing an acute myocardial infarction. 
Objective: It is known that left ventricular systolic function improves in patients with 
ischemic cardiomyopathy (ICM) undergomg coronary artery bypass graft surgery 
(CABG). We sought to study the impact of gender on the improvement in left ventricular 
ejection fraction (LVEF) following CABG in patients with ICM. Methods: We reviewed 
CABG database at our institution from 1990-97 and identified patients with LVEF ~40% 
who underwent isolated CABG and had echocardiography withm 6 months prior to and 
12 months after CABG. Multivariate linear regression analysis was performed to Identify 
independent predictors of improvement in LVEF. Results: Study population included 516 
patients (128 females, mean age 65 f 11 years). Although female patients were older (67 
1 10 years vs. 63 + 11 years, p=O.O03), they had a significantly higher pre-operative 
LVEF compared with male patients (30 2 7% vs. 28 ? 7%, p=O.O04). Following surgery, 
LVEF continued to be significantly higher in female patients (34 i 11% vs. 30 ? 9%, 
pcO.0001). A higher percentage of women had a significant improvement in LVEF 
(>lO%) than men (30.5% vs. 21 .Q%, p&05). There was a greater absolute increase in 
LVEF (AEF) in female patients (4 * 11% vs. 1.5 r Q%, p=O.Oi). After adjusting for age, 
diabetes, htstory of smoking, prior myocardial Infarction, pre-operative LVEF, number of 
s&nosed coronary arteries and number of arterial bypass grafts, female gender 
remained assdciated with a significantly higher AEF. 
Conclusions: A higher percentage of women than men had a significant improvement in 
left ventricular systolic function following coronary artery bypass graft surgery for 
ischemic cardiomyopathy. Furthermore, the absolute increase in left ventricular ejection 
fraction was more in women. 
1216-76 Myocardial Stunning Severity Is Related to the Intensity of 
lschemia in Patients With Coronary Artery Disease 
Edward Barnes, David P. Dutka, Roger J. C. Hall, Paolo G. Camici. National Heart and 
Lung Institute at Hammersmith Hosptal, London, United Kingdom 
Background: It is well established from animal models that the severity of myocardial 
stunning IS related to the degree of the preceding episode of ischemia. Using dob- 
utamine-induced ischaemia in patients with angiographically proven coronary artery dis- 
ease (CAD) and stable angina pectoris, we assessed the relationship between the 
degree of post-ischemic left ventricular (LV) dysfunction (echocardtography), the severity 
of coronary stenosis (angtography) and peak myocardial blood flow (MBF) measured 
with positron emlasion tomography (PET) and oxygen 15.labeled water. Methods: 14 
patients (61*7 years) with normal resting LV function were studied(ejection fraction 
64~5%). Regional systolic function (shortening fraction [SF]) was assessed at baseline 
and regular intervals after dobutamine. MBF was measured at baseline, peak stress and 
after stress just prior to the 30 minute echo data acquisition. Results: Global reversible 
post-ischemic LV dysfunction, that had recovered 60 minutes after peak stress, occurred 
in 9 of the 14 patients. In these 9 patients, there was no difference in regional MBF (cor- 
rected for rate pressure product) at baseline and 30 minutes after dobutamine when LV 
function was impaired, but subsequently recovered, confirming stunning. Moreover, the 
severity of stunning was related to the severity of the coronary stenosis and to MBF at 
peak stress (table). Conclusions: This study is consistent with previous work in animals 
and demonstrates that in patients with CAD the degree of myocardial stunning is related 
to coronary stenosis severity and to the degree of attenuation in peak MBF 
Table: Mean+SD (*=p<O.Ol vs. 50-80% stenosis) 
Stenosis Severity SF p vs. Peak MBF (ml/ p vs. peak MBF ~50% 
(%dtameter) (30mins) baseline minig) stenosis 
c50 93.9125 NS 2.01~0.71 
50-80 85.4+21 <O.OOi 1.75*0.40 =0.002 
>80 67.4&25* ~0.001 1.47*0.30 =0.003 
1216-101 The Influence of Diabetes and Hypertension on 
Microvascular Dysfunction in Chronic Total Coronary 
Occlusions 
Gerald S. Werner, Barbara M. Richartz, Oliver Gastmann, Markus Ferrari, Hans R 
Figulla. Fnedrich-Schiller-Universify, Jena, Germany 
Background: Microvascular dysfunction (MD) after PTCA is detected by a reduced coro- 
nary flow reserve (CFR) in the absence of a residual epicardial lesion. MD is observed 
with diabetes mellitus and hypertension, extensive coronary artery disease (CAD), and 
prior myocardial infarction (Ml). In nonocclusive lesions about 20% of pts show MD. It is 
unknown to what extent it occurs in total chronic coronary occlusions (TCO). 
JACC February 2001 
Patients: Thirty patients (pts) underwent a successful recanalizatlon of a TCO (mean 
duraton of occlusion: 17 months (l-117) lntracoronary Doppler was used to measure 
average peak velocity (APV) and to assess CFR after stent placement during maximum 
hyperemia induced by 201-19 adenosin i.c. A cut-off value of CFR<Z.O was used to dis- 
crlminate pts with and without MD. Angiographic follow-up was done after 5.5tl.4 
months. CFR was reassessed in all pts, in case of target Iwon revascularization after the 
repeat PTCA. 
Results: A history of hypertension was known in 57% diabetes mellitus in 47% of pts. 
Multivessel disease was present in 73%, prior MI I” 73%. CFR afler stenting of the TCO 
was 1.87t0.51; and a CFRc2.0 was observed in 67%. CFR at baseline was independent 
of the history of MI or extent of CAD. CFR was lower in pts with hypertension and/or dia- 
betes ihan without this comorbidity (1.6490.36 vs. 2.22r0.43; p<O.OOi). This was due to 
a trend towards a lower maximum hyperemic APV with hypertension and/or diabetes 
(47.9t19.6 vs 61.9+37.0 cm/s;p=0.15). At the ttme of follow-up, CFR had improved sig- 
nificantly in the whole study group. This was due to the change in patients with hyperten- 
sion and/or diabetes: CFR mcreased to Z&3+0.99 (p<O.OOl as compared to baseline) 
The increase in pts without comorbidity was not significant (lo 2.55+0.81). At follow-up 
the CFR were similar in both groups, and also the basal and maximum hyperemic APV 
had reached a similar level. 
Conclusion: The majority of pis with TCO had evidence of MD. This may be explained 
by the change from collateral dependent to antegrade perfusion in TCO with impairment 
of microvascular response in the presence of hypertension and diabetes mellitus. MD 
has the potential to recover over a penad of several months. 
1216-102 Protective Effects of a Beta Blocker on Progressive Left 
Ventricular Remodeling in Chronic lschemic 
Cardiomyopathy With Hibernating Myocardium 
Chunguang Chen, Serge1 Aksenov, Huashan Hong, Jing Liu, Joseph Marak, John Fallon, 
David Waters.. Newark Beth lsraei Medical Center. Newark. NJ 
Background: We have previously shown that progressive LV remodeling occurs if hrber- 
nating myocardium is not reperfused. We hypothesized that although myocardial hiber- 
nation resiores the delicate balance of oxygen consumption and supply in LV regions 
supplied by a severe coronary stenosis with minimal flow reserve, it may not protect myo- 
cardium from iniermittent ischemia due to episodes of increased oxygen demand during 
daily activities. Unprotected ischemic episodes may contribute to the daterioratlon of LV 
dysfunction and progression of LV remodeling Beta-blocker ~111 decrease ischemia and 
prevent progressive LV remodeling u hibernating myocardium. Methods and Results: 
Three groups of 22 pigs were studied. Group 1 (n=9): Severe LAD stenosis was created 
with a resting coronary flow reductcon of 30-40% and was maintained for 4 weeks; Group 
2 (n=7): The same severe LAD stenosis was maintained for 4 weeks as in Group 1 and 
oral metoprolol (100 mg x Z/day) was given starting immediately after creaiion of the cor- 
onary stenosis. Group 3 (n=6). controls without a stenosis. Coronary flow (CF), LV wall 
thickening (WT) in the hibernating region, LV volume, mass and EF, and myocardial fibro- 
sis measurements are summarized in the table: 
*: p < 0.01 compared to control; #: ~~0.05 compared to Group 2. 
Group 1: qW Group 2: 4W CAD & beta- Group 3: con- 
CAD blocker tm 
CF (mligimln) 0.81+1-O ii- 0.83+/-0.12* 1.21+/-0.14 
WT (%) Ii+/-5* 14+1-4* 39+/-3 
LVEDV (ml) 145+/-25*# 125+/-19* 98+/-i 1 
LV mass (g) 128+/-8*k 120+/-7* 95+/-4 
LV E F (%) 35+/-5 39+/-f?* 58+/-3 
lnierstiial fibrosis 19+/-m 12+/-4* 6.2+/-3 
W) 
Conclusions: Progessive LV remodeling occurred m hibernating myocardium without 
reperfusion. However, beta-blocker administration significantly attenuated LV remodeling 
and decreased myocardlal fibrosis in hibernating myocardium. 
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reserve was measured ai baseline and 60 minutes to assess microvascular function. 
Radioactive microspheres were injected during coronary occlusion to measure collateral 
blood flow and at 28 days for infarct size determination. Left ventricular angiography was 
performed at baseline and 28 days. Area at risk was determined with perfusion of Evan’s 
Blue. TTC staining was performed as a second measurement of mfarcr sze. 
Results: GIK infusion resulted In a significant reduction in free fatty acid levels indicating 
a meiabollc effect. GIK did not improve CFR at 60 minutes or reduce ischemia-reperfu- 
sion arrhythmias. Myocardial infarct size and left ventricular function at 28 days was 
unchanged by GIK infusion. 
Conclusion: The study indicates that GIK does not reduce microvascular dysfunction, 
myocardial Infarct size. ischemia-reperfuslon arrhythmias, or left ventricular function. 
Effects of GIK 
FFA (“g/l) Infarct Sire (%AAA) LVEF VT frequency% 
GIK 0.2 +/- 0.1 36 +I- 5 51+/-11 67 
Placebo 0.8 +/- 0.2 15 +I- 14 45+1-14 67 
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1217-77 By What Mechanism Does Glucose-Insulin-Potassium 
Improve Survival Following Myocardial Infarction? 
Dieter Lubbe, John D. Altman, Birgit Kantor, David R. Holmes, Jr.. Robert S. Schwartz, 
Bernard J. Gersh. ryraYo Clinic, Rochester, IUN 
Background: Glucose-insulin-potassium (GIK) infusion during an acute myocardial inf- 
arction improves survival. This study was performed to determine if GIK reduces 
microvascular dysfunction, myocardial infarct size, postischemic ventricular contractlIe 
dysfunction, and ischemla-reperfusion arrhythmias. 
Methods: In 8 pigs the left anterior descending artery was occluded for 60 minutes fol- 
lowed by 28 days of reperfusion, GIK or placebo Infusion was started at the time of occlu- 
sion Free fatty acids (FFA) were measured to document GIK effect Coronary flow 
*pcO.O3 vs placebo 
1217-78 Ischemia-Reperfusion of Rat Myocardium Activates NF-kB 
and Induces Neutrophil Infiltration via Lipopolysaccharide- 
Induced CXC Chemokine 
Bysani Chandrasekar, Jeffrey 8. Smith, Gregory L. Freeman. The University of Texas 
Health Science Center, San Antonio, TX, UCLA School of Medicine, Los Angeles, CA 
Background: Mechanisms by which neutrophils are attracted to the myocardium follow- 
mg ischemlaireperfusion are not fully defined. The goals of the present study were to 
evaluate the roles of chemokines LIX (lipopolysachharide-induced CXC chemokine), KG 
(cytokine-induced neutrophil chemoattractant), and MIP-2 (macrophage inflammatory 
protein-2) in viva in a rat model of reperfusion injury, and to examine the mechanisms of 
chemokine Induction by oxidative stress and cytokines in cultured adult rat cardiomyo- 
cytes. Methods and Results: Male WKY rats underwent 45 minutes of LAD coronary 
artery ligation followed by reperfusion for various periods. Compared to sham-operated 
controls, myocardium from reperfused animals had: higher levels of free radicals, 
increased neutrophll infiltration evidenced histologically and by elevated myelopero$ 
dase activity, and increased NF-kappaB DNA binding activity. Ischemia-reperfusion also 
Induced the expression of IL-lb&, TNF-alpha. LIX. KC, and MIP-2 mRNA and protein. 
LIX expression was localized to resident myocardial cells, whereas KC and MIP-2 were 
expressed only in infiltrating inflammatory cells. Neutralization of LIX inhibited 74% of 
neutrophil infiltration into previously ischemic myocardium. In cultured cardiomyocytes, 
LIX expression was induced by oxidative stress or TNF-alpha, and blocked by the NF- 
kappaB Inhibitor pyrrolidinedithiocarbamate. Conclusions: The induction of LIX expres- 
soon, via an NF-kappaB dependent mechamsm, may be a key step in the recruitmenl of 
neutrophils to reperfused myocardium following ischemia in the rat. 
1217-79 Expression of Matrix Metalloproteinase-2 (MMP 2) and 
Tissue Inhibitor of Matrix Metalloproteinase-2 (TIMP 2) In 
Vivo During Myocardial lschemic Injury and In Vitro in 
Cardiac-Derived Fibroblasts and Endothelial Cells 
Dolores Cortez, James C&ton, Teresa Frosto, Bysani Chandrasekar, Gregory Freeman. 
Univ. of Texas He&h Science Center at San Antonio, San Antonio, TX 
Background: The exact role of matrix metalloproteinases (MMPs) and tissue inhibitors 
of matrix metalloproteinases (TIMPs) in myocardlal ischemia is not completely defined 
MMP2 degrades extracellular matrix, is regulated by TIMPP, and is cleaved to its active 
form by membrane-type matrix metalloproteinase-1 (MT+MMP). The aims of this study 
were i) to evaluate MMPP, TIMPP, and MTl-MMP expression in ischemic myocardium. 
and ii) to determine which cardiac constituent cells express MMP2 and TIMP2 at steady 
state. Methods: Four male Wistar-Kyoto rats were sacrificed after ligation of the left anie- 
rior descending coronary artery for one hour. lschemic myocardium was analyzed by RT- 
PCR for MMP2 and TIMP2 “RNA expression. MTI-MMP was localized in ischemic myo- 
cardium by immunohistochemistry. Serum MMPP activity and TIMPP levels were deter- 
mmed by enzyme immunoassay (ELISA). MMPZ and TIMPP expression was evaluated 
by RT-PCR and ELISA in cardiac-derived fibroblasts and endothelial cells I” vitro. Sham- 
operated and normal, non-operated rats served as controls. Results: lschemic and con- 
trol myocardium expressed MMP2, TIMPP and MTl-MMP constituitively. MT&MMP was 
detected by immunohistochemistry in ischemic and normal myocardium. Both MMP2 and 
TIMP2 “RNA were detected in the ischemic myocardium and controls. However, aver- 
age MMPP serum levels in ischemic rats were greater (2.05 “g/ml) than in sham (0.59 
ngimi) and normal rats (0.497 ngiml). Average TIMPZ levels in ischemic rats were lower 
(105.5 “g/ml) than in sham (125.7 “g/ml) and normal animals (146.7 nglml). Our results 
also showed that MMP2 and TIMP2 expression is cell specific. In vitro studies showed 
that at steady state, endothelial cells produce TIMPP but not MMPZ mRNA or protein. In 
contrast, fibroblasts at steady state express MMP2 “RNA and protein as well as TIMPZ 
“RNA but not TIMP2 protein. Conclusion: This study is novel in that it describes consti- 
tuitive expression of MMPP, TlMP2, and MTI-MMP during cardiac ischemia and local- 
izes the protein of MMP2 to fibroblasts and that of TIMPP to endothelial ceils. Further 
work is in progress to define the roles of these enzymes in myocardial remodeling. 
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1217-80 The Hyperthyroid Rat Heart Produces Diminished HSP 70 m 
RNA by Preconditioning Investigation of Mechanisms 
Dennis Cokkinos, Costas Pan&, V. Malliopoulou, S. Tzeis, DD Cokkinos, N. Steimberg, 
H. Carageorgiou, DV Varonos. Onassis Cardiac Surgery Center, Athens, Greece 
Background: The aim of the study was to investigate whether thyroxine (TH) administra- 
tion modifies the HSP70 m RNA expression Induced in response to ischemic precondi- 
tioning (PC) in the rsolated rat heart. Methods: L-thyroxine was adminrstered in mate 
Wistar rats (25 ig / 100 g SC daily for 2 weeks, THYR), whrie rats treated wrth saline 
served as controls (NORM). Isolated hearts were perfused in the Langendorff mode and 
subjected after stabilization to 20 min of zero flow global ischemia (I) and 45 min of reper- 
fusion, THYR, n=8 and NORM, n=6. PC hearts after the stabilization period, underwent 3 
min of I, 5 min of R, followed by 5 min of I and 5 min of R, followed by 20 min of I and 45 
min of R, NORM 2PC, n=6 and THYR 2PC, n=6. Hearts from normal and THYR rats 
were also subjected to additional 2 cycles of PC consisting of 5 min of I and 5 min of R, 
NORM 4PC, “=6 and THYR 4PC, n=6. The Induction of HSP70 m RNA at 45 min of rep- 
elusion was detected by Northern blot hybridization. Total and phosphorylated ~38 MAP 
kinase and PKC a expression were measured by Western blot analysis. Results: HSP70 
m RNA expression was 3.fold greater in NORM ZPC compared to NORM hearts. HSP70 
m RNA induction in THYR 2PC was 2.fold less than in THYR hearts, p<O.O5. In NORM 
4PC hearts, HSP70 m RNA expression was increased 1.5 fold as compared to NORM 
2PC hearts, pcO.05, while in THYR 4PC hearts HSP70 m RNA induction was not altered 
in comparison to THYR 2PC. The levels of total ~38 MAP kinase were similar between 
the THYR and NORM hearts. However, phorsphorylated ~38 MAP kinase was Z-fold 
lower in THYR 2PC compared to NORM 2PC hearts, ~~0.05 Basal PKCB expression 
was 1.7 fold more in the normal as compared to the hyperthyroid hearts, ~~0.05. Con- 
clusion: Thyroxine administration decreases the HSP70 m RNA expression induced by 
ischemic preconditioning. This mechanism through diminished phosphorylation of ~38 
MAP kinase, because of repressed PKCB expression, is being proven for the first time. 
1217-81 Predictive Value of NT-proBNP in 118 Patients With Acute 
Myocardial Infarction Undergoing Primary Coronary 
Angioplasty 
Franz S. G. Hartmann, Volkhart Kurowski, Ali Maghsoudi, Hendrik Bonnemeier, Thomas 
Kurz, Hugo A. Katus, Gert Richardt. Medizinische Klinik II, UK Luebeck, Luebeck, 
Germany 
Background: In acute myocardial infarction predictive value of the degree of neurohu- 
moral activation is well established. Recently, the natriuretic-peptide metabolite NT- 
proBNP received interest as prognostic marker, which is possibly superior to plasma cat- 
echolamines. So far, however, neither time-course nor predictrve value of NT-proBNP 
plasma concentrations has been prospectively evaluated in patients undergoing suc- 
cessful reperfusion by primary PCI. Methods: Therefore, we conducted a prospective 
study in 118 consecutive patients with acute myocardial infarction receiving successful 
@perfusion (TIMI 2 and 3) by primary PCI. Arterial plasma levels of epinephrine, norepi- 
nephrine and NT-proBNP were determined before, 60 min and 10 days after reperfusron 
and compared to established p&infarction risk markers. Follow-up was performed for 
18-36 months recording major cardiac events, defined as cardiac death, reinfarction, ven- 
tricular fibrillation or hospitalization for heart failure. Results: Catechofamine concentra- 
tions (mean&EM) reached a maximum in the first hour of myocardial infarction 
(norepinephrine: 602 +_44 mg/dl, epinephrine: 213 +24 mg/dl), but returned to nearly nor- 
mal values at IO days. In contrast, NT-proBNP levels were equally elevated at 0 and 60 
min (791 *46 mmol/l at 60 min), but further increased to 924 i-54 mmol/l at 10 days. For 
prediction of cardiac events, an 60 min NT-proBNP postinfarction level of >761 mmolil had 
sensitivity, specificity, positive and negative predictive values of 78% 64%, 33% and 
93%, respectively and was superior to any other neurohormone and to early LVEF By 
multivariate analysis, NT-proBNP provided predictive information for cardiac events inde- 
pendent of patient age, sex, early LVEF or history of myocardial infarction. Conclusion: 
Plasma NT-proBNP measured 60 min after reperfusion was superior to plasma cate- 
cholamines and LVEF in predicting event-free survival. Stratification of patients into low- 
and high-risk groups can be facilitated by early plasma NT-proBNP measurements. 
Therefore, this natriuretic peptide should reasonably be included in the routine clinical 
work up of patients after myocardial infarction. 
1217-82 Sphingosine-I-Phospate Is an Early Serum Marker for Acute 
Myocardial Infarction (AMI) 
Jeffrey S. Carstens, Douglas H. Deutschman, M. Trevor Page, Robert E. Klepper, Roger 
A. Sabbadini. San Diego State University, San Diego, CA, Naval Medical Center, San 
Diego, CA 
The MIRF (Myocardial lschemia Rating Function) trial was a 318 patient trial designed to 
test the diagnostic utility of serum sphingolipids as markers for ischemia. The primary 
endpoints were the assessment of coronary artery stenosis by angiography and serum 
sphingolipids, including sphingosine-l-phosphate (Sl P). For analysis, the patients were 
grouped by disease severity accordrng to the number of major coronary arteries involved 
by stenosis. This included a” ‘active ischemia’ group consisting of hospitalized pts found 
to have 2-3 vessel drstribution with greater than 70% stenosis. This active ischemia group 
had the highest Sl P level (1108 pmoliml). Post-hoc analysis revealed that 87% (33 of 38 
pts) of the active ischemia group had acute coronary syndrome (ACS) and 42% (16 of 
38) had Ml as a discharge diagnosis. At the time of catheterization, 10 of the MI patients 
had normal CKs, but had Sl P levels which averaged 1097 pmol/mL which ware signifi- 
cantly (p<.Oi) higher than the baseline levels (882 pmoliml) for “on-hospitalized pts with 
mild (~50%) coronary stenosis. It is concluded that serum SiP may be an early marker 
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for the ischemia assocrated with ACS. In addition it may be useful for early diagnosis of 
AMI before the traditional cardiac death markers appear. This finding warrants further 
investigation. 
1217-83 Effects of Heparin on Plasma Tissue Factor (TF) and Tissue 
Factor Pathway Inhibitor (TFPI) in Patients With Acute 
Myocardial Infarction (AMI) 
Shaker A. Mousa, Jeffrey M. Bozarth, Marc Cohen, Mrchael F. Wilson, Mofid N. Khalil- 
Ibrahim. DuPont Pharmaceuticals co., Wiimington, DE, Kaleida Health & univ. of New 
York, Buffalo, NY 
Background: Several studies have show” that thrombosis and inflammatron play a key 
role in the pathogen&s of coronary artery diseases. Elevated plasma levels of tissue 
factor might be responsible for the thrombogenicity of the atherosclerotic plaque by initi- 
ating and amplifying thrombin generation. The aim of the present study was to determine 
the circulatrng plasma levels of TF and TFPI and to assess the effect of hepari” in 
patients with AMI. Methods: Plasma samples obtained from 25 AMI patients pre- and I- 
2 days during heparin (50 IUikg, IV followed by 5000 IU x 3 for 5 days) use as well as 
from 12 healthy subjects were assayed for plasma TF and total TFPI usrng specrfic 
ELISA. Results: A significant elevation (* p c 0.05) in both TF and TFPI was demon- 
strated in AMI patients as compared to levels in healthy subjects. Heparin treatment was 
associated with a significant (P c 0.01) reduction I” TF back to normal levels. Further- 
more, heparin resulted in a significant (** P < 0.01) elevation in plasma TFPI by about two 
fold over normal levels. 
Plasma Levels of TF & TFPI In AMI Patients: Effects of Heparin 
Biochemical Markers Control AMI, Pre-Heparin AMI, Heparin 
TF @gW 140 +/- 25 255 +/- 45* 175 +/- 21 
TFPI (ngiml) 56+/-15 llO+/-26 203 +/- 55** 
Data in the table represent Mean ti- SD, * P < 0.05, ** P < 0.01. Conclusion: Increased 
pro-thrombotic events in AMI patients might be related to elevated TF circulating levels 
not sufficiently inhibited by elevated TFPI levels. These rnitial results suggest potentral 
anti-inflammatory and cytoprotective benefits of heparin via Its TFPI release in addition to 
its known antithrombotic actions in AMI patients. 
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1218-84 Elevated C-Reactive Protein and Increasing Severity of 
Coronary Artery Disease: independent or Interdependent 
Predictors of Risk? 
James S. Zebrack, Joseph B. Muhlestein, Benjamin D. Home, Tami L. Bair, Dale G. 
Renlund, Jeffrey L. Anderson. University of Utah, Salt Lake City UZ; LDS Hospital, Salt 
Lake City, UT 
Background: C-reactive protein (CRP), a marker of inflammation, has been proposed as 
a new coronary risk factor. However, questions remain about the implications of an ele- 
vated CRP. Is it a surrogate for the extent of coronary artery disease (CAD), and are CRP 
and CAD independent or interdependent predrctors of risk? 
Methods: To assess the relation of CRP and CAD, we studied 2701 patients (pt) without 
acute myocardial infarction (Ml) undergoing angiography; 1722 had severe CAD (21 
stenosis 570%) 284 mild/moderate, and 695 no CAD. CAD was quantified in 6 ways: 
presence of severe disease; # of vessels with severe disease (>70% stenosis) or moder- 
ate/severe disease (>50% stenosis); and # of severe lesions, mild/moderate lesions (IO- 
69% stenosis), or total lesions. CRP was measured at angiography by a high sensitivity 
method (Abbott). Associations between CRP and CAD were assessed by Pearson’s cor- 
relation coefficient. Pt were followed for up to 5 years (mean, 2.0 * 1.4). Associations with 
death and nonfatal MI were evaluated usrng Cox regressions (9 co-variables). 
Results: Pt were 64 i 12 years old; 68% were me”. During follow-up, 174 CAD pt died 
and 105 had non-fatal Ml. Correlations of CRP with measures of CAD were highly signd- 
icant (p<.OOi) for all but moderate lesions, but the correlation coefficients were low 
(0.051-0.081). The number of pt with severe disease and number of severe vessels cor- 
related best. Subsequent death was predicted univariateiy by CRP (p< 0001) and all 
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CAD measures (p<.OOO8) except moderate lesrons. In bivariate analyses, significance 
was preserved for CRP and the 5 CAD measures. In multivarrate analyses, significance 
was retained for CRP (p<.OOl), number of severe vessels (p=.OO2), total lesions (p=.Oi), 
and severe lesions (p=.O3). Results were similar for the combined endpornt of deathlnon- 
fatal Ml. 
Conclusions: CRP correlated with several measures of extent and severity of CAD at 
catheterizatran, but the degree of correlation was low. suggesting the importance of addi- 
tronai factors. During follow-up, both CRP and selected measures of CAD retained inde- 
pendent predrctive value. CRP and CAD correlate partially, but each retains significant 
independent predictive value. 
121 a-85 Percutaneous Intervention in Unstable Plaques: The 
Significance of Temperature Measurement in Prognosis 
Christodoulos I. Stefanadis, Konstanhnos Toutouzas, Eleftherios Tsiamis, Costas 
Stratos, loannis KallikararoS. Manolis Vavuranakis, Costas Tentolouris, Dorothea 
Tsekoura. Pavlos Toutouzas. Hippokration Hospital, Athens, Greece 
Background: Previous studies have shown that local temperature is increased in unsta- 
ble angina. The aim of the present study was to evaluate the significance of increased 
temperature of culprit lesions in patients suffering from acute coronary syndromes, 
undergoing successful percutaneous intervention. Methods: In the study we included 56 
patients. mean age 61.2a9 years, sufferrng from unstable angina or acute myocardial inf- 
arction. All patients underwent balloon angioplasty in order to accomplish TIMI Ill flow. 
Thereafter, using a thermography catheter previously validated, we measured the tem- 
perature difference (AT) between the atherosclerotic plaque and the healthy vessel wall. 
Optimal angiographic result was achieved wrth the deployment of a stent. All patients 
were followed-up clinically for 17.1+512 months for an adverse cardiac event. Results: 
Balloon angioplasty. temperature measurements and stent implantatron were performed 
rn all patients, without complrcatrons. The mean AT was 0.84kO.54 "C. Seventeen 
patients suffered from an adverse cardrac event during the follow-up period. Patients with 
adverse cardiac events had increased AT compared to patients without events. (AT. 
0.58+0.37 “C vs. 1.02+0.42 “C; PcO.001). The risk for an adverse cardiac event was 
increased in patients with c*hot,, plaques (odds ratio: 2.01). This difference was mainly 
attributed to patients with unstable angina. Conclusion: During the mid-term follow-up 
period, adverse cardiac events are more likely to present to patients undergoing percuta- 
neous intervention with unstable plaques, which have increased local temperature. 
Accordrngly, these patients may require additional treatment, in order to stabilize the 
unsiable atherosclerotic plaques and thus improve the mid-term clinical outcome. 
1218-86 Chlamydia Pneumoniae and Inflammatory Markers in Acute 
Coronary Syndrome: 12 Months Outcome 
Hansh Ft. Chandra, Nivedita Choudhary, Carol O’Neill, Marcus J. Zervos, Judith Boura, 
Gerald C. Timmis, William W. O’Neill. Wiiliam Beaumont Hospitai, Royal Oak, MI 
Background: The role of infection with Chlamydia Pneumoniae (CP) and inflammation m 
coronary artery disease is controversial. There is a paucity oi prospective data regarding 
their significance in populations at high risk for cardiac events. 
Method: We conducted a prospective study on 418 consecutive patients (mean age 65 f 
13 yrs, 63% males) with no confounding co-morbiditres who presented to a chest pain 
center between March and June 1999 and were diagnosed with acute coronary syn- 
drome (ACS). Pertinent clinical and laboratory data were obtained at the trme of admis- 
sion. At 12 month the incidence of major adverse cardrac events (MACE) was 
ascertained (death, MI, and revascularization). Data were analyzed to evaluate the asso- 
ciation between MACE at 12 months and baseline systemic markers of inflammation 
including high sensrtivity C-reactive protein (CRP) and IgG titles against CP 
Results: 80% of the patients were seropositive to CP (IgG 2 1:64). At 12 months there 
were It6 MACE (28%) which included 35 deaths (8.4%), 21 MI (5%) and 84 revascular- 
ization (20%). No associahon between IgG titres against CP at baseline and MACE was 
found (p=NS). The baseline inflammatory markers were significantly higher in the MACE 
group (CRP: 2.45 i 4.3 vs. 1.39 f 2.78 mg/dl, ~~0.02, fibrinogen: 367 i 142 vs. 331 rt 
114 mg/dl, p=O.O2, and leukocyte count: 8.6 f 3.6 vs. 7.6 i 2.7 log/L, p=O.Oi). There was 
also an incremental incidence of MACE with ascending tertiies of CRP (Figure) On mul- 
tivariate analysis the only predictors of MACE were CRP (p=O.O07), leukocyte count 
(p=O.O4) and not having prior bypass surgery (p=O.Oll). 
Conclusion: Elevated systemic inflammatory markers are independent predictors of 
adverse cardiac events at 12 months following acute coronary syndrome. Although infec- 
tion with C. Pneumoniae is endemic in patrents with acute coronary syndrome, it is not 
associated with adverse long term outcome. 
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1218-87 Plasma Concentrations of Fibrinolytic Factors in the 
Subacute Phase of Acute Myocardial Infarction Predict 
Recurrence of Myocardial Infarction 
Takeshi Soeki, Yoshiyuki Tamura, Hisanori Shinohara, Yuki Sawada, Nobuo Fukuda. 
Zentsuji National Hospifai, Zenrsuj, Japan 
Background: The intravascular fibrinolytic system is regulated by a balance between trs- 
sue type plasminogen activator (t-PA) and plasminogen activator inhibitor-i (PAI-1). The 
prognostic vatue of these fibrinolytic proteins has also been reported in patients with cor- 
onary artery disease. However, the association between recurrent MI and plasma con- 
centrations of fibrinolytic factors during the acute and subacute phases of MI is unknown 
Methods: We recruited 106 patients who survived a confirmed first AMI between 1993 
and 1998 in our hospital. From these patients, a total of 94 (72 men and 22 women, 
mean 66 years) wrth complete follow-up were included in the present study. The control 
group for comparison of plasma concentrations of t-PA and PAI- consisted of 50 patients 
who had no coronary artery stenosis. Blood samples were obtained at the time of admis- 
sion for first acute Ml and on the 28th day after admission. Plasma concentrations of t-PA 
and PAI- antigens were measured by enzyme immunoassay. Patients were foliowed for 
a mean of 45 months after these measurements, or until March 2000. The primary end 
points of this study were fatal or nonfatal acute Ml. Results: Of the 94 patients who were 
available for follow-up, 6 had recurrent MIS. Both the plasma t-PA and PAI- concentra- 
trons were elevated on day 1 of acute Ml compared to the control group and decreased 
by day 28, but remained higher than those in the controls. Using a stepwise variable 
choice model of Cox proportional hazards analysis, only t-PA concentrations rn the sub- 
acute phase were sigmficant predictors of recurrent Ml (relative risk per SD 3.17, 
p<O.Ol). We further found that independent of other risk factors, the number of vessels 
with stenosis, and the use of drugs, an elevated t-PA concentration was predictive of 
recurrent Ml. Conclusions: The increase in plasma fibrinolytic factors seen durrng the 
acute phase of MI is probably a reaction to thrombus formation, and that seen in the sub- 
acute phase is more lkkely to be due to dysfunction of vascular endothelial cells, based on 
progressive atherosclerosrs. A rise in endogenous t-PA concentration during the sub- 
acute phase of MI can predict the recurrent Ml. 
1218-88 Minor Myocardial Damage and Prognosis: Are Spontaneous 
and Percutaneous Coronary Intervention-Related Events 
Different? 
Martijn Akkerhuis, John H. Alexander, Barbara E Tardiff, Eric Boersma, Robert A. 
Harrrngton, Michael Lincoff Maarten L. Simoons. Thoraxcenter, University Hosp~fal 
Rotterdam, Rotterdam, The Netherlands 
Background: The relevance of the adverse prognostic Implications of CK-MB elevation 
after PCI remains controversial. Therefore, we compared the relationship between the 
level of post-procedural CK-MB elevation and the risk of death after B-month follow-up 
with the relationship between the level of CK-MB elevation and mortality in patients with 
acute coronary syndromes (ACS) without ST-elevation treated medically. 
Methods and Results: In the PURSUIT trial, 5583 of 9461 patients with a non-ST-eleva- 
tion ACS did not undergo PCI or CABG and had at least 1 CK-MB sample collected dur- 
ing index-hospitalrzation. There was a gradual increase in B-month mortality with hrgher 
CK-MB levels (Table). The prognostic significance of cardiac enzyme elevation after PCI 
was assessed in a combined analysis using data from the CAPTURE, EPIC, EPILOG, 
IMPACT-II and PURSUIT trials. This analysis in 8838 patients revealed a direct, propor- 
tional relation between post-procedural (<48h after PCI) CK-MB levels and 6.month mor- 
tality (Table). 
The 6.month mortality rates were lower after procedure-related compared with spontane- 
ous Infarcts. Yet, the relative increase in 6.month mortality with each increase in the cate- 
gory of peak CK-MB level was of the same magnitude as all tests for heterogeneity of the 
odds ratios were nonsignificant. 
Conclusion: The dose-response relationship between the magnitude of post-procedural 
CK-MB elevation and B-month mortality, as well as the consistency of thus finding among 
the different studres indicate that peri-procedural myocardial damage is an important 
marker of adverse outcome. 
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1219-91 Myocardial Reperfusion With intravenous Myocardial 
Contrast Echocardiography in Patients With Optimal 
Coronary Recanalization (TIMI 3 Flow) After Acute 
Myocardial Infarction 
Paolo Colonna, Massimo Ruscazio, Roberta Montisci, Christian Cadeddu, Grorgio Lai, 
Mauro Cadeddu, Raimondo Pirisi, Luigi Meloni, Sabino Iliceto. Department of 
Cardiovascular and Neurological Sciences , University of Cagliari, Cag/iari, /ta/y 
Background: Myocardial contrast echocardiography is capable to Identify coronary 
microvascular reperfusion in patients after acute myocardial infarction. We hypothesized 
that microvascular reperk&on is superior to TIMI flow grade in predicting myocardial via- 
bility and left ventricle functional recovery in patients with acute myocardial infarction. 
Methods: We studied 55 patients (mean age 59.827.4) with acute myocardial infarction 
(20 anterior, 8 lateral and 27 inferior) with intravenous myocardial contrast echocardio- 
graphy using power Doppler in intermitting mode during injection of Levovist. A patient 
was considered as having adequate reflow if 250% of segments within the risk area was 
fully opacified. A dobutamine echocardiography was performed 3 days after the acute 
phase, to evaluate the presence of myocardial viability. According to TIMI grading in the 
Infarcted related artery at catheterization and presence or absence of reflow at intrave- 
nous contrast echocardiography, patients were divided into 3 groups: patients with TIMI 
0, 1, 2 flow (n=26); patients with no-reflow despite restoration of TIMI 3 flow (TIMI 3 no- 
reflow group, n=lO), patients wrth reflow after restoration of TIM13 flow (TIMI 3 reflow 
group, n=19). Results: 
Results TIMI 0,1,2 TIMI 3 No TIMI 3 
1219 Novel Diagnostic and Pathological 
Techniques in Acute Coronary 
Syndromes 
Tuesday, March 20, 2001, Noon-2:00 p.m. 
Orange County Convention Center; Hdl A4 
Presentation Hour: 1:00 p.m.-2:OO p.m. 
1219-89 The Temperature of Atherosclerotic Plaques is Correlated 
With Matrix Metalloproteinases Concentration in Patients 
With Acute Coronary Syndromes 
Konstantinos Toutoueas, Christodoulos Stefanadis, Eleftherios Tsiamis, Manolis 
Vavuranakis, Costas Tsioufis, Dorothea Tsekoura, Sofia Vaina, Pavlos Toutouzas. 
Hippokration Hospital, Athens, Greece 
Background: Acute coronary syndromes are the result of atherosclerotic plaque rapture, 
which may be enhanced by local secretion of matrix metalloproteinases (MMPs). Thus, 
an inflammatory process may be involved in plaque rupture, The aim of the present study 
was to investigate the association between inflammation, as it is estimated by the mea- 
surement of MMPs plasma and serum level and the temperature of the atherosclerotic 
plaques in patients with acute coronary syndroms. Methods: We used sandwich enzyme 
immunoassay and we measured serum MMP-2 and plasma MMP-9 in 15 patients suffer- 
ing from acute coronary syndromes (10 with acute myocardial infarction and 5 with 
unstable angina) and in 17 with stable effort angina. A thermography catheter, which was 
developed in our institution was used, in order to measure temperature difference (AT) 
between the atherosclerotic plaque and the normal wall vessel. Results: Patients with 
acute coronary syndromes had elevated MMP-9 compared to patients with effort angina 
(table). There ‘was no difference in MMP-2 concentration between the two groups. 
Patients with acute coronary syndromes had greater AT compared to patients with effort 
angina. A good correlation was detected between MMP-9 concentration and AT in 
patients with acute coronary syndromes (PcO.05, r=0.62). Conclu&ons: Patients with 
acute coronary syndromes had increased concentration of plasma MMP-9, which was 
well correlated with AT. This finding suggests, that plaque rupture may be due to an 
inflammatory process, leading to increased temperature of the culprit atherosclerotic 
plaques. 
AT (“C) 
MMP-9 (ngiml) 
MMP-2 (rig/ml) 
ACS EA 
0.85 +- 0.5 0.12 +- 0.1 
16.1 c- 12.3 10.4 +- 6.4 
391.7 +- 95.5 378.4 +- 77.7 
P Value 
< 0.03 
< 0.05 
NS 
1219-90 Identification of Lipid-Rich Plaques in Human Coronary 
Artery Autopsy Specimens by Near-Infrared Spectroscopy 
Pedro Ft. Moreno, S. Eric Ryan, David Hopkins, Barry Wise, K-Raman Purushothaman, 
William E. Charash, William O’Connor, James E. Muller. Gill Heart InsWute, University of 
Kentuck% Lexington, KI: /nfraReDx, Inc, Cambridge, MA 
Background: A method is needed to identify non-stenotic, lipid-rich coronary plaques 
that are likely to cause acute coronary events. Near-infrared spectroscopy (NIRS) can 
provide information on the chemical composition of tissue, and could be adapted for vul- 
nerable plaque identification in living patients. Methods: We tested the ability of NIRS to 
identify lipid-rich coronary plaques in 146 arterial sectrons from 14 cadaver hearts. Sec- 
tions were scanned using the fiber optic probe of the NlRSystems 6500 instrument. 
Reflectance spectra were measured over the range from 400 to 2500 nm (visible and NIR 
light). After scanning, sections were processed with elastrc trichrome stain. Lipid areas 
were identified by light microscopy, and quantified by computerized planimetry (Zedex 
system). The 146 sections were divided into a training set of 70 sectrons for algorithm 
development, and a test set of 76 sections. Two chemometricians (DH, BW), each using 
a separate method, performed predictive analysis in the test set, while blinded to the his- 
tologic results. Results: Lipid areas varied from 0.07 to 2.0 mm2, with a mean of 0.58 
mm2. The chemometric partial least square (PLS) model detected lipid areas above or 
below 0.6 mm2 with 83% sensitivity and 94% specificity (Table). A different approach 
(PLS-DA model) detected sections with lipid areas above and below 0.07 mm2 with 95% 
sensitivity and 96% specrficity (Table). Conclusion: Near infrared spectroscopy can clas- 
sify human coronary plaques according to their lipid content, the primary determinant of 
vulnerability. These findings support efforts to develop a NIRS catheter system to detect 
vulnerable coronary plaques in living patients. 
PLS Model NIR (+) NIR (-) PLS-DA Model NIR (+) NIR (-) 
Lipid > 0.6 mm2 5 1 Lipid (+) 21 1 
reflow Reflow 
No-reflow ratio (%) 57.9+35.4 60.4~12.5 17.3?20.4’ 
Risk area wall motion score rn the first day 2.7t0.3 2.7kO.3 2.6eO.3 
index At dobutamine 2.2&0.6+ 2.1*0.4$ 1.5_tO.5’$ 
After 3 months 2.2+0.6$ 2.1*0.2* 1.4?0.6’$ 
Global wall motion score index in the frrst day 1.7co.3 1.7kO.3 1.8r0.3 
At dobutamine 1.6~0.4 1.6kO.2 1.3+0.3tS 
After 3 months 1.6kO.4 1.6+0 2 1.3*0.4t* 
* p<O.OOl and t ~~0.05 vs TIMI 0,1,2 and TIMI 3 No-reflow patients; t p&O01 vs same 
group in the first day. 
Conclusions: In patients with acute myocardial Infarction and optimal angiographic reca- 
nalization (TIMl3), the preserved microvasculature at contrast echocardiography is 
strongly related to viable myocardium and functional recovery. Patients with no-reflow at 
contrast echocardiography, despite a coronary recanalization with a TIMI 3 flow grade, 
behave similarly to patients with a bad or absent coronary recanalization. 
1219-92 Reperfusion Imaging in Anterior Myocardial Infarction. The 
Open Perforator Hypothesis 
Paolo Voci, Enrica Mariano, Francesco Pizzuto, Francesco Montr, Gianluca Plaustro, 
Giovanni Testa,lMario Cardini, Paolo E. Puddu. Section of Card!ology /I University of 
Rome “La Sapienza”, Rome, /fa/x “Celia” Milftary Hospital, Rome, lfaly 
Background. The TIMI flow scale may not reflect the adequacy of myocardral reperfu- 
sion after myocardial infarction (Ml). Hugh-resolution transthoracic color-Doppler allows to 
image the left anterior descending coronary artery (LAD) and its perforating branches in 
anterior MI. We have assessed the impact of open LAD and perforators on recovery of 
left ventricular function after Ml. Methods. We have studied 53 unselected patients (40 
M, 13 F, age 63+13 years, werght 76t12 kg) with anterior MI, undergoing thrombolysis 
(24 pts), primary LAD stenting (18 pts) or none (11 pts). Reperfusion imaging was per- 
formed by a 7MHz probe, connected to an Acuson Sequoia C256 ultrasound unit. The 
mid-distal tract of the LAD and perforators in 4 segments of the anterior apical wall (mid 
anterior, apical anterior, apical lateral, septal lateral) were imaged. Reperfusion score 
was: 1: LAD closed, no perforators; 2: LAD open, no perforators; 3: LAD open 1-2 seg- 
ments with perforators; 4: LAD open, 3-4 segments with perforators. Wall motion score 
index (WMSI), ejection fraction (EF), end-diastolic volume index (EDVI) and end-systolic 
volume Index (ESVI) were measured at baselrne and 3 months follow-up (50 pts). Coro- 
nary angiography was used to assess TIMI flow. The linear regression method was used 
to describe the relationship between perfusion score and WMSI, EF EDVI, ESVI. 
Results. The sensitivity of color-Doppler to detect LAD patency was 97.8%, specificity 
83% and diagnostic accuracy 96.1%. There was a significant correlation between perfu- 
sion score at baseline and recovery of WMSI at follow-up, with an intersect correspond- 
ing to perfusion score 2 (Figure). Perfusion score also predicted EF, EDVI and ESVI at 
Lipid < 0.6 mm2 4 60 Lipid (-) 2 46 
JACC February 2001 
follow-up, better than TIMI flow. Conclusions. Noninvasive coronary Doppler allows to 
assess LAD patency after MI Petforaiors are landmark of myocardial viability, and may 
reflect the adequacy of myocatdial reperfusion. 
b=-0.33026~0.0310 N=50 
IA.647 
oi 
p<O.OOl 
I 
0 I 3 4 
Perhsiou score 
1219-93 Coronary Flow Velocity Reserve as a Predictor of Left 
Ventricular Volume and Functional Change After Acute 
Myocardial Infarction 
Seung-Jea Tahk, Myeong-Ho Yoon, Joon-Han Shin, Zhe-Xun Lian, So-Yeon Chat, Hyuk- 
Jae Chang. Han-Soo Kim, Byung-il W. Choi. Ajou University, Suwon, South Korea 
Background: It has been known that coronary flow velocity reserve (CFR) represents 
the degree of microvascular Integrity. This study was designed to evaluate the value of 
CFR in the prediction of left ventricular volume and functional change after acute myocar- 
dial infarction (AMI). Methods: To avoid the eifect of epicardial stenosis on CFR, intracor- 
onary adenosine-induced CFR of infarct-related artery (IRA) was measured by Doppler 
wire after successful elective angiopiasty ot stenting (diameter stenosis<30% and TIM1 
flows2) in 80 AMI patients (67 male, mean age: 55rll years) within 7 days after onset 
To evaiuate the atea of ischemic injury as a whole, CFR was measured at distal segment 
adjacent to angioplasty site. Left ventricular end diastolic volume index (LVEDVI), ejec- 
tion fraction (LVEF), and global left ventricular wall motion score index (LVWMSI) wete 
assessed by echocardiography before and after angioplasty (mean: 927 months). 
Receiver operating curve of CFR were used to determine the accuracy (area under 
cutve: AUC) and best cut-off value (BCV) tn relation to LV volume and functional change. 
Results: Mean CFR was 1.88-rO.58. In relation to the prediction of LVEDVI and LVWMSI 
change, accuracy was 83.1% on the BCV of 1.7, and 66.8% on the BCV of 1.3, respec- 
tively. Patients weie dlvtded into 3 groups according to the level of CFR. LVEDVI, LVEF 
and LVWMS changes between baseline and follow-up were compared. Patients with 
CFRal.7 showed significant decrease in LVEDVI with improvement in LVEF and 
LVWMSI Pakents with CFR 1.3-1.7 showed significant increase in LVEDVI with improve- 
ment in LVEF and LVWMSI. Patlents with CFRc1.3 showed significant increase in 
LVEDVI without improvement in LVEF and LVWMSI (table). 
Baseline Follow-Up 
LVEDVI LVEF LVWMSI LVEDVI LVEF LVWMSI 
CFR>1.7(n=39) 45tl7 52rQ 1.491t0.28 38kl4’ 61k9 1.22*0.22’ 
CFR 1.3-I .7(n=32) 44tl7 47~8 1.64i-0.26 48r14' 55+10* 1.4Oi:O31' 
CFR<I .3(n=9) 48ct21 43kQ 1.72t0.30 68*24’ 43*10 1.73t0.38 
* pcO.05 for Baseline vs. Follow-Up Conclusion: Coronary flow veloctty reserve, mea- 
sured after relief of eptcardial stenosis, may be useful predictor of left ventricular volume 
and functional change after acute myocardial infarction. 
1219-94 Left Ventricular Electra-Mechanical Mapping in Patients 
Without Previous Myocardial Infarction: Comparison with 
Stress Perfusion Imaging 
Irene Boast Glen Van Langenhove, Jean Fajadet, Patrick Serruys, Nicolas Fourquet. 
Catherine Klersy. Jean Marco. Clinique Pasteur, Toulouse. France, Thorax Center, 
Rotterdam, The Netherlands 
Background. The &sense Noga is a catheter-based system for electro-mechanical 
mapping of the left ventricle. The combination of linear local shortening (LLS) data as 
tests of local mechanical function and local intracardiac signals (unipolar voltage = UV) 
as tests of electrical function provides information about local electromechanicaf cou- 
pling. Methods. Linear local shortening and unipolar voltage wen? measured in 20 
patients without previous myocardial infarction, with documented coronary artery disease 
and revers!ble defects at stress/redistribution nuclear perfusion Imaging. The endocardial 
sites were divided into 10 anatomic regions and compared with the equivalent segments 
visualized scintigraphically. Stress nuclear images were analyzed by single photon emis- 
sion tomography and petfusion defect severtty was defined using a semlquanhtative 
scoring of segments (O=normal petfus~on, l=moderate reduction, 2= severe reduction, 
3=absent uptake). Results. A total of 176 endacardial segments had adequate scinti- 
graphic and Noga data for comparison. The distribution of means f SD LLS and accord- 
ing to thallium uptake is reported in Table. Conclusions. UV correlated significantly with 
the Severity and extent of stress perfusion defects in patients wih no prevtous Ml. UV 
potentials appears able to identify regions with severe perfusion defects and preserved 
mechanical function 
0 1 2 3 p-“&E.S 
LLS (%) 12.5 c 7.8 8.28 t 8.6 9.88 * 5.9 10.9 + 4.6 “S 
UV (mV) 14.72 5.3 11.9i5.6 13.5 24.7 8.9 i 5 6 0.0003 
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1220-95 Effect of Anti Arrhythmic Treatment for Sustained 
Ventricular Tachycarclia in the Setting of Acute Myocardial 
Infarction 
David M. Yamada, Sana M. Al-Khatib, E. Magnus Ohman, Eric J. Topol. ClevelandClinic 
Foundation, Cleveland, OH, Duke University, Durham, NC 
Background: The effect of anti-arrhythmic treatment for sustained ventricular tachycar- 
dia (VT) during hospitalization for acute Ml remains largely unknown. Amiodarone has 
demonstrated promise as an acute agent for cardiac arrest and for selected patients fol- 
lowing MI. Sotolol is not well studied in acute MI patrents, but has properties related to 
beta blockade that may be cardioprotective. Our purpose was to determine effect of 
these anti-arrhythmic agents on mortality in this setting. Methods: We studied patients 
enrolled in GUSTO-ilb and GUSTO-III who presented with acute Ml and suffered in-hos- 
pital sustained VT. Baseline variables and outcomes were analyzed based on administra- 
tion of anti-arrhythmic agents during hospitalization. Results: Of 765 patients, 165 
received amiodarone, 474 received anti-arrhythmic treatment not inciudlng amiodarone, 
and 126 were given no anti-arrhythmic drug. Sotolol was used in 33 patients. Those 
given amiodarone were older, had wotse Killip class, and a higher frequency of previous 
Ml compared to the other patients. By univariate analysis, patents receiving amiodarone 
had a non-significantly higher rate of 30.day death when compared to those given other 
anti-arrhythmic agents (36.4% vs 27.8%, p=.13) and those given no anti-arrhythmic drug 
(36.4% vs 28.6%, p=.35). In a Cox proportional hazards analysis, amiodarone adminis- 
tration was associated with a non-significantly lower rate of 30.day death (hazard ratio 
(HR)=0.72, 95% CI=O.46- 1.1, p=O.14) and one-year death (HR=0.81, 95% Cl 54-1.2, 
p=O.28). Although sotolol was used Infrequently (N=33), its use was associated with 
lower so-day mortality when compared to other medications (6.1% vs 31.4%, p=O.OOi) 
and no medications (6.1% vs 28.6%, p=O.O06). Conclusions: In the setting of sustained 
VT during hospitalization for acute MI, amlodarone treatment is not strongly associated 
with improved survival. Sotolol may improve prognosis. Prospective randomized trials 
should be undertaken. 
1220-96 Advanced Age Impairs Development of Collateral Vessels to 
Infarct Related Artery in Patients With Acute Myocardial 
Infarction 
Toshiya Kurotobi, Hiroshi S&o, Hideyuki Sate, lssei Shiotani, Eiji Hishida, Kumhiro 
Kingjoe, Daisaku Nakatani, Atsushi Iiirayama, Tsunehiko Kuzuya, Kazuhisa Kodama, 
Masatsugu Han Osaka University Graduate School of Medicine, Suita, Japan, Osaka 
Police Hospital, Osaka, Japan 
Background: Animal experiments have shown that advanced age blunts angiogenesis 
and development of new vessels in response to angiogenic cytoktnes. We investigated 
the hypothesis that development of collateral vessels (Coil) to infarct related artery (IRA) 
is impaired with aging in pahents with acute myocardial infarction (AMI). Methods: Of 
consecutive 1360 patients with AMI, 622 patients who fulfilled the following criteria were 
enrolled in this study : 1) Coronary angiograms were obtained within 72 hrs after the 
onset of AMI, and 2) IRA showed complete occlusion (TIMI grade 0 or 1). Coil to IRA was 
evaluated according to the Rentrop scote. The grades from 1 to 3 were defined as signif- 
icant Coil. in random selected 50 patients, vascular enddheliaf growth factor (VEGF) and 
hepatic growth factor (HGF) were measured at chronic phase. Results: Prevalence of 
Coil significantly decreased with advanced age (45.6% in ~50 y.o., 44.6% in 50-59 y.o., 
426% in 60-69 y.o., 32.0% in >70 y.o., p&05), and advanced age was an independent 
predicting factor to decrease collateral development to IRA (odds ratio 1.02, 95% 1.01. 
1.03, ~~0.05). Serum VEGF and HGF level were not significantly different in each 
decade. Pre-Infarction angina significantly increased the prevalence of Coil development 
below 70 y.0. (48.5% vs. 39.5%, pcO.OS), but this effect was impaired above 70 y.o. 
(33.9% vs. 31.5%, ns.). Multivariate analysis showed that the absence of Coil was an 
independent predictor of in-hospital mortality in elderly patients above 70 y.o. (odds ratio 
5.8, 95% 1.2-26.8) although this effect was not observed in patients below 70 y.o. (odds 
ratio 1.7, 95% 0.4-7.7). Conclusion: Advanced age may blunt development of Coil to 
IRA in patients with AMI due to lack of response against toll promoting stimuli. This 
abnormality may contribute to poor prognosis in elderly patients with AMI. 
1220-97 Angiographic Findings in Non Q vs. Q wave Myocardial 
Infarction After Thrombolysis for ST Segment Elevation 
infarction. Results From the DANAMI Trial 
Peter Clemmensen, Peer Grande, Jan K. Madsen, Walter B. Nielsen, Galen S. Wagner, 
Kari Saunamakt, Eli Kassis, Per Thayssen, Klaus Rasmussen, Torsten T. Nielsen, Torben 
Haghfelt, Stig Haunsoe. The Heart Center. Rlgshospitalet, Copenhagen. Denmark 
Background. Acute myocardial infarction (AMI) is often classified as Q or non-Q wave 
based on the ECG morphology. Although non-Q wave AMI are smaller the prognostic 
implicationsand need for invasive study remains controversial. Methods. 1008 patients 
with Inducible ischemia after being treated with thrombolysis for ST-segment elevation 
AMI were randomized in the DANAMI trial to conservative treatment or invasive evalua- 
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tion. For the present substudy the patients were classified as Q wave or ion-Q AMI, and 
the analysis limited to those in the invasive arm, with complete angiographic assess- 
ments (483 / 503 patients). Results. The loyalty to the randomization was the highest 
ever reported in a trial of invasive vs. conservative treatment. At 2 months revasculariza- 
tions had been performed in 83% randomlred to an invasive strategy and only 1.5% in 
those randomized to conservative treatment. As previously reported, the invasive strat- 
egy was associated with a more favorable outcome but the largest relative reduction in 
the combined end-point (death, re-infarction, and readmissions with unstable angina) 
was attained among patients with non-Q wave AMI (RR 43% vs. RR 32%; difference= 
11%; 95% Confidence Interval: 8.6.14.0%, 0.023). The table demonstrate the cardiac 
catheterization findings in patients with non-Q and Q wave AMI. “Normal coronaries” was 
defined as ~50% stenosis. Conclusions. Non-Q AMI evolving after ST-segment eieva- 
tion AMI treated with thrombolytic therapy IS associated with more preserved LVEF 
Despite inducible &hernia prior to discharge “normal” coronary arteries is a common 
finding in non-Q AMI patients, but these patients also have a higher incidence of left main 
stem stenosis and should be offered invasive evaluation to the same extent as Q-wave 
AMI patients. 
Conclusion: These data demonstrate that reperfusion-induced bradycardia and 
hypotenslon commonly occur in patients with proximal RCA occlusions affecting the RV 
and LV, but rarely occurs with distal occlusions supplying the LV alone. These findings 
suggest that reperfusion induced reflexes arising from the ischemic RV may play a role in 
abrupt bradycardia and hypotension. 
1220-100 US and Non US Outcomes Are Similar for Patients With 
Cardiogenic Shock: A Report From the SHOCK Trial 
Venu Menon, Jacques Cal, Lynn A. Sleeper, Mark Menegus, Christopher E. B&r, John 
French, Mark Porway, Harvey D. White, John G. Webb, Jean Boland, Philip Aylward, 
Judith S. Hochman. St Luke+Rooseve/f Hospital Center, New York, NY 
Cardiac catheterization finding in patients with non-Q and Q wave AMI 
N Non-Q 132 Q wave 351 p value 
Normale coronaries (%) 21 (15.9) 18 (5.1) 0.0001 
1 vessel disease (%) 50 (37.9) 187 (53.3) 0.0035 
2 vessel disease (%) 27 (20.5) 66 (18.8) NS 
3 vessel disease (%) 24 (18.2) 65 (18.5) NS 
Left main stem (%) 10 (7.6) ‘15 (4.3) 0.075 
LVEF (%) 62 (55.70) 56 (47-64) 0.00001 
Background: Superior outcomes for US compared to non-US patients with cardiogenic 
shock(CS) in both GUSTO-l and GUSTO-III megatrials have been previously reported. 
This disparity was hypothesized to be due to decreased rates of revascularization 
(PTCAICABG) and IABP in non US institutions. If outcome following CS is determined by 
rates of revascularization, then analysis of the early revascularization (ERV) arm of the 
randomized SHOCK trial which was protocol mandated should result in US/non-US out- 
comes being similar. Methods: Outcomes in US (n=89) vs. non-US patients (n=63) ran- 
domized to ERV were compared. Protocol mandated PTCAICABG was performed as 
indicated in both groups within 6 hours of randomization and 18 hours of shock. 
Results:US and nonUS patients were similar with respect to age, gender, prior diabetes, 
prior MI, and PCWP (all p > 0.10). There was a greater h/o prior HTN amongst US 
patients (58 vs. 36%, p=O.OlZ)and time from Ml to CS tended to be longer (p =0.061). 
us vs. non-us 
Variable US (n=89) non-US (n=63) p-value 
Revascularization Rate 85% 89% 0.630 
IABP Rate 85% 89% 0.630 
30.day Mortality Rate 44% 51% 0.414 
By protocol, rates of revascularization and IABP use were similar at both US and non-US 
sites. No difference in 30.day mortality rates based on geographic location were 
observed. Crude OR and Adjusted OR(adjusted for prior hypertension and time from MI 
to CS) for death amongst non US patients was 1.32 (95% Cl 0.69,2.53) and 1.44 (95% Cl 
0.73, 2.89, p= 0.299) respectively. Conclusion: The SHOCK trial demonstrated similar 
rates of revascularization and IABP utilization and similar mortality for US and non-US 
patients. Although limited by small numbers and wide confidence intervals, our observa- 
tions suggest therefore that worldwide outcome following cardiogenic shock is similar 
when a uniform treatment strategy is adopted. 
1220-98 Hospital Outcomes in Patients Presenting With Congetive 
Heart Failure Complicating Acute Myocarclial Infarction 
Audrey H. Wu, Lori Parsons, Nathan R. Every, Eric Bates. Universify of Washington, 
S&aft/e, WA, Universify of Michigan, Ann Arbor, MI 
Background: The impact of congestive heart failure (CHF) in the setting of acute myo- 
cardial infarction (AMI) on hospital outcomes is not established. 
Methods: The NatIonal Registry of Myocardial Infarction 2 database was analyzed to 
determine hospital outcomes for thrombolytic-eligible patients admitted with CHF (Killip 
class II or Ill) complicating AMI. 
Results: A total of 190,518 patients were identified (36,303 wth CHF). Patients pre- 
senting in CHF were older (72.6t12.5 vs. 63.2k13.5 yrs.), had a longer tlme from symp- 
tom onset to hospital presentation (2.8Ok2.6 vs. 2.5Ot2.4 hrs.), and had a higher 
prevalence of anterior/septal AMI (38.8% vs. 33.3%), diabetes (33.1% vs. 19.5%), and 
hypertension (54.6% vs. 46.1%) (all pcO.00005). Patients with CHF were more likely to 
receive ACE inhibitors, but those without CHF were more likely to be treated with aspirin, 
beta-blockers, thrombolflics or primary angioplasty. Patients presenting in CHF had a 
longer length of stay (8.1+7.1 vs. 6.8r5.3 days, pcO.00005) and greater risk for adverse 
hosoital outcomes. CHF on admission was the stronaest oredictor of hosoital death in 
mul&ariate analysis (OR 1.69; 95%CI 1.62, 1.75). - 
Treatment /outcome N No CHF (%) CHF (%) P 
Aspirin 164,695 89.0 75.7 <0.00005 
ACE inhibitor 29,213 13.0 25.4 <0.00005 
Oral beta blocker 74,080 41.7 27.0 <0.00005 
Thrombolytic 101,581 58.0 33.4 <0.00005 
Primary PTCA 25,596 14.6 8.6 <0.00005 
Recurrent AMI 5,182 2.7 3.0 0.002 
Cardiogenic shock 10,604 3.9 ‘12.6 <0.00005 
Cardiac arrest 9,783 4.4 8.3 <0.00005 
Hospital death 18,839 7.2 21.4 <0.00005 
Conclusion: Patients with CHF complicating AMI have more medical comorbidities and 
anterioriseptal AMI at presentation, and are at higher risk for hospital mortality and 
adverse outcomes. Despite this, they are less likely to be treated with aggressive raper- 
fusion strategies and some medications with proven mortality benefit. 
1220-99 Reperfusion Induced Bradycardia and Hypotension Is 
Common With Proximal but Not Distal Acute RCA 
Occlusions: Role of the lschemic Right Ventricle 
Daniel T. Lee, Vinh D. Nguyen, William W. Oneill, James A. Goldstein. William Beaumont 
Hospital, Royal Oak, MI 
Background: Reperfusion of the acutely occluded right coronary artery (RCA) may 
result in abrupt bradycardia and hypotension, which has been attributed to stimulation of 
BezoldJarisch reflexes arising from the ischemic left ventricle (LV). Based on clinical 
observations in patients with RV infarction from our group and others suggesting that 
bradycardia and hypotension commonly occurs following reperfusion of proximal RCA 
occlusions, we hypothesized that reflexes arising from the ischemic RV may play a role. 
Methods: We retrospectively analyzed the incidence of reperfusion induced bradycardia 
and/or hypotension in patients with acute inferior myocardial infarction undergoing pri- 
mary angioplasty of RCA lesions proximal to the RV branches (n = 144) or distal to the 
RV branches but before the LV branches (n =51). 
Results: Reperfusion of proximal RCA occlusions resulted in abrupt hypotension in 62 
(43%) patients and bradycardia in 54 (38%) patients. In contrast, reperfuslon of distal 
RCA occlusions rarely resulted in hypotension (6% p < 0.001 vs proximal) or bradycardia 
(IO%, p < 0.001 vs proximal). 
ORAL CONTRIBUTIONS 
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2:oo pm. 
What Is an Ml? Prospective Analysis of the Diagnostic and 
Prognostic impact of Adding Troponins to the Definition of 
Myocardial Infarction 
Shaun Goodman, Jeanna Johnson, Cynthia Sullivan, Ph Gab& Steg, Kim Eagle, Keith 
A. A. Fox, Jose Lopez-Sendon, Gilles Montalescot, Andrzej Budaj, Brian Kennelly, Joel 
Gore, for the GRACE Investigators. Canadian Heart Research Cent% Toronto, ON, 
Canada, Division of Cardiovascular Medicine, University of Massachusetts Medical 
School, Worcester, MA 
Background: The new consensus of The Joint ESCIACC Committee for the Redefinition 
of Myocardial Infarction suggests that any amount of myocardial necrosis caused by 
ischemia should be labelled as an infarct. This is in part based upon data derived from 
either selected clinical trial populations or retrospective analyses linking troponins with 
worse prognosis. The resulting increase in the sensitivity of defining criteria for myocar- 
dial infarction with the use of troponins could have a substantial impact on the worldwide 
incidence of myocardial infarction. Further, the prognostic value of this new definition has 
not been evaluated prospectively in a large, unselected population of patients with acute 
coronary syndromes (ACS). 
Methods: We examined the myocardial infarction rates and prognostic value of peak 
standard (CK, CK-MB) and new (troponin ITT) cardiac markers in 3,420 of 8,213 ACS 
patients with both measurements enrolled in the Global Registry of Acute Coronary 
Events (April 1999.June 2000). GRACE is a prospective, multinational, observational 
study of patients hospitalized with ACS in 94 centers in 15 countries from 4 continents, 
including Europe and the Americas. 
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Results: The addition of tsolated fropomn posttive (Tn+) patients resulted in a further 
15%, 26%, and 9% increase in the rate of myocardial infarctton dtagnosis beyond the uti- 
lization of either CK > upper limit of normal (ULN), CK t 2 times (2x) ULN, or CK-MB t 
ULN, respectrvely. The odds ratio (OR) for in-hospital mortality was significantly* hrgher rn 
iroponin-positive pattents (see Table). 
CK <= 2X CK c= 2X CK>2X CK > 2X ULN, 
ULN, Tn- ULN, Tn+ ULN, Tn- Tn+ 
tl(%) 1,285 (36%) 900 (26%) 124 (4%) 1,111 (32%) 
OR (95% Cl) for in-hospi- 1 3.0* (1.6, 2.1 (0 6, 7.4) 5.8’ (3.3, 
tal death 5.7) 10.1) 
Conclusions: The addition of troponin positivity leads to as many as 1 in 4 additional 
ACS patients meeting the criteria for the diagnosis of myocardial infarction. This group of 
patients experiences a a-fold increase rn short-term mortakty when compared to normal 
enzyme lsveis and a 1.5fold increase compared to the traditional cardiac enzyme defini- 
tion 
Conclusions: CKMB elevations following CABG are associated wtth increased risk of 
adverse k-hospital and long term outcomes. The degree of risk is proportional to the rise 
in CKMB with a clear excess of shock, cardtac arrest and mortality with CKMB 2 1 Ox ULN 
(p < 0.0001). Other factors may be important and confirms&on in larger patient popula- 
tions is needed. 
863-4 
2~45 p.m. 
Revacularization in Patients With Unstable Coronary Artery 
Disease: is There Still a Need For CABG? 
Elisabeth Stable, Odd Geiran, 60 Lagerqvist, Hans Pilegaard, Rolf Svedjeholm, Eva 
Swahn, Lars Wallentin. Dept Thoracic and Cardiovascular Surgery, University hospital, 
Uppsala, Sweden, Dept Cardiology: University hospital, Uppsala, Sweden 
Objective: In the FRISCII-study an early invasive strategy reduced the risk for death 
after 12 months by 44 % in patients wrth unstable angina as compared to a selective 
approach with invasive procedures only If indicated by symptoms or severe ischemia at 
excersice testing. A crucial question was whether early surgery could be accomplished 
without increased risk of mortality as compared to PCI with treatment only of the suspect 
culprit lesion. Methods: 2,457 patients with unstable angina were randomised to an inva- 
sive strategy (11~1,222) or to a non-invasive approach (n=1,235). After 6 months 953 
patients (78%) in the invasive group were revascularrzed, 431 with CABG and the 
remaining 522 with PCI. In this presentation early mortality in the early invaisve group 
were analyzed. Results: Out of the patients undergoing CABG in the invasive group 8 % 
had insulin-treated diabetic disease, 4 % had treated heart failure, 7 % had peripheral 
artery disease, 48 % were 70 yrs or older and 70 % had 3.vessel disease. Comparable 
figures for those who had PCI were 4 %, 1 %, 4 %, 29 % and 9 %, respectively. If high- 
risk patients were defined as those having &her of these criterias 86 % of the CABG 
patients were allocated to that group versus 39 % of the PCI patients, 16 % of the high- 
risk patients had no revascularisation. Overall mortality within 30 days was 1.6 %; 0.4 % 
for the low-risk group and 2.5 % for high-risk patients. 1.9 % for the CABG patients, 0.2% 
for the PCI patients and 3.6 % for those who had no interventron. Female sex [odds ratlo 
5.01 and diabetes [odds ratio 4.21 were independent risk factors for early mortality in 
patients who underwent CABG. Conclusion: The FRISCII trial is to date the only ran- 
demised trial that has shown a significant and maintained mortality reductton accom- 
plished with early revascularisation and preceded with antithrombotic treatment in 
patients with unstable coronary drsease. In this trtal the vast majority of high risk patients 
underwent CABG wrth very low mortality. The study confirm that complete revascularisa- 
tion with early surgery can be achieved with very low mortality It can thus be concluded 
that there is a need for early CABG in patients with unstable coronary syndromes. 
863-5 
3:00 p.m. 
A Comparison of the Impact of Practice Patterns on the 
Outcomes of Patients With Acute Coronary Syndromes in 
the USA and Canada: Post Hoc Analysis of ESSENCE and 
TIMI 1lB 
Wayne B. Batch&r, David Radley, Marc Cohen, Alexander G. G. Turpie, Anatofy Langer, 
Shaun Goodman. Terrence Donnelly Heart Center, Ontario, Canada 
Background Several studies have compared the U.S. and Canada for differences in 
health care delivery and outcomes in patients presenting wrth ST elevation MI. The TIMI- 
III registry focussed on non-ST elevation acute coronary syndromes, and showed higher 
rates of death, myocardial infarction (Ml) or recurrent rschemia in US patients at 6 weeks 
(18.4% “s Canada 13.9%, p=O.O04). However, these results may not reflect contempo- 
rary practice patterns for a broad range of hospitals in each country. 
Methods We compared the practice patterns and long-term outcomes between 1522 US 
and 2001 Canadian patients presenting with non ST-segment acute coronary syndromes 
(unstable angina and non-Q wave myocardial infarction) in the ESSENCE and TIMI 11 B 
studies. 
Results Most baselrne charactenstrcs, including age (64% vs. 64%) male gender (64% 
“s 63%) prior MI, aspirin (97% vs. 97%) and beta-blocker use (70% vs. 70%) were semi- 
iar in the two groups. Baseline TIMI risk scores were also comparable. Obesity (53% vs. 
51%) and non-caucasian race (24% “s 7.4%) were more common in the U.S. The cumu- 
lative frequency of the composite endpoint of death/Ml/urgent revascularization and 
revascularization procedures are shown in Table 1. 
Table 1 
863-2 
295 p.m. 
Elevated Plasma Levels of the Plasmin Activation System, 
but Not of Thrombin Activation System Correlate With the 
Sonographic Signs of Plaque instability in Patients With 
Unstable Angina 
Manann Gyongyosr, Paul Yang, Air Hassan, Franz Werdrnger, Hans Domanovrts, Anton 
Laggner, Dietmar Glogar, Kurt Huber. Dwision oi Cardiology, University of Vienna 
Medical Center. Vienna, Austria 
Eackground: We determined the possible association between the echocardiographic 
signs of plaque instability (expansive remodeling. plaque rupture and thrombi) and the 
increased plasma levels of piasmin and thrombin activation systems in patients with 
unstable angina. Methods: The basal plasma levels of the thrombin activation system 
(thrombrn-antithrombin complex, homocystein, tissue factor pathway Inhibitor, and pro- 
thrombin fragments 1+2) and the plasmin activation syste,m (tissue-type and urokinase- 
type plasminogen activator, plastninogen activator inhibitor type-l) were measured in 52 
consecutive admitted patients (35 male, 6Oi-12 y) with unstable angina. All patients 
underwent coronary angiography and intravascular ultrasound 3?2 hours after hospital 
admission. The atherosciarotic plaque morphology assessed by intravascular ultrasound 
was determined as plaque composition and eccentricity, plaque disruption, visible 
thrombi and calcification. Quantitative intravascular ultrasound analyses involved the 
measurements of lumen, vessel and plaque area of the culprit lesion, proximal and distal 
reference segments and the types of arterial remodeling. Results: Expansive remodel- 
ing was associated with significantly larger plasma levels of plasminogen activator inhibi- 
tor type-l (121.6*55 “s 87.7161.5 and 77.4k42.8 ngiml, p=O.O39) and urokinase 
plasminogen activator (3.04*1.2 vs 2.15iO.52 and 2.46+0.67 ngiml, ~~0.0263) as com- 
pared to constructive and neutral remodeling. Increased plasma level of urokinase plasmi- 
nogen activator was associated with plaque rupture (2.95~0.66 “s 2.51t0.87 ngiml, 
p=O.O621). Plasma levels of plasminogen activator inhibitor and urokinase plasminogen 
activator correlated positively with plaque (p=O.O297 and 0.0093) and vessel areas 
(p&O10 and p=O 0002). There was no correlation between the plasma levels of throm- 
bin activation system and qualitative and quantitative plaque morphology. Conclusion: 
Elevated levels of parameters of the plasmin activation system, but not the increased lev- 
els of thrombin activation system are associated with signs of plaque instabtlity of the GUI- 
prit lesion tn patients with unstable angina. 
863-3 
230 p.m. 
Cardiac Enzyme Elevations After Coronary Artery Bypass 
Grafting Associated With Increased Risk of Death: Results 
From PARAGON-B 
Kenneth W. Mahaffey, Matthew T. Roe, Rodney Sparapani. Christopher B. Dyke, John H. 
Alexander, Lisa G. Berdan. Christopher B. Granger, Magnus Ohman, Robert M. Califf, 
Eric J. Topol, Robert A. Harnngton. Duke Clinica Research Institute, Durham, NC 
Background: The clinical importance of cardiac enzyme elevations following coronary 
artery bypass grafting (CABG) is controversial. 
Methods: To evaluate the assocration between creatrne kinase-MB (CKMB) enzyme ele- 
vations following CABG and clinical outcomes, we analyzed patients from the PARA- 
GON-B trial that evaluated the glycoprotein llbillla inhibitor. lamiftban, in patients with 
non-ST-segment elevation acute coronary syndromes. 
Results: A total of 5,225 patients were enrolled of which 790 underwent CABG a median 
(25’“, 75’h) 5.9 (2.9, 10.2) days after enrollment. Enzyme data following CABG were 
avarIable for 390 (49%) of CABG patients. Enzyme elevations were analyzed as a ratio of 
the peak CKMB and the laboratory upper limit of normal (LJLN). Clintcal outcomes occur- 
ring after CABG in-hospital, at 30 days. and at 6 months stratifred by ratio of CKMB eie- 
vation are shown: 
MB MB MB MB MB 
5 ULN 1.3xULN 3-5 x ULN 5-l 0 x ULN tlOxULN 
N 56 131 66 74 63 \ 
In-hospital 
Cardiac Arrest 3.6% 1.5% 0% 2.7% 14.3% 
Shock 1 .8% 1 .O% 0% 4.1% 12.7% 
30.day 
Death 3.6% 1 0% 0% 2.7% 14.3% 
Stroke 7.1% 3.8% 6.2% 0% 7.9% 
B-month 
Death 3.8% 2.3% 0% 4.1% 14.3% 
Canada (n=ZOOl) USA (n=1522) Log Rank p value 
3 Month n (“q n (!A) 
DeathiMVUrg Revasc 366 (18.5) 278 (18.6) 0.74 
Death/Ml 176 (8.9) 135 (9.1) 0.78 
Any revasc 606 (31.0) 611 (40.8) <O.OOl 
CABG 272 (14.0) 267 (17.9) <O.OOi 
6 Month n (70) n (%) p value 
DeathiMIIUrg Revasc 407 (20.6) 306 (20.6) 0.79 
Death/Ml 206 (10.5) 152 (10.3) 0 99 
Any revasc 663 (34.1) 622 (41.6) <O.OOl 
CABG 312 (16.1) 281 (19.0) 0.0019 
12 Month n (%) ” ( %) p value 
Death/Ml/&g Revasc 459 (23.3) 357 (24.4) 0.39 
Death/Ml 249 (12.7) 186 (12.8) 0.85 
Any revasc 703 (36.3) 644 (43.3) <O.OOi 
CABG 352 (18.3) 294 (20.0) 0.02 
Conclusions In the largest US-Can&an comparative study of acute coronary syndrome 
outcomes to date, despite the more frequent use of revascularization procedures in the 
US, long-term clmical outcomes are similar to those observed in Canada. 
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3:15 p.m. 
Quality of Life One Year After Invasive Intervention in 
Unstable Coronary Artery Disease: Results From the FRISC 
II Invasive Trial 
Magnus Janzon, Lars-,&ice Levin, Eva Swahn, FRISC II Investigators. Insfrtution of 
Medicine and Care. Linkiiping Universi~ Linkdping, Sweden, GMT, Center for Medica/ 
Technology Assessment, Linkiiping Univers,ty Linkaping, Sweden 
Background: Both early invasive and non-invasive treatment strategies in patients pre- 
senting with unstable coronary artery disease have been used during the acute phase of 
the disease. Until today there is no published study analysing the quality of life in this 
important and large patient group in the long-term follow-up. The aim of this study was to 
identify differences in quality of life between the two treatment groups. 
Methods: A total of 2 457 patients, median age 66 years and 70 % men, with unstable 
angina or non-Q-wave myocardial infarction were random&d to early invasive or non- 
invasive treatment. The quality of life was measured with the generic quality of life instru- 
ment SF 36 (Short Form 36 Health Survey) at time for randomisation, outpatient visits at 
3 and 6 months. At one-year follow-up SF-36 was measured in a subgroup of 620 
patients. SF-36 is presented in eight scales (range O-100, where 100 corresponds to full 
health). 
Results: In the FRISC II trial the invasive treatment showed a significant reduction in 
mortality (2.2 % vs. 3.9 %, p=O.O16). At time for randomisation there was no significant 
differences in quality of life between the groups in six of the scales. At 3 and 6 months fol- 
low-up It was a significant difference (p<O.Ol in all eight scales) in quality of life favouring 
the invasive group. The differences still remained significant at one-year follow-up in six 
of the scales. 
Conclusions: Patients with unstable coronary artery disease treated with early invasive 
strategy have better quality of life measured with SF-36 up to one-year follow-up com- 
pared to patients treated with non-invasive strategy. 
Method: We prospectively studied 901 patients (01196 - -5/OO) treated with PA ~12 hr of 
symptoms, out of which 170 (19%) were elderly. Two angiographers performed quantita- 
tive analysis and prespecified cllnical variables were entered in to a dedicated database. 
Independent risk of old age after adjusting for explanatory variables was quantified by 
logistic regression modeling for 30 day MACE. 
Results: The elderly were more likely to hypertensive (64% vs 42%), women (54% vs 
26%) and with prior Ml (19% vs 13%) but less likely to be current smoker (29% vs 54%), 
hyperlipidemic (23% vs 48%) and with family history of premature coronary disease 
(10% “s 42%) [All p<O.O5]. 
Elderly were more likely to present late (325&i 15 vs 278+86 minutes), in cardiogenic 
shock (24% vs 12%), three vessel disease (55% vs 30%), fail to achieve TIMI grade 3 
flow (15% vs 6%), develop persistent no reflow (13% vs 4%) and have higher 30.day 
MACE (22.4% “s 13.1%) [All p<O.O5]. 
All clinical and angiographic variables significant (~~0.05) in univariate analysis were 
included in a forward stepwise logistic regression model. In this model, cardiogenic 
shock, prolonged symptom-to-balloon time, a final TIMI flow of ~3, use of abcixlmab and 
higher acute luminal gain were independent predictors of 30.day MACE 
Conclusion: Elderly patlents suffer increase MACE compared to young. Prolonged 
ischemia time and cardiogenic shock at presentation increase the risk of MACE. 
Because of the protective effect, use of glycoprotein Ilb/llla inhibitors and larger luminal 
gain should be advocated in the elderly. 
Logistic regression model 
Multivariate predictors Odds Ratio 95% Cl Lower UPPer 
Cardiogenic shock 4.425 2.616 7.484 
Symptom onset to balloon time 1.006 1.004 1.009 
Final TIMI grade flow <3 4.865 2.516 9.411 
abciximab use 0.449 0.279 0.723 
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1249-75 Primary Angioplasty in Acute Myocarclial infarction: Does 
Age Matter? 
Carol Regueiro, Alison Hart, Linda Crawshaw, Shelly McCormick, Michael Anshelevich, 
Terry Hentosr, Richard Shannon. Allegheny General Hospital, Pittsburgh, PA 
Background: Recent data suggest that there are substantial variations in the treatment 
of acute myocardial infarction (AMI) based on age, race, gender and socioeconomic sta- 
tus. Advanced age is associated with graver outcomes in AMI that may benefit from acute 
coronary interventions. We evaluated the use of primary angioplasty (PA) in AMI in eld- 
erly patients treated in an academic referral center. Methods: We reviewed the records 
of a convenience sample of 166 patients with AMI from 1997.2000. Our primary outcome 
was PA in AMI, defined as coronary intervention within the first 24 hours of admission. 
Secondary outcomes included use of post-AM1 therapies such as Aspirin (ASA), beta- 
blockers (BE), angiotensin converting enzyme inhibitors, and other anticoagulants (AC). 
We collected variables including demographics, comorbidities, do-not-resuscitate status, 
physician characteristics, and severity of illness using the ATLAS system. Univariate 
analysis was performed on the variable of interest as well~as all candidate variables. Sub- 
sequent logistic regression modeling incorporated all variables significant on univariate 
analysis. Insignificant variables that were confounded with age were kept in the final 
model. Results: Unadjusted analysis revealed that older patients were significantly less 
likely to receive both PA for AMI, and post-AM1 BB, or AC (all p<.O5). Other factors which 
had a significant negative impact on use of PA included do-not-resuscitate status, 
increasing acuity of presenting signs and symptoms, severity of illness, and dementia (all 
p< .05). After adjustment for these potential confounders, Increasing age remained 
inversely associated with both PA (pc .OOl), and use of standard post-AM1 BB or AC 
(pc.05 ). Conclusions: Our results indicate differences in the use of both PA and post- 
AMI therapies in the elderly AMI patients. These differences are not explained by severity 
of illness and suggest that interventions and standard therapies may be withheld from 
those who may benefit most. 
1249-76 Primary Angioplasty in the Elderly: Predictors of 
Angiographic and Clinical Outcome in the Era of Stents and 
Ilb/llla Inhibitors 
Satyendra Giri, Jeffrey A. Hirst, Francis J. Klernan, Daniel B. Fram, Jeffrey J. Popma, 
Charles A. Primlano, Joseph Mitchel Brigham & Women’s Hospital, Boston, MA, 
Hartford Hospital, Hartford, CT 
Prior studies have suggested that primary angioplasty may be the preferred method of 
reperfusion in the elderly (>75yr) compared to thrombolytic therapy. Less is known about 
the impact of stems and llbillla inhibitors on major adverse clinical outcomes (MACE) in 
this population. 
1249-77 Early ST-Variability Predicts Thrombi in the Infarct Related 
Artery. A Report From the ASSENT PLUS ST-Monitoring 
Substudy 
Per Johanson, Monica Erlksson, Gerd K&illstrijm, Gunilla Norman, Jenny Riissberg, Ann- 
Marie Svensson, Helena Svensson, Mikael Dellborg. Sahlgrenska University Hospital/ 
bstra, Gdteborg, Sweden 
Background: Rapid, complete and sustawed reperfusion is the goal when treating an 
acute myocardial infarction. Continuous ST-monitoring has been shown to accurately 
evaluate reperfusion and reocclusion. Early dynamic changes in the ST-segment shift 
has been connected to worse outcome, intermittent reocclusions and a higher thrombo- 
genie activity. 
Methods: A total of 214 patients from 11 hospitals were included in the vectorcardio- 
graphic substudy of the ASSENT PLUS-trial. Inclusion-criteria were the same as in the 
ASSENT 2.trial. All patients received alteplase and either heparin or daltepann. An 
angiogram was planned on day 4-7. Patients were ST-monitored for 24 hours. ST-trend 
curves were analysed blindly by two independent observers. During the acute phase, O-4 
hours, an increase in ST-vectormagnitude of 25pV for >= 2 minutes was considered as a 
significant episode of ST-variability. During hours 4 to 24 the cut-off 5OpV was used to 
define a ST-episode, according to our previous vectorcardiographic definitions. Patients 
with bundle branch block were excluded. 176 of the patients underwent an angiography, 
which also was core-lab analysed by two persons. 
Results: 33 patients showed a thrombus in the infarct related artery. Patients with a 
thrombus had a longer total duration of ST-variability during the first 4 hours 28 vs. 17.6 
minutes, p=O.O09. They also had more, 2.1 vs. 0.25 (p<O.O005), and longer ST-episodes 
during hours four to twenty-four, 25 vs. 2.4 minutes (p<O.O005). Seven patients had vec- 
torcardiographic signs of reocclusion. Out of these, 6 had a thrombus in their infarct 
related artery, as compared to 27 out of 169 in patients with no sign of reocclusion, 
p=O.OOOOt, Vectorcardiographic signs of reocclusion during the first 4 hours predicted 
occurrence of a thrombus in 100% (3 out of 3 vs. 30 out of 173), p=O.O063. 
Conclusion: Vectorcardiographic signs of reocclusion, and small dynamic changes here 
defined as ST-variability and ST-episodes, predict occurrence of thrombi in the infarct 
related artery, and may lead to consideration of adjunctive therapeutical steps, such as 
use of a GP Ilb llla inhibitor or urgent revascularization. 
1249-78 Direct lnfarctlntervention in Women: Is There a Gender 
Difference in Clinical Outcomes? 
Ambika Bhaskaran, Robert M. Siegel, Barbara Barker, Warren Breisblatt, Charles Jest, 
Warren Zeitlin, Stephen Cantor, Sheryn Shimamoto, Deborah Frazier, Jennifer 
Vermillion. Advanced Cardiac Specialists, Gilbert/ Phoenix, AZ 
Background: Female gender is regarded as an independent predictor of mortality follow- 
ing Ml. We evaluated our registry data over 5 years (5/95-7/00) on 1,036 consecutive 
patients (336 female; 696 male) who underwent direct infarct intervention (d-PTCA) 
within 12 hours of onset of symptoms. Methods: We analyzed baseline variables, proce- 
dural, in-hospital and 12.month clinical outcomes. Compared to men, women were older 
(61 vs. 66 years; p <O.OOOl), more frequently diabetic (17% vs 25%; pcO.0001) or hyper- 
tensive (46% vs 57%; p=O.O05). Men were more frequently smokers (38% vs 31%; 
p=O.O02), had higher rate of prior Ml (22% vs 14%; p <O.OOOl) and prior CABG (12% vs 
5%; p=O.OOl). Women took longer to arrive at the hospital (120 vs 97 minutes; p=O.O5) 
but mean time to open vessel from arrival was similar (13 vs 16 minutes; p=O.O8). Both 
groups had similar baseline angiographic variables and LV function (mean LVEF 42.5%). 
Results: Procedural success was comparable (97.6% women, 97.6% men; p=O.31). 
Acute re-occlusion was more frequent in women (0.7% vs 0; p=O.O5) with longer hospital 
stay (4.1 vs 2.9 days; p<O.OOOl). In-hospital CABG (2% women vs 1% men) and death 
(0.3% in both) was similar in both groups. The use of anti-platelet drugs, beta-blockers 
and ACE-inhibitors was similar in both. At 12-month follow-up, mortality (4.2% women, 
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3.8% men), target vessel re-PTCA (6.9% women, 6.4% men), CABG (3.4% women, POSTER SESSION 
3.7% men) and event-free survival (84.6% women, 85.8% men) showed no significant 
difference between both groups (p ~0.05) Women showed a significant we in mean 
LVEF (9%; peO.046) unlike men (3%; p=O.SO). Conclusions: D-PTCA appears to be 1250 Morbidity and Mortality Associated With 
safe and effectwe in women. Despite unfavorable baseline comorbldities, procedural suc- 
cess is high and comparable to men. Acute reclosure IS higher in women and hospital Surgical Revascularization 
stay longer. At 1 year follow-up, wxnen demonstrate event-tree survival rates similar to 
men. Our experience reinforces Ihat female gender should not be a contraindication to 
Tuesday, March 20, 2001, 3:00 p.m.-5:OO p.m. 
invasive strategy in acute Ml. Women appear to achieve greater gains than men in LV Orange County Convention Center, Hall A4 
systolic performance. suggesting that aggresswe straiegies may be particularly war- 
ranted, for effective myocardial salvage and improved survival. 
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jociated With the Risk of Stroke Following 
ults From the National Cardiovascular Network 1249-101 Creatinine Clearance but Not Serum Creatinine on 
1250-79 Factors As! 
Admission Predicts Early and Late Death After Primary 
CABG: Res 
Angioplasty 
VW 
Simon R. Dixon, Cindy L. Grines, David A. Cox, Gregg W. Stone, Eulogio Garcia, LUIZ A. 
Maltos, Bruce Ft. Brodie, Alessandro Giambartolomei. Lorelei L. Grines, Judith A. Boura, 
William W. O’Neill, Marie-Claude Morice. Wiliam Beaumont Hospital, Royal Oak, MI 
Elizabeth M. Mahoney, Trevor D. Thompson, Emir Veledar, Joy Burn&?, Jeremy Morton 
Willis H Williams, William S Weintraub. Emory Universi!y School of Medicine, Ailanta. 
in 
Background: Few data exist regarding the influence of mild or moderate renal dysfunc- 
tion on early or late ouicome after acute myocardial infarction (AMI). 
Methods: AMI patients presenting within 12 hours of symptom-onset were randomized 
to primary Sent or PICA. Baseline serum creatinine was available for 851 patients. Cre- 
atinine clearance was calculated using the Cockcroft-Gault formula: CI=((140-age) x 
weight)/(72 x .serum creatinine); corrected x 0.85 for women. Clinical follow-up was 
obtained at g-months. 
Results: The mean serum creatinine and creatinine clearance on admission were 1.05 f 
of early and late death after primary angiopiasty or stenting for acute myocardial infarc- 
0.35 mg/dL and 89 + 34 mlimin respectively. Serum creatinine alone did not correlate 
with in-Ihospital or six-month event rates. However, by univariate analysis a creatinine 
clearance of < 75 mlimin (mean creatinine 1.2 f 0.4 mg/dL) was associated with hypoten- 
sion in the cath lab (10.6 vs 6.5%. p=O.O35), intubaiion (1.3 vs O%, p=O.O18), in-hospital 
tion. These dais suggest thai routine calculation of admiswn creatlnine clearance may 
death (5.1 vs 0.8%, p=O.O001), in-hospital MACE (6.8 vs 3.0%, p=O.Ol) and death at 6. 
months (7 4 vs 1 .i%. p<O.OOOl). Creatinine clearance predicted in-hospital and S-month 
death in a multivariate model [excluded age and sex since these were used to calculate 
better risk stratify AMI oatienls. 
clearance). Mean contrast volume was not significantly higher for patients with events. 
Four patients required dialysis post intervention; admission creatinine and creatinine 
clearance were: 0.7. 1.0, 1.5, 4.r mg/dL and 80, 95. 53, 22 mlimin in these patients 
respectiveiy. 
Conclusion: Creatinine clearance, bui not serum creatinine, on admission is a predictor 
Background: Stroke is a devastating complication of coronary surgery. Improved ability 
to identify patients at high risk of peri-operative stroke could be used to improve medical 
decision making. 
Methods: We examined factors associated with risk of peri-operative stroke using a 
large national outcomes database. DemographIc, clinical and peri-operative characieris- 
tics were examined in 20,585 patients undergoing CABG at 16 NCN centers between ii 
98 and 6/99. 
Results:Mean age was 66&l 1 yrs with 31% female. The incidence of peri-operative 
stroke was 1.9% (n=398). For patients with stroke, in-hospital mortality was 24.9% as 
compared to 2.8% for non-stroke patients (pc.0001). Multivariable logistic regression 
revealed 11 factors independently associated with the risk of stroke, as well as an inter- 
action with sex whereby the risk associated with cerebrovascular disease was greater for 
men than women. The c-index for the model was .74 (73 from bootstrap validation) Indi- 
eating very good discrimination 
NCN In-Hospital Stroke Following CABG Model 
Factor x2 (df) p-value Odds Ratio 95% Cl 
Age ( 10 yrs.) 41.78 (1) c.0001 1.47 1.31-l .65 
<.OOOi 1.09 1.06-1.12 Bypass Time (20 min) 41.34 (1) 
Unstable Angina 10.14 (1) .0015 1.41 1.14-1.75 
Hx. CVD 53.02 (2) <.OOOl 
Female 1.45 1.03-2.05 
Male 2.73 2.07-3.61 
PVD 8.80 (1) .0030 1.45 1.13-1.85 
1249-102 Women With Acute Anterior Myocardial Infarction Have Female 10.73 (2) .0047 
Less Precordiai ST Elevation Than Men Independent of Age No Hx. CVD 1.50 1.14-1.98 
of Presentation Hx. CVD 0.80 0.55-1.16 
R. S. Wright Wayne L. Miller, lhor Gussak, David L. Dvorak, Thomas P Aufderheide. 
John H. Haley. Stephen L. Kopecky, Guy S. Reeder. Stephen C. Hammill. Mayo Clinic 
Rochester, MN 
detection of anterior acute MI from 42% to 48% for women < 60 years. 
ECG Lead Women ~60 Men ~60 p-value Women >60 Men >60 p-value 
Introduction: Women who experience acute myocardial infarction (AMI) have signifi- 
cantly higher mortality rates than men. Previous studies have demonstrated that women 
are treated less aggressively than men. It is not clear why these gender differences exist. 
v2 
It is possible that the electrocardiographic changes in women differ compared to men in 
307dZO6 
AMI. Populations and Methods: We analyzed 1366 patients who had digitally stored 
432i300 
admiswn ECG’s with acute myocardial infarction (n=1159) and 207 age-matched con- 
0.007 
trol patients with non-cardiac chest pain. We subdivided them into age < 60 years 
336+252 
(n=402) and age > 60 (n=757) and compared to 207 age matched controls and by 
421+271 
whether they were ST elevation or non-ST elevation AMI. We compared Ihe magnitude of 
0.009 
ST elevation (STE, expressed in WV) usmg a new computerized ECG analysis system at 
the ST-E-point. STE was separated from non STE by the presence of r 50 IJ-V on the 
index ECG. Results: QRS duration was slightly different between women and men in our 
study population. The QRS duration for females over age 60 was 93+ 16 msec compared 
to lOl+ 22 in males > 60, p&001. Such differences were less pronounced in females < 
60 (91+ 16 msec) vs males < 60 (96+ 14 msec), p=O.O54. We did observe that women 
had signlficantiy less STE than men independent of age. A computerized ECG program 
(GE Marquette) using these new findings on admission ECGs improved the sensitivity for 
Hx. CHF 7.37 (1) .0066 1.35 1.09-l .68 
Hypertension 6.74 (1) .0094 1.39 1.08-l .78 
Renal IrlSUff. 6.36 (1) .0117 1.52 1.10-2.10 
Diabetes 4.39 (1) .0362 1.26 1.01-1.56 
Wt. (kg.) 9.93 (4) .0416 non-linear . . 
A nomogram can be created from this model which may be useful in identifying patients 
at high risk of peri-operative stroke. 
Conclusion: The risk of p&operative stroke is increased in older patients, and patients 
with: previous CVD, prolonged bypass time, unstable angina, peripheral vascular dis- 
ease, heart failure, hypertension, renal insufficiency, diabetes and/or obesity. Predicted 
probabilities of peri-operative stroke can be derived from this model in order to identify 
high-risk patients who may benefit through the consideration of alternaiive treatment 
strategies. 
1250-80 Hospital Care After Coronary Artery Bypass Grafting 
Procedures 
Elisabeth Stable, Paul Blomqvist, Johnny Steuer, Anders Ekbom. Depf Thoracic 
Cardiovasc Surgery Universify hospital, Uppsala. Sweden, Dept Medical Epidemiology, 
Karolinska institute, Stockholm. Sweden 
v3 336+274 478+383 0.017 446r292 528r291 0.023 
v4 2oozt210 323*307 0010 322i-222 419+237 0.0076 
v5 1072143 157%155 0.045 190~156 229+183 0.069 
Conclusions: It is important to recognize that women have less STE than men with 
anterior AMI. These differences exist independent of age. It is possible that women with 
AMI may experience worse in-hospital outcomes and receive less aggressive therapies 
in pari due to these electrocardiographic differences which mask a subset of women with 
AMI who fail to meet traditional criteria for repetfusion therapy, 
need for reinter;entions due to progkession of the CAD or graftclosure. Method;: 7,721 
patients underwent primary CABG 1987 through 1996. Follow-up of survival and admis- 
sion to any Swedish hospital was updated in january 1998 by computerized linkage to 
Background: After a coronary artery bypass grafting procedure patients still have a sub- 
national registrers. The mean follow-up was 52 months. Results: During follow-up 792 
stantial risk for readmission to hospital. This risk is partly influenced by an increased mor- 
patients died corresponding to a survival rate of 95% after one year, 94 % after years and 
91 % after 5 years. Early mortality definied as death from any cause before hospital dis- 
charge was 3.0 % (22917,721). 36 % (2,71U7492) of those thai survived the first hospital 
stay needed no hospital readmission. 66 patients out of those died without prior hospltal- 
isation. 4,780 patients were readmitted at 36,073 occasions. First readmission most 
often occurred within the first postoperative year. Freedom from readmission was 56 % 
after 1 year and 37 % after 3 years. The absolute vast majority of readmissions were 
related to some extent to the ischemic heart disease 2,446 (7 %) admissions were 
blditv caused bv the arterioslerotic orocess and related diseases but also the possible 
caused by peripheral artery disease, 353 (1 %) by neurologxal disorders and 276 (1 %) 
by fractures.lndependant riskfactors for readmission among patients surviving surgery 
was high age (c 60 yrs relative hazard [RH]=i .O, 60-70 yrs RHz1.2, > 70 yrs RH=i .4), 
hypertension (RH=l i), diabetic disease (RH=l.3), severely reduced left ventricularfunc- 
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tion (RH=i .3) and advanced preoperative NYHA functional class(ll-IIIA =I .O, lilB=1.2, 
IV=l.3). Conclusion: Considering that CABG patients constitute a severely drseased 
group, the finding that 40 % of the patients did not need readmission within 3 years fol- 
lowing surgery, is encouragrng and strongly supports complete revascularisation with 
CABG. 
1250-81 Elimination of Cardiopulmonary Bypass Improves Early 
Clinical Outcome After Coronary Artery Bypass Surgery in 
Patients With Chronic Renal Insufficiency 
Sotiris C. Stamou, Michael Mack, Syma Prince, Albert .I Pfister, Mercedes K. C. Dullum, 
Paul J. Corso. Washington Hospitai Center, Washington, DC, Medical City Dallas 
Hosp,ta/, Dallas, TX 
Background: Chronic renal insufficiency (CRI) has been associated with a high morbid- 
ity and mortality (7.15%) after coronary artery bypass grafting (CABG) with cardiopulmo- 
nary bypass (On-pump). It is unknown, however whether CABG without cardiopulmonary 
bypass (OPCAB) may yield a” improved clinical outcome over On-pump CABG in 
patients with preexrsting CRI. Methods: We compared the perioperative outcomes of 
patients with CRI, (baseline serum creatinine > 2.0 mgidl), who underwent On-pump 
(n=210) versus OPCAB (“=91), between October 1998 and April 2000. Only patients 
who received > 1 graft were included. Patients were well matched with respect to the 
baseline characteristics, except for a higher percentage of male patients (76.4% vs. 
60.4%, p=O.O08) at the On-pump vs. OPCAB group. Results: Early clinical outcome is 
show” (see table). No patient scheduled for OPCAB required conversion to On-pump 
CABG. Complete revascularization was achwed in all patients. Conclusions: The dele- 
terious effect of CRI on the early clinical outcome after CABG is especially pronounced 
after On-pump than OPCAB. Pulmonary, cardiac and further renal function deterioration 
in patients with preexisting CRI may account for this phenomenon and favor OPCAB as a 
low risk revascularizatio” option at this subset of patients. 
On-pump CABG OPCAB P 
Prolonged Ventilation 15.7% 5.5% 0.014 
Low Cardiac Output 13.8% 1 1% <O.OOl 
Hemodialysis 9.5% 2.5% 0.028 
Packed red blood cell units 4.7 (SD=3) 3.1 (SD=2) 0.046 
Ooeratw mortality 10.0% 4.4% 0.12 
1250-82 Early Mortality And Morbidity of Bilateral Versus Single 
Internal Thoracic Artery Revascularization: Propensity and 
Risk Modeling 
Demosthenes Katritsis, John loannidis, Otho” Galanos, Cliff P. Cannery, George 
Drossos, Daniel G. Swistel, Constantine Anagnostopoulos. ATHENS EUROCLINIC, 
ATHENS, Greece 
Objective. We examined whether bilateral internal thoracic artery (BITA) revasculariza- 
tion is associated with any increased in-hospital mortality and complications compared 
with single internal thoracic artery (SITA) revascularizat/on. Background. Despite prove” 
long-term benefits, BITA revascularizatio” has been slow to adopt because of fear of 
increased early morbidity. Methods. We evaluated 1697 consecutive patients undergo- 
ing BITA (“=867) or SITA (n=630) revascularizatio”. We used propensity score analyses 
and adjusted risk models to address drfferences between arms. Results. There were 20 
(2.3%) deaths in the BITA group vs. 26 (3.1%) in the SITA group (odds ratio 0.73, 
p=O.30). Propensity analysis identified several parameters that affected the decision to 
use BITA. Adjusting for propensity score and all potential risk factors, the odds ratio for 
death with BITA vs. SITA was exactly 1 .OO. BITA did not increase the number of in-hospi- 
tal complications with the possible exception of deep sternal wound infections (11 [1.3%] 
vs. 3 [0.4%], p=O.O57). In multivariate modeling BITA increased the risk of deep sternal 
wound Infections only in emergent cases and in older patrents; the excess risk was “egli- 
gible among 1206 patients (71.1% of total) who did not have emergent revascularization 
and were *70 years old (risk difference 0.3%, ~~0.74). There was no difference in length 
of stay after adjustment for propensity factors (mea” 11.3 vs. 11.7 days, p=O.66). Con- 
clusions. BITA grafting confers no increased risk for early death and does not prolong 
hospital stay. The small increase in the risk of deep sternal wound infections does not 
affect the majority of patients. 
1250-83 ___ Clopidogrel for Prevention of Thrombotic Complications 
After Cardiac Surgery: A Word of Caution 
Mercedes K. C. Dullum, Borjanka 0. Leiboff, Sotiris C. Stamou, Peter C. Hill, Steve” W. 
Boyce, Albert J. Pfister, Ammar S. Bafi, Robert C. Lowery, Qazi Anjum, Jorge M. Garcia, 
Paul J. Corso. Washington Hospital Center. Washington, DC 
Background: Ciopidogrel is a relatively new platelet aggregation inhibitor, but both its 
efficacy and its safety as a pharmacological adjunct to cardiac surgery have not bee” 
fully elucidated. 
Methods: We retrospectively analyzed the patients who underwent coronary artery 
bypass surgery (CABG, n=979), valve replacement (n=95) or CABG plus valve replace- 
ment (1x126) between January and August 2000. We compared the early clinical out- 
come between two groups: Group A who received preoperative clopidogrel (75 mg, once 
per day, orally) and aspirin (325 mg, once per day), (“=121) and Group B who received 
aspirin alone (325 mg, once par day), (~1079). Early thromboembolic and hemorrhagic 
complications were recorded in patients from both groups. Patients from the two groups 
were comparable with respect to baseline characteristics. 
Results: Comparative analysrs is summarized in Table. 
Complications Group A (“~121) Group B “x1079) p 
Hemorrhagic 
Postoperative transfusions 61% 45% 0.001 
Reoperation for bleeding 3% 2% 0.32 
Gastrointestinal bleeding 7% 1% <O.OOl 
Thromboembolrc 
Pulmonary embolism 2% 1% 0.38 
Deep venous thrombosis 0% 0.2% 1 
Stroke 2% 3% 0.57 
Acute myocardial infarction 1% 0.4% 0.41 
Conclusions: Clopidogrel plus aspirin preoperative has a significantly higher rate of 
postoperative hemorrhagic complications than aspirin alone. 
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1251-84 Basal Nitric Oxide Synthesis in Coronary Stenoses: 
Relation to Morphology, Length, Severity 
Dimitris Tousoulis, Costas Tentolouris, George S. Goumas, Costas Xenakis, Tom Crake, 
Costas Toutouzas, Ads Androulakis, Christodoulos Stefanadis, Graham Davies, Pavlos 
Toutouzas Hippokration Hospital, Athens, Greece, Hammersmrfh Hospital, London, 
United Kingdom 
Background: Nitric oxide(NO), a major component of endothelium derived relaxing fac- 
tor, is synthesized from the amino acid-L-arginine by a family of enzymesThe synthesis 
of NO is competitively inhibited by NG-monomethyl-L-@nine (LNMMA). The effect of 
inhibition of NO synthesis on coronary &noses in relation to their geometric characteris- 
tics is unknown. Methods: I” 28 patrents(24 male, 4 female) with coronary artery dis- 
ease (CAD) and chronic stable angrna, normal saline (NS) and 4 imol/mi” LNMMA were 
infused intracoronary, each for 4 minutes, followed by a” intracoronary bolus of 250 ig 
nitroglycerin(GQi). Coronary stenoses were classified as smooth (smooth concentric or 
eccentric with regular borders) or irregular. The diameter of 26 smooth and 12 irregular 
coronary stenoses and their adjacent reference (Pi) segment was measured by comput- 
erized quantitative angiography. Results: The mea” (+SEM)% change from baseline 
NS LNMMA GTN 
Smooth stenoses 0.3*0.5 -1.8kO.8 11.2&i 
R segments 1.0*0.3 -1.7+0.8 8.3+1.5 
Irregular stenoses 1.0+0.7 -7.0?1.6*+ 19.3i3.v+ 
R segments 0.910.4 -1.2+1 .l 10.8+2.1 
‘=p<O.Oi vs smooth stenoses, +=p<O.Oi vs R segments. 
The severity of stenoses at baseline correlated with the magnitude of LNMMA response 
irrespective of the type of morphology (p<O.Ol), whereas there was a weak correlation 
(r=0.39, ~~0.05) between length of stenoses and the magnitudeof constriction to 
LNMMA. No correlation was found between eccentricrty ratio and the response to 
LNMMA (p=NS). Conclusion: I” patrents with CAD, irregular coronary stenoses constrict 
significantly more than smooth stenoses, following inhibition of nitric oxide synthesis with 
LNMMA. This enhanced constriction is focal at the site of stenoses than at the adjacent 
reference segment. The degree of response to LNMMA is related to stenoses length and 
stenoses severity and is unrelated to eccentricity ratio. 
1251-85 Amelioration of Ischemia- and Reperfusion-Induced 
Myocardial Injury by Raloxifene: Roles of Nitric Oxide and 
the Opening of Calcium-Activated Potassium Channels 
Hisakazu Ogita, Masafumi Kitakaze, Koichi Node, Hiroshr Asanuma, Shoji Sanada, Seijr 
Takashima, Masanori Asakura., Yulin Lvao, Yoshiro Shinozaki, Hidezo Mori, Tsunehiko 
Kuzuya, Masatsugu Ho”. Osaka University Graduate School of Medicine, Suita, Japan 
Background: 17P-Estradiol reduces myocardial infarct size via nitric oxide (NO) and the 
opening of calcium-activated potassium (KCa) channels. Raloxifene, a selective agonist 
of estrogen receptors, is reported to cause acute coronary artery vasorelaxing effects. 
We investigated whether raloxifene reduces infarct size, and what mechanisms are 
involved in the effects.Methods: In the anesthetized open chest beagle dogs, the left 
anterior descending coronary artery (LAD) was canulated and perfused with blood from 
the left carotid artery through a” extracorporeal bypass tube. We occluded the LAD for 
90 minutes followed by 6 hours of reperfusio”. Infarct size was measured by TTC stain- 
ing. Infusion of raloxifene (5uglkgiminute) into the LAD through a” extracorporeal bypass 
tube was initiated 10 minutes before coronary occlusion and continued up to 1 hour of 
reperfusion except the coronary occlusion period.Resu1t.s: Heart rate (134 +/- 4 beats/ 
minute) and mea” arterial blood pressure (100 +/- 3 mmHg) remained stable throughout 
the study and were not significantly different among groups. Infarct size was significantly 
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reduced in the raloxifene group compared with the control group (6.8 +I- 4 2% vs 40.9 +I- 
3.9% of the area at risk, piO.01). Both NG-nitro-L-arginine methyl ester (an Inhibitor of 
NO synthase) (infarct size: 22.8 +I- 5.4%, ~~0.05 vs either raloxifene or control group) 
and charybdoioxin (a blocker of KCa channels) (infarct size: 23.5 +/- 5.1%, ~~0.05 vs 
either raloxifene or control group) attenuated tiw infarct size-limiting effecr of ralox- 
ifene.Conclusion: Raloxifene reduces myocardiai infarct size by NO and ihe opening of 
Kca channel-dependent mechamsms in canine hearts. 
1251-86 Endothelial Constitutional Nitric Oxide Synthase Gene 
Polymorphism Is Associated With Coronary Vasospasm 
Yuan He, Masahiro Yasuiake, Yoshifumi Tomita, Yoshiki Kusama, Morimasa Takayama, 
Karuo Munakata, Teruo Takano. Nippon Medical School, Tokyo, Japan 
Background: Nitric oxide (NO) exerts various pathophysiological effects on the cardio- 
vascular system and there was a reduction of NO activities in both coronary and brachial 
arteries of the patients with coronary vasospasm. Recently, it has been reported that 
endothelial constitutional nitric oxide synthase (ecNOS) gene intron 4 polymorphism is 
one of the genetic factors to control plasma NO. However, the correlation between 
ecNOS gene polymorphism and coronary vasospasm has not been thoroughly invesii- 
galed. Methods: In this study, 60 admitted patients with chest pain were investigated. 
Coronary vasospasm was provoked by the intracoronary administration of acetylcholine 
in all paiients and the lumen diameters of large epicardial coronary arteries were 
assessed by quantitative coronary arteriography. According to the presence or absence 
of coronary vasospasm, ihe patients were divided into two groups, coronary vasospasm 
group (CVS; n=42, maleifemale=2.0, 57.3+10.8 years) and control group (control; w18, 
male/female=0.8, 58.4i10.8 years). The intron 4 polymorphism of ecNOS gene was then 
determined by polymerase chain reaction method. Results: The incidence of a/b geno- 
type of ecNOS gene was significantly higher in CVS than that in control (0.40:0.11, 
p=O.O25) with no presence of a/a genotype. The ratio of smokers was higher in CVS than 
ihat in control (0.60:0.28, p=O.O2) and other conventional coronary risk factors such as 
hypertension, diabetes mellitus, hyperlipidemia, BMI and serum level of lipids showed no 
significant differences between two groups. Furthermore, there were 17 cases with a/b 
genotype and 25 case3 with bib genotype in CVS. The incidence of multi-vessel spasm 
and diffuse spasm was significantly higher in sib genotype than in b/b genotype 
(0 88:0.52, p=0.0145; 0.76:0.48, p=O.O65). Stepwise mulTivariate regression analysis on 
gene polymorphism and the conventional coronary risk factors showed that smoking and 
a/b genotype were Lhe independent factors to predict coronary vasospasm (F=5.364 and 
5.297 respectively; p=O.O2). Conclusion: It suggested that ecNOS gene a/b genotype as 
well as smoking habit might be the key factors to coronary vasospasm. 
1251-87 The Dihydropyridine Ca Channel Blocker, Nifedipine, Limits 
Infarct Size via Bradykinin- and NO-Dependent Mechanisms 
in Dogs 
Masafumi Kitakaze, Yoshiro Shinozaki, Hidezo Mori, Hiroshi Asanuma, Shoji Sanada, 
Masanori Asakura, Hisakazu Ogita, Yulin Liao, Koichi Node, Seij! Takashima, Tsunehiko 
Kuzuya, Masatsugu Hori. Osaka University Graduate School of Medicine, Osaka, Japan 
Recently, dihydropyridine Ca channel blockers, such as amlodipine, are reported io 
increase NO levels of coronary vessels. We have also reported that either nifedipine or 
benidipine increases the cardiac NO levels and coronary blood flow in Lhe ischemic 
hearts. Since NO is cardioprotective, affecting the coronary circulation: myocardial 
metabolism, and neurohumoral factors such as the renin-angiotensin sysiem and the 
sympathetic nerve system. nifedipine may limit infarct size via NO-dependent mecha- 
nisms. To test this idea, 49 beagle dogs were studied. In the open chest dogs, the left 
anterior descending coronary artery was perfused with blood through a bypass tube and 
occluded for 90 min followed by 6 hours of reperfusion. Infarct size was assessed by TTC 
staining. When nifedipine of 3 or 6 uglkglmin was infused into the bypass tube between 
10 min prior to the onset of ischemia and 60 min of reperfusion, systemic blood pressure 
did not change significantly during infusion of nifedipine (102 13 or 96+4 mmHg at the 
onset of ischemia and 60 min of reperfusion, respectively). Infarct size was reduced by 
the administration of nifedipine (3 or 6 uglkgimin) compared wth the untreaied condition 
(25.612.6 and 19.1h3.5 vs. 43.4+5.6%, respectively), which was completely blunted by L- 
NAME (45.0+3.6 and 45.4+4.2 vs. 47.9+3.9% in the nifedipine (3 or 6 uglkglmin) with L- 
NAME (10 ugikglmin) groups vs. the L-NAME group). Furthermore, the antagonist of 
bradykinin 82 (HOE140) also blunted the infarct size limitation of nifedipine (39.8+3.1 vs. 
43.2+2.9% in the nifedipine (6 uglkgimin) with HOE140 (10 ng/kg/min) groups vs. the 
HOE140 group). There were no significant differences in collateral blood flow assessed 
by the microsphere method al 45 rnln of &hernia between each group (7.8+1.8 mlllOOg/ 
min). We conclude that nifedipine limits infarct size via bradykinin- and NO-dependent 
mechanisms. The cardioproteciive effect of nifedipine against ischemia and reperfusion 
injury may be partially attributed to NO. 
1251-88 lschemia-Selective Early Increase in Nitric Oxide Synthesis 
Confer Acute Cardioprotection Against Myocardial 
Infarction Afforded by Pravastatin 
Shoji Sanada, Masafumi Kitakaze, Hiroshi Asanuma, Seiji Takashima, Koicki Node, 
Hisakazu Oglta, Masanorl Asakura, Yulrn Lisa, Tsunehiko Kuzuya. Masatsugu Hori. 
Osaka university Graduate School of Medicine, Suita, Japan 
Background; HMG-CoA reductase inhibitors (statins) reduce the risk for cardiovascular 
diseases independeni of cholesierol-lowering effect. Although nitric oxide (NO) is thought 
to mediate this mechanism, no study has clarified the acute cardioprotection and NO 
synthesis by statins. We tested whether pravastatin acuiely limit infarct size, and whether 
NO and neuirophil infiltration are involved. Methods; In open-chest beagle dogs, coro- 
nary artery was occluded for 90 minutes followed by B-hours of reperfusion. In other 
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dogs, the continuous low flow studies were performed Results; Collateral flow and per- 
cent risk area were consistent for ail groups. Pravastatln (Zmgikg) reduced myeloperoxi- 
dase activity in the border region of the lschemic myocardium (Mean+SEM.: 7X+2.8 vs. 
22 8+6.0unit control, pcO.Oi) and infarct size (22.6+4.5 vs. 37.1+4.2% control, ~~0.05). 
which was blunted by preischemic and postischemic NO synthase inhibItIon by Nw-nitro- 
L-arginine methyl ester (L-NAME) (22.1+4.6umt and 36.8+4.1%), not by only preischemic 
L-NAME treatment (11.9+4.2unit and 26.1+5.3%). In the continuous hypoperiusion stud- 
ies with low coronary blood flow (CBF) or low coronary perfusion pressure (CPP), prav- 
as&tin increased the differences in ihe level of NO metabolites between coronary venou.s 
and arterial blood (15.6+2.3 vs. 9.3+1.5nmol/L control under constant CBF, ~~0.05) and 
coronary blood flow (57+3.2 vs. 44+2.6mUlOOg/min control under constant CPP, ~~0.05) 
only under hypoperfusion after 3 hours, whereas not under normoperfusion (6.0+1.2 vs 
5.3+1.3nmol/L control, and 991-4.6 vs. 96+5.0mL/lOOg/min control). Conclusion; Pre- 
treatment wiih pravastalln confers the whemla-selective early increase in NO production 
and NO-dependent acute infarct size-limitation which might be associated with the inhi- 
bition of regional neutrophil infiltration in vim 
1251-89 Regional Myocardial Function in Chronic Total Coronary 
Occlusions and Its Relation to the Collateral and Peripheral 
Myocardial Resistance 
Gerald S. Werner, Oliver Gastmann, Barbara M. Richartz, Markus Ferrari, Hans R. 
Figulla. Clime Internal Medicine I//; Friedrich-Schiller-University Jena, Germany 
Background: Collateral function in chronic total coronary occlusions (TCO) is deter- 
mined by the resistance of rhe collaterals (Rc) and the myocardial resistance distal to the 
occlusion (Rp). The aim of this study was to study the relation between the collateral 
function and ihe functional integrity of the myocard distal to the occlusion. 
Patients: We studied 26 patients with a TCO of at least 4 weeks duration before the 
occlusion was reopened by PTCA, and after the recanalization procedure was completed 
with stenting. We measured aortic pressure (Pao), intracoronary pressure distal to the 
occlusion (PO) by a pressure wire, and the intracoronary flow velociry integral distal to the 
occlusion before (Vo) and after recanalization (Va) by a Doppler wire. The resistance was 
calculated as Rp=PoiVi, and Rc as (Pao-Po)iVi. The measurement of Vo and PO were 
done before the first balloon inflation, and 45 min later afier PTCA with a repeat balloon 
occlusion. 14 Patients with a well preserved regional function (group N) were compared 
with 12 patients with a severely impaired regional function (group I). 
Results: AC, Rp and Vo are summarized for both groups before and after recanalization 
in the (table; differences between groups: ’ p=O.O8; t ~~0.05; changes before and after 
PTCA within each group for all 3 parameters: p<O.OOl). 
group N group I 
Before PTCA After PTCA Before PTCA After PTCA 
vo (cm) 11.9e5.6 5.8h2.6 10.8111 .o 5.726.4 
Rc (mmHg/cm) 6.6k4.4 14.7k9.5 10.2?6.7*) 28.5224 3t) 
Rp (mmHg/cm) 4.9i3.3 7.5A4.4 6.8k4.4 13.7211.6t) 
Rc tended to be lower in group N before PTCA, Vo and Rp were sin&x. After PTCA Rp 
and Rc increased in both groups significantly, while Vo dropped by more than 50%. The 
increase of Rc and of Rp was smaller in group N than in group I. Well preserved regional 
function distal to an occlusion lead to a lower Rc and to a lower Rp after PTCA. 
Conclusion: Specific differences in collateral function were found in TCO which were 
related io the preserved regional ventricular function distal to the occlusion. Collateral 
function changed instantaneously by the reopening of a TCO. Lower Rp and RC after 
PTCA with normal regional function could indicate a higher degree of remaining colla@ral 
function. 
1251-90 Why Does Severe Coronary Stenosis Decrease Perfusion 
Reserve in the Remote Myocardium? 
Olaf M. Muehling, Prasad Panse, Andrey Zenovich, Fan Zhao, Ylmei Huang, Abdul 
Mansoor, Michael Jerosch-Herold, Norberl M. Wilke. Center for Cardiovascular MRI of 
the Department of Radiology at the University of Minnesota, Minneapolis, MN, Division of 
Cardiology of the Department of Medicine at the University of Minnesota, Minneapolis, 
MN 
Background: We determined myocardial blood flow (MBF) and vascular resistance with 
quantitative MR firsi-pass (MRFP) Imaging to assess the underlying mechanism of a 
reduced perfusion reserve (PR, hyperemialrest perfusion) in remote myocardium due to 
severe single-vessel disease. 
Methods: MRFP-imaging was performed in 24 pigs with a 1.5T MRI (Siemens). One 
week before imaging a severe stenosis (>90%) was induced by placing a hollow bead in 
the left circumflex artery (LCx) in 12 pigs (Group A). Group B had normal coronary arter- 
ies. Signal intensity curves were generated from the images with ARGUS software (Sie- 
mens). Blood flow estimates (MBF, mliglmin) were determined from the curves with 
former validated Fermi-model constrained deconvolution. Myocardial vascular resistance 
(MVR) was calculaied as mean blood pressure (BP)IMBF (mmHg*g’min/ml). MBF and 
MVR were determined at resi and hyperemia (by a maximal vasodialating dose of ade- 
nosine) in stenosis-dependent and remote (antero-septal) myocardium of A and the cor- 
responding LCx- and lefi anterior descending (LAD)-region of B. MBF was normalized for 
the rate pressure product (RPP) (MBF x mean group/individual RPP). 
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ischaemia. The same experienced cardiologist validated all the AECG records. Results: 
1022 patients aged 64.6 +/- 11 .O years have undergone an electrocardiographic record 
by an R-test. During the recordings, 751 patients (73.5%) did not present any ECG sign 
of myocardial ischaemia, 148 (14.5%) presented only silent ischaemia, 92 (9.0%) silent 
ischaemia and symptomatic ischaemia, 31 (3.0%) of symptomatic ischaemla only. These 
results show that more than one patient in two (54.66%) (1481271) presenting myocardial 
ischaemia is clinically asymptomatic. Of the 3258 recorded ischaemic events, only 9% 
(n=295) were symptomatic. Important circadian variations of ischaemia are noticed. The 
frequency of these events increases suddenly from 7 AM culminating at 10 AM and then 
decreases quickly until after till 2 PM. The pattern then increases again from 2 PM to 5 
PM and decreases gradually during the evening to reach to a threshold of low incidence 
until the early morning. Conclusion: The circadian variations of silent myocardial 
ischaemla and in particular the increase in the frequency if ischaemic events early in the 
morning chronologically correspond with the variations of the symptomatic ischaemia 
observed in the study. They are also related with the sudden rise of the blood pressure 
and the peak of frequency of myocardial infarction described in the literature during this 
period. 
1252-93 Ultra Long-Term Prognosis of Vasospastic Angina With 
Normal Coronary Arteriogram Treated by Calcium Channel 
Antagonists: Results From Twenty-Year Prospective Follow- 
Up Study 
Kenichl Ito, Masakazu Yamagishi, Hiroshi Tsutsui, Kazuo Haze, Tetsuya Sumiyoshi, 
Kenichi Fukami. National Cardiovascular Center, Suita, Japan 
Background: Although the patients (pts) with vasospastic angina treated with calcium 
channel antagonists have relatively good outcome, few data exist regarding ultra long 
term prognosis particularly I” pts with normal coronary angiography. Therefore, we stud- 
ied the relationship between the ultra long term outcome of vasospastic angina prospec- 
tively followed up to 20 years and the factors influencing the prognosis. Methods: Total 
193 pts (163 men and 30 women with mean age of 54 I 8.0) who had angiographic evi- 
dence of intense coronary vasospasm without preexisting disease at the sites of vasos- 
pasm were enrolled and prospectively followed to 20 (mean 122 5.2) years. Cardiac 
events consisted of the cardiac death and the ischemic events which included acute myo- 
cardial infarction and unstable angina. Cox analysis, that was used to identify potentially 
important prognostic variables, selected coronary risk factors such as hypertension, dia- 
betic mellitus, hyperlipidemia and history of smoking. Results: Cardiac death occurred in 
10 pts (5.2%) and the ischemic events in 31 pts (16%) during the follow up period. Under 
these conditions, hyperlipidemia (OR=0.28, 95% Cl=O.O87-0.14, P=O.O35) was the only 
independent predictor of event-free survival by the Cox analysis. Kaplan-Meier survival 
analysis revealed a event-free survival curve I” vasospastic angina with normal coronary 
(survival rate; Syrs, lOyrs, 15yrs, and 20 yrs, 85.5%, 79.6%, 76.5%, and 73.9 % respec- 
tively). Conclusions: These results demonstrate that vasospastic angina with normal 
coronary angiography treated with calwm channel antagonists has good outcome. 
Under these conditions, the most important factor affecting the prognosis is revealed to 
be hyperlipldemia that might alter underlying coronary endothelial function. We suggest 
that intensive management of hyperlipidemia should be considered even with normal COT- 
onary angiography. 
1252-94 Minimal Coronary Artery Disease Is Associated With 
Persistent Chest Pain in Women: Results From the NHLBI- 
Sponsored WISE Study Coronary Angiographic Core 
Laboratory 
Barry L. Sharaf, B. Delia Johnson, Marian B. Olson, Carl J. Pepine, Steven E. Fieis, 
William J. Rogers, Nathaniel Reichek, C. Noel Bairey Merz. Rhode /s/and Hospital and 
Brown University School of Medicine, Providence, -RI 
Background: Many women presenting with chest paw? suspected to be ischemic, have 
persistent symptoms at follow-up despite coronary anglography identifying no significant 
stenosis (~50%). Methods: In order to identify angiographlc predictors of persistent 
chest pain at 1 year follow up, we performed a detailed quantitative angiographic analysis 
(QCA) of coronary angiograms from 142 women with (43%) and 186 without (57%) per- 
sistent chest pain all of whom initially presented with symptoms believed to be ischemia 
and were enrolled in the Women’s lschemia Syndrome Evaluation (WISE) study but who 
were found to have no > 50% stenosis at coronary angiography. Results: Women with 
persistent chest pain were younger (54+10 vs 58rll years, p=O.OOl respectively) than 
those without. Overall angiographic severity score was higher in those women with chest 
pain (7.4+4.l vs 7.153.9 respectively, p=O.O6 controlling for age) than in those without. 
Importantly, 46% of the women with versus only 41% of those without (p=O.O5 controlling 
for age) had minimal (as opposed to none) coronary artery disease (20.49% s&noses). 
Overall ejection fraction, coronary artery size and evidence for complex plaque was not 
different between the 2 groups. There was a trend towards slower flow in women with 
persistent chest pain versus without, with TIMI Frame Count >40 in 14% vs 7% (p=.17) 
respectively. There was also a trend towards worse endothelial function in those women 
with vews without symptoms at follow-up with 62% versus 41% (Left Main), 61% versus 
53% (LAD) and 52% versus 37% (LCX) having an abnormal vasomotor response to 
intra-coronary Acetylcholine (all p=ns) respectively. Conclusion: We conclude that the 
coronary angiographic findings in women without significant CAD but with persistent 
chest pain are different than in those women who become asymptomatic. Women with 
symptoms more often have evidence of early CAD as measured by QCA, flow and endot- 
helial function. These are women who should be targeted for aggressive risk factor modi- 
fication. 
Results: MBF at rest in remote myocardium of A was elevated vs. B as a result of a 
decreased MVR. Hvaeremic MBF in the remote mvocardium of A was decreased vs. B 
along with a decreased BP. 
Rest Hyperemia 
Group A (L&stenosis, 6 A (LCx-stenosis, B 
LAD remote) LAD remote) 
MBF LC 0.9*0.2 1.1+0.2t 1.2+0.3 3.1i1.2t 
LAD 1.5iO.3’ 1.2*0.3t 2.o*o.s* 3.421.3t 
MVR LC 121+71 122i;25 70+24 45k16t 
LAD 62~18~ 123r41t 44+9* 43+21 
BP (mmHg) 85+6 133+7t 78211 124*16t 
HR (llmin) 102*25 114+13 136*34 138127 
PRP (mmHg/ms) 0.14*0.03 0.2510.03t 0.18iO.05 0.29+0.09t 
* pqO.02 vs. stenosis, t ~~0.04 vs. A, p ~~0.05 vs. Rest 
PR was reduced in A vs. B in stenosis-dependent (1.5+ .3 vs. 2.4r .7, p< .Ol) and remote 
myocardium (1.3* .3 vs. 2.9+ .9, p< .Ol) with no significant difference between the 
regions in A. 
Conclusion: A reduced resting MVR of possible metabolic origin and a reduced coro- 
nary perfusion pressure at hyperemia cause an increase in rest and a reduction in hyper- 
emit MBF resulting in a decreased PR of the remote myocardium in seven? single vessel 
disease. 
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1252-91 Silent lschemia During Daily Life Is Related to Increased 
Thrambin Generation in Patients With Chronic Stable 
Angina 
lgnatios Ikonomidis, Felicitta Andreotti, Christodoulos Stefanadis, Christos Pitsavos, 
Emanuel Economou, Pavlos Toutouzas, Petros Nihoyannopoulos. Hammersmith 
Hospital, London, Greece, lppokration Hospital, Athens, Greece 
Background: Patients with chronic stable angina (SA) and silent ischemia during daily 
life usually present complex and thus potentially thrombogenic atheromatous plaques at 
coronary angiography. We investigated whether thrombin generation, platelet activation 
or high plasma levels of procoagulant cytokines are related to silent ischaemia in SA and 
whether reduction of the above factors by aspirin (ASA) IS associated with reduction of 
silent ischaemia. Methods. We measured prothrombin fragments (PFl+P, nmole/l),mac- 
rophage Colony stimulating factor (MCSF), inerleukins lb (ILlb) and 6 (IL6) (pgiml) 
plasma levels and 24h urine excretion of 11 dehydrothromboxane 82 (DTXB2, nglmg 
creatinine) in 60 patients with SA and in 24 matched controls. Samples and urine collec- 
tions were obtained at the end of a 48h Halter (HM). Patients had angiographically docu- 
mented disease. Fourty had ischaemia at HM and were randomly treated with ASA 
300mg, ad. or placebo for 3 weeks in a double blind, cmss-over trial. Results. PFl+2, 
MCSF, and IL6 were increased in patients compared to controls (pcO.05). Patients with 
ischaemia at HM had higher MCSF and DTXB2 compared to those without (MCSF: 
1124~651 vs 528*417, DTXBP: 4.2k3.2 vs 2.3k1.9, p<O.Ol). Only patients with silent 
ischaemia (20160) had higher PFl+2 than patients with both silent and symptomatic epi- 
sodes (20/60) or patients with no ischemia (20/60) (PFI +2: 2.2611.8 vs 1.73tl.2 vs 
0.9310.5, p<O.Ol). MCSF was related to DTXB2 before and after ASA treatment (r=0.47 
and r=0.50, p<O.Ol). ASA reduced cytokine levels, PFl+2, pTXB2 (~~0.05) as well as 
the number and duration of silent ischemic episodes (number before ASA: 6.521 .I vs 
3+1.0 after ASA, ~~0.01 and duration (min) before ASA: 26i5 vs 15i4.2 after ASA, 
~~0.01) with no effect on symptomatic episodes. Conclusion. Daily life ischemia in 
patients with SA is related to increased platelet activation induced by high cytokine levels. 
Only silent &hernia is related to increased thrombin generation and is reduced by aspi- 
rin possibly due to the anticoagulant and antiinflammatory effect of the drug. 
1252-92 Circadian Variations of Silent and Symptomatic lschaemia 
in Patients With Stable Coronary Insufficiency 
Franpois Allaert, Marianne Z&r, Christian Causs& Gabriel Laurent, Jean-Pierre 
Marcantoni, Jean-Eric Wolf. CHU, Dijon, France 
Background: The aim of the study was 1) to determine in standard living conditions the 
circadian variations of the symptomatic and silent electrocardiographic ischaemia in 
patients with chronic stable coronary insufficiency and 2) To evaluate the influence of the 
past history of the patients on the circadian variations of the symptomatic and silent 
ischaemic events. Methods: The patients included in the study presented. with stable 
angina pectoris and have undergone a 96 hours Ambulatory ECG (AECG) monitoring 
with a low-weight and compact material which did not modify their daily activities (Rtest). 
The system records the trace that the patient has initiated by himself following the onsel 
of symptoms and makes possible to distinguish between silent and symptomatic 
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1253-97 The Use of Enoxaparin and Ilb/llla Antagonists in Acute 
Coronary Syndromes, Including PCI: Final Results of the 
NICE 3 Study 
James J. Ferguson, Elliott M. Antman, Eric R. Bates, Marc Cohen, Nathan R. Every, 
Robert A. Warrington, Carl J. Pepine. Pierre Theroux, The NICE 3 Investigators. Texas 
Hearf Institute, Houston, TX 
Background: Although recent clinical trials such as ESSENCE and TIM1 IIB have 
shown enoxaparin to be clinically superior io UF heparin for the treatment of ACS, fhe 
use of LMW heparins in ihis clinical situaIion has been significantly limited by concerns 
about the safety of combining them with Ilb/llla antagonists, and logistical issues about 
making the transitIon to the cath lab in patients who have already received subcutaneous 
LMW heparin. 
Methods and Results: NICE 3 was a multIcenter (46 siies;US and Canada), non-ran- 
domized, open-label. observational study to assess the safety profile of enoxaparin, 1 
mglkg SC bid, plus a Ilb/llla antagonist (tirofiban, n=217, eptifibatide, n=252; or abcix- 
imab, n=147) in ACS patients. Patients were initially treated with enoxaparin and a llbi 
llla antagonist; the choice of llb/llla antagonist was assigned by institution. If PCI was 
required, combination therapy was continued through the time of the procedure; if the last 
enoxaparin dose was > 8 hours prior to PCI, an addItional iv bolus of 0.3 mg/kg was used 
at the time of the procedure. The primary endpoint of the study was the incidence of 
non-CABG major bleeding (n-CABG MB) during the hospitalization, compared to a rate 
Of 2% estimated from prior studies. Secondary endpoints included clinical outcomes. 
Tirofiban Eptlfibatide Abciximab All Ilb/llla 
All Patients ( n = 616 ) 
Non-CABG major bleeding 1.4 % 3.2 % 0.7 % 1.9 %* 
Death 0.5 % 0.4 % 0 0.3 % 
Ml 4.1 % 3.2 % 2.7 % 3.4 % 
Urgent TVR 3.2 % 2.7 % 0.7 % 2.1 % 
Platelels < lOOK 1.4% 0.0 % 0 0.9 % 
30% Decrease in platelets 3.8 % 4.7 % 9.4 % 5.5 % 
PCI Pabents ( ” = 292 ) 
Non-CABG major bleeding 0.9 % 2:4 70 0 1.0% 
’ p=NS compared to historical estimate of 2 % 
Conclusions: 1) The combination of enoxaparin and a Ilb/llla antagonist does not result 
in an excess of non-CABG major bleeding; 2) patients on combination therapy can safely 
undergo PCI; 3) clinical outcomes in NICE 3 were comparable to those in prior studies; 
4) it is not necessary to use UF heparin in ACS patients undergoing PCI who are treated 
with enoxaparm and a Ilb/ llla antagonist. NICE 3 establishes a strong foundation for 
future definalive large scale randomized efficacy trials. 
1253-98 Glycoprotein Ilb/llla Inhibitors in the Medical Management of 
Unstable lschemic Syndromes Without Persistent ST 
Segment Elevation: A Meta-Analysis of the Randomized 
Trials 
Marco Roffi, Derek P Chew, Debabrata Mukherjee, Deepak L. Bhatt. Mark A. Robbins. 
Eric J. Topol. Cleveland Clinic Foundation, Cleveland, OH 
Background: The role of intravenous glycoprotein (GP) Ilb/llla receptor inhibitors in the 
setting of unstable lschemic syndromes without persistent ST-segment elevaiion treated 
medically has recently become controversial. So far SIX placebo-controlled trials have 
been performed in this setting. Methods: PRISM, PRISM PLUS, PARAGON A, PUR- 
SUIT, PARAGON 6, and GUSTO IV ACS enrolled a total of 29,855 patients. We per- 
formed a me&-analysis of these trials and addressed the incidence of death or 
myocardtal infarction (Ml) at 30 days. The analysis included all patients enrolled in the tri- 
als. Results: The results are reported in the figure. The pooled incidence of death or Ml 
at 30 days was significantly reduced by the use of GP Ilb/llla inhibitors: 10.7 % of the GP 
llbillla inhibitor’s treated patients and 11.5 % of the placebo treated patients had an event 
(OR 0.924; 95% Cl 0.859-0.995, p=O.O37). The p-value of the Bresiow-Day test was 
0.339, excluding heterogenity of Ihe trials. 
107% 
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Conclusions: The m&a-analysis of the so far performed placebo-controlled trials dem- 
OnStlateS that the use of GP Ilb/llla inhibitors was associated with a modest (8%) but sig- 
nlficant reduction in death or Ml at 30 days I” patients with unstable ischemic syndromes 
without persistent ST-segment elevation treated medically. 
POSTER SESSION 
1253 Evolving Antithrombotic Approaches in 
Acute Coronary Syndromes 
Tuesday, March 20, 2001, 3:00 p.m.-500 p.m. 
Orange Counfy Convention Center, Hall A4 
Presentation Hour: 4:00 p.m.-500 p.m. 
1253-95 Enoxaparin Versus Tinzaparin in the Management of 
Unstable Coronary Artery Disease (EVET Study) 
Lambros K Michalls, Nicolaos Papamichail, Christos S. Katsouras. Ageliki Karahaliou, 
Eleni Sourla, John Novas, Lambros S~oros, Andreas Papalambrakopoulos, John A. 
Goudevenos. Dimitris A. Sideris. Univers~ly Hospital of loannina, loannina, Greece 
Low molecular weight heparins are rapidly emerging as an alternative form of antithrom- 
botic therapy to the standard unfractionated heparin These drugs inspite of similarities in 
origin, synthesis and structure, have different pharmacokinetic and pharmacodynamic 
characteristics and possibly elicit different efficacy. The aim of the present study was to 
compare head to head the efficacy of enoxaparin versus tinzaparin in the management of 
acute coronary syndromes. Methods. In a prospective study 438 patients with unstable 
angina or non Q-wave myocardial infarction were randomized to receive either subcuta- 
neous injections of 100 Ui/kg enoxaparin twice daily (N=220) or 175 UI/Kg tinraparin 
once daily (N=218) for 7 days. The primary end-points were death, myocardial infarction, 
refractory angina and recurrence of unstable angina. Secondary end points ware rehos- 
pitaiisation due to unstable angina or myocardial Infarction. death and need for revascu- 
larisatlon at 30 days. Results. At 7 days recurrence of unstable angina occurred less 
frequently in the enoxaparin than in ihe tinzaparin group (24/‘220 vs 41/218, p=O.O29). No 
statistical significant differences were observed between these 2 groups with respect to 
death, myocardlal infarction or refractory angina at 7 days. At 30 days there were no dif- 
ferences between the 2 groups regarding rehospitalisatlon and death. The need for 
revascularisation at 30 days was significantly less frequent in the patients assigned to 
enoxaparin (36/2PO vs 571218, p=O.O19). Bleeding complication rates were similar in the 
two groups. Conclusions. Antithrombotic treatment with enoxaparin for 7 days was more 
effective than tinzaparin in reducing the incidence of recurrent angina in patients with 
unstable angina or non-Q wave myocardial infarction in the early phase. Enoxaparin 
recipients had also significantly reduced need for revascularisation at 30 days. This ben- 
efit was achieved without an increase of bleeding complicalions. 
1253-96 Safety and Efficacy of Unfractionated Heparin (UH) Versus 
Enoxaparin (E) in Obese Patients and Patients With Renal 
Impairment: Analysis From ESSENCE and TIMI IIB Studies 
Stephanie M. Inverse, Marc Cohen, Elliott M. Amman, Sarah A. Spinier, for the 
ESSENCE and TIMI 116 Investigators. Philadelphia Cokge of Pharmacy at the 
University of the Sciences in Philadeiphia, Philadelphia, PA 
Background: There is no publlshed data evaluating low-molecular-weight heparins in 
obese and renally-impaired patients with acute coronary syndromes. 
Methods: The composiie endpoint of death, myocardial infarction or urgent revascular- 
lzation (DIMIIUR) at 43 days, as well as major bleeding and any bleeding (measured dur- 
ing the weight-adjusted treatment phase of the initial hospitalization) were compared 
between subgroups of patients: obese (N=3439) versus non-obese (N=3558) and renal 
impairment (N-143) versus no renal impairment (N=3558) from ESSENCE and TIMI 
116. 
Results: In obese and non-obese patients. E significantly decreased the risk of DIMIIUR 
when compared to UH (RR 0.88, p=O.O006 and RR 0.90, p=O.O02). Similar major bleed- 
ing rates were observed between UH and E in obese patients (0.9% vs 0.7%) and non- 
obese patients (1.2% vs 1.8%). There was less major bleeding in the obese treated with 
E compared to the non-obese (RR 0.55, p=O.O03). E significantly decreased the rate of 
D/MI/UR in patients without renal impairment (RR 0.91, p=O.O03). An increased risk of Di 
MliUR was seen in patients with renal Impairment receiving UH when compared to those 
with no renal impairment (RR 2.1, p=O.O04). There was no difference in the rate of D/MI/ 
UR m those with and without renal impairment receiving E (18.8% vs 15.7%). Increased 
rates of major bleeding were observed in patients with impalred renal function compared 
to those with no renal impairment receiving both E (7.5% vs 1.2%, p=O.OOa) and UH 
(5.8% vs 1.0%, p=O.OOl). Similarly, there was arl increase in any bleeding in patients 
with renal impairment compared to those with no renal impairment receiving both E 
(17.9% vs 9.8%. ~~0.028) and UH (18.8% vs 3.9%, p=O.OOi). 
Conclusion: E significantly reduced the risk of D/MI/UR at 43 days in obese, non-obese 
and patients without renal impairment. A reduction in D/Ml/UR was noi dIscerned wiih E 
in patients with renal impairment perhaps due to small sample size. Similar to other tri- 
als, obesity did not increase the risk of DIMIIUR and less major bleeding occurred in 
obese patients. Renal impairment is a risk factor for bleeding with both UH and E. Large 
clinical trials focusing on patients with renal lmpalrment are needed. 
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1253-99 Lack of Beneficial Effect of Intravenous Glycoprotein Ilb/llla 
Platelet Receptor Inhibitors in Patients With Acute Coronary 
Syndromes: Time to Reconsider Their Routine Use and 
Need for a Mortality Trial 
Udho Thadani, Saihari Sadanandan. University of Oklahoma Health Sciences Center, 
Oklahoma City, OK 
Background: Intravenous (IV) Glycoprotein llbillla inhibitors (GP Ilb/llla) are being rou- 
tinely used in addition to aspirin and unfractronated heparin in the management of pts 
with non-ST elevation acute coronary syndromes (ACS), who are considered to be at 
high risk (ACS with ST depression on the EKG and/or positive serum markers). Routine 
use of this class of drugs has been justified on the basis of their effect on combined end- 
point of death and myocardial infarction (Ml). However, two recent large trials with these 
agents have failed to demonstrate a significant benefit on the end points of death and MI. 
Methods: We reviewed data on Death, Ml, and major bleeding complications at 30 days 
from large trials on ACS involving various IV GP llbillla inhibitors which have been either 
published or formally presented at major meetings. Results: 
Trial Death (%) p-value MI (%) p-value Severe Bleeding (%) p-value 
PURSUIT 
Eptifibatide 
Placebo 
PRISMPLUS 
3.5 12.6 1.5 
3.7 0.53 13.5 0.14 0.9 <O.OOl 
Tirofiban 
Placebo 
PARAGONB 
3.6 6.6 4.0 
4.5 0.36 9.2 0.05 3.0 0.34 
Lamifiban 
Placebo 
GUSTO ACS 
2.9 8.8 1.3 
3.3 NS 9.8 NS 0.9 NS 
Abciximab 24h 3.4 5.6 0.6 
Abciximab 48h 4.2 5.9 1.0 <O.OOl 
Placebo 3.9 NS 5.1 NS 0.3 
None of these trials independently showed a reduction in 30.day mortality with the use of 
any of these agents. Only one study (PRISM-PLUS) showed a reduction in the incidence 
of Ml at 30 days. However the definition of Ml in these trials has varied making it difficult 
to evaluate this endpoint. An increased risk of major bleeding was observed with all these 
agents and the incidence was statistically signifcant in two of the four clinical trials. In 
addition, the drug was discontinued due to bleeding more often in PRISM-PLUS trial 
compared to placebo (3.5% vs. 1.3%, p=O.O04). Conclusions: IV GP llbillla inhibitors do 
not seem to have a beneficial effect on 30&y mortality in pts with ACS, but may 
increase the risk of bleeding complications. The gold standard for efficacy of thrombolytic 
agents in pts with ST elevation Ml has been their effect on mortalrty. Before IV GP llbillla 
inhibitors can be routinely used in a similar fashion in pts with ACS, their beneficial effect 
on mortalrty must be proven in large adequately powered mortality trials. 
1253-100 Laser Angioplasty in Acute Ischemic-Thrombotic Coronary 
Syndromes 
On Topaz, Rakesh K. Shah, Robert H. McQueen, Pratik Desai, Yves Janin, Alexandra J. 
Lansky, Marc E. Carr, Nelson L. Bernardo. Medical College of Virginia, Richmond, VA 
Background: Patients(pts) presenting with ischemic coronary syndromes oftentimes 
need mechanical removal of the occlusive thrombus. Thrombi avidly absorb laser energy 
in the ultraviolet (excimer: 308nm) wavelength. We report analysis of acute results of 
excimer laser coronary angioplasty (ELCA) in pts presenting with acute thrombotic- 
ischemic syndromes, i.e.: acute myocardial infarction (AMI) and unstable angina (UA). 
Methods: Fifty-nine pts presenting with acute coronary syndromes were treated with 
percutaneous ELCA (308nm wavelength, 45mJ/mm2,25Hz) including 33 pts (39 lesions) 
with unstable angina (UA) and 26 pts (29 lesions) with AMI. 88% of AMI pta underwent 
stent implantation versus 76% UA (p=ns). Q.C.A. was performed at an independent core 
laboratory. 
Results: A reduced left ventricular ejection fraction was present in both groups (42+15% 
AMI vs 49+14% UA, p=ns). 15% of pts with AMI had cardiogenic shock vs 6% for UA 
(p=O.Ol). 86% laser success was achieved in the AMI group vs 87% in the UA group 
(p=ns). Procedural success of 100% was gained in the AMI group vs 97% within the UA 
group (p=ns). By Q.C.A. analysis MLD increased from 0.8*0.6mm to 1.4~0.5mm post 
lasing to a final 2.710.5 in the AMI group, and from 0.8t0.4mm to 1.4?0.4mm post lasing 
to 2.7t0.5mm final in the UA group, and pre-laser stenosis was reduced from 76+17% for 
AMI vs 70+16% for UA (p=ns), to post laser 52*16% for AMI vs 51*14% for UA (p=ns)to 
final of 15+17% for AMI vs 12+15% for UA (p=ns). Laser induced a 96% reduction of 
thrombus burden area at the target lesion in the AMI vs 97% in the UA group (p=ns), 
accompanied by an increased TIM1 1 to TIMI 3 in AMI vs TIMI 2 to TIMI 3 in UA group. 
There were no death, CVA, emergency bypass surgery, acute closure, perforation, major 
dissection or bleeding complications in either group. One UA patient had abnormal CPK 
rise. All 59 pts survived the procedure and were discharged. 
Conclusions: In selected pts who present with acute thrombotic-ischemic coronary syn- 
dromes, application of excimer laser for thrombus removal and plaque debulking IS feasi- 
ble and safe. Significant laser-induced reduction of thrombus burden occurs. 
ORAL CONTRIBUTIONS 
871 Regulation of Angiogenesis in Myocardial 
lschemia and New Models 
Tuesday, March 20, 2001, 4:00 p.m.300 p.m. 
Orange County Convention Center, Valencia D 
871-I 
4:oo p.m. 
Classic lschemic Preconditioning Promotes Myocardial 
Angiogenesis: Unique Approach to Enhance Contractile 
Functional Reserve in Rat With Myocardial Infarction 
Shoji Fukuda, Genbu Yamaura, Li Zhu, Dipak K. Das, Nilanjana Maulik. Departmenf of 
Surgery University of Connecticut Medical Center, Farmington, CT 
Background: A recent therapeutic approach for treating myocardial ischemia is to 
induce neovascularization of the heart by use of angiogenic mediators. However, 
ischemia itself is known to induce angiogenesis. Here we report the ability of a precondr- 
tibning stimulus in the form of in viva brief repetitive cycles of coronary artery occlusion 
followed by short duration of reperfusion repeated 4 time3 (4xPC,ischemic precondition- 
rng[lP]) to stimulate myocardial angiogenesis at the capillary and arteriolar levels, assess 
the functional relevance of such neovascularization by examining the contractile func- 
tional reserve as well as blood flow (BF) using radioactive (141Ce) microsphere injection 
in the rat myocardium after myocardial infarction (Ml). Method: 120 rats were divided into 
4 groups: Control+sham surgery (CS) , control+LAD occlusion (CMI) , 4xPC+sham sur- 
gery (IPS) , 4xPC+LAD occlusion (IPMI) (n=12). Rats were subjected to pharmacologrcal 
stress testing 7 days post-op with dobutamine (DOB) infusion at incremental doses and 
left ventricular dP/dtmax values were recorded. Radioactive microspheres were used to 
measure relative BF in sham, control and IP groups (n=12) Capillary density (CD) and 
arteriolar density (AD) were evaluated 7 days post-op by immunohistochemistry using 
anti-CD31 and anti-smooth muscle cell-actin, respectively. Western Blot and immunohis- 
tochemrstry were performed to measure the protein expression level of vascular endothe- 
lial growth factor (VEGF) (n=6) Results: dP/dtmax after DOB infusion was significantly 
better preserved in the IPMI in comparison to the CMI 
(6733.5r84.9vs4458.0m181 .OmmHg/s) after 7 days. CD as well as AD in IPMI were also 
significantly increased when compared to the CMI. The rate of BF was increased in the 
IPMI compared to the CMI. The protein expression level of VEGF in IPMI demonstrated 
significant upregulation compared to CMI. Conclusion: The results indicate first time 
that IP stimulates VEGF an important mediator of angiogenesis and such stimulation 
possesses considerable functional relevance in the post-MI state as evidenced by 
enhanced preservation of contractile functional reserve in a progressing heart failure 
model. 
871-2 
4:15 pm. 
Vascular Endothelial Growth Factor in Myocardium During 
Occlusion and Reperfusion 
Bo-Qing Zhu, Yi-Ping Sun, Richard E. Sievers, Randall J. Lee, Kanu Chatterjee, William 
W. Parmley. Universify of California, San Francisco, San Francisco, CA 
Background: Vascular endothelial growth factor (VEGF) is a mediator of developmental 
and tumor induced angiogenesis. In adult tissue and myocardial cell culture, VEGF is sig- 
nificantly increased by myocardial infarction and hypoxia. However, the effects of a differ- 
ing time cour?.e of occlusion and reperfusion has not been investigated. Methods: 54 
Sprague-Dawley rats were randomly divided into 18 groups: Sham as a control (each 
group had sham); Occlusion: 5, 10, and 17 min; with Reflow: 0, 1, and 2 hrs. After anes- 
thesia and midline stern&my, a reversible snare occluder was placed around the proxi- 
mal left anterior descending coronary artery. After different durations of occlusion and 
reperfusion (sham was not occluded), the heart was excised. VEGF proteins in the 
ischemic and nonischemic LV myocardium were measured by Western blot analysis. 
VEGF change was expressed relative to control (1 .O). Results: Compared to controls, 
VEGF in the ischemic myocardium was significantly increased after 10 and 17 min of 
occlusion (1.5 and 1.7 fold increase over controls, respectively), and significantly 
decreased after t and 2 hrs of reperfusion. Conclusion: VEGF in the ischemic myocar- 
dium increased after occlusion and decreased after reperfusion. These data suggest that 
VEGF level is a sensitive indicator of myocardial ischemia. 
“EGF changes 
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871-3 
4130 p.m. 
Temporal and Spatial Localization of the Angiopoietin-TIE-2 
System After Myocardial infarction in the Rat: Evidence of a 
Role for Ang-2 in Angiogenesis 
Michael J. 5. Kutryk, Reena Sandhu, Krystyna Teichert-Kulisrewska. Michael A. 
Kufiszewski. Sue Nag, Andrew I. M. Campbell. Duncan J. Stewart. Terrence Donnelly 
Heart Centeer, St. Michael’s Hospital, Toronto. ON, Canada, Dept of Neuropathology: 
iJnivers,ty of Toronto Health Network. Toronto. ON, Canada 
Background: Angiopoietin-I (Ang-i) is a newly described angiogeneic Cctor that pro- 
motes vessel maturation and stabilization. In contrast, (Ang-2) is thought to act as an 
endogenous antagonist of the endothelial cell receptor TIE-Z. We examined the expres- 
sion of Ang-I, Ang-2 and TIE-2 in a rat myocardtal Infarction (Ml) model. 
Methods: Hearts were explanted from male SD rats at 24h, 1 and 6 weeks after ligation 
of the left coronary artery (n=5-7 animals/group). Sham operated (n=6) and untreated 
(n=9) animals ware con:rols. In all animals, mRNA expression in the infarct (I), peri-inf- 
arct (PI). and non-infarcted (NI) zones was determined using semi-quantitative RT-PCR, 
normalized to GAPDH mRNA expression and conflrmed by Northern and Western blot- 
ting, and Immunohistochemistry. 
Results: At 24h Ang-1 levels were decreased in both the I (56+7%, p=O.Ol) and PI zones 
(89*6%, ~~0.05) compared with the NI zone, while Ang-2 levels were increased in the I 
(241*63%, p=O.O4) and PI zones (222+56%, p=O.O3). At 1 week, the I zone showed per- 
sistent decreases in Ang-I (84+3%, p=O 02) and increases in Ang-2 expression 
(144?9%, p=O.O09), whereas Ang-1 and Ang-2 expression had returned to baseline in 
the Pi zone (91*5% and 9413% respectively). At 6 weeks, levels of Ang-1 and Ang-2 
ware not significantly different from conirol in both territories. TIE-2 receptors levels 
remained constant in all areas and time points. Northern and Western blotting paralleled 
the changes in mRNA expression by RT-PCR lmmunostainlng for Ang-1 revealed 
reduced staining of endothelial cells within the ischemic zone at 24h, whereas Intense 
Ang-2 expression was found associated with inflltratlng granulocytes and neo-vessels at 
time points up to 7 days. 
Conclusion: The rat model of Ml is associated with profound changes in axpress~on of 
Ang-1 and Ang-2 in the I and PI zones. which support a role for Ang-2 in the angiogenic 
response to :schemia. 
hypothesized that large resting brachial artery diameter, a marker of peripheral athero- 
sclerosis measurable by ultrasonography, independently predicts CAD in women. 
Methods: Women (n=219, mean age 57 years) with chest pain in the NHLBI Women’s 
lschemia Syndrome Evaluation underwent B-mode ultrasound measurement of brachial 
artery diameter at rest and during hyperemic stress (to assess % flow-mediated dilata- 
tlon [FMD]), quantitative coronary angiography, and risk factor assessment. 
Results:Women with angiographic CAD (stenosisrbO%) had significantly larger resting 
brachial artery diameter than those without CAD (4.0210.79 vs. 3.60~0.55 mm, 
pcO.001). Brachial artery diameter was also associated with risk factor profile (p=O.O06): 
Resting Brachial Artery Diameter (mm; mean&D) by CAD Risk Profile 
Number of CAD Risk Factors 
0 (rl=l3) 1 (nz22) 2 (n=52) 3 (n=59) 4 (rl=41) 5 (k9) 
3.45+0.60 3.58iO.50 3.6520.67 3.85iO.77 3.9810.70 3.88iz0.93 
Factors: agez65, dyslipidemia, hypertension, smoking history, family history of CAD. 
Women with missing data excluded from table. 
After adjustment for age, body size and CAD risk factors, women with large resting bra- 
chial diameters (>4.2mm) had 4.6.fold increased odds (95% CI=l.9-11.5, p=.OOl) of sig- 
nificant CAD compared to those with small brachial arteries (53.7mm). Women with 
intermediate resting brachial diameters (3.7.4.2mm) had a nonsignificant, 2.1-fold 
increase in CAD odds (95% Cl=O.9-4.7, p=.O8). Impaired FMD, the traditional surrogate 
CAD biomarker, was weakly associated with significant CAD (2.17t6.96 vs. 4.52*9.97% 
in CAD vs. no CAD, p=O.O42). 
Conclusions: Large resting brachial artery diameter is independently associated with 
the presence of significant angiographic CAD in women with chest pain. Therefore, mea- 
surement of resting brachial diameter provides a noninvasive method to identify women 
at high risk for CAD. 
878-2 
8:45 a.m. 
Patients With Inadequate Coronary CollaterafSupport Are 
Resistant to Angiogenic Growth Factors 
Pier D. Lambiase, Richard Edwards, Slmon R. Redwood, Clifford A. BucknaIl, Michael 
Webb-Peploe, Prodromos Anthopoulos, Jeremy D. Pearson, Michael S. Marber. St 
Thomas’ Hospital, KCL, London, United Kingdom, Cardiovascular Eiolog~ New Hunt’s 
House, Guy’s Campus, KCL, London, United Kingdom 
The factors causing variation in myocardial collateral development are poorly under- 
stood. Inadequate collateral form&Ion may be due to impaired anglogenic growth factor 
(GF) production or an intrinsic myocardial resistance to GF’s. Methods: 28 patients (age 
63Qyr) with stable angina due to isolated LAD disease underwent 2 balloon lnflatlons of 
>18Os separated by 5 mins reperfusion. Coronary occlusion pressure (Poccl) was mea- 
sured with an 0.014” pressure wire distal to the balloon. Collateral flow index (CFI) was 
calculated from simultaneous measurements of coronary sinus (CS) & mean aortic pres- 
sure (Ao) (CFI= Poccl-CSiAo-CS). Blood was collected from CS at baseline. Serum rela- 
tive mitogenicity (RMit) was determlned using a 3H thymidine incorporation assay in both 
human umbilical artery smooth muscle (HUASMC) & venous endothelial cells (HUVEC) 
& is expressed relative to standard pooled human serum. Angiogenic potential was 
assessed in a matrigel assay employing HUVEC. Myocardial ischemia was assessed by 
the greatest degree of ST shift (mm) recorded from intracoronary and surface ECG dur- 
ing balloon occlusion. Results:11 patients had CFl>O.25 (40% ; Group 1) and 17 (60% ; 
Group 2) had inadequate collateral support; (CFl<O.25). Baseline RMit was 1.7 fold 
higher in Group 2 (1.9 ~.2 vs tit.1 mean&E p=O.O05) with an inverse correlation 
between RMit & CFI (r=-0.6 p=O.O02). In vitro tube formation was significantly greater in 
Group 1 (90% of control vs 60% p=O.OOS). No differences were detected in HUASMC 
mitogenicity or CS plasma VEGF & FGF levels between the 2 groups. Time to Imm ST 
depression during a pre-PTCA exercise ECG was equivalent for each group. However, 
during PTCA, the degree of ST elevation was 9 fold higher in the CFI co.25 patients 
(9.3*.3mm vs 0.8i.4mm p=O.OOOl). Conclusions: Compared to patients with well devel- 
oped collateral support patients with inadequate collaterals have 1) More mitogenic 
serum despite similar ischemlc burden & 2) Reduced in vitro angiogenic potential. These 
findings suggest that impalred collateral formation may reflect an intrinsic myocardial 
res&mce to angiogenic GFs. 
878-3 
9:00 a.m. 
Morbidly Obese Patients Undergoing Cardiac 
Catheterization: Less Disease, Less Aggressive 
Revascularization, and Similar Outcomes 
John H. Alexander, Karen P. Alexander, Peter J. Joski. Michael S Cuffe, Robert H. Peter. 
Duke University Medic& Center, Durham, NC 
Background: LIttIe is know about cardiac catheterization in the morbidly obese 
(BMl>40). These patients have a high prevalence of cardiac risk factors but are particu- 
larly difficult to study non-invasively and are thus often referred for cardiac catheteriza- 
tion. The Duke Cardiovascular Database, which possibly contains the world’s largest 
database of obese patients undergoing cardiac catheterization, offers a unique opportu- 
nity to Investigate the characteristics and long-term outcome of this population. Meth- 
ods: The Database includes baseline and angiographic variables and long term survival 
for all patients undergoing cardiac catheterization at a single Institution. We compared 
extent of coronary artery disease, revascularization rates for those with more than 1 ves- 
sel CAD, and survial in morbidly obese patients (BMl>40 and>50) and non-morbidly 
obese patlents (BMl~40) undergoing cardiac catheterization at Duke between l/l/l986 
to 12/31/1999. Results: Out of 37,999 patients included in the sample 1304 had a 
871-4 
4:45 p.m. 
lntramyocardial Levels of Vascular Endothelial Growth 
Factor (VEGF) Are Reduced in a Porcine Model of 
Hibernating Myocardium 
PatrIck W. Domkowski, Shankha S. B~swas. Luis H. Diodato, Anne M. Pippen, Michael A. 
Thompson, Kevin P Landoifo, Brian H. Annex. Duke University Media/ Genter, Durham, 
NC 
Background: &hernia is known to be a potent stimulus for the upregulation of angio- 
genie growth factors, such as vascular endothelial growth factor (VEGF). Indeed VEGF is 
upregulated in animal models of hind limb and myocardial ischemia but these models 
typlcaliy examine time points of < 1 month. Oui laboratory utilizes a stable model of hiber- 
nating myocardium where later time points may be examined. Therefore, the goal of this 
study was to examine VEGF protein levels in the myocardium at three months following 
the onset of myocardial Ischemia. Methods: Six mini-swine with 90% left circumflex 
artery (LCX) stenosis and documented hibernating myocardium by positron emission 
tomography (PET with N13 ammonia) and dobutamine stress echocardlography (DSE) 
were studied 3 months post-operatively. At sacrifice, 6, 3X3mm samples were harvested 
from both the circumflex (hibernating myocardium) and septal (control, normal perfusion) 
areas. VEGF levels ware determined using commercially available ELISA kits, which 
have a sensitivity of 10 pg. Results: In all animals. the intramyocardial VEGF levels from 
the circumflex areas were 1 f 0.2 pgiml. Comparatively, the VEGF levels in the septal 
region were 152 f 18 pgiml (p<O.OOl) Conclusions: These data indicate that intramyo- 
cardial VEGF protein levels are markedly reduced in hibernating myocardium. The angio- 
genlc effects of growth factors delivered into the myocardium with decreased levels of 
growth factor, as compared to models with increased levels, needs to be determined. 
ORAL CONTRIBUTIONS 
87 Stabile lschemic Syndrome: Mechanistic 
Insights 
Wednesday, March 21, 2001, 8:30 a.m.-10:OO a.m. 
Orange County Convention Center, Valencia B 
830 a.m. 
878-l Large Brachial Artery Diameter Is Associated With 
Angiographic CAD in Women: A Report From the NHLBI 
Women’s lschemia Syndrome Evaluation (WISE) 
Richard Holubkov, Richard H. Karas, Carl J. Pep&, Cheryl R. Rickens, Nathaniel 
Reichek, William J. Rogers. Barry L. Sharaf, George Sopko, C. Noel Bairey Merz, Sheryl 
F Kelsey, Susan P McGorray, Steven E. Reis. Cardiovascular inst;tute, University of 
Pittsburgh, Pittsburgh, PA 
Background: Modification of atherosclerosis risk factors reduces cardiac event rates in 
women with and without established coronary artery disease (CAD). Since population- 
based risk factor modification is costly, noninvasive methods are needed to Identify 
women at high CAD risk who might benefit from aggressive preventfve therapy. We 
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BMl>40 and 223 had a BMl>50. Obese patients were younger, more likely to be female, 
of Africa” American race, and to have diabetes, hypertension, and hyperlipidemia but 
were less likely to be smokers or have previously documented coronary disease. 
Results 
BMI < 40 BMI > 40 BMI > 50 P 
Weight 173.8 270.6 349 8 co.001 
0 vessel 33.9 53.6 60.8 <O.OOl 
1 vessel 23.7 16.9 11.0 
2 vessel 19.1 15.5 12.7 
3 vessel 23.3 14.0 15.5 
LM (>75%) 5.0 3.0 1.6 
PTCA 29.2 37.7 35.2 <O.OOi 
CABG 32.7 24.4 22.5 <O.OOl 
5/10 yr survival 0.80 / 0.61 0.81 / 0.54 0.668 
Conclusion: Dispite being younger and having less severe coronary disease, morbidly 
obese patients undergoing cardiac catheterization at Duke have similar 5 and IO-year 
survival. This may represent the impact of morbid obesity on either ischemic or non- 
ischemic causes of premature death or reflect less aggressive managment of exisiting 
coronary artery disease. 
878-6 
, 9:45 a.m. 
Polymorphisms of Factor V Leiden, Prothrombin e 
Methylenetetrahydrofolate Reductase in Patients With 
Coronary Disease 
Antonio I? Mansur, Joyce M. Annicchlno-Bizzacchi, Jose A. F Ramires. Heart Institute 
(/nCor), University of S;io Paula Medical School, So Paula, Brazil 
878-4 
.9:15 a.m. 
Energy Metabolism of Human Hibernating Myocardium: 
Implications for Contractile Dysfunction 
Factor V Leiden, prothrombin 20210A allele and methylenetetrahydrofolate reductase 
(MTHFR) have been associated with coronary artery disease (CAD) in some studies but 
not in others. Negative study results were due to the small number of study patients or to 
single gene analysis in a multifactorial disease. Analysis of a panel of Iwo or more poly- 
morphisms may increase CAD identification. Methods: In a case-control study, we ana- 
lyzed factor V Leiden, prothrombin 20210GiA mutation and 677C->T mutation of 
methylenetetrahydrofolate reductase (MTHFR) I” 368 paiients with CAD and 368 control 
subjects matched by age, sex, and race. Gene polymorphisms were determined by the 
polymerase chain reaction. Panels were constructed of two or three polymorphisms pre- 
viously associated with CAD. Results: Factor V Leiden mutation was higher in patients 
with CAD (4.4% vs 0.8%; p=O.O03), in me” with CAD (4.6% vs 0.4%; p&004), in 
patients < 45 years (4.8% vs 0%; p=O.O32), or > 45 years (4.2% vs 1.2%; p=O.O36). Poly 
morphisms were not associated in women with CAD. A panel of two polymorphisms that 
included factor V Leiden mutation was associated with CAD. Multivariate analysis dis- 
closed factor V Leiden as a” independent variable for CAD [OR=4.4 (CL95%: 1.2-16.7; 
p=O.O2)]. Conclusion: Of all polymorphisms, only factor V Leiden was shown to be a” 
independent marker for CAD The panel of two or more polymorphisms did not increase 
CAD identification. 
Achim M. Vogt, Klaus D. Mfiller, Woitek Skwara, Jutta Schaper, Christoph Bode, 
Wolfgang Kiibler, Albrecht ElsBsser. Dept. Cardiology Heidelberg Universify, Heideiberg, 
Germany, Dept. Cardiology, Freiburg University Freiburg, Germany 
ORAL CONTRIBUTIONS 
Background: In myocardial ischemia, the energy level determines contractile perfor- 
mance. To elucidate the pathomechanisms underlying contractile dysfunction of human 
hibernating myocardium (HHM), a” in-depth analysis of its energy metabolism was per- 
formed. 
Methods: In 16 patients with documented coronary artery disease and impaired left ven- 
tricular function, HHM was identified by thallium 201~scintigraphy, radionuclide ventricu- 
lography, and low-dose dobutamine echocardiography, performed preoperatively and 
three months after revascularization. During open-heart surgery (OP), transmural biop- 
sies were removed from the hibernating areas. Both, metabolite contents (HPLC) and 
fibrosis (microscopy) were assessed from the same hibernating area, allowing to normal- 
ize total myocardial metabolite content to the cellular myocardial fraction (CMF). HHM- 
data were compared to normal human myocardium (control; n=7). 
Results: All patients showed diagnostic concordance of the clinical markers of HHM pre- 
OP and a significant improvement of regional contractile performance following revascu- 
larization. In HHM, total myocardial as well as cellular levels in ATP and phosphocreatine 
(CP) were reduced (see table), as were energy charge (EC), phosphorylation potential 
(P-Pot) and the free energy of ATP hydrolysis (AGnTp). 
High energy phosphate contents and energetic parameters in human hibernating myo- 
cardium 
879 Advances in the Pharmacotherapy of 
Acute Myocardial Infarction 
Wednesday, March 21, 2001, 8:30 a.m.-l 0:OO a.m. 
Orange County Convention Center, Room 231A 
a:30 a.m. 
879-l Is llblllla Blockade State-of-the-Art for Catheter Based 
Reperfusion? A Meta-Analysis of Five Randomized Trials in 
Acute Myocardial Infarction 
Umesh N. Khot, Franz-Josef Neumann, Sorin J. Brener, Albert Schomig, Gilles 
Montalescot, Shelly Sapp, Eric J. Topoi. The Cleveland Clinic Foundation, Cleveland, OH 
ATP CP EC P-Pot A%P 
Control total conient 3.755.23 5.1 lr.63 .96i-.02 2.91k.84 -55.9G39 
CMF 4.17r.26 5.67A.70 
HHM total content 1.24~.18‘ .62&l 1’ .73*.03’ .96+.10’ -53.2&47’ 
CMF 1.72+.25’ .85t.13’ 
*: pc.005 (ANOVA), metabolite contents in pmol/g wet wt, AG,, in kJ/mol. 
Conclusion: This first description of HHM’s energy metabolism reveals that HHM is 
severely energy depleted myocardium. Due to the well establIshed impact of energy 
metabolism on contractility we suggest that these energetic alterations contribute to 
HHM’s impaired contractile performance. 
878-5 
9:30 a.m. 
Percutaneous Intervention in Plaques With Increased 
Temperature is Associated With Unfavorable Outcome in 
Patients With Effort Angina 
Christodoulos I. Stefanadis, Konstantinos P. Toutouzas, Eleftherios Tsiamis, Manolis 
Vavouranakis, loannis Kallikazaros, Charalambos Vlachopoulos, Athanasios Trikkas, 
Sophia Vaina, Pavlos K. Toutouzas. Hippokration Hospital, Athens, Greece 
Background: It has been shown that patients with effort angina have increased temper- 
ature of the culprit atherosclerotic plaque. The present study was designed to investigate 
the significance of temperature measurement of the atherosclerotic plaque in patients 
with effort angina. Methods: Balloon angioplasty was performed in 30 patients, mea” 
age 61.4&.1 years, with effort angina. We measured the temperature difference (AT) 
between the atherosclerotic plaque and the healthy vessel wall with a thermography 
catheter previously validated, after accomplishing TIMI Ill flow. A metallic stent was 
implanted in all patients. Results: All procedures were petiormed successfully and with- 
out complications. In the study population mean AT was 0.132+0.18”C. All patients were 
followed-up for 17.Ok5.2 months, during which 4 patients suffered from a” adverse car- 
diac event. Patients with adverse cardiac events had increased AT compared to those 
without events (AT:0.07*0.09’C vs. 0.52t0.07”C;C.l [-0.54 - -0.361, P<O.OOl). The risk 
for a” adverse cardiac event was increased in patients with “hot” plaques (odds ratio 
1:41). Conclusions: The increased temperature of the culprit atherosclerotic plaques of 
patients with effort angina, in whom elective percutaneous intervention was performed, is 
associated with unfavorable clinical outcome. 
Background: Glycoprotein Ilb/llla inhibitors have bee” shown io improve clinical out- 
comes in patients with unstable and stable angina undergoing various types of percuta- 
neous intervention. Whether there is a similar benefit in patients undergoing 
percutaneous intervention for acute myocardial infarction is not established. 
Methods: To address this issue we performed a meta-analysis of 1369 patients from five 
randomized clinical trials (EPIC, RAPPORT, ISAR-2, ADMIRAL, and STOPAMI) of abcix- 
imab in percutaneous intervention for acute myocardial infarction. We compared clinical 
outcomes in 684 patients who received abciximab with 685 patients who did not receive 
abciximab. 
Results: Abciximab caused a significant 43% reduction in the jncidence of both death 
and myocardial infarction at 6 month followup (P=O.O03). 
Conclusion: When used in percutaneous intervention for acute myocardial infarction, 
abciximab use led to a pronounced reduction in mortality and furthermore decreased the 
incidence of recurrent myocardial infarction. This benefit was apparent at 30 day fol- 
lowup and was more pronounced at 6 month followup. 
Aggregate Data from 5 Randomized Trials 
Abcix- NO Odds 95% Confi- P 
imab Abciximab Ratio dence Interval Value 
30 Day Death 2.8% 4.2% 0.65 0.36 - 1.16 0.141 
30 Day DeatwMyocardial 4.2% 7.2% 0.57 0.36 - 0.92 0.02 
Infarction 
6 Month Death 4.2% 6.7% 0.61 0.38 0.98 0.043 
6 Month DeathiMyocardial 7.0% 11 .7% 0.57 0.39 0.83 0.003 
Infarction 
879-2 
8:45 a.m. 
Aspirin Plus Medium Intensity Coumadin Versus Aspirin 
Alone in the Prevention of Reocclusion After Successful 
Thrombolysis for Suspected Acute Myocardial Iniarction: 
Results of the APRICOT-2 Trial 
Marc A. Brouwer, Paul J. P. C. van den Bergh, Ralf I? J. W. Vromans, Wim Fi. M. 
Aengevaeren, Gerrit Veer?, Hans E. Luijten, Do” P Hertzberger, Ad J. van Boven, Gerard 
J. H. Uijen, Freek W. A. Verheugt. Heartcenter, University Medical Center, Nijmegen, The 
Netherlands, lnteruniversily Cardiology Institute Netherlands, Utrecht, The Netherlands 
Background: Within a year after successful thrombolytic therapy reocclusion of an inf- 
arct related artery occurs in about 30% of patients, despite the use of aspirin. It is associ- 
ated with an increased risk of death and reinfarction, and has been reported to preclude 
left ventricular contractile recovery. Methods: The APRICOT-2 trial (Antithrombotics in 
the Prevention of Fieocclusion In COronary Thrombolysis) is a multicenter, randomized, 
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clinical and angiographic follow-up study: 308 patients (< 76 years) received thrombolytrc 
therapy for signs and symptoms of suspected acute transmural myocardlal infarction 
within 6 hours of onset. and showed TIMI 3 flow at coronary angiography performed 
within 48 hours after thromboiysis. Thereafter, they were randomized to either aspirin 80 
mg daily, or to the combination of aspirin 80 mg and medium intensity Coumadin (target 
INR: 2-3). Follow-up angiography was scheduled at three months. Results: Reocclusion 
rate (< TIMI 3 flow) was 30% for patients on aspirin, compared with 18% for those on 
combination therapy (RR 0.60; Cl 0.39 - 0 93; p = 0.02). Patients on aspirin showed TIMI 
O-1 flow in 19% of patients, compared with 11% for those on aspirin and Coumadin (RR 
0.52: Cl 0.28 - 0.96; p = 0.03). Death and/or reinfarction were seen in 7% and 3% of 
patients, respectively (RR 0.38; Cl 0.12 - 1.20; p = 0.09). Conclusions: These findings 
strongly suggest that the combination of aspirin with medium intensity Coumadin mark- 
edly reduces clinical and x&graphic reocclusion after successful ihrombolysis for sus- 
pected acute myocardial infarction. Adjudicated trial data and 1 year follow-up will be 
presented. 
Conclusion: The combination of bolus tPA agents and bolus i.v. followed by S.C. dalte- 
parin was related to fewer coronary occlusions, a lower incidence of coronary thrombus 
and fewer reinfarctions during the first 7 days compared to standard heparin. This was 
observed without any increase in bleeding events. Possibly due to rebound after cessa- 
tion of dalteparin, ‘no difference in clinical outcome was observed at 30 days. Confirma- 
tlon of these findings in larger studies is warranted. 
879-5 
9:30 a.m. 
Therapeuttc Margin of Safety With Weight-Optimized Dosing 
of Tenecteplase 
Brad G. Angeja, Richard Chin, Xln Li. Hal V. Barron, Christopher Granger, Frans Van de 
Werf, C. Michael Gibson. University of California, San Francisco, Duke Clinical Research 
institute, Durham, NC 
879-3 
9:oo a.m. 
Early Statin Treatment Improves Long-Term Survival in 
Patients Discharged Alive After Acute Myocardial Infarction 
Ulf Stetnestrand, Lars Waiientin, the RIKS-HIA group. Heart Center, University Hospifai, 
Linkopiflg, Sweden, Dept of Cardiology University Hospifal, Uppsala, Sweden 
Background: Randomized trials have shown that statin treatment is beneficial as sec- 
ondary prevention in patients with cardiovascular disease. It is still unclear if statin treat- 
ment started already in hospital will influence long-term outcome. Furthermore it is also 
unknown how results from randomized trials translate into effects in an unselected 
patient population. We investigated the effect of early statin treatment on one-year sur- 
vival in an large cohort of consecutive unselected acute myocardial infarction (AMI) 
patients. 
Methods: From the Swedish Register of Cardiac Intensive Care, which included every 
CCU admitted patient at 58 partopating hospitals 1995-98, the 20,547 AMI patients ~80 
years old who were alive at discharge were included in the analyses. Cox regression 
analysis was performed evaluating the effect of statin treatment Initiated before or at dis- 
charge regarding one-year mortality taking into consideration 26 factors known to influ- 
ence survival such as clinical background, medication, interventions and complications. 
Results: In the 14,752 patients without statin treatment the unadjusted one-year mortal- 
ity was 9.4% (1,385) compared to 4.1% (235) in the 5,795 patients on early statin treat- 
ment. In Cox regression analysis adjusting for the 26 covariates early statin treatment 
was associated with a risk reduction of 35% for one-year mortality RR 0.65 (95% Cl 0.55 
0.77), p<0.001. 
Background: The Assessment of Safety and Efficacy of a New Thrombolytic (ASSENT)- 
2 trial demonstrated that tenecteplase (TNK) IS equivalent to alteplase (tPA) for treatment 
of myacardial infarction using weight-optimized doses, and we sought to evaluate the 
safety of errors in weight-optimized dosing. Methods: Rates of intracranial hemorrhage 
(ICH) and death were determined 1) among all patients treated with the highest dose (50 
mg) of TNK; 2) among patients weighing c 90 kg who received 50 mg TNK in error: and 
3) among all patients receiving any incorrect dose of TNK. Results: 1) A total of 1,915 
patients received 50 mg TNK, whom we compared to 1,919 tPA patients weighing > 90 
kg (control group matched for weight). The rate of ICH with 50 mg TNK (0.57%) was sim- 
ilar to that with tPA (0 47%, P = 0.65), as was the rate of death (4.70% vs. 3.96%, P = 
0.26). Multivariate adjustment did not change these results (P = 0.21 for both). 2) Of 
patients receiving 50 mg TNK, 150 (7.8%) weighed < 90 kg as specified by the protocol 
and received an excess dose of TNK in error. Rates of ICH (1.33%) and death (6.67%) 
were not significantly different than those among patients < 90 kg who received other 
thrombolflic doses (ICH = 1.06%, P = 0.68; death = 6.66% P =i .OO). 3) Of all patients 
given TNK, 218 patients (2.7%) received doses greater than recommended, and 326 
(4.0%) recwed doses less than recommended. The median weight error in overdose 
was 8 kg and in underdose was 1 kg. Neither underdoslng nor overdosing of 1 - 2 dosing 
intervals (up to 20 Kg or 44 pounds in error) was associated with ICH (odds ratio = 0 63 
[P = 0.531 & 1 .OO [P = i.OO], respectively) or death (OR = 1.09 [P = 0.731 & 0.84 [P = 
0.641, respectively) in a multivariate model accounting for weight. Conclusions: In this 
limited sample, there were no obvious differences in the rates of ICH and death with dose 
errors of TNK compared to rates among weight-matched controls treated with the correct 
dose. While correct dosing remains the goal, there appears to be an acceptable margin 
of safety with errors in weight-optimized dosing of TNK. 
Conclusion:Early initiated statin treatment in AMI patients significantly reduces one-year 
mortality. Furthermore this register study shows that the results from randomized statin 
trials will have important implications also when transferred to an unselected AMI popula- 
tion 
879-6 
9:45 a.m. 
Protection of Left Ventricular Function with Recombinant 
Soluble P-Selectin Glycoprotein Ligand-lg in the Canine 
Coronary Balloon Occlusion Model 
Kai Wang, Zhongmin Zhou, Xiaorong Zhou, Khaidoun Tarakji, Jian Xin Qin, Marta Sitges, 
Marta Sitges, Takahiro Shiota, Eric Topol, A. Michael Lincoff. The Cleveland Clinic 
Foundation, Cleveland, OH 
Background: Recombinant P-selectin glycoprotein ligand-lg (rPSGL-Ig) is a soluble 
form of high-affinity counterreceptor for P-selectin. Its effect on left ventricular function 
after AMI was evaluated in a canine ischemia-reperfusion model. 
Methods: A balloon-occluded model was used in this study. LAD occlusion was achieved 
using balloon inflation for a total of 90 minutes in 10 hound dogs (20.22kg) (rPSGL-Ig=5, 
placebo=5). rPSGL-lg (lmg/kg) or saline was given as a bolus intravenously 15 minutes 
before repetfusion. All animals were followed for one week. Real-time 3.dimensional 
echocardiography was used to evaluate the left ventricular function. 
Results: Infarct size was significantly reduced in the treatment group when expressed 
either as percentage of the area at risk (rPSGL-Ig, 7.19+7.27%; placebo, 21.80t5.41%; 
p&007) or as absolute Infarct size (Table). Left ventricular function expressed as ejec- 
tion fraction (EF) was much improved at 2 hours after repelfus~on (rPSGL-lg, 
43.3t4.13%; placebo, 28.48i8.07%; p=O.O17), however. at 1 week follow-up this differ- 
ence was no longer significant due to recovery of the placebo group (rPSGL-Ig, 
47.55?10.85%; placebo, 45.54r5.00%; p=O.781). 
Table. Myocardial Area at Risk and Effects of rPSGL-lg on Infarct Size 
Placebo rPSGL-Is P value 
879-4 
9:15 a.m. 
Lmw Heparin (Dalteparin) for Improvement of Patency After 
Thrombolysis in AMI: A Prospective Randomized 
Multicentre Coronary Angiography Study 
Mikael Dellborg, Lott Bergstrand, Chris Granger, Bertil Lindahl, Tage Nllsson, Kenneth 
Persson, Eva Pihl, Agneta Siegbahn, Eva Swahn, Lars Wallentin, The ASSENT PLUS 
Investigators. Dept. of Medicine, Sahlgrenska University Hospifa//Osfra, Gdfeborg, 
Sweden, Uppsala University, Uppsala, Sweden 
Background: Despite improvement of 60 minutes coronary blood flow there are no 
added benefits in clinical outcome by the new fibrinolytic agents. This might be caused by 
reocclusion during and after the associated 48.hour heparin infusion. The primary aim of 
the present trial was to evaluate whether S.C. dalteparin until a coronary angiogram after 
4 - 7 days is more effective than 48-h heparin infusion in obtaining patency and TIMI- 
flow after thrombolysis with r&PA in acute myocardial infarction (AMI). 
MethodxPatients with an AMI and an indication for thrombolysis wlthin 6 h of symptom 
onset were openly randomised to heparin infusion for 48 h or i.v. bolus followed by S.C. 
dalteparin 120 IUikg every 12 h until coronary angiography after 4 - 7 days. All coronary 
angiograms were centrally and blindly evaluated concerning TIMI flow grade (lo abjec- 
tive). Other objectwes were safety, noninvasive signs of early reperfusion coagulation 
and bleeding parameters, clinical events during treatment (max. 7 days) and 30 days 
Results: 439 patients. mean age 65 yrs, 70% male, were random&d in 18 Swedish and 
4 US. hospitals , 378 performed per protocol angiography, 
Dalteparin Standard heparin p 
TlMI-3 flow (n=202/176) (%) 69.3 62.5 0.16 
Visible thrombus (n=Z02/176) (%) 18.9 27.3 0.054 
TIMI 2/3 T no thrombus (n=202/176) (%) 72.1 58 0004 
Reinfarction until 7 days (n=216/204) (W) 1.4 5.4 0.02 
At 30 days, no significant differences in death, reinfarction or revascularization were 
observed. No significant differences were observed in bleeding or other side-effects 
Area at risk, cm’ 53.14~8.95 52.55t6.14 NS 
Infarct size, cm2 12.01&280 3.90*4.39 0.008 
Conclusion: The adminlstration of rPSGL-Ig results in significantly Improved left ventric- 
ular function in the early time period after AMI through salvage of jeopardized myocar- 
dium. 
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and non cardiac in 3. Preoperatively, 117 out of the 207 (57%) were in NYHA class Ill-IV, 
80 pts (39%) had an EF less than 30% and 72 patients (35%) had an ESVI greater than 
120 mlim2. For these patients late mortality rate was 21%, 26% and 28%, respectively. 
Graphic shows Kaplan Meyer survival curve in patients divided by preoperative end sys- 
tolic volume index and NYHA class. Perioperative deaths are excluded. At Cox regres- 
sion analysis predictors of late deaths were preoperative left ventricular volumes, ejection 
fraction, NYHA class and the presence of remote asynergy (p <O.OOOO). Conclusion: 
Dor procedure has a favorable impact on survival in postinfarction patrants with severe LV 
dysfunction and high functional class. Predictors of late deaths are severe clinical condi- 
tions and pump dysfunction and this suggests that an earlier Intervention might further 
imorove survival. 
a83 New Horizons for Surgical Myocardial 
Revascularization 
Wednesday, March 21, 2001, 8:30 a.m.-l 0:OO a.m. 
Orange County Convention Center, Room 304A 
8:30 a.m. 
883-I Prospective Ten-Year Patency of Saphenous Vein and Left 
Internal Mammary Artery Grafts After Coronary Artery 
Bypass Surgery 
Steven Goldman, Karen Zadina, Thomas Moritz, Theron Ovitt, Gulshan Sethi, Jack 
Copeland, William Henderson, VA Cooperative Study #364. Southern Arizona VA 
Healthcare System, Tucson, AZ Edward Hines, Jr, VA Hospital, Hines, IL 
Background: This Department of Veterans Affairs Cooperative registry prospectively 
defined long term saphenous vein graft (SVG) and left internal mammary artery (IMA) 
graft patency in patients undergoing coronary artery bypass grafting (CABG) in the late 
1980s. 
Method: As part of an ongoing trial, we obtained serial angiographic data at one week, 
one year, three years, and ten years after CABG. Initially, 1196 patients were enrolled in 
the trial. At ten years, we obtained angiographic data on 365 patients, while 441 patients 
had died, and 390 patients did not undergo angiography. 
Results: The SVG and IMA patency rates at ten years were 65.8% and 90.4%, 
respectively. If a patient had a patent SVG or IMA at one week, that graft had a 72.2% 
and 92.8% chance, respectively, of being patent at ten years. For SVGs, the first year 
patency rate was 82.4%, three-year patency was 77%, and ten-year patency was 
65.8%. For IMA grafts, the first year patency rate was 94.9%, three-year patency was 
90.5%, and ten-year patency was 90.4%. There was a significant difference between the 
patency rates by location (p<O.O5). At ten years, the SVG patency of the left anterior 
descending was better (70.7%) than that of the right coronary artery (60.5%). There was 
no significant difference in patency rates between the left anterior descending and the 
circumflex (64.9%). 
Conclusions: Our conclusion is that when prospective angiographlc follow-up are 
obtained on patients undergoing CABG in the 198Os, the long-term patency for SVGs is 
better than previously thought. For SVGs, the most important predictor of long-term graft 
patency is patency at one week after CABG. 
883-2 
8:45 a.m. 
Minimal Invasive Bypass Surgery Versus Stentimplantation 
in Isolated Proximal High Lesions of the LAD in More Than 
200 Patients 
Holger Thiele, Anno Diegeler, Bernward Lauer, Rainer Hambrecht, Friedrich W. Mohr, 
Gerhard Schuler. University of Leipzig, Heart Center, Leipzig, Germany 
Background: Minimal invasive bypass surgery (MIDCAB) has been shown to yield com- 
parable results to conventional bypass grafting with less operative trauma. Therefore it 
may be considered an alternative treatment to stentimplantation in patients with proximal 
high-grade lesions of the LAD. Methods: 220 patients with high-grade lesions of the 
proximal LAD were randomized between MIDCAE? (110) and stentimplantation (110). 
Cllnical symptoms were assessed by CCS-class. After 6 months patients underwent 
repeat coronary angiography. Results: During MIDCAB 4 patients (4%) were converted 
to conventional bypass surgery and 2 patients required repeat operation due to stenosis 
of the distal anastomosis within 1 week. Acute stem thrombosis occurred in 2 P (2%). 
After 6 months 33197 patients (34%) in the stent group showed in-stent restenasis >50% 
of who 26 (27%) underwent re-PTCA. In the MIDCAB-group 13/91 (16%) showed steno- 
sis >50% of the distal anastomosis, 5 patients (6%) required PTCA (p=O.O2). Relieve of 
angina at 6 months was more complete at 6 months in MIDCAB as compared to stentim- 
plantation (CCS 0.3kO.6 vs. 0.7+1 .O; p<O.OOi), although physical work capacity did ,not 
differ between the groups (p=n.s.). Subgroup analysis showed no differences for type A, 
B, C stenoses or patients with diabetes mellitus after MIDCAB or stentimplantation. Con- 
clusions: In patients with high-grade lesions of the proximal LAD both MIDCAB and 
stentimplantation yield excellent results, although MIDCAB is associated with a higher 
rate of periprocedural events. After 6 months the reintervention rate is higher in the stent 
group and symptomatic relieve is more complete after MIDCAB. 
883-3 
9:00 a.m. 
Efficacy of Dor Procedure on Late Survival in Patients With 
Postinfarction Akinetic or Dyskinetic Scar and Predictors of 
Outcome 
Marisa Di Donato, Michel Sabatier, Anna Toso, Mauro Maioli, Vincent Dar, Gian France 
Gensini, Gerald Buckberg. Dpt of Critical Care Medicine, Florence, /t&y, Cardio Thoracic 
Center, Monaco, Monaco 
Background: Dor procedure is a surgical technique consisting in endoventricular patch 
plasty repair (EVCPP) of the left ventricle (LV) and associated coronary grafting, that 
applies to postinfarction pts with either akinesia or dyskinesia and LV pump dysfunction. 
Methods: This study examined the effects of this procedure on long term survival and 
the association with preoperative clinical and hemodynamic variables in 207 consecutive 
surviving patients (perioperative mortality 7.9%) submitted to EVCPP at the Cardiotho- 
racic Center of Monaco during 4 years activity. Mean age was 58i8 yrs; delay from Ml: 
42+52 m: EF: 35%+12. Results: There were 27 late deaths and 3 heart transplantation 
during follow up (45+27months). Causes of death included CHF in 16, sudden death in 8 
883-4 
9:15 a.m. 
Correlation of NOGATM Left Ventricular Electromechanical 
Mapping and Radionuclide Perfusion Imaging 
Demonstrating Augmented Perfusion of lschemic 
Myocardium in Patients Undergoing Direct Myocardial 
VEGF-2 Gene Transfer 
Peter R. Vale, Charles E. Milliken, David Fortuin, Richard A. Schatz, Maria 6. McDonald, 
Darryl D. Esakof, Michael Maysky, Alan B. Ashare, James F. Symes, Jeffrey M. Isner, 
Douglas W Losordo. St Nizabeth’s Medical Center. Boston, MA, Scripps Clinic. La Jolla, 
CA 
Background: We present the combined results of NOGATM left ventricular (LV) electro- 
mechanical mapping (EMM) and radionuclide perfusion imaging in pts undergoing direct 
myocardial gene transfer (GT) with naked DNA encoding for vascular endothelial growth 
factor-2 (phVEGF-2). Methods: A total of 16 pts (14 men, mean age 62.3i2.3 yrs) with 
non-revascularlzable chronic stable angina underwent SPECT-Sestamibi imaging and 
EMM prior to direct myocardial injection of phVEGF-2 via mini-thoracotomy, receiving 
doses of 200yg (n=7), 8OOpg (n=4) and 20009 (n=5) as part of a multicenter, open 
labelled, non-randomized clinical trial. Foci of ischemic myocardium were identified on 
EMM by preserved viability (unipolar (UpV) and bipolar (BpV) voltage recordings >=5mV 
and >=2mV respectively) associated with an impairment (~12%) in linear local shorten- 
ing (LLS). A 20.segment scoring system was used to calculate stress and rest perfusion 
scores. Results: Myocardial segments with normal radionuclide perfusion (n=195) had 
normal LLS (pre-GT=12.2*0.7 vs post-GT=13.8r0.8%), and normal UpV (12.4+0.8 vs 
13.3t0.6mV) and BpV (3.2~0.3 vs 3.5t0.3mV). Segments with reversible ischemia and 
normal resting perfusion (n=37) showed improved LLS (7.4~1.3 vs 14.2+0.9%, pcO.001) 
associated with reduced (ix improved) stress score (4.5i-1.2 vs 2.4+0.9, p=O.O05) post- 
GT. This correlated with reduced area of ischemic myocardium (7.8+1.5cm2 vs 
3.121.4cm2 p=O.OOOl). Segments with resting periusion defects (n=92) had ischemic 
LLS and normal voltages pre-GT, but showed normalization of LLS (8.7+0.7 
vs12.0+0.6%, pcO.001) post-GT, while UpV (12.5kO.8 vs 12.1*1.lmV) and BpV (4.0~0.4 
vs 3.4+0.4mV) remained unchanged. Conversely, ischemic segments on EMM (n=77) 
had improved stress (9.3A2.4 vs 5.4kl.6, p=O.O19) and rest (6.21-1.6 vs 3.6i1.1, 
p=O.O27) periusion scores post-GT. Conclusions: The results of EMM constitute objec- 
tive evidence that phVEGF-2 GT augments perfusion of ischemic myocardium and corre- 
lates with findings on Sestamibi imaging. Resting perfusion defects may constitute areas 
of hibernating myocardium that can be successfully’revascularized by therapeutic angle- 
genesis. 
883-5 
9:30 a.m. 
Perioperative Antioxidant Treatment With Vitamin C 
Reduces the Incidence of AtriatFibrillation After Coronary 
Artery Bypass Surgery 
Mina K. Chung, Barbara Elias, Stephen Pavia, Cynthia A. Carries, Patrick M. McCarthy, 
David R. Van Wagoner. The C%veland Clinic Foundation, Cleveland, OH 
Cardiac surgery can cause lschemic or reperfusion injury, which can produce free radi- 
cals acutely, during repetfusion or during later inflammatory phases. We hypothesize that 
the oxidative stress associated with cardiac surgery has a direct negative impact on elec- 
trophysiologic properties of the atria. The response to this oxidative stress depends on 
the antioxidant capacity of the patient. To test this hypothesis, we evaluated the impact of 
vitamin C (VitC) treatment on the incidence of postoperative atrial arrhythmias (AF). 
Methods: In a pilot series of 50 sequential patients undergoing primary CABG with nor- 
mal renal function and in sinus rhythm, VitC 2 g the night before CABG and 500 mg bid 
x5 days postoperatively was prescribed. This series was compared to an age- and gen- 
der-matched Control group that underwent CABG the 6 weeks following the pilot study. 
Results: Age (61.8~11.1 Control vs 61.7~12.1 VitC) and LVEF (48.6+10.9% Control vs 
49.7+11.1% VitC, p=ns) were similar between groups. Postoperative AF developed in 61 
43 (14.0%) patients pretreated with VitC, compared to 14/43 (32.6%) in the control group, 
p=O.O41. Significant univariate predictors of postoperative AF included older age 
(p=O.O06) and LVEF (P&021), but additional postoperative beta blocker use in the VitC 
patients and off-pump CABG did not confer additional reduction in AF. Multivariable logis- 
tic regression analysis identified VitC pretreatment (odds ratio OR 0.237, 95% Cl 0.0678. 
JACC February 2001 
0.829, p=O.O24), age (OR 1.087, 95% Cl 1.027-1.151, p=O.O04), and LVEF (OR 0.937, 
95% Cl 0.890-0.986, p 0.012)as independent factors associated with postoperative AF 
with V&n-in C having a protective effect. Conclusions: Vitamin C may reduce the inci- 
dence of atrial fibrillation by more than half after CABG. Additional randomized, blinded 
studies are needed to confirm and extend this finding. 
883-6 
9:45 a.m. 
Robotically Assisted Cardiac Surgery: The Dresden 
Experience 
Romuald Cichon, Utr Kappert, Jens Schneider, Ina Schade, Vassilios Gulielmos, Sems 
Make Tugtekin, Klaus Matschke, Stephan Schueler. Cardiovascular Insflfute, University 
of Dresden, Dresden, Germany 
Background: The consequent development of minimally invasive techniques in coronary 
artery surgery, focussing on the avoidance of median sternotomy, has lead to a differenti- 
ated therapeutical concept for the treatment of patients suffering from coronary artery 
disease (CAD). With the introduction of the da VinciTM robotic surgical system (Intuitive 
Surgical) into mrnimally invasive cardiac surgery the outlook of performing coronary 
artery bypass operations ‘closed chest’ became a reality. Methods: Between 5/99 and 
6/00 this new wrist-enhanced instrumentation was used in 134 patients (100 male, 34 
female, median age 63 * 10.1 years). Twelve patients suffering from single vessel CAD 
and one patient suffering from double vessel CAD were treated as totally endoscopically 
coronary artery bypass (TECAB). Seventy-three patients with single vessel CAD under- 
went a minimally invasive direct coronary artery bypass procedure. Thirty-two patients 
with double vessel CAD were treated “sing the robotic-enhanced Dresden Technrque. 
Sixteen patients received a median sternotomy: Seven patients necessitated an intraop- 
erative conversion to a median stenotomy. Nine patrents received robotic-assisted coro- 
nary artery bypass grafting via a median sternotomy already preoperativefy planned. 
Results: Perioperative survival was 100%. internal mammary arteries (IMA) were always 
harvested totally endoscopically except in four patients. All IMA’s had excellent flow. All 
patients out of the TECAB group were operated upon via a three or four point stab inci- 
sions “sing the da VincrTM robot for left IMA or bilateral IMA takedown and for perfor- 
mance of anastomoses. The time of dissection of the left IMA could be srgnificantly 
reduced. In the TECAB group all patients were operated upon via a three (TECAB) or 
four (beating heart TECAB) point stab incisions. Preoperative, perioperative, and postop- 
erative data were observed. Conclusions: Our prelrminary experiences with this new 
surgical techniques for robotic-enhanced minimally rnvasive treatment of CAD promote 
an optimistic way of thinking about the further development of these procedures and its 
application in patients suffering from CAD 
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1282-75 Improving Trends in Evidence-Based Treatment of Acute 
Myocardial Infarction: Impact of a Population-Wide Disease 
Management Program? 
Jafna L. Cox, lqbal R. Bata, Blair J. O’Neitl, David E Johnstone, on behalf of the ICONS 
Investigators. Dalhousie Universify, Haiiiax, NS, Canada 
Background: Despite a wealth of evidence with which to direct clrnical practice in cardi- 
ology, a care gap persists between actual and ideal rates of use of various treatments. 
One way of addressing this gap is through disease management, an attractive but hith- 
erto untested paradigm, at least at a population level. 
Methods: Improving Cardiovascular Outcomes in Nova Scotia (ICONS) is a large, popu- 
lation based disease management study, involving multiple stakeholders, and funded 
through a public-private partnership. It has been operational in the province of Nova 
Scotia since October 1997 where it has focussed on optimizing the care of, among other 
condrtions, acute myocardial infarction (AMI). Research teams operate at IO sites 
across the province and trained abstracters carry out detailed chart audits on every sin- 
gle Nova Scotia resident hospitalized with AMI. Information is electronically relayed to 
the project office in Halifax where it is analyzed and fed back through multiple media to 
providers and policy makers across the province. Various interventions aimed at optimiz- 
ing care run concurrently to the data gathering. 
Results: Data are provided concerning temporal trends rn the discharge rates of various 
therapies from the start of the project in October 1997 through to the end of 1999. These 
include antiplatelet therapy (AP), beta-blockers (BB). ACE Inhibitors or All receptor block- 
ers (ACEI/ARB). statins (HMG), as well as rate lrmiting and non-rate limiting calcium 
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Conclusion: Rates of “se of evidence-based therapies, already high at the outset of 
ICONS, have further increased. Therapies for which lrttle evidence for benefit exists in 
this setting, such as CCBs, have remained correspondingly low. While difficult to prove, it 
is likely that ICONS has at least stimulated these changes. The final important link to 
improved outcomes requires longer follow-up. 
1282-76 Impact of Prehospital Care in the Management of Acute 
Myocardial Infarction 
Thomas P. Mathew, Ian B. A. Menown, Loreena M. Hill, Jennifer Adgey. Royal Victoria 
Hospital, Belfast, United Kingdom 
Background:Pre-hospital care for patients (pts)with acute myocardial infarction (AMI) 
may improve outcome by enabling earlier administration of fibrinolytic therapy (FT) and 
management of complications. We prospectively assessed the impact of pm-hospital 
care in our routine practrce. Methods: Consecutive pts with AMI presenting out-of-hospi- 
tal (0H)to a 24 hour physician-manned mobile coronary care unit were compared wth 
those presenting in-hospital (IH)(rn the emergency department or other medical wards). 
We studied 458 pts over a 21 month period (97-99) 200 of whom presented OH, and 258 
of whom presented IH. Results: OH and IH pts were comparable with respect to age 
(mean:SD 63.2+12.1 vs 65.1~12.8 years), history of hypertension (62/200:31% vs 73/ 
258:28%), dyslipidemia (1491200: 75% vs 1901258: 74%), current smokers (79/200: 40% 
vs 991258: 35%) aspirin on admission (761200: 38% vs 112/258: 42%) sytolic blood 
pressure less than 80 mm of Hg on admission (12/200: 6% vs 111258: 4%) and the num- 
ber of anterior Ml’s (67/200: 34% vs 811258: 31%) p=ns. Male sex(148/200: 74% vs 1641 
258: 64% p=O.OZ), ST elevation on admission ECG (1711200: 86% vs 188/258: 73% 
p=O.OOi), history of documented ischaemic heart disease (IHD ie:MI or revascularisa- 
tion)(72/200: 36% vs 671258: 26% p=O.O2), and primary ventricular fibrillation (VF)(33/ 
200: 17% vs 16/258: 6% p =O.OOOl) were more common in OH pts, whereas diabetes 
was less common in OH pts (20/200: 10% vs 491258: 19% p=O.O08). FT was more com- 
monly used in OH (1571200: 79%) than in IH pts (136/258: 53%) p =O.OOOl. Median 
delay from pain to FT was significantly shorter for OH pts(2.2A3.2 vs 4.1k7.5 hours 
p=O.OOOl). Death during hospital stay occurred in 52/458 (11%) pts and was more fre- 
quent in IH than OH pts (331258: 13% vs 19/200: 10% ~~0.3). For pts who received FT, 
mortality was again higher in the IH than OH pts(l81136: 13% vs 111157: 7% p=O.O8). 
Conclusion: Use of pm-hospital care enabled earlier admrnistration of FT and showed a 
trend towards reduction in early mortality, despite higher incidence of anterior Ml’s, 
hypotension, primary VF and previous documented IHD in the OH group. 
1282-77 The Smoker’s Paradox: Angiographic Insights From the 
TIMI Trials 
Sarah Ft. Kermgard, Michael S. Chen, Sabina A. Murphy, Jessica S. Lim, Colin A. Hynes, 
Matthew H. C. Otten, Lily L. Luu, Susan J. Marble, Christopher P Cannon, Eugene 
Braunwald, C. Michael Gibson. University of Califorma San Francisco, San Francisco, 
CA, Brigham and Women’s Hospital, Boston, MA 
Background: Previously, it has been demonstrated that smokers have improved clinical 
outcomes in the sethng of acute myocardial infarction (AMI). We hypothesized that 
improved outcomes might be explained by improved epicardial and microvascular perfu- 
won, as well as favorable baseline demographics. Methods: Data were drawn from the 
TIMI 4, lOA, 106 and TIMI 14 angiographic trials of AMI. Results: Univariate analysis 
showed that smokers had lower mortality rates (2.57% vs. 6.22%, p=O.OOi) and lower 
rates of intracranial hemorrhage (ICH) (0.71% vs. 1.51%, p=O.O54). However, in a multi- 
variate model correcting for age and infarct artery location, there was no difference 
among active smokers and non-smokers in the odds of death (O.R.=0.78, pzO.29, C.I. 
0.49-1.24) or ICH (O.R.=0.78, p=O.56, C.I. 0.33-1.81). Higher rates of TIMI grade 3 flow 
in smokers were confined to those patients wiih LAD infarctions (TFG 3, 55.7% vs. 
43.9%, p=O.O06), but no difference was seen I” patients with non- LAD infarctions (TFG 
3, 64.2% vs. 64.3%). Conclusion: Smokers have improved clinical outcomes in AMI. 
However, this is largely explarned by their younger age and lower incidence of anterior 
AMls. Despite improved epicardial flow, microvascular flow was impaired (lower TMPG 3 
and longer chest pain duration), with larger infarct sizes by peak CK. 
Smokers Non-Smokers p-value 
Age 54.4 +/-10.2, n=1240 62.4 +/-10.3, n=1310 <0.0001 
LAD Infarct Location 34.5% (425/1232) 39.2% (50811’295) 2 way, 0.01 
No. of patients wrth triple 16.5% (20211227) 21.5% (27711288) 0.001 
vessel stenosis 
CTFC (frames)-open and 47.9+/-32.9, n=l124 50.8+/-32.7. n=1173 0.002 
closed arteries 
TIMI Grade 3 Flow 61.2% (72211179) 56.2% (698/1242) 2 way, 0.01 
TIMI Myocardial Perfusion 24.3% (911374) 28.8% (114/396) 2 way, 0 16 
Grade 3 
JACC February 2001 
1282-102 Time of In-Hospital Death in Patients With Acute Myocardial 
Infarction Treated With Primary Angioplasty Compared to 
Patients Treated With Intravenous Thrombolysis. Results 
From the Pooled Data of the MITRA and the MIR Registries. 
Ralf Zahn, Steffen Schneider, Rudolf Schiele, Anselm K. Grtt, Harm Wienbergen, Claus 
Bossaller, Martin Gottwik, Jochen Senges. Heart center, Ludwigshafen, Germany 
Background: The in-hospital time course of death in acute myocardial infarction (AMI) 
after treatment with primary angioplasty (PA) compared to intravenous thrombolysis (TL) 
is unknown. Methods: We analyzed the pooled data of the Maximal Individual Therapy in 
Acute Myocardial Infarction (MITRA) Registry and the Myocardial infarction Registry 
(MIR). Results: Out of 8744 lytic eligible patients (pts) with a pre-hospital delay 612 
hours, 7638 (87.4) pts were treated with TL and 1106 (12.6%) pts with PA. The table 
shows hospital mortality for different time periods. 
time after admission mortality PA mortality TL multivariate OR (95%CI) 
48 hours 2.7% 4.9% 0.46 (0.30-0.72) 
first week 1.6% 2.3% 0.84 (0.49-i .43) 
second week 1.5% 1.5% 1.03 (0.56-l .91) 
third week 1.4% 0.9% 1.69 (0.74-3.87) 
> third week 1.7% 1.5% 0.97 (0.29-3.31) 
all 6.2% 9.6% 0.63 (0.47-0.84) 
Conclusions: PA is superior to TL for the treatment of pts with AMI. This advantage is 
achieved during the first 48 hours after admission and is maintained during the hospital 
stay. 
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Peak CK ((X/upper limit of 13.411-13.3, n=ll60 11.2+/-10.9, n=1218 <0.0001 
normal) 
Duration of Chest Pain 2.21+/-4.6, n=596 1.7+/-3.6, n=643 0.03 
1282-78 Prediction of intracranial Hemorrhage in the InTIME-II Trial 
Michael A. Sloan, Robert P. Grugliano, Susan L. Thompson, Elliott M. Antman, Carolyn 
H. McCabe, Eugene Braunwald. Rush Msdicai College, Chicago, IL, Brigham and 
Women’s Hospital, Boston, MA 
Background: Risk factors for intracranial hemorrhage (ICH) have been established in 
large coronary thrombolysis trials and registries. Limited data exist on the ability to strat- 
ify risk of ICH from thrombolytic therapy. 
Methods: In InTIME-II, 15060 patients presenting with ST elevation acute Ml at 853 
hospitals in 35 countries were randomized in a 2:l ratio to receive either single-bolus lan- 
oteplase @PA) 120KUIKg or 1OOmg alteplase (tPA) as a 90 minute accelerated infusion. 
We reviewed the occurrence of ICH in each group, identified independent predictors of 
ICH in a logistic regression model, and developed a risk stratification scale to identify 
patients at low and high risk of ICH from thrombolytic therapy. 
Results: ICH occurred in 144/15060 (0.96%) of patients enrolled, with 112110038 
(1.12%) in nPA-treated patients, and 3214990 (0.64%) in tPA-treated patients (p=O.O04). 
Independent predictors of ICH were age 275 years (RR=2.77, p<O.OOOi), prior cere- 
brovascular disease (CVD) (RR=4.01, p=O.O004), nPA treatment (RR=1 81, p=O.O04), 
weight ~67 kg (RR=1.66, p=O.O08), prior nifedipine treatment (RR=2.02, p=O.OlZ), SBP 
>160 mm Hg (RR=1.54, p=O.O47), and prior anti-platelet therapy other than aspirin 
(RR=2.84, p=O.O48)(model c-statistic = 0.65). A weighted risk stratification score after 
omitting thrombolytic assignment, assigned 4 points for prior CVD: 2 points each for age 
> 75, prior anti-platelet therapy, prior nifedipine; 1 point each for weight < 67 kg, SBP > 
160. ICH rates ranged from 0.55% to 4.6% across 6 risk groups’(see figure). Similar pat- 
terns of ICH rates were observed across risk groups in separate analyses stratified by 
thrombolytic agent. 
Conclusion: A simple weighted score based on 6 variables can stratify the risk of ICH 
among patients receiving thrombolysis. This type of risk assessment would be valuable 
to aid clinicians in the decision to administer thrombolytic therapy. 
1282-101 Characteristics and Outcomes in AMI Patients Who 
Subsequently Develop ST Segment Elevation After Hospital 
Arrival 
Katherine A. Littrell, Mary Lou Skovron, Robert J. Zalenski, Hal V. Barron. Genentech, 
Inc., South San Francisco, CA 
Background: The initial ECG is diagnostic of acute injury in approximately 40% of AMls. 
The characteristics of AMI patients who develop ST segment elevation (STE) after an ini- 
tially non-diagnostic ECG and the risk of in-hospital mortality is unclear. OBJECTIVE: 
The purpose of the study was to determine whether patients who arrive without STE but 
develop it on a subsequent ECG (STE -ii) are at increased risk of mortality compared to 
patients who arrive at the hospital with no STE and do not evolve subsequent ST seg- 
ment elevation (STE -/-). Methods and Results: The population consisted of 61,522 AMI 
patients with an initially non-diagnostic ECG discharged from 1511 U.S. hospitals partici- 
pating in the NRMI 3 from July 1998 . March 31, 2000. To estimate the increase in mor- 
tality risk in patients evolving STE -/+ we used a stepwise multivariate logistic regression 
model controlling for demographics, presentation characteristics, medications within 24 
hours of admission and use of reperfusion strategies. Median time from first 12.lead ECG 
to 12-lead ECG with STE was a median of 63 min. STE -/+ patients ware younger (mean 
64.6 vs. 70.6 yrs) and a higher proportion male (67.4% vs. 57.9%) compared with STE -/ 
-, STE -I+ patients less frequently presented with a history of diabetes, previous MI, HTN, 
CHF, and previous CABG compared with STE -/-. STE -/+ patients were more likely to 
have chest pain, be a current smoker and present with Killip Class 1. In-hospital mortality 
was 8.5% for patients with ST -/+ vs. 7.7% in patients with ST -/-. In the multivariate 
model STE -i+ was associated with a 77% increased odds of in-hospital death compared 
to STE -I- patients (OR=1.77; 95% Cl 1.556-2.013). Conclusions: Patients with subse- 
quent STE are younger, more frequently male and have fewer comorbidities compared to 
STE -/- yet they have a higher risk of in-hospital mortality The time from initial ECG to 
subsequent STE suggests that patients evolve STE early in the course of their admis- 
sion. To optimize diagnosis and management of these patients with STE -/+, a routine 
practice of early serial ECGs or continuous ST segment monitoring may be advanta- 
geous. Further research is necessary to demonstrate the effectiveness of such a routine 
practice. 
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1283-79 Three Simple Factors for Rapid Initial Risk Assessment in 
ST-Elevation Ml: An InTIME II Substudy 
David A. Morrow, Elliott M. Antman, Robert P. Giugliano, Richard Cairns, Andrew 
Charlesworth, Sally S. Cutler, Carolyn H. McCabe, Eugene Braunwald. Brigham & 
Women’s Hospital, Boston, MA 
Available models for predicting mortality in ST elevation MI (STEMI) include up to 20 clin- 
ical factors, but have consistently shown advanced age, increased heart rate and 
decreased blood pressure to be among the strongest predictors. Methods: Using infor- 
mation from multivariable analysis among 14,450 pts with STEMI treated with fibrinolytics 
in the InTIME II trial, we developed and evaluated a risk index based on age in decades. 
heart rate (HR) and systolic BP (SBP) for the predlction of mortality by 30 days. The risk 
index [HR*Decad&SBP] was evaluated both as a categorical predictor in deciles, and 
as a continous variable by logistic regression. Results: Age, HR and SBP accounted for 
85% of the predictive information available from the full multivariable model. Stratification 
by the risk index in deciles revealed a highly significant increasing gradient of mortality 
(Fig). Moreover, the logistic model showed excellent prognostic discrimination (c-statistic 
= 0.78) comparable to that for the full multivariable model (c-statistic = 0.80). External 
validation in the TIMI 9 data set (N = 3659) showed a similar strong prognostic capacity 
(c-statistic = 0.79). Conclusions: A vary simple risk index using only age, HR and SBP 
captures the majority of prognostic information offered by a full logistic regression model 
but is convenient for rapid initial risk assessment in the field or by any clinical provider. 
1283-80 Diabetes Doubles the Risk of Death Among Patients 
Presenting With Acute Coronary Syndromes: Insights From 
SYMPHONY, a Large International Trial 
Darren K. McGuire, L. Kristin Newby, Manju V. Bhapkar, David J. Moliterno, E. Magnus 
Ohman, F Chris Dougherty, Robert A. Harrington, Harvey D. White, Frans Van de Werf, 
Robert M. Califf, Eric J. Topol, the SYMPHONY Investigators. Duke Clinical Research 
Institute, Durham, NC 
Background: Diabetes mellitus (DM) is associated with worse outcomes after myocar- 
dial infarction (Ml). Less is known about the influence of DM, especially on long-term 
prognosis, following the broader spectrum of acute coronary syndromes (ACS). Meth- 
ods: Baseline characteristics, treatments used, and outcomes were compared between 
patients with and without DM in the SYMPHONY trial (sibrafiban vs aspirin post-ACS). 
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Results: 1,577 of 9,233 (17%) patients had DM. DM patients were older, more often 
female and obese; had more hypertension, hyperlipidemia, and prior cardiovascular dis- 
ease; and were less often smokers. Patients with DM were more likely to get ACE inhibi- 
tors, lipid lowering therapy, calcrum blockers and nitrates, and less likely to get R blockers. 
There were similar rates of angiographylrevascularizaiion rn the groups. At 90 days and 1 
year (table), DM patients had worse outcomes, includrng a Z-fold increased risk of death. 
DM increased the risk of death/Ml/severe recurrent ischemra (SRI) at 1 year regardless 
of the presenting event; (Q Wave MI 18.2% vs 15.6%), non Q Wave MI (25.8% vs 
17.5%), or unstable angina (26 6% vs 17.5%). 
Conclusion: Drab&es IS associated with worse long-term outcomes aoross the spec- 
trum of ACS. Beiter treatment strategies are needed for this high-risk population. 
Clinical Outcomes by Diabetes Status 
Endpoint DM Patients (%) Non-DM Patients (%) OR (95% Cl) 
SO-days 
Death/MI/SRI 12.4 9.5 1 35 (1.14, 1.59) 
Death/Ml 10.3 69 1.55 (1.29, 1.86) 
Death 3.4 1.7 2.04 (1.48, 2.83) 
1 -year 
Death/Ml/SRI 23.7 16.8 1.53 (1.37, 1.87) 
Death/MI 15.8 10.5 1.60 (1.37, 1.87) 
Death 6.0 3.5 1.79 (1.40, 2.27) 
1283-81 What Angiagraphic Measure of Extent of Coronary Artery 
Disease Best Predicts Subsequent Risk? 
David 5. Jessup, Joseph E. Muhiestein, Dale G. Renlund, Benjamin D. Home, Tami L. 
Bair, Robert R. Pearson, Jeffrey L. Anderson. Universifyof Utah, San Lake City, UT; LDS 
Hospital, Sdf Lake my, UT 
Background: The extent of prevalent coronary artery disease (CAD) is a strong predic- 
tor of future risk of cardiovascular events,, but the best clinical predictive measure of the 
extent of CAD is uncertain. We studied the predictive value for death or myocardral inf- 
arction (Ml) of 6 readily assessed rnea~ures of GAD. 
Methods: To assess the relationship of CAD measures to outcome, we studied 2827 
patients (pt) without acute myocardial infarction (MI) undergorng angiography: 1792 had 
severe CAD (21 stenosis 270%) 303 mild/moderate, and 732 no CAD. CAD was quanti- 
fied in 6 ways: presence of severe CAD, number of vessels with severe disease (270% 
stenosis), moderate/severe disease (>50% stenosis), severe lesions. mild/moderate 
lesions (10.69% stenosis), and total lesions. Information was entered prospectively into a 
database, and pt were followed for up to 5.3 years (mean, 2.0 i 1.4). Associations 
between measures of CAD and death/nonfatal Ml were evaluated using univariate and 
mbltrvariate Cox regressions (9 co-variables). 
Results: Pt were 64 + 12 years old; 68% were men. During follow-up, 180 pt died and 
110 had non-fatal Ml. Subsequent death/Ml was predicted univariately by all CAD rnea- 
sures (pc.OOOi), with the order of: number of severe vessels>total lesionsmoderate/ 
severe vessels>severe lesionsxevere CAD>moderate lesions. In multivariate analyses, 
all measures retained significance, with the order of: number of severe vessels>severe 
CADxnoderateisevere vesselsztotal lesionsxevere lesionsmoderate lesions. Other 
independent predictors were ejection fraction, age, diabetes, and hyperlipidemia. Results 
were generally similar for the endpoint of death alone 
Conclusions: Extent/severity of angiographic CAD was confirmed to be a highly signifi- 
cant and independent predictor of future death/Ml. The most powerful single predictor is 
the number of vessels with severe (270%) stenosis. The total number of lesions is a bet- 
ter predictor than number of severe or moderate lesions alone. Simple, qualitative or 
semi-quantitatrve measures of angiographic CAD severity provide useful prognostic infor- 
mation. 
1283-82 Clinical Implications of the No-Reflow Phenomenon. A 
Predictor of Left Ventricular Remodeling in &perfused 
Acute Myocardial infarction 
Paolo Colonna, Roberta Montisci. Marco Corda, Christian Cadeddu, Lijun Chen, Enrico 
Onnis, Luigi Meloni, Sabino lliceto. Department of Cardiovascular and Neurological 
Sciences, University of Cagkri, Cagiiari, b/y 
Background: After acute myocardial infarction the damage of microvasculature and the 
no-reflow phenomenon implies the presence of advanced rnyocardial necrosis. intracoro- 
nary myocardial contrast echocardiography after acute myocardial infarction can detect 
the presence and extent of microvascular damage. In this study, we verified the value of 
early Intravenous myocardial contrast echocardiography in predicting left ventricular 
remodeling after acute myocardial infarction. Methods: The study population of 55 con- 
secutive patients with first acute myocardial infarction (20 anterior, 8 lateral and 27 infe- 
rior) underwent an echocardiogram on the first day of acute myocardial infarction, a 
myocardial contrast echocardiography with intravenous injection of Levovist with har- 
monic power Doppler (Agilent, Sonos 5500) in intermittent imaging mode (triggering I:3 
15) 29~0.6 days after acute myocardial infarction, and an echocardiogram at 3 months 
follow-up. R&Its: At contrast echocardiography, 37 patients showed contrast enhance- 
ment in >50% of acutely dissynergic myocardial segments(reflow) and 18 a sizeable con- 
trast defect (no-reflow). Left ventricular volumes increased in the convalescent stage in 
patients with myocardial contrast echocardiography no-reflow (end-diastolic from 
72.2t15.9 to 101.4-41.8 mUm2, pcO.0001; end-systolic from 43.3k8.9 to 62.2k35.8 mU 
m2, p<O.OOOl), while remained constant in reflow patients (end-diastolic from 72.1~21.3 
to 71.3t16.7 mUm2, p=ns; end-systolrc from 40.1+12.6 to 37.3t13.3 mUm2, p=ns) 
Conclusion: Intravenous myocardial contrast echocardrography with harmonic power 
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Doppler is capable of identifying, in the acute phase of myocardial infarction, patients 
prone to late left ventricular dilation thus permitting a more aggressive diagnostic and 
therapeutic algorithm. 
1283-83 Bundle Branch Block Carries a Poor Prognosis for Patients 
Presenting With Acute Coronary Syndromes. Results From 
the Prospective Registry of Acute lschaemic Syndromes in 
the United Kingdom (PRAIS-UK) 
Ameet Bakhai, Marcelo C. Shibata, Julian R. Collinson, Diego Perez de Arenara, Marcus 
D. Flather, Jaspal S. Kooner, Jennifer A. A. Adgey. Royal Brompfon and Harefield NHS 
Trust Hospital, London, United Kingdom 
Background: Patrents presenting with MI and bundle branch block (BBB) carry a poor 
prognosis. The usefulness of BBB as a prognostic marker in patients presenting with 
non ST elevation acute coronary syndromes (ACS) is not known especially as these 
patients are usually excluded from most trials. 
Method: We enrolled 1,046 patients admitted with non-ST elevation ACS to 56 UK cen- 
tres (20 consecutive patients per centre) and followed them for 6 months. These centres 
covered 24% of the UK population and were selected to represent a national cohort. 
Results: Baseline characteristics and cardiac outcomes are shown in the table. Death 
and Ml at 6 months occurred in 30% of patients with BBB compared to 11% without BBB, 
odds ratio=3.52, 95% Cl: 2.20 5.67 wrth a multivariate analysis odds ratio of 2.63 (95% 
Cl: 1.60 - 4.32, p<O.OOl). The outcomes of death or Ml at 6 months were higher for 
patients with LBBB (36%) than those with RBBB (23%) or with ST depression (19%). 
Conclusion: Patients with BBB represent 10% of patients with ACS and are older with 
more risk factors than those without BBB. Despite this, BBB is an independent marker for 
higher risk of cardiac events than patients with no BBS or even ST depression on the 
admission ECG. We believe these patients should be treated aggressively on admissron 
with Gpllbillla antaqonists irrespective of the results of cardiac markers and coronary 
Characteristics LBBB RBBB All BBB Non BBB P (All vs. 
% N=57 N=44 N=iOi N=945 Non) 
Mean Age (SD) 72 (10) 72 (12) 72 (11) 65 (12) co.oo1 
Female 36.8 34 .I 35.6 39.7 0.43 
Prior MI 64.9 47.7 57.4 47.2 0.05 
Diabetes 26.3 22.7 24.7 15.3 0.015 
Hypertension 49.1 34.1 42.6 36.5 0.23 
Ml on admission 12.3 18.2 14.9 14.4 0.90 
Outcomes 
Death / Ml 8.9 6.8 8.0 4.1 0.07 
7days 
Death I Ml 35.7 22.7 29.7 10.8 <O.OOi 
Gmths 
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1284-84 Gender-Based Differences in Left Ventricular Structure, 
Remodeling, and Function After Myocardial Infarction 
France Macor, Rita Piazza, Pierluigr Temporelli, Eugenio Cervesato, Pantaleo Giannuzzi, 
loanna Stoian, Aldo P Maggioni, Gianluigi Nicolosi. Centro Studi ANMCO, Firenze, /ta/y, 
Cardiology Dpt A. R.C., Pordenone, k/y 
Background: Despite women affected by myocardiai infarction are known to be a sub. 
group with greater comorbidity and at worse prognosis, their left ventricular (LV) struc- 
ture, function and remodeling over time have received little attention. 
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Methods: 757 patients (622 males and 135 females) from the GISSI-3 echo substudy 
with their first myocardial infarction were considered. Serial echocardiograms were per- 
formed 24-48 hours after myocardial infarction (tl), before discharge (t2), after 6 weeks 
(t3) and after 6 months (t4). Early @‘Xl) and laie (t4-t2) LV remodeling was calculated by 
repeated measures ANOVA. 
Results: When compared to men, women were older (7Ot8 vs 58f12 years, p<O.OOl), 
had higher prevalence of hypertension and diabetes (respectively 54 vs 32% and 25 vs 
11%. p<O.OOl) and had larger LV wall motion asynergy (29+15 vs 25rt14%, p<O.Ol). At tl 
women had lower LV indexed volumes (diastolic: 71+18 vs 80fl9 ml/m’, pcO.001, sys- 
tolic: 38+14 vs 42+14 ml/m’, p<O.O05), greater LV diasiolic spheric&y index (0.44r0.11 vs 
proliferation (an increase in nuclei was also seen). These changes were present in ves- 
sels that existed prior to infarction and in those that grew afterwards, and were often 
associated with formaiion of eccentric lumens. 
Concluiions: lntramyocardial vessels undergo biphasic remodeling after Ml. The pro- 
cesses of constriction and expansion are similar to restenosis seen after angioplasty and 
in atheromatous arteries. Thus, ihe MI model may provide a novel setting for analysis of 
vascular remodeling, with the advantage that a single experiment produces a large num- 
bers of vessels. 
1284-W Elevated Bodv Temoerature Durino Acute Mvocardial , . 
0.41+0.09, p<O.O05), lower LV ejection fraction (46?-8 vs 48f7%, p<O.O5), higher preva- lschemia Exacerbates Necrosis 
lence of moderate to severe mitral regurgitation (IO vs 3%, p<O.OOl), higher LV wall thick- 
ness to radius ratio (0.38iO.07 vs 0.35+0.06, fxO.0001) and higher Doppler-derived peak Sharon L. Hale, Robert A. Kloner. Heart Institute, Good Samaritan Hospital, Los Angeles 
A wave velocity (74~22 vs 6692 cm/s, p<O.O05). After correction for abe, LV indexed vol- 
umes, diastolic sphericity index and wall thickness to radius ratio remained significantly 
In most patients, fever accompanies acute myocardial infarction, beginning within a few 
different between iwo sexes. Both early and late LV remodeling occurred in women but it 
hours after the ischemic event, and it often goes untreated. We tested the role of elevated 
did not differ from that of men (time*sex interaction: p>O.lO for diastolic and systolic vol- 
body temperature on infarct size in an open-chest, anesthetized rabbit model of 
umes and sphericity indexes). 
ischemiairepelfusion. Methods: Before coronary artery occlusion, body temperature 
Conclusions: Myocardial infarction in women is associated with larger LV damage, more 
was raised using a heating pad from baseline at 101.4 ? 0.2” F, which is normal in this 
depressed LV systolic function and greater relative LV mass and sphericity. Some of 
model, to 104.6 + 0.3” Fin 9 treated rabbits. Temperature in 8 control rabbits was 101 .I f 
these changes are not due to age differences and their possible prognosiic role needs to 
0.3’ F. Temperature was elevated in treated animals throughout the study. Both groups 
be further explored. The pattern of early and late LV remodeling did not differ between 
received 30 min of coronary artery occlusion and 3 hr reperfusion. Results: In control 
rabbits. 36 i 6% of the ischemic risk reaion became necrotic. but in hvoerthermic rabbits 
sexes. myocardial necrosis was significantly increased to 57 i 3% of the ri61( region (p<.OO5), 
1284-85 Beneficial Effects of Probucol oh Neurohumoral Activation 
and Cardiac Cytokine Expression in the Postinfarction Rat 
model 
Ying T. Sia, Jean-FranGois Sarrazin, Jean-FranGois Jasmin, Angelino Calderone, Jean- 
Lucien Rouleau. Montreal Heart Institute, Montreal, PO, Canada, Toronto General 
Hospital, Toronto, ON, Canada 
Increased oxidative stress in heart failure may represent an underlying mechanism con- 
tributing to the progression of the disease. Indeed, Singal et al. have found that the 
occurrence of oxidative stress coincides with the appearance of hemodynamic abnormal- 
ities secondary to myocardial infarction (Ml) in rat. The following study tested the hypoth- 
esis that treatment with the antioxidant probucol (PROB) may improve left ventricular (LV) 
function and morphology in the post-infarction rat and this is associated with inhibition of 
myocardial cytokine expression and plasma norepinephrine (PNE) secretion. Acute Ml 
was induced by LAD ligation, and at the 20th post-MI day surviving rats were randomized 
either to placebo or to probucol (61 mg/Kg) for 80 days by daily gavage. PROB treatment 
of sham rats had no effects on either LV function or morpholgy but significantly reduced 
cardiac TGFbl and TNFa expression. In the Ml group, mean infarct size was 50+2%. As 
compared to sham rats, Ml leads to decreased LV systolic pressure (9OA3 vs 
131*4mmHg, PcO.05) and +dP/dt (3103t171 vs 6211+370mmHg/s, PcO.05) and 
increased LV end-systolic pressure (28r2 vs 8+1 mmHg, P<O.O5). This is accompanied 
by the increase in LV circumference (355.1 vs 25r3mm, P<O.O5), in PNE (938+203 vs 
307*77pg/mL, PcO.05) and by a decrease in TNFa expression (0.79+0.02 vs 
1 .O+O.O3pg/mg of tissue, PcO.05) as compared to the sham group. Probucol treatment of 
Ml rats results to improved LV systolic (1 10+4 vs 90+3mmHg, PcO.05) and end-diastolic 
pressure (24+2 vs 28+2mmHg, P<O.OS)and LV cdP/dt (42501-290 vs 3103c171mmHg/s, 
PcO.05) as compared to control Ml rat. Moreover, LV circumference is reduced in MI rats 
by probucol (30+1 vs 35*imm, P<O.O5). Likewise, PNE (450r77 vs 938?203pg/mL, 
PcO.05) and cardiac TNFa (0.67+0.03 vs 0.79+0.02pg/mg of tissue, PcO.05) and TFGbl 
(0.13r0.02 vs 1.02*0.13pg/mg of tissue, PcO.05) expression are also inhibited in Ml rats 
by probucol. Theses data indicate that long-term treatment with ihe antioxidant probucol 
can improve LV function and morphology in the chronic post-infarction rat model and that 
part of the underlying mechanism may be the inhibition of cardiac cytokines expression 
and neurohumoral activation. 
1284-86 Biphasic Vascular Structural Response After Myocardial 
Infarction: A Novel Paradigm for Vessel Remodeling? 
despite similar risk regions (36 f 6% of the lefi ventricle in control and 34f 4% in treated 
hearts, p=ns), and an equal degree of regional myocardial blood flow (RMBF) reduction 
during ischemia in both groups. Infarct size correlated positively with body temperature 
(r= 0.66, pc.004). Elevated temperatures caused higher heart rates in hyperthermic rab- 
bits during occlusion (192 f 6 bpm vs 173 r 7, p<.Ol); mean arterial blood pressures 
were similar in both groups. RMBF was 43% lower during reperfusion in the previously 
ischemic areas of hyperthermic hearts compared with control hearts (p<.O4), suggesting 
worsened no-reflow. Conclusion: Elevation in body temperature by even a few degrees 
can aggravate necrosis during acute myocardial intarction and may worse.” no-reflow. 
Thus fever might not be just an innocuous side effect of myocardial infarction but should 
perhaps be treated proactively. 
1284-88 Reduction of Ischemia-Reperfusion Injury in the Rat In Vivo 
by DF1681A, an Inhibitor of Interleukin-8 
Laura Calvillo, Riccardo Bertini, Stefano Porzio, Stefano Chimenti, Serge Masson, 
Francesco Colotta, Roberto Latini. lstituto di Ricerche Farmacologiche Mario Negri, 
Milan, /tafx Dompe’ Research Center, L’Aquila, /ta/y 
Background: Leukocytes (PMN) infiltrate the myocardium subjected to ischemia (I) and 
reperfusion (Fi), and contribute to the so called R injury. Interleukin-8 (IL-8) is a,mediator 
of PMN migration relevant in IR: a non-protein inhibitor of IL-8 (DF1681A) could reduce R 
injury. Methods: lschemia was induced in rats by ligation of left coronary artery (I, 30 
min) followed by a 4 or24 h of R. DF1681A was given iv (10 mgikg bolus) 5 min before Fi, 
then SC (8 mgikg) every 90 min: a dose regimen yielding plasma concentrations found to 
inhibit PMN chemotaxis in vitro. Before sacrifice, Evans blue was injected to outline non- 
perfused area (area at risk, AAR). Myeloperoxidase (MPO) and creatine kinase (CK) 
were assayed biochemically in the AAR. Vehicle treated IR rats (controls) and sham- 
operated rats were done. Cyclophosphamide (CP) pretreated rats with more than 90 
depletion of circulating PMN underwent IR to quantify damage attributable to PMN after 4 
h (No=10 for all groups). Results: AAR was not different among IR groups (mean 59% of 
LV mass). After 4 h R, in controls MPO increased by 3.2 folds (p<O.OOl), and CK 
decreased by 39% (p<O.Ol) vs sham-operated. DF1681A reduced MPO increase and 
CK loss by 77% (~~0.05) and 56% (pcO.O5), respectively. In PMN depleted rats, MPO did 
not increase vs sham-operated, and CK decreased by 14% (p=NS). After 24 h R, in con- 
trols MPO increased by 32 folds (p<O.OOl), and CK decreased by 60% (p<O.OOl) vs 
sham. DF1681A reduced MPO increase and CK loss by 46% (~~0.05) and 16% 
(pcO.O5), respectively. Conclusions: IR caused infiltration of PMN (MPO increase) and 
cardiac damage (CK loss) in the AAR which were more marked after 24 h than after 4 h 
Peter Whittaker. Heart Institute, Good Samaritan Hospital, Los Angeles, CA, University of 
of R. The role of PMN in causing myocardial damage was confirmed by its prevention 
Southern California, Los Angeles, CA 
after PMN depletion with CP. The non-protein IL-8 inhibitor DF1681A, started right before 
reperfusion reduced PMN migration and CK loss in the AAR. Protection appears to be 
lower, but still significant, after24 h of R than after 4 h. Background: A crucial determinant of many vascular injury pathologies is vessel remod- 
eling, which involves both constrictive and expansive forces. The hypothesis to be tested 
was that injury caused by coronary artery occlusion would result in remodeling of 
intramyocardial vessels within the infarct. 
Methods: The nature and temporal profile of the remodeling was assessed in histology 
sections of rat hearts examined 1 week (n=8), 3 weeks (n=8), and >3 weeks @i&25+3 
weeks) after transmural myocardial infarction (Ml). Vessels from uninfarcted hearts 
(n=14) were also examined. The area (mm’ x 10.‘) occupied by the lumen and muscle 
was measured by planimetry in 226 vessels. 
Results: The muscle:lumen (M:L) ratio increased after Ml (*P<O.O5 versus control); how- 
ever, the mechanism for the increase differed over time. At 1 and 3 weeks, lumen area 
decreased versus control 
Control 1 week 3 weeks > 3 weeks 
M:L ratio 1.54* .15 4.06 +1.04* 4.60 +1.08* 4.99 +.84’ 
Total area .62 r .07 .27 k .05 .36 t .06 .97* .09$ 
Lumen area .26 i .04 .08 + .Olt .lO * .oit .21 * .03 
Muscle area .36 r .04 .21 Ir .04 .26 A .03 .76 f .08$ 
(tPcO.Ol), but muscle area did not change consistent with constriction. However, at 23 
weeks, lumen area returned to control values, but with an increase in muscle and total 
vessel area (*P<O.Ol versus all groups), consistent with vascular expansion and muscle 
1284-89 Heme Oxygenase-1 Expression and Apoptosis Colocalize in 
a Rat Myocardial Infarction Model 
Paivi Lakkisto, Eeva Palojoki, Antti Sara&, Tom Backlund, Liisa-Maria Voipio-Pulkki, 
llkka Tikkanen, Kari Pulkki. University of Turku, Turku, Finland, Helsinki University 
Hospital, Helsinki, Finland 
Background: Apoptosis of cardiomyocytes may play a role in the post infarction remod- 
elling. Since there is evidence that induction of heme oxygenase-1 (HO-l) may protect 
against cell death and apoptosis, we examined the expression and localization of HO-1 in 
a rat myocardial infarction model. Methods: Male Wistar rats were subjected to left ante- 
rior coronary artery ligation or sham operation and sacrificed on days 1, 7 and 28. Sec- 
tions of infarcted hearts were divided into the p&-infarct border area and the non- 
infarcted remote area. The expression of HO-l mRNA was assessed by real-time quanti- 
tative RT-PCR and the expression of HO-1 protein by immunoconfocal microscopy. 
Results: At 24 hours after ligation HO-1 mRNA was increased about 4-fold in the border 
vs. remote area or sham operated hearts (p<O.O5). At 7 days, HO-1 mRNA levels 
remained high in the border area. In addition, HO-1 mRNA had increased P-fold in the 
remote non-infarcted myocardium (p<O.O5). HO-l mRNA returned to basal levels by 28 
days. The increase in HO-1 mRNA was accompanied by increased HO-1 immunoreactiv- 
ity which was localized into the cardiomyocytes and fibroblasts of ihe infarct border zone 
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and vascular structures. Accordrng to our previous studies the dtstribution and frequency 
of cardiomyocyte apoptosis follows a similar pattern as HO-I expression. Conclusion: 
HO-1 is induced in a rat myocardial infarction model and the expression of HO-1 colocal- 
‘izes with apoptosis, suggesting that HO-1 may play a role in the regulation of apoptotic 
cardiomyocyte loss and ventricular remodelling. 
1285-92 Who Refers Negative Coronary Angiograms? 
Dominic Y. Leung, Craig P. Juergens, Sidney Lo, Andrew P Hopkins. Liverpool Hospital, 
Sydnex Australia 
1284-90 Coronary Sinus Oxygen Saturation (SV02) as a Marker of 
Myocardial lschemia 
Yves Gall&, Stephane Champagne, Jin Bo Su, Lucien Sambin, Bertrand Crozatier, Luc 
Hrttinger. lnserm lJ400, Creteil, France. Anesthesiology Departmeni, J Rostand Hospital, 
Ivry /Seine, France 
Background: Coronary sinus oxygen saturation (SVO2) reflects the balance between 
myocardial oxygen supply and demand. This study was designed to examine whether 
S/O2 is affected by changes in myocardlal blood supply and myocardial contractile func- 
tion and whether the temporal changes in SVOZ during ischemia are related to temporal 
ECG ST segment changes. Methods: Eight open-chest dogs were instrumented with a 
left ventricular pressure gauge, an oxymetry Swan-Ganz catheter in the coronary sinus 
for continuous SV02 monitoring, a circumflex coronary cuff occludei, a doppler flow 
probe to measure circumflex coronary blood flow velocity (CBFv) and piezo-electric crys- 
tals to measure left ventricular anterior and posterior wall thicknesses. Myocardial blood 
supply and myocardial contractile function were modified by partial coronary stenosis 
(50% reduction in CBFv, Smin), total coronary occlusion (zero CBFv, Bmin), ATP injectron 
(20 mg iv) and dobutamine infusion (10 pgikglmin, iv), Results: SVOZ changes were 
closely correlated to CBFv changes induced by coronary stenosis, coronary occlusion 
and ATP injection (r=O.784, p&001) and also to left ventricular posterior wall thickening 
changes induced by coronary stenosis, coronary occlusion and dobutamine Infusion 
(r=O.851, p<O.OOl). SV02 was reduced (p<O.OOl) 15 seconds after the onset of coronary 
occlusion from 38-tl% to 12&Z% while ECG ST segment changes reached the significant 
threshold (1 mv) 60 seconds after coronary occlusion. During partial coronary stenosis, 
SVO2 was reduced from 38+1% to 2612% (~~0.01) 75s after the onset of partial coro- 
nary stenosrs while ECG ST segment changes never reach the significant threshold dur- 
ing the 180 s period of coronary stenosis. Conclusion: SVO2 reduction is associated 
with myocardial ischemia. SV02 measurement is a more sensitive marker of myocardial 
ischemia than EGG ST segment analysis and may be useful in the monitoring of myocar- 
dial ischemic events during cardiac or non cardiac surgery. 
Background: Coronary angiography IS the definitive test for suspected coronary dis- 
ease. However, the referral patterns and referrer characteristics of angiagraphically nor- 
mal coronary arteries or minor disease (negatrve angiogram) in patients wrth suspected 
coronary disease are seldom reported. 
Methods: From 12/92 to 7100, a total of 6,409 patients underwent 8,069 coronary angio- 
grams at Liverpool Hospital. Only studies referred primarily for coronary disease 
(n=6,862) were analyzed. Studies for valvular disease (n=279), failed access (n=52) and 
angioplasty (n=876) were excluded. Patient characteristics, main practice location and 
specialty of referrers were correlated with the negative angiogram rate. 
Results: 783 patients (790 procedures, 12.5%) had normal coronary arteries. 719 
patients (740 procedures, 11.7%) had minor disease (~50% stenosrs on >=l epicardial 
coronary artery). For referrers with >40 referrals (n=33, mean referrals 19lr244, range 
42 1102), negative angiogram rate was 22+8% (10 41%). Cardiologist referrers (n=20) 
had a higher negative rate compared with non-cardiologist (n=13) referrers (25*7% vs 
1816%, p=O.O05). Proceduralists (n=9) had srmilar negative rate compared with non-pro- 
ceduralists (n=24, 24+4% vs 21&g%, p=NS). Referrers with main practice m Liverpool 
area had a higher negative rate compared with referrers outside Liverpool area (2518% 
vs 19&5%, p=O.O19). There was no difference in the negative rate before and after coro- 
nary surgery and angioplasty services commenced at Liverpool Hospital (8197, 24.7% vs 
24% p=NS). Multiple logistic regression revealed patient aged <=50 years (OR 2.8). 
female gender (OR 2.9) cardiologist referrer (OR 1.5) and referrer with closer access to 
catheterization laboratory (OR 1.2) to be significant independent predictors of negative 
angiogram. 
Conclusions: Negative angiogram rate varied widely between referrers. Cardiologists 
had a higher negative rate compared with non-cardiologist referrers. Whether the referrer 
was a proceduralist did not affect the negative rate. The availability of revascularization 
service did not but the easier access to a catheterisation laboratory did affect the nega- 
tive rate. 
1285-93 Isolated Left Main Trunk Stenosis: How Common Is It? 
Samir R. Kapadia, Gary V. Martin, J. Ruben Floras. Richard V. Anderson, James H. 
Caldwell, Kenneth G. Lehmann. \/A Puget Sound Health Care System, Seattle. WA, 
Universify of Washington, &aft/e, WA 
Background: Identification of left main (LMT) stenosis in the cardiac catheterization lab- 
oratory is critically important not only for patrent management but also to increase safety 
of the catheterization procedure. Occasionally LMT stenosis is not associated wrth signif- 
icant atherosclerosis of other epicardial coronary vessels. We sought to determine the 
prevalence of isolated left main stenosis from a prospective registry of consecutive 
patrents. Methods: At our institution 8004 patients underwent diagnostic cardiac cathe- 
terization between 1990 and 2000. Patients with prior by-pass surgery (n=l415) were 
excluded from the analysis, as the natural hrstory of LMT stenosis in these patients may 
be different. Prevalence of LMT stenosis (>=50%) was studied according to the severity 
of the most severe lesion rn the coronary arteries other than the LMT The patients were 
drvided into 5 groups. Group 1 included patients with the most s?vere lesion >70%, group 
2 between 50.70%. group 3 between 30.50%, group 4 between O-30% and group 5 with 
patients having no angiographrcally identifiable lesions. Results: Significant LMT steno- 
sis was detected in 348 (5%) patients. Significant lesions (>70%) in other coronary arter- 
res were more frequently present in patients with LMT stenosis than in patients without 
(81% vs 45%). The prevalence of LMT stenosis in association with presence of other cor- 
onary artery lesions is shown in the figure. Significant LMT stenosis was almost 20 times 
less likely to be present in patients with otherwise normal coronaries compared to 
patients with other significant coronary lesions.(0.48% vs 9.1%) Conclusion: Isolated 
LMT stenosis is rare. Therefore, when encountered in the cath lab, careful angiographic 
determination supplemented with approprrate use of intravascular ultrasound is war- 
ranted to help exclude misleading angiographic views or catheter induced spasm. 
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1285-91 RSR’ Pattern Without the Evidence of Bundle Branch Block: 
Diagnostic Value as a Sign of Left Ventricular Aneurysm 
Mithrlesh K. Das, Kuruvilla Cheriparambil, Majesh Makan, John Kassotis, Barry Saul, 
Chatla 6. V. R. Reddy. Come// Universrfy Medical College, New York, New Yorlc Methodist 
Hospita/z Brooklyn, NY 
Background: A left ventricular aneurysm (LVA) is associated with increased risk of heart 
failure, thromboembolism, ventricular arrhythmias and also the increased risk of sudden 
and non-sudden death. An RSR‘ pattern without evidence of bundle branch block ( QRS 
duration 5120ms) on the ECG may be associated with a LVA as a result of myocardial 
scar formation A LVA is common in the anterolateral and circumapical region of the left 
ventricular wall. We, therefore, postulate that an RSR‘ pattern in the left sided leads (I, 
aVL,V3 to V3) is a highly specific sign of LVA. Methods: EGG’s of 110 consecutive 
patients with LVA documented by left ventricular angiography (300 right anterior oblique 
view) was compared with 110 patients without LVA. Results: The RSR‘ pattern or its 
variant (RSr‘, rSR‘ or RsR‘) pattern on left sided leads were present in 55(50%) patients 
with LVA as compared to 6 (5%) patients without LVA ( p value 40.0005). The sensitivity 
of RSR‘ pattern for LVA was only 50% whereas the specificity was 94.5%. The false neg- 
ative and the false positive rates ware 50% and 5.4%, respectively. It has a high positive 
predictive value of 90% with a relatively moderate negative predictive value of 65%. The 
overall accuracy of the test is 75%. 
Total no. of patients studied Patients with LAA Patients without LAA 
Positive results (RSR‘ present) 
(N= 110) 
63 (True Positive) 
(N = 110) 
6 (False positive) 
270% 50-70% 30.50% 0.30% 0 
Total n 3094 455 404 170 2466 
Negative results(RSR‘ absent) 47 (False negative) 104 (True negative) 
Conclusion: Our study has revealed that an RSR‘ pattern in the left sided leads, as a 
highly specific and moderately sensitivity sign of LVA. It also has high positive predictive 
vaiue. 
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128594 Differences in Presentation and 1 Year Outcomes in 
Coronary Artery Disease (CAD) Patients of South Asian vs 
European Ethnicity Treated in an Outpatient Cardiology 
Practice 
NarendraSingh, Milan K. Gupta, Arsh k. Jain, Frank Halperin, David Borts. Rouge Valley 
Health System, Toronto, ON, Canada, William O&r Health Centre, Brampton, ON, 
Canada 
Background: Previous studies have shown differences in cardiac presentation and 
wow outcomes for South Asian (SA) vs European Canadian (EC) hospitalized inpa- 
tlenis. Methods: We retrospectively reviewed 400 consecutive outpaiients wiih CAD hav- 
ing 1 yr follow-up with respect to pt ethnicity, cardiac risk factors, utilization of evidence- 
based drug therapies, hospitalization and outcomes over 1 year (1996-97). Results: Of 
the 400 pts, 65% were males, 22% were SA. Mean age was 60+11 yrs. Comparison of 
SA vs EC pts showed SA pts were slightly younger (59 vs 61 yrs, p=.O9), more often dia- 
betic (37 vs 20%, p=O.OOl) less often smokers (29 vs 54%, p=.OOl), and had similar risk 
factors of hyperlipidemia (44 vs 49%) hypertension (54 vs 49%) or family Hx of CAD (24 
vs 34%) p=ns. At initial visit 49% were on ASA, 33% beta-blockers, 20% statins, and 26% 
ACE inhibitors. SA patients were less likely to be on an ACE inhibitor at presentation 18 
vs 28% p=O.OOl. Utilization increased substantially to 73%, 45%, 55% 32% respectively 
at 1 yr. No significant difference in utilization between SA vs EC pts was noted ai 1 year. 
At 1 yr, SA pts as compared to EC pts, were more likely to have quit smoking (50% vs 
9%,p=.OOl) but had poorer BP control (142181 vs 137/78 mmHg, p=.Ol), similar fasting 
glucose levels (6.5 vs 7.3 mmol, p=ns), similar LDL (3.0 vs 2.8mmol,p=ns) bui lower HDL 
(1.06 vs 1.17mmol,p=0.02) levels. Cardiac hospitalizations (36% vs 41%) and revascu- 
larization (17 vs 20%) occurred frequently after Initial consultation bui were no different 
between the groups at 1 yr. Conclusions: SA outpatients have a different CAD risk fac- 
tor profile than EC paiients both at presentation and at 1 yr follow-up. Utilization of evi- 
dence based drug therapies at 1 yr improved following cardiology consultation and may 
explain the similar outcomes despite differences at presentation. These data suggest that 
early intervention by cardiologists for this high risk ethnic population could potentially 
reduce subsequent morbidity and mortality 
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1286-95 Atypical Presentations Among Medicare Beneficiaries With 
Unstable Angina: Is It Time to Redefine the Classical 
Clinical Presentation? 
John G. Canto, Contessa Fincher, Catarina I. Kiefe, Jeroan J. Allison, Qing Li, Suzanne 
Baker, Robert Centor, Norm W. Weissman. University of Alabama at Birmingham, 
Birmingham, AL 
Background. The presence of chest pain (CP) is a hallmark symptom in patients with 
unstable angina (UA). However, little is known regarding the prevalence of atypical pre- 
sentation among these patients and their related symptoms. Methods. We examined the 
medical records of 3,015 Medicare patients hospitalized at 22 Alabama hospitals with a 
confirmed diagnosis of UA between 1994 and 1998. Confirmation of UA required that the 
presenting symptom(s) be consisient with an acute coronary syndrome by documenta- 
tion of the admitting physician, and that there be no evidence of acute myocardial infarc- 
tion at the time of initial presentation. We categorized the presenting characteristics into 
typical or atypical. Typical presentation was defined as 1) CP located substernally, in the 
left chest, or right chest; and 2) the character of CP described as squeezing, tightness, 
aching, crushing, discomfort, dullness, fullness, heaviness, pressure, relieved with rest or 
nitroglycerin, or worse with activity. Atypical presentation was defined as’the absence of 
l), Z), or both. 
Results 
Table 1. Comparison of Atypical and Typical Patients 
Atypical Presentation Typical Presentation P 
Value 
N (“‘o) 1,342 (44.5) 1,673 (55.5) 
Mean age, years 73.0 71 .o < 
0.001 
Women. % 58.3 54.6 0.05 
Non-White, % 43.2 56.6 0.61 
Diabetes, % 43.7 56.3 0.55 
Hypertension, % 44.7 55.3 0.77 
Prior MI, % 41.8 58.2 0.02 
Mortality hospital, %, (N=18) 50.0 50.0 0.73 
Mortality - 30 days, %, (N=358) 47.2 52.3 0.27 
Mortality - 1 year, %, (N=509) 46.8 53.2 0.26 
Table 2. Presentation Characteristics of Atypical Patients 
Atypical chest pain, % 5.1 
Pain in other region (maw, shoulder, arm, neck, face, ear, epigastric), % 32.3 
Shortness of breath, % 73.9 
Nausea, % 40.2 
Vomiting, % 10.8 
Diaphoresis, % 27.7 
syncope, % 10.7 
Conclusion. Almost one-half of all elderly Medicare patients with confirmed UA had 
“atypical’ presentattons. Important characterisiics of these patients included age, gender 
and no prior MI, but not race. Our results suggest that the classical presentation of UA 
may need to be redefined and that national educational initiatives to increase awareness 
of atypical presentations in UA are indicated. 
1286-96 Site Investigators Do Not Accurately Report Myocardial 
Infarction Events: Results of Event Adjudication by a 
Clinical Events Committee in the PARAGON-B Trial 
Kenneth W. Mahaffey, Patricia A. Connolly, Matthew T. Roe, Rodney Sparapani, Lisa G. 
Berdan, Neal S. Kleiman, Debra Fasteson, Christopher B. Dyke, Maria C. Bahit, Darren 
K. McGuire, Kristin L. Newby, Paul W. Armstrong, Robert M. Califf, Eric J. Topol, Robert 
A. Havington. Duke Clinical Research Instiute, Durham, NC 
Background: Myocardial infarction (Ml), an important clinical trial endpoint, can be diffi- 
cult to classify due to inconclusive symptoms, enzyme data, or electrocardiograms. In 
prior trials, disagreement between Ml events reported by site investigators and a clinical 
events committee (CEC) have been observed. 
Methods: To better understand disagreements in MI reporting between investigators and 
a CEC, we analyzed data from the PARAGON-B trial which evaluated the glycoprotein 
Ilb/llla inhibitor, lamifiban, in 5,225 patients with acute coronary syndromes. The primary 
endpoint was the 30-day composiie of death, Ml‘or recurrent ischemia. All suspected MIS 
were adjudicated by a CEC. 
Results: Overall, 1,736 patients (33%) had suspected MIS identified from data on the 
case report form; 483 (28%) were adjudicated by the CEC as MIS that met protocol end- 
point criteria. In 404 (23%) patients, investigator and CEC assessments of Ml differed; 
270 MIS were identified by the CEC but noi the investigators, and 134 were identified by 
investigators but not the CEC. To prospectively reconcile disagreements between the 
CEC and the investigator, we sent letters to investigators that described the disagree- 
ment and asked for re-evaluation by the investigator. For the 404 patients with disagree- 
ment, letters were sent and returned for 382 patients. The remaining 22 had clear MIS by 
core lab enzyme criteria. investigators came to agree with CEC assessmenis in 307 
(80%). For the remaining 75 cases (20%); the CEC supported investigators’ assess- 
ments in 10 and confirmed original CEC decisions in the other 65 cases. Of cases with 
persistent disagreement, 44% were periprocedural MIS but 20% were enzyme elevations 
associated with ischemic symptoms and/or ECG changes. 
Conclusions: Investigators underreported Ml endpoints, but most agreed wiih CEC 
assessments of MIS after further follow-up. We support standardized, independent adju- 
dication of suspected MI endpoints in order to accurately identify Ml endpoint events. Dis- 
agreements may be due to inadequacies in event ascertainment using standard case 
report form tools as well as differences in Ml definitions used in clinical trials compared 
with clinical practice. 
1286-97 Cost-Effectiveness of Early Invasive Treatment in Unstable 
Coronary Artery Disease: A One-Year Follow-Up From the 
FRISC II Invasive Trial 
Magnus Janzon, Lars-ake Levin, Eva Swahn, FRISC II Investigators. institution of 
Medicine and Care, Linkiiping Universitv, Linkdping, Sweden, GMT: Center for Medical 
Technology Assessment, Linkiiping University, Link@ing, Sweden 
Background: Both early invasive and non-invasive treatment strategies in patients pre- 
senting wiih unstable coronary artery disease have been used during the acute phase of 
the disease.. It has not until recently been conclusively demonstrated which of these strat- 
egies has a better clinical outcome. ,Until today there is no prospective study analysing 
the economic implication in this important and large patient group in the long-term follow- 
up. The aim of this study was to evaluate the cost-effectiveness of early invasive strategy. 
Methods: We determined in-hospital and one-year follow-up costs for 2 457 patients in 
the FRISC II trial with unstable angina or non-Q-wave myocardial infarction who were 
randomised to early invasive or non-invasive treatment. Medical costs as hospitalisa- 
tions, investigations, interventions, pharmaceuticals and outpatient visits as well as non- 
medical costs as loss of production and home cars were documented prospectively. The 
costs were based on Swedish hospital charges at 1997 price level. Results: In the 
FRISC II trial the invasive treatment showed a reduction in the incidence of death or Ml 
(10.4 % vs. 14.1 %, p=O.O05). In the cost analysis there was a significant higher cost in 
the invasive group. The cost difference per patient was 27.500 SEK (2.900 US$). The 
cost-effectiveness ratio was 740.000 SEK (77.000 US$) per avoided event, myocardial 
infarction or death. Expressed in cost per life saved the cost-effectiveness ratio was 1.6 
MSEK (167.000 US$). Conclusions: Due to the costly initial interventions there was still 
a higher total cost in the invasive treatment group ai one-year follow-up. The cost-effec- 
tiveness ratio was 740.000 SEK (77.000 USS) per avoided myocardial infarction or death. 
To determine the final cost-effectiveness ratio for invasive strategy a longer follow-up 
period is needed as well as the use of QALYs, quality adjusted life years. 
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1286-98 Relationship Between ST Segment Elevation After Acute 
Myocarclial Infarction and Microvascular Reperfusion Injury 
Evaluated With Myocardial Contrast Echocardiography 
Paolo Colonna, Abdel Hakeem S&em, Marco Orrb, Chrisian Cadeddu, Roberta 
Montisci, Lljun Chen, Enrico On&s, Luigi Meloni, Sabino Iliceto. Department of 
Cardiovascular and Neurological Sciences, Universiry of Cagiiari, Cagkari, #a/y 
Background. After acute myocardial infarction, the return to baseline of ST segment in 
the surface electrocardiogram predicts good myocardial functional recovery and progno- 
sis. In patients with acute myocardial infarction the microcirculatory reperfusron may 
remain impaired due to a process of m~~ro~as~~lar injury, detectable with intravenous 
myocardial contrasi echocardiography. We hypothesized that patients with a rapld ST 
segment return to baseline have a better microvascular preservation at myocardial con- 
trast echocardiography. Methods. Seventeen patients with a first anterior acute myocar- 
dial infarction, 9 treated with primary PTCA and 8 with intravenous thrombolysis, were 
studied. A surface ECG was obtained at admission and after recanalization (90 minutes 
after admission EGG); the ST elevation was summed in all anterior leads and the per- 
centage of recovery of the summation at 90 minutes ECG was computed. Intravenous 
myocardial contrast echocardiography (Levovist rapld infusion) with harmonic power 
Dopp!er (Agilent Sonos 5500) and ECG triggering every 3 to 5 fives cardiac cycles was 
performed 2.8~0.4 days after the acute phase. The no-reflow extent was computed as 
the percentage ratlo of segments not opacified to the total segments in the risk area. 
Patients ware considered to have no-reflow ii its extent was > 50% of the total myocardial 
segments in ihe risk area. Results. No-reflow phenomenon was present in 6 of the 7 
(85.7%) pat&is with persistent (>50% of initial value) ST segment elevation after raca- 
nalization, while only in 2 of the IO (20%; ~~0.05) patients with ST segment resolution. 
The average no-reflow extent at contrast echocardiography was 60.it22.2% in patients 
with persistent ST elevation versus 28.8237% (~~0.05) in patients with ST resolution. 
Conclusion. In acute anterior myocardial infarction the persistence of ST segment eleva- 
tion after recanalization is suggestive of more extensive ~IC~OV~SCU~~~ damage, as 
detectable with intravenous myocardial contrast echocardiography. 
1286-99 In Patients With Unstable Angina High Levels of C-Reactive 
Protein Are Associated With Irregular Plaques in Carotid 
Arteries: A Sign of a Diffuse, Systemic Inflammatory 
Involvement? 
Pasquaie Silvestri, Luigi M. Biasucci. G~ovanna Liuzzo, Attiiio Maseri, Antonella 
Lombardo. Cathoiic Universi& Rome, /ta/y 
Background: In unstable angina (UA) high levels of inflammatory mediators, such as C- 
reactive protein (CRP), has been demonstrated in up to 65% of pts. However it is still 
unknown whether this response is associated with a selective coronary or a more gen- 
eral arterial instability. Methods: In order to evaluate whether the inflammatory response 
is associated with an unstable morphology of atherosclerotic plaques in other vascular 
districts, we performed Color-Doppler-Echography of carotid arteries in 46 pts admitted 
to our Coronary Care Unii (CCU) with Brauwald’s class IIIB UA. Extracranial carotid 
arteries were classified as: normal (no plaques); arteries with smooth plaques (smooth 
sulfate and homogeneous echogenicity also in the presence of calcifications) and arter- 
ies with irregular plaques (irregular surface or dishomogenous echogenicity). On admis- 
sion to CCU, CRP levels ware assessed by high sensitivity nepheiometry (Dade-Behring 
Latex NII) in all pts. Results: 15 pts had irregular plaques, 15 pts had smooth plaques 
and 16 pts had normal carotid arteries. CRP levels ware significantly higher in pts with 
irregular plaques than in those with smooth plaques and with normal carotid arteries 
(respectively: median: 8.8 mg/L [range 2527.81, 2.1 mg/L [0.8-11.61, 3.35 mg/L [0.7- 
19.51, p&O5 irregular plaques vs regular and normal arteries). Conclusions: Unstable 
angina patients with irregular carotid artery plaques have CRP levels higher than UA 
patients with normal carotid or smooth plaques. Thus, our data suggest that in UA a com- 
mon inflammatory mechanism may be associated with instability of coronary and carotid 
plaques. 
1286-100 Coronary Artery Calcification in Patients With Acute Chest 
Pain 
Dimitris Aiexopoulos, Chris& Stathopoulos, George Hahalis, John A. Chiladakis, 
Abraham Kotsaridis, Antonis S. Manoiis. Patras University P&as, Greece 
Background: Coronary artery calcification (CAC) indicates presence of atherosclerotic 
plaque. Many patients (pts) with acute chest pain due to ischemia or infarction present to 
the emergency department (ER) with diagnostic difficultw due to non-ischemic electro- 
cardiogram (ECG) and normal cardiac enzymes (CE).The aim of this study was to 
assess whether CAC is a useful adjunct for risk stratification in pts with acute chest pain. 
Methods: 74 pts (51 men) with no prior history of coronary artery disease (CAD). mean 
age 57+/-10 years, ware admitted to the hospital for evaluation of acute chest pain. Pts 
had a non-diagnostic EGG and normal CE in the ER. Within 24 hours from admission, all 
pts underwent digital cinefluoroscopy of the heart in the 450LA0/15oCRANIAL projection 
for about 5 sac and the video recording was then examined for the presence of CAC. Pts 
were divided into 2 groups: Group-A, with CAC (n=30) and Group-B without CAC (n=44). 
Ail pts were monitored for 24 hours and serial CE (CPK, CPK MB) and ECGs were 
obtained at 0, 8. 16 and 24 hours.8 negative evaluation led to an exercise stress test 
(EST). Pts with a negative EST were discharged home, while pts with a positive EST 
underwent dobutamine stress echo or thallium-201 scintigraphy, and/or coronary angiog- 
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raphy. CAD was considered present if a pi had: 1) elevated CE 2) subsequent EGG 
changes suggestive of infarctton or ischemia 3) abnormal dobutamine stress echo or 
thallium-201 scintrgraphy and/or coronary angiography. Results: Table 
Group A Group B p value Group A Group B 
Age 60+/-g 55+1-i 0 0.039 CAD+ 23 (77%) 5(11%) 
Man 26(87%) 25(57%) 0.001 CAD- 7 (23%) 39 (89%) 
Risk factors for CAD 2.6+/-l 2.0+/-l 0.048 p<0.0001 
(Fisher’s exact test, unpaired t-test) (Fisher’s exact test) 
The presence of CAC had 82% sensitivity, 85% specificity, 77% positive predictive value 
and 89% negative predictive value for detection of CAD (relative risk = 6.7). Male gender, 
advanced age and the presence of risk factors for CAD were more frequent in pts with 
CAC. Conclusion: CAC detected by digital cinefluoroscopy can be useful for the man- 
agement of pts with acute chest pain, presenting to the ER with a non-diagnostic ECG 
and normal CE. 
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889-i LXR1035 a Novel Lysophosphatic Acid Analog Attenuates 
Ischemia-Reperfusion Injury 
Christian Zellner, Richard E. Sievers, Amanda E. M. Browne, Samuil R. Umansky, J. 
Graham Goddard, William W. Parmley, Kanu Chatterjee, Randall J. Lee. University of 
California, San Francisco, San Francisco, CA, LXR Biotechnology Inc., Rfchmond, CA 
Background: Modulation of apoptosis is a promising pharmacologic target in the treat- 
ment of myocardial infarction. We studied the effects of LXR1035, a novel analog of lyso- 
phosphatidic acid, on cardiac myocytes in cell culture and on myocardlal infarction and 
ischemia-reperfusion (IR) injury in viva. Methods: Apoptosis was induced in rat neonatal 
cardiomyocytes using glucose deprivation and hypoxiainormoxia, simulating apoptosis 
after IR injury. Upregulation of caspase3 and DNA fragmentation were quantified to 
assess degree of apoptosis. To test the hypothesis that LXR1035 reduces myocardial IR 
injury in viva, rats pretreated with either vehicle (n=lO) or LXR1035 (75nmollkglh and 
750nmoiikgih, n=8 for each dose) were subjected to 17min of occlusion of the left coro- 
nary artery (LCA) and 2 hours of reperfusion. Infarct size and area at risk were deter- 
mined using triphenyltetrazolium chloride and blue dye staining and digital image 
analysis. Results: In cell culture, LXR1035 prevented all steps in apoptotic cell death 
including caspase-3 activation, internucleosomal DNA degradation, cell permeabilization 
and detachment. The effects on cell survival ““are superior to classic caspase inhibitors, 
particularly rn the setting of simulated IR Injury, suggesting that LXR1035 modulates mul- 
tiple pathways in apopototic cell death. In “I”O studies of myocard!al IR showed that the 
percent myocardial infarct par heart was significantly reduced with low and high doses of 
LXR1035 (22.9r9.4 and 22.4i8.9, respectively for 75 and 750nmollkgih) as compared to 
control (35.3fi1.4). Percent infarct for area at risk was also significantly reduced with low 
and high doses of LXR1035 (37.0t12.2 and 39.2+13.7), respectively for 75 and 750 
nmollkgih) as compared to control (55.3+10.6). Conclusions: Treatment with the struc- 
tural analog of lysophospatic acid LXR1035 attenuates myocardial IR injury by modula- 
tion of multiple pathways of apoptotic ceil death. LXR1035 may thus have utility as 
adjunct therapy in both catheter-based and pharmacologic reperfusion strategies for 
acute myocardiai infarction by preventing IR injury. 
889-2 
IO:45 a.m. 
Blockade of Lectin-Like Oxidized Low-Density Lipoprotein 
Receptor Reduces Myocardial Infarction Size After 
Ischemia-Reperfusion 
Kazuakl Kataoka, Ryu]~ Nohara, Koji Hasegawa, Tetsuhiko Yanazume, Taku Hirai, 
Tatsuya Sawamura, Masatoshi Fujita, Shlgetake Sasayama. Department of 
Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 
Department of Bioscience, Nationa/ Cardiovascular Center Research Institute, Suita, 
Japan 
Background: Lectin-like oxidized low-density lipoprotein receptor (LOX-l) is a receptor 
for oxidized low-density lipoprotein. Recent reports indicated that LOX-l mediates oxi- 
dized low-density lipoprotein-induced apoptosis and intracellular production of reactive 
oxygen species. Since several studies have revealed that apoptosis and reactive oxygen 
species have significant role in myocardial reperfusion injury. we are interested in exam- 
ining whether blockade of LOX-l reduces myocardial infarction size after ischemia-reper- 
fusion. Methods: Male Wistar rats, weighing 300 g were used. Polyethylene catheters 
were placed I” the internal carotid artery and the femoral vein for measurement of arterial 
blood pressure and infusion of drugs. Myocardial ischemia was induced by ligation of the 
lefi coronary artery for 1 hour, followed by reperfusion. The anti-LOX-l monocional anti- 
body (Group A; w7) and normal IgG (Group B; n=7) were administered 15 minutes 
before and 30 minutes after coronary ligation in a total dose of 5 mgikg. Control rats were 
received normal saline (Group C; n=7). Two hours after the reperfusion, the rats were 
sacrificed to remove the hearts for the determination of the area at risk and infarct size by 
staining with patent blue violet and triphenyltetrazolium chloride, respectively. Results: 
There were no significant differences in heart rate or mean arterial blood pressure 
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among the three groups. The percentage of the area at risk did not differ among the three 
groups (Group A; 37.6+8.7%, Group B; 34.0&.9%, Group C; 39.2+12.2%). However, 
Group A (21.2*17.2%) displayed a 50% reduction in myocardial infarct size compared 
with Group 6 (42.5+7.4%) or Group C (38.3+11.5%) (P<.O5). Conclusions: The present 
study deinon?Srates that administration of anti-LOX-l monoclonal antibody significantly 
reduces myocardial Infarction size after ischemra-reperfusion in spite of no differences in 
hemodynamic data and size of the area at risk. These data suggest that the LOX-l path- 
way is involved in the extent of myocardial ischemia-reperfusion injury and that inhibition 
of LOX-1 is feasible for treatment in acute myocardial infarction. 
__. 
889-3 
11:OO a.m. 
Inhibition of Mannose Binding Lectin Reduces Myocardial 
Reperfusion Injury: A Role for the Lectin Complement 
Pathway in Cardiovascular Disease 
James E. Jordan, Gregory L. Stahl. CET&RI, Dept. of Anesthesia, Brigham and 
Women’s Hospital, Boston, MA 
Background: Complement activation plays an undeniably important role in the patho- 
genesis of myocardral ischemia-reperfusion injury. However, the initiating mechanism of 
complement activation in this setting is largely unknown. We have recently demonstrated 
that the lectin complement pathway is activated by mannose binding l&in attaching to 
human endothelial cells following oxidative stress, suggesting that inhibition of mannose 
binding lectin may afford tissue protection following periods of ischemia and reperfusion. 
Methods: In the present study, we developed a monoclonal antibody (mAb P7E4) that 
functionally inhibits rat mannose binding lectin and evaluated its cardioprotective effects 
in an established model of myocardial ischemia and reperfusion. Rats (n=7lgroup) were 
treated with an isotype control mAb or P7E4 (0.05 or 1 mgiml) 5 min prior to occlusion of 
the left anterior descending coronary artery for 30 min. Following 4 hrs of reperfusion, 
the hearts were excised and evaluated for mannose binding lectin and C3 deposition, inf- 
arct size (triphenyl-tetrazolium chloride staining), creatinine kinase activity and neutrophil 
infiltration (myeloperoxidase). 
Results: Mannose binding lectin and C3 deposition was apparent on the coronary vas- 
culature following myocardial ischemia and reperfusion and was decreased with P7E4 
treatment. Pretreatment with P7E4 significantly reduced infarct size (area of necrosis/ 
area at risk) in a dose-dependent manner compared to an isotype control (Isotype con- 
trol: 6X1% vs 55*1% and 38~1% for 0.05 and 1 mg/kg P7E4, respectively). Left ventric- 
ular loss of creatine kinase was significantly reduced by lmglkg P7E4 compared to 
control (2.7r3.4 vs 11 .Oi2.0 U/mg protein, respectively). Similarly, myocardial myeloper- 
oxidase activity was significantly decreased by P7E4 compared to control (1 .1+0.3 vs 
2.4+0.2 U/mg protein, respectively). 
Conclusion: These data demonstrate that inhibition of mannose binding lectin, the first 
nlolecule of the &tin complement pathway, protects the rat myocardium from ischemia 
and reperfusion-induced injury. 
889-4 
ii:15 a.m. 
Effects of Different Durations of Pretreatment With Losartan 
on Myocardial infarct Size and Endothelial Function 
Bo-Qing Zhu, Yi-Ping Sun, Richard E. Sievers, Amanda E. M. Browne, Randall J. Lee, 
Kanu Chatter@?, William W. Parmley. University of California San Francisco, San 
Francisco, CA 
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889-5 Occlusion of the lnfrarenal Aorta Protects the Rat Heart 
From Infarction: Characterization of a New Humoral 
Mechanism Responsible for Mediating Remote 
Preconditioning 
Christof Weinbrenner, Manfred N&es, Nicole Herzog, L&z16 S&vary, Ruth H. Strasser. 
Deparfment of Cardiology, University of Dresden, Dresden, Germany Department of 
Cardiology, University of Heidelberg, Heidelberg, Germany 
Background: lschemic preconditioning (PC) is a powerful tool in reducing infarct size of 
the. The mechanism of signal transduction of PC, however, is not clear yet. To address 
the question if the protective signal of PC is transduced by neuronal or humoral factors 
and if the mechanism is also inducible at a distance we developed an in viva model of 
infrarenal occlusion of the aorta (IOA) in the rat. Methods: 7 protocols were used: (i) con- 
trol hearts which underwent 30 min of regional ischemia (Is) followed by 2 hrs of reperfu- 
sron (Rep); (ii) classical PC with 3 cycles of repetitive Is and Rep prior to Is; (iii) IOA for 15 
min prior to Is and throughout the following experiment (IOA); (IV) IOA for 15 min and Rep 
of the aorta at the same time as Is started (IOAl5); (v-vii) IOA for 5, 10, and 15 min resp., 
followed by 10 min Rep of the aorta before the beginning of Is (IOA5R, IOAlOR, 
lOAl5R). Results: Control hearts had an infarct size of 56.5+6.2% of the risk zone 
whereas PC reduced it to 11.2+4.1% (p<O.OOl). IOA and IOAl5, i.e. IOA without Rep, 
had no influence on infarct size thus excluding a blood pressure induced effect in the 
model (43.1r5.2, 52.2r4.4%, resp., p=n.s.). In IOA5R and IOAlOR hearts infarct size 
tended to be smaller than in controls (41.6+2.2, 36.9&.2%, rasp.) whereas in IOAl5R 
hearts infarct size was significantly smaller than rn controls (21.4+7.9%, pcO.01). There 
was a significant time-dependent linear trend for reduction of infarct size between IOA5R 
IOAlOR, and lOAl5R hearts (p<O.O05). Conclusion: Protection of the heart can be 
induced at a distance by IOA. Surprisingly this protection is nearly as powerful as PC in 
reducing infarct size. Reperfusion of the occluded aorta prior to the infarction of the heart 
is essential, excluding a neuronal factor in the signal mechanism of PC. The power of 
protection is dependent of the duration of the ischemic period in the lower limb. This sug- 
gests a time-dependent production of an ischemia induced protective humoral factor 
which is transferred to the heart by the blood circulation. This is the first study to clearly 
characterize that effective remote PC is mediated by a humoral factor. The mediating 
substance remains to be elucidated. 
889-6 
Ii:45 a.m. 
lschemia and Reperfusion-induced Changes in Myocardial 
Contrast and Tissue Doppler Echocardiography Patterns in 
a Porcine Model of Patchy Myocardial Necrosis Achieved by 
Acute Partial Occlusion of the Coronaries 
Philippe Garot, Marc Simon, Olivier Pascal, Saleh el Amine, Sophie Benacerraf, Luc 
Hittinger, Jean-Luc Dubois-Rand& Pascal Gueret, Emmanuel Teiger. Hopi&l Henri 
Mondor, Creteil, France 
Background: Coronary plaque rupture does not always imply complete arterial occlu- 
sion. It also may lead to prolonged coronary blood flow reduction. In this setting, changes 
in myocardial perfusion and contraction remain unclear. Methods: 12 closed-chest anes- 
thetized pigs underwent partial occlusion of the right coronary artery using a balloon 
inflation until distal flow measured by a Doppler guide wire fell by 80%. Myocardial perfu- 
sion in the ischemic subendo- (Sendo) and subepicardrum (Sepi) was assessed by myo- 
cardial contrast echocardiography (MCE) performed with the intracoronary injection of 
sonicated microbubbles. Peak systolic velocities (PSV) were assessed in the ischemic 
segment for the Sendo and for the Sepi using M-mode color tissue Doppler echocardio- 
graphy (short axis view). Both perfusion and contractility were assessed 30 and 90 min- 
utes after ischemia onset and then 10 and 90 minutes after reflow. MCE images were 
analyzed with the use of the NIH software package (NIH, Bethesda, MD) to determine 
the peak intensity ratio (PI ratio) defined by the ratio of contrast peak intensity in the 
enhanced ischemic myocardium and the intensity in the anterior unenhanced wall. The 
extent of Ml was assessed by TTC staining after animal sacrifice. Results: Results for PI 
ratio and PSV in the Sendo and the Sepi are presented as mean * SD. PSv are 
expressed 
Base lschemia 30 lschemia 90 Rep&. IO Repelf. 90 
min. min. min. min. 
PI ratio 3.21+.48 2.74*.50t 2.02*.55* 2.7&.43* 3.08k.33 
Sendo 
PI ratio Sepi 3.14k.62 3.25k.67 3.22i.71 2.84+.50 3.35~32 
PSV Sendo 4.4kl.7 1.811 .os 1.5+1.3$ 2.8+1.8* 2.5*1.2* 
PSV Sepi 2.0&l .o 1.3*.6* 1.5i-1.2* 2.1+1.4 l&.9 
I Troponin .2+.2 .3*.3 2.1 *I .o* 21.1+15.8? 85.9?35.4$ 
Conclusion: Severe myocardial ischemia achieved by prolonged partial occlusion of the 
coronaries is responsible for concomittant and consistent perfusion and contraction 
abnormalities predominating in the Sendo and yielding to non transmural “patchy” myo- 
cardial necrosis. 
Background: Our previous studies showed that 10 weeks of pretreatment with the AT1 
receptor antagonist losartan reduced myocardial infarct size and arrhythmias in a rat 
model of ischemia-reperfusion. However, the effect of a differing time course of pretreat- 
ment has not been investigated. Methods: 104 Sprague-Da&y rats were randomized 
into 4 groups: a control, and 3 pretreatment groups in which losartan was given 40 mgi 
kg/day in drinking water for 1 day, 1 week, and 4 weeks respectively. After different dura- 
tions of pretreatment, the rats were subjected to 17 win of left coronary artery occlusion 
and 120 min of reperfusion with hemodynamic and ECG monitoring. Effective refractory 
period (ERP), VF threshold, angiotensin II (Ang II) levels in plasma, and infarct size were 
measured.Aortic rings were removed for vascular reactivity studies. Vascular endothelial 
growth factor (VEGF protein) in the ischemic myocardium was measured by Western blot 
analysis. VEGF change was expressed relative to control (1 .O). Results: The mortalities 
during the occlusion and reperfusion period were not different among the four groups. 
The hemodynamic variables were not significantly different between the four groups. 
Endothelium-dependent vasorelaxation induced by a calcium ionophre (A23187) was 
significantly increased by 4 weeks of pretreatment with losartan. As an indicator of myo- 
cardial ischemia, VEGF levels in the ischemrc myocardium decreased after 1 and 4 
weeks of pretreatment with losartan. Myocardial infarct size was unchanged after 1 day 
and 1 week pretreatment, but was significantly reduced by 4 weeks of pretreatment with 
losartan. Conclusions:Losartan has time-dependent cardiovascular protective effects. 4 
weeks of pretreatment with losartan decreased infarct size and VEGF, and increased 
endothelial dependent vasorelaxation. 
Pretreatment with losartan (*p<O.O5, ‘*pcO.Oi) 
GP2”pS A”9 II Infarct SW2 ERP “F threshold “asorelax “EGF 
b3W (%) (ms) @A) (%I 
COih 13*3 55*3 3111 .95* 11 -%2*7 1.0 
Losartan-Id 53+14 5Pk7 3422 872.13 -75f1s .x3+.11 
LO*StZi”-lW &%I4 574 ***I 1 15r.47 -x*7 .751-.05 
Losartan4w !30*37 3**63 a,** 1 a*.*7 -814 5*+.10’* 
